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Abstract 
Background:  
Coronary artery disease (CAD), Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) are all 
global health problems. This is particularly evident amongst South Asian population groups. The 
conventional risk factors do not fully explain the higher prevalence of these diseases among South 
Asians.  
The endothelial Nitric Oxide Synthase (eNOS) gene is responsible for the production of Nitric 
Oxide (NO), which may contribute to the physiology of all three disease states. Endothelial 
dysfunction (which is characterised by a reduction in basal NO) has been shown to be present in, or 
prior to all three diseases. Numerous variations exist within the eNOS gene, of these variations 
three have been shown to have a possible functional effect. The first is the Glu298Asp 
polymorphism within the exon region of the gene, resulting in an amino acid substitution of 
Glutamate (Glu) to Aspartate (Asp). The second, known as the T-786C polymorphism, is a 
thymine to cytosine mutation at position -786 in the promoter region. Finally a VNTR 
polymorphism in Intron 4 causes either a 4 27bp repeat or a 5 27bp repeat. It is hypothesised that 
these variations could have an effect on the ability of eNOS to produce NO and thus may increase 
the risk or contribute to the development of the diseases. Previous studies on these variants have 
shown conflicting results and further studies are warranted to understand and confirm the role of 
eNOS gene polymorphisms in cardio-metabolic diseases. There is very limited research into the 
distributions of these genetic variants and their interaction in diseases processes in North Indian 
populations.  
Objectives: 
1.  To analyse through a case control study three different  polymorphisms of the eNOS gene 
for possible association with Coronary Artery Disease (CAD), Hypertension (Ht) and Type 
2 Diabetes Mellitus (T2DM) in North Indian population groups.  
2. To statistically evaluate descriptive statistics including; age, gender, smoking, dietary 
behaviours and lipid parameters for possible influence on disease and potential interaction 
with genetic polymorphisms. 
3. To evaluate linkage disequilibrium between the three eNOS variants and carryout 
haplotype analysis to work out haplotype risk in different diseases. 
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4. To analyse through a case control study the deletion variant of the Angiotensin-converting 
enzyme (ACE) gene for possible association with Coronary Artery Disease (CAD), 
Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) in North Indian population 
groups.  
5. To determine a possible interactive effect of the eNOS polymorphisms with the ACE 
polymorphism. 
Subjects and Methods:  
The Glu298Asp and Intron 4 variants were genotyped using a PCR-RFLP technique, the T-786C 
variant was genotyped using a real time-PCR technique. The ACE deletion variant was also 
genotyped using a standard PCR technique. The genotyping was undertaken in a total of 457 CAD 
patients and 220 matched controls from Lucknow, Uttar Pradesh in North India, 319 T2DM 
patients and 307 matched controls from Punjab, North India and 210 Ht and 162 matched controls, 
also from Punjab, North India.  
Results:  
CAD: The Glu298Asp was significantly associated with CAD among smokers (TT+GT vs. GG 
OR=2.84 (CI: 1.61-5.0), p<0.001). The Intron 4 variant was also significantly associated with CAD 
in a smoking dependent manner (4aa+4ab vs. 4bb OR=0.56 (CI: 0.33-0.96). The T-786C variant 
showed no overall influence on CAD risk. There was also evidence for both synergistic and 
haplotypic effects of the eNOS gene on CAD status (haplotype G-C-4b OR=4.76 (CI: 1.43-15.78), 
p<0.001).   
The ACE genetic variant was confirmed to be a strong independent risk factor for CAD under a 
dominant model (OR=2.18 (CI: 1.46-3.25), p<0.001). There was no evidence for an interactive 
effect between the ACE deletion and any of the three eNOS variants incorporated in the current 
study.  
Ht: The Glu298Asp variant was not shown to increase Ht risk, with a reduced risk association 
found under a recessive model (OR=0.316 (CI:0.089-1.116), p=0.061). The T-786C variant’s role 
in disease remained unclear with the findings showing a non significant increased risk. The Intron 
4 variant was also shown to increase Ht risk, in a non significant manner. Sufficiently powered 
studies would be required to clarify these possible associations. The combined analysis, using 
logistic regression and haplotype analysis revealed no significant associations, but there was a 
possible protective effect of the T-C-4b haplotype (OR=0.46 (CI: 0.21-1.01), p=0.054).  
Abstract 
iii | P a g e  
 
The ACE gene variant was confirmed to be a strong independent risk factor for Ht under a 
recessive model (OR=1.81 (CI: 1.20-2.74), p=0.01). Again there was no evidence for an interactive 
effect between the ACE deletion and any of the three eNOS variants in hypertension.  
T2DM: The Glu298Asp variant was found to be associated with T2DM under a dominant model, 
the protective effect remained significant following adjustment for conventional risk factors and 
other gene variants (OR=0.407 (CI: 0.231-0.717), p=0.002). The T-786C variant showed no 
overall influence on T2DM risk. The Intron 4 variant also found no overall influence. Haplotype 
analysis found the T-T-4b was found to be significantly protective for T2DM (OR=0.41 (CI: 0.26-
0.65), p=0.0002). Finally the ACE gene variant was confirmed to be a risk factor for T2DM under 
a dominant model (OR=2.62 (CI: 1.51-4.54), p=0.001). 
Overall Conclusions:  
To conclude, this study successfully identified the frequency of three eNOS gene variants and the 
ACE deletion variant in three complex diseases within north Indian populations. There is a clear 
role of the eNOS gene in all three diseases and consequently the genetic variants have 
susceptible/protective associations. The association with disease was found to be present at an 
individual level, in association with risk factors and at a haplotypic level. These findings warrant 
further studies to confirm and untangle the genetics of complex diseases and genetic risk profiles 
calculations which will contribute to the field of medical genomics/personalised medicare and 
interventions among North Indian populations.  
Key Words:  Genetic association, coronary artery disease, hypertension, type 2 diabetes mellitus, 
nitric oxide, endothelial nitric oxide synthase (eNOS) gene, susceptibility, North Indian, South 
Asian, Glu298Asp, T-786C, Intron 4 and ACE deletion. 
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1 Chapter 1-Background 
Medical genomics is an ever advancing field, with nearly all diseases now believed to have an 
element of genetic influence. The completion of the Human Genome Project in 2003 has made 
genetic testing, earlier diagnosis and personalised medicines a more achievable reality 
(Http://www.ornl.gov/sci/techresources/Human_Genome/home.sHtml). The rate of research into 
documenting the genetic variation responsible for disease has been substantial, vastly contributing 
to our knowledge of the molecular physiology of diseases and drug discovery (Cooper et al. 2010). 
However, a large proportion of the genetic basis of disease remains unexplained and the more that 
is discovered the increasingly complex this task becomes (Nebert et al. 2008). 
The current study will aim to contribute to the field of medical genomics by evaluating the 
involvement of the endothelial nitric oxide synthase (eNOS) gene in three complex diseases within 
North Indian populations. 
1.1 What and why of Human Genetic Variation 
The first documented example of human genetic variation was almost 100 years ago. In 1919 
Hirszfeld & Hirszfeld identified the first human gene; the ABO gene, responsible for determining 
the ABO blood group (Hirszfeld & Hirszfeld 1919). Since the discovery of this gene it has become 
clear that genetic variation is not rare and is abundant throughout the human genome (Cavalli-
Sforza & Feldman 2003). 
1.1.1 What are these Variations? 
A genetic variant or mutation is a permanent change in the deoxyribonucleic acid (DNA) sequence. 
The presence, location and size of the mutation collectively contribute to the severity and 
physiological effect the variant will exhibit. Mutations vary in size, ranging from one individual 
DNA nucleotide base to a large segment of a chromosome (Sharp et al. 2006). A mutation is 
termed a polymorphism if it is at a frequency greater than 1% (arbitrary) in a population.   
Primarily there are two classifications of mutation: germline and de novo. Germline are inherited 
and thus present throughout the entire genome. Conversely a de novo mutation is an acquired 
mutation. De novo mutations are continually appearing at a predicted frequency of 175 per diploid 
human genome per generation (Nachman & Crowell 2000). Mutations may result in a loss or gain 
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of function in their respective gene products and consequently can contribute to the variance in 
disease susceptibility (Sharp et al. 2006, Lupski 2007).  
Variations within the human genome exist at multiple levels and are classified accordingly. One 
example of variation is variable number of tandem repeat polymorphisms which include 
microsatellites and minisatellites, they are widely dispersed throughout the human genome and 
multiple alleles may exist at the loci (Sharp et al. 2006, Lupski 2007). Repeat polymorphisms are 
popular in the field of forensics (Tamaki & Jeffreys 2005).  Alternatively, a mutation may be a 
single nucleotide polymorphism (SNP) a point mutation affecting one nucleotide only such as a 
single nucleotide base change of guanine (G) being replaced by a thymine (T). There are also 
insertion and deletion polymorphisms (Indel), where a stretch of DNA is either deleted or inserted 
into a DNA sequence. More recently a new class of polymorphisms have been described called 
copy number variants (CNV) in which either the whole gene or stretches of DNA are duplicated or 
deleted.  The location of the mutation dramatically alters their phenotypic and disease outcome 
(http://www.ncbi.nlm.nih.gov/About/primer/snps.html, Sharp et al. 2006).   
Human evolution has vastly shaped the presence and frequency of these genetic variations. Ancient 
polymorphisms are shared by all populations and account for 90% of human genetic variation, the 
10% of variance that is unaccounted for is a result of the emergence of new alleles (McClellan & 
King 2010). The vast numbers of more recent alleles exhibit a silent manner, consequently their 
frequency has not been shaped by natural selection and will be a result of chance alone, and only a 
small number of the new alleles will have functional relevance contributing to disease. Functional 
mutations if severe are less frequently passed on affecting an individual on two levels; either 
causing death prior to a reproductive age, or by affecting an individual’s ability to reproduce, as a 
result these severe mutations are rare (McClellan & King 2010). 
Some of these variants although exhibiting a major contribution to disease have remained present 
among populations and identification has proven to be a useful tool with respect to medical 
genomics. The most prominent example of this would be for sickle cell anaemia and thalassemias, 
where multiple polymorphisms in the haemoglobin genes have been identified. The most important 
of these is a point mutation in the β-globin chain of haemoglobin in the β-globin gene causing an 
amino acid substitution in the protein. This alters the shape of the resulting red blood cell, creating 
an elongated and curved shape under low oxygen tension; this can result in severe oxygen 
deprivation. This variant is also the first known evidence for natural selection for a mutation, with 
heterozygotes for the polymorphism exhibiting greater resistance to malaria than either 
homozygote. In malarial environments this led to a heterozygote advantage to maintain the risk 
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allele (http://omim.org/entry/603903, Cavalli-Sforza & Feldman 2003). A second example of a 
common variant remaining at a high frequency is provided by the E4 allele of  the apolipoprotein E 
(APOE) gene, this have been shown to be carried by between 40-80% of Alzheimers patients 
(Mahley et al. 2006).  A common factor to both these mutations is a clear functional role, 
indicating a direct effect of variant. It is important to determine if association with disease is 
directly causal, acting through a different mutation, or false association.   
Currently there are two views in identifying the underlying variations responsible for complex 
disease. The first view ‘the common disease, common variant’ hypothesis assumes that the variants 
responsible for the pathophysiology of disease are common polymorphisms (frequency >1%) 
influencing common diseases associated with a late onset, these diseases would have occurred past 
a reproductive age and thus would not have been subjected to natural selection (McClellan & King 
2010). The second view ‘the common disease, rare variant’ hypothesis assumes an inverse 
relationship between the effect size and the frequency of the variant. It has the basis that the 
frequencies of these common diseases are a reflection of the prevalence of environmental 
influences as oppose to prevalence of the disease alleles (Iyengar & Elston 2007). 
The search for functional variants is problematic, with complex diseases exhibiting a polygenic 
nature with complex interactions. Complex diseases show substantial heterogeneity; any one gene 
may contain multiple mutations, individual mutations may result in differing phenotypic 
consequences between individuals, whilst an identical clinical effect may be a consequence of 
separate mutations in separate genes (McClellan & King 2010). There is a requirement to identify 
common multiple biologically relevant mutations in the same gene for complex late onset diseases. 
1.2 Disease Contribution and State of Affairs in Human Genomics 
(HapMap, GWA and Candidate gene studies) 
Identifying common variants associated with disease has seen contrasting success (McClellan & 
King 2010, Kitsios et al. 2011, Rafiq et al. 2010, Baudhuin 2009, Vimaleswaran & Loos 2010, Jin 
& Patti 2009). Among the successes are variants in the APOE4 gene associated with Alzheimer’s 
disease and lipids and variants of the PPARG and KCNJ11 genes associated with T2DM (Mahley 
et al. 2006, Strittmatter & Roses 1996, Altshuler et al. 2000, Gloyn et al. 2003).  
The identification of variants and genes involved in disease has been made possible by the 
completion of The Human Genome Project, which has discovered there to be total of 20,000-
25,000 genes in the human genome. The identification of genetic mutations has been further eased 
by projects including; the International HapMap, 1000 genomes, Encyclopaedia of DNA Elements 
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(ENCODE) and the SNP Consortium (Nebert et al. 2008).  The International HapMap project is a 
collaborative project of many different countries, including the United Kingdom and the United 
States. The project aims to aid researchers in their efforts to search for genes involved in health and 
disease. Secondary aims are to increase understanding of an individual’s personal response to 
medication and other environmental variables. The project provides a catalogue of common 
genetic variants to form a reference sequence of the human genome. This was undertaken primarily 
in 270 individuals in four different population groups with African, Asian and European ancestry 
and then extended to include a total of 1,301 samples 
(http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html, 
http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en). 1000 genomes is a more recent project which 
aims to sequence genomes of a large number of individuals creating a comprehensive reference 
sequence indentifying polymorphisms (Http://www.1000genomes.org/about). 
There are three main designs adopted for investigating genetic variants involved in common 
diseases: Family-based linkage studies, population based candidate gene association studies and 
genome wide association studies (International HapMap Consortium 2005). Each technique 
encompasses different strengths and weakness. 
1.2.1 Family-based Linkage Studies 
Linkage analysis aims to identify regions predisposing an individual to a disease. It’s largely 
dependent on linkage and linkage disequilibrium between variants. When two genetic loci are in 
linkage disequilibrium, they are consequently transferred dependently from parent to offspring at a 
greater frequency than chance alone, this is a result of recombination and is dependent on the 
distance between variants. The farther two variants are from one another the greater the chance of 
them being transferred independently, conversely the nearer two variants are the greater the chance 
that recombination in meiosis will not break them up. A recombination fraction can be provided to 
measure this. Consequently by examining genetic markers through a family’s pedigree, 
information on their positional location is gathered and it is possible to map the disease and genetic 
markers (Dawn Teare & Barrett 2005).  
Complex, multifactorial diseases, utilise linkage analysis using a model free method, due to the 
multiple contributors towards the development of the disease, there is an absence of a clear mode 
of inheritance (Dawn Teare & Barrett 2005). The hypothesis is that individuals affected will 
consistently show a greater frequency of haplotypes within the region of a disease causing gene. 
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1.2.2 Candidate Gene Association Studies 
Alternatively population based candidate gene association studies may be adopted, these have been 
shown to be more effective for complex diseases (Risch & Merikangas 1996). This method 
involves selecting a candidate gene and identifying variants within the candidate gene. Currently it 
is estimated that there are around 25,000 genes present in the human genome, thus to increase prior 
odds of a gene’s involvement in disease investigation focuses on these ‘candidate’ genes proven to 
have a physiological effect that may be implicated in the disease progression (Hattersley & 
McCarthy 2005). A group of patients and controls are then genotyped for the variants and the 
frequencies analysed. A variant is identified as being associated with the disease in the presence of 
a statistically significant difference in the allele/genotype frequency observed between the cases 
and controls.  
Hattersley and McCarthy (2005) describe clear criterion for the choice of a candidate gene; firstly, 
there must be a clear biological role for the gene; this requires that the gene put forward has a 
functional protein exhibiting a clear involvement in the disease or trait. Secondly, there may be a 
pharmacological role suggesting that the action of a drug that is used to treat/modify the disease 
has an involvement with the gene in question. Thirdly, the gene may have been implicated through 
animal models; a gene that influences a disease in animals often shows strong correlation with 
human influence (Hattersley & McCarthy 2005). For example the endothelial nitric oxide synthase 
gene (eNOS) has been shown to induce hypertension in eNOS knock out mice (Huang et al. 1995). 
This effect has been replicated in human candidate gene association studies (Srivastava et al. 
2008). Fourthly, positional information may have highlighted a region or gene of interest through 
association suggested in genome wide association studies as a possible susceptibility gene 
(Hattersley & McCarthy 2005). An example of this would be the chromosomal region 9p21 
identifiedfor CAD, where susceptibility was further investigated and successfully confirmed 
through a candidate gene approach (Chen et al. 2008, Samani et al. 2007).  Finally, many complex 
diseases have monogenic forms that have very rare variations as the causal factors, common 
variants in the same gene are often act as candidate variants (Hattersley & McCarthy 2005). 
This method is not only more successful for complex disease but the study design has further 
benefits over the use of a family study. Practical compliance of participants is less crucial because 
the criterion is not matched by family only by ethnicity. Successful identifications of variations are 
also more widely applicable than successes of family linkage studies, which can be specific to the 
family (Hattersley & McCarthy 2005). 
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1.2.3 Genome Wide Association Studies 
Genome wide association studies (GWAS) are the final method commonly adopted to detect 
association of genetic variants with disease. Unlike candidate gene association studies GWAS are 
hypothesis generating rather than based on a predetermined hypothesis. GWAS require a large 
group of patients and controls in which the entire human genome is scanned for multiple SNPs 
simultaneously (http://www.genome.gov/20019523). One of the first GWASs to identify an 
association was undertaken by Ozaki et al. (2002), who found functional SNPs in the lymphotoxin-
α gene to be associated with myocardial infarction (Ozaki et al. 2002).   This method has become 
very popular in recent years with advances in genotyping technology. GWAS has been successful 
in identifying susceptibility variants in identifying new susceptible loci in a number of complex 
diseases (see A Catalogue of Published Genome-Wide Association Studies- 
Http://www.genome.gov/26525384).  GWAS detect any variations that are significantly more 
frequent in patients compared to controls and can highlight specific regions/genes that are 
associated with disease, which then require verifying through further candidate gene association 
studies; an example of which was the region 9p21 (Chen et al. 2008, Samani et al. 2007). GWAS 
have led to the identification of hundreds of risk alleles for common diseases, often identifying 
variants that would previously have been left undetected due to a lack of known functional effect. 
However as with any method a number of limitations exist, the limitations of GWAS include the 
potential for population stratification. False association may be a result of differences in the 
ancestry between cases and controls, ethnicity in the majority of studies undertaken is self-
reported, there can be large interethnic differences in allele frequencies and consequently a small 
error in ancestry can result in false association.(McClellan & King 2010). This limitation is not 
unique to GWAS and is also present in candidate gene association studies. A second major 
limitation of GWAS is that when a region of genome is identified to exhibit association with 
disease, this can often be indirect, acting as a marker for an alternative variant nearby. 
Consequently candidate gene association studies are required to replicate the findings in order to 
verify any association found.  
1.3 Aetiology and Epidemiology of CAD, T2DM, Ht in an Indian 
Population 
This study is focusing on three inter-related complex diseases, Coronary Artery Disease (CAD), 
Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM). This section will provide an overview of 
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the basic disease aetiology, risk factors, the current knowledge and findings from a genetic 
perspective and finally the epidemiological data specifically within an Indian population. 
1.3.1 Coronary Artery Disease 
Coronary artery disease (CAD) is the most common underlying cause of heart disease, primarily 
caused by atherosclerosis; a narrowing of the arteries (Mallika et al. 2007). It manifests as angina, 
unstable angina, silent ischemia, myocardial infarction (MI), heart failure, and sudden death. It is a 
multifactorial disease affected by both environmental and genetic factors (Grech 2003). A global 
spread of CAD has been evident; since 1990 no other disease has caused more morbidity and 
mortality than CAD (Watkins & Farrall 2006). CAD forms part of the cardiovascular disease 
(CVD) group which represents diseases affecting the heart and blood vessels. The World Health 
Organisation (WHO) estimates that 17.1 million people died from CVD in 2004.This is increasing, 
with predictions this will rise to 23.6 million people per year by 2030. 
(http://www.who.int/mediacentre/factsheets/fs317/en/index.html). The actual burden of CVD is 
likely to exceed even these estimates due to undiagnosed and asymptomatic cases (Goyal & Yusuf 
2006). 
1.3.1.1 Aetiology of CAD 
Atherosclerosis is a degenerative disease and is the underlying process responsible for CAD 
primarily affecting medium and large sized arteries (Crowther 2005). Atherosclerosis can be 
described as a vascular inflammatory disease caused by disturbed vascular homeostasis resulting in 
the formation of atherosclerotic lesions (Schafer & Bauersachs 2008).  
There are three central theories hypothesised to be the trigger for CAD and endothelial 
dysfunction, these are: the response to injury theory, the response to retention theory and the 
oxidation theory. Under the first hypothesis the process is initated in response to the endothelium 
becoming damaged, for example by diabetes, smoking, raised blood pressure, injury or infection 
resulting in an inflammatory response (Mallika et al. 2007, Pongnimitprasert 2009). The second 
theory is that the atherosclerosis process arises as a response to accumulation of extracellular 
matrix molecules and lipoproteins (Pongnimitprasert 2009). Finally, the oxidative theory proposes 
that the process begins with the oxidation of low density lipoprotein (LDL) through free radicals, 
this oxidation results in the recruitment of  monocytes to the vessel wall and also damages the 
endothelium resulting in endothelial dysfunction (Mallika et al. 2007, Pongnimitprasert 2009). 
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The progression of atherosclerosis is characterised by inflammation at every stage, initiated by 
endothelial dysfunction/damage (Chilton 2004). The first visible lesions of atherosclerosis are fatty 
streaks within the intimal layer of the artery. This process begins with adhesion of leukocytes 
(mainly monocytes) to the vessel wall from the blood stream to the subsequent area of injury of the 
endothelium, where the monocytes mature into macrophages contributing to the start of the plaque 
development (Crowther 2005, Clarke & Bennett 2006). The fatty streaks overtime evolve into a 
fibrous plaque which is the well known feature of established atherosclerosis, the plaque can 
further evolve accumulating large amounts of lipids and ultimately the growing plaque can become 
unstable and rupture; forming a thrombus and resulting in complete occulation of the blood vessel 
(Crowther 2005).  
1.3.1.1.1 The role of Lipids and Plaque Formation 
Oxidised low density lipoprotein (LDL) is a prominent required step of the atherosclerotic process 
(Mallika et al. 2007).  LDL moves from the blood stream and into the vessel wall where three 
different consequences may occur, firstly; the LDL cholesterol may move back into the blood 
stream causing no further problem, secondly; the LDL may become oxidised through the action of 
free radicals, finally; the LDL may be taken up by macrophages causing them to become foam 
cells. The final step can only occur if the LDL cholesterol has become oxidised, illustrating the 
oxidation of LDL as a key contributor of the atherosclerosis process (Crowther 2005). When the 
LDL cholesterol becomes trapped in the arterial wall it injures the endothelium resulting in 
endothelial dysfunction and initiating an inflammatory response (Chilton 2004).  
LDL becomes oxidised when oxygen reacts with the lipids, specifically with unsaturated fats. This 
oxidation is brought about by a number of influences, in particular reactive oxidative species 
(ROS). LDL cholesterol is packed with antioxidants such as vitamin E, however the longer it 
remains in circulation the greater this source is depleted and the greater the chance of the LDL 
becoming oxidised. The oxidation of LDL causes a number of consequences, among these is the 
inability to be recognised by the LDL receptor and therefore the oxidised LDL remains in the 
blood circulation where it can now be taken up by macrophages (Mallika et al. 2007).   
When the macrophages take up the oxidised LDL they become less mobile and transform into 
foam cells. The activated foam cells maintain metabolic activity releasing a range of cytokines, 
chemoattractant molecules and growth factors. The lesion attracts further lymphocytes maintaining 
the inflammatory response. The cycle of events continues to repeat, as it does the plaque creates a 
stable structure due to the development of a fatty core, enclosed by a fibrous matrix (Crowther 
2005, Chilton 2004).  The role of LDL in atherosclerosis is determined by a number of features 
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including their particle number and size and HDL levels. Figure 1 provides an overview of the 
development of plaque development in atherosclerosis.  
 
Figure 1- An overview of fibrous plaque development in atherosclerosis 
1.3.1.2 CAD Risk Factors 
CAD is a complex disease with a multifactorial nature, affected by both genetic and environmental 
factors. It also has a polygenic nature; numerous genes with multiple alleles will have small to 
moderate effects. Collectively these variants will contribute to a high proportion of the variance in 
a population’s disease risk (Ellsworth et al. 1999).  
These genetic and environmental risk factors result in a varying risk of CAD, with each individual 
having their own unique risk profile for the disease. A number of physiological and environmental 
influences are well established as CAD risk factors, these can be separated into non-modifiable and 
modifiable (Table 1). Each risk factor is complex with its own multiple genetic and environmental 
influences (Padmanabhan et al. 2010). 
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Table 1- CVD risk factors separated into modifiable and non-modifiable 
Modifiable Non-modifiable 
Smoking (active and secondary) Increasing age 
Being overweight/obese Gender (male) 
Abnormal blood lipids Ethnicity 
High blood cholesterol Family History/Genetics 
High blood pressure  
Insulin resistance/ impaired glucose tolerance/ 
Diabetes Mellitus 
 
Physical Inactivity  
Alcohol intake  
Psychosocial stress  
Social economic status   
Reduced homocysteine   
Increased c-reactive protein  
Source: adapted from Grech 2003 
Risk factors are continuing to emerge as the understanding of the physiology of CAD and other 
CVDs grows. These unidentified risk factors will aid the understanding of the proportion of the 
disease left unexplained, but may also have interactive effects with genetic variants and other 
conventional risk factors.  
1.3.1.3 Genetics of CAD 
CAD risk factors act as key targets for modification and highlight high risk individuals. CAD as 
stated has a multifactorial polygenic nature for which genetic influences play a key role in both 
CAD initiation and development. Investigation into the genetic basis of CAD has had limited 
success. This has been attributed to a number of reasons, including the complex nature of the 
disease. Further factors that have prevented/limited the success of these studies are the 
characteristics of the disease such as the late onset (Wang 2005b). 
A positive family history has repeatedly been shown to be one of the most influential independent 
risk factors for CAD, even when adjusted for other classical risk factors (including cholesterol and 
blood pressure) (Yusuf et al. 2004, Lloyd-Jones et al. 2004, Assmann et al. 2002, Nasir et al. 
2004). Twin studies have also confirmed a strong genetic basis to the disease (Marenberg et al. 
1994, Zdravkovic et al. 2002). An example of this is a  large scale study undertaken by Zdravkovic 
et al. (2002), 20,966 twins were monitored over a 36 year period, heritability for fatal CAD events 
was shown to be as high as 57% (Zdravkovic et al. 2002).  
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The genetic contribution of genes to disease can be classified into disease-causing genes, 
susceptibility genes and disease-linked genes. Disease causing genes are genes that when mutated 
are directly causal of the disease, they can therefore be predictive for the disease and used in 
genetic testing. Susceptibility genes have varying risk levels for the development of the disease; 
shaped by other genetic and environmental factors, whilst disease linked genes act as a biomarker 
for the disease (Wang 2005a). 
The first disease-causing gene identified for CAD was the MEF2A gene. Wang et al. (2003) 
performed a genome-wide linkage scan in a large family with 13 patients, where an autosomal 
dominant inheritance pattern for CAD was present. This study resulted in the localisation of the 
first autosomal dominant genetic locus for CAD on chromosome 15q26 (Wang et al. 2003). Wang 
et al. (2003) showed that a 21-basepair deletion identified within the exon 11 of the MEF2A gene 
was present in all individuals with the disease, and absent in a further 119 individuals with normal 
angiograms. This 21-basepair deletion exhibits this effect by disrupting the transcriptional 
activation of the gene (Wang et al. 2003).  
The risk factors for CAD have acted as key targets for research. One well established CAD risk 
factor is raised LDL levels where successful identification has been made for genetic mutations on 
the LDL receptor gene responsible for a defective or absent LDL receptor. These mutations result 
in a disorder known as familial hypercholesterolemia (FH) which can cause premature CAD (<20 
years) (Schaefer & Levy 1985, Brown & Goldstein 1986, Crowther 2005). FH is an example of a 
disease causing gene that acts indirectly upon CAD risk. Similarly, disease causing genes have 
been identified for associated diseases such as Tangier disease. 
GWASs have been conducted to identify susceptibility genes directly involved in CAD pathways, 
thus far these have had limited results. The Wellcome Trust Case Control Consortium (WTCCC) 
and the German MI Family Study are two of the main GWAS that have researched into CAD, 
investigating thousands of chromosomal loci. Both studies found a strong association of the 
specific chromosome locus 9p21 (Samani et al. 2007, Wellcome Trust Case Control Consortium 
2007). The association of the SNP variants on chromosome 9p21 has been replicated. Two variants 
(rs10757278 and rs2383207) have been associated with an increased risk for premature CAD in a 
Chinese population (Chen et al. 2008), and four variants in an Italian population (Shen et al. 2008). 
The risk association of 9p21 has also been confirmed in other candidate association studies and 
meta-analyses (Larson et al. 2007, Muendlein et al. 2009, Schunkert et al. 2008). 
Baudhuin (2009) provides an excellent overview of genetic association with CAD, with particular 
focus on GWAS. Much of the success came from Samani et al. (2007) and the Wellcome trust case 
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control consortium (2007) (Baudhuin 2009, Samani et al. 2007, Wellcome Trust Case Control 
Consortium 2007). 
A meta-analysis is a powerful tool in the task of identifying genetic variants associated with 
disease, combining multiple studies to increase power. A recent meta-analysis of 14 GWAS, 
including more than 22,000 patients and nearly 65,000 controls (European descent) identified 13 
new loci possibly associated with CAD. The 13 new loci included gene regions unknown to be 
implicated in the pathophysiology of CAD (Schunkert et al. 2011). Five new loci associated with 
CAD have also been identified through a very recent GWAS (Coronary Artery Disease (C4D) 
Genetics Consortium 2011). These studies also provide possible new pathways involved in CAD 
susceptibility. 
However, successes from GWAS should be taken with caution and need to be further clarified 
through population specific candidate case control studies. An example of this requirement is 
demonstrated by the twelve year prospective cohort study undertaken by Paynter et al. (2010), 
incorporating more than 19,000 women and 101 SNPS previously identified through GWAS. Their 
study failed to find any significant association for any of the 101 variants (Paynter et al. 2010).  
Currently, the heritability of CAD has not been fully explained, and thus the use of GWAS and 
candidate gene association studies are necessary to further the current advances.  
1.3.1.4 CAD in Indians 
The vast increase in the prevalence of CAD is particularly evident in developing countries such as 
India. It is predicted that by the year 2015 CVD will be the leading cause of mortality among 
Indians (Singh et al. 1997). Projections based on the Global Burden of Disease study have made 
estimations that by the year 2020 CVD in India will be at a greater prevalence beyond any other 
region of the world (Murray & Lopez 1997). The elevated prevalence of CVD in India is more 
prominent among urban areas compared to rural (Singh et al. 1997). The prevalence of CVD over a 
40 year period was shown to increase two fold in rural areas compared to a six fold in urban India 
(Goyal & Yusuf 2006).  
This elevated prevalence among Indians has been attributed to a number of factors, one of which is 
the evident increasing age among this population; India is demonstrating a transition to an older 
population with 19.61 million people categorised as above 60 years of age in 1950, rising (by more 
than 3.5 times) to 75.93 million by the year 2000 (Sharma et al. 1992, cited in Sharma & Ganguly 
2005). Secondly, there has been evidence supporting a relationship between low birth weight and 
Chapter 1 – Background and Literature Review 
13 | P a g e  
 
 
CAD known as the ‘Barker hypothesis’, this is particularly critical in an Indian population where 
newborns are demonstrating a high prevalence of low birth weights (Barker et al. 1993). Thirdly, 
there could be a contrast of conventional and non- conventional risk factors; conventional risk 
factors such as diabetes mellitus and smoking are on the rise due to growing urbanisation and a 
transition towards a western culture in India.  
Whilst non conventional risk factors (insulin resistance and lipoprotein (a)) may partly explain 
some of the elevated prevalence, there are a number of key characteristics that support a genetic 
predisposition to the disease and highlight the need for further research (Singh & Sen 2003). 
 Higher prevalence 
Indians show two to four fold higher figures for incidence, prevalence and mortality compared to 
white European populations (Singh & Sen 2003, Mohan & Deepa 2004). Asian Indians are at the 
highest risk of CVD with an estimated 1.17 million deaths attributable to CVD in 1990, by the year 
2010 this is expected to almost double (Ghaffar et al. 2004). 
The evidence from previous studies have suggested that migrant Indian populations have a higher 
level of CAD morbidity and mortality, with estimates ranging between a 1.5 to 10 fold greater 
incidence of CAD among migrant Indians compared to the respective indigenous populations 
(Balarajan 1991, Bahl et al. 2001, Anand et al. 2000, McKeigue et al. 1989, McKeigue & Marmot 
1988).  
 Early onset 
It is well established that CAD shows a greater prematurity in Indian populations, occurring earlier 
in life than in other ethnic groups (Bahl et al. 2001, Barnett et al. 2006). This is apparent when 
observing the presence of myocardial infarctions (MI); the most serious and single recordable 
event associated with CAD. MIs are shown to occur on the first instance between five and ten 
years earlier in Indians than other populations (Goyal & Yusuf 2006, Singh & Sen 2003, Hughes et 
al. 1989).  This results in a five to ten fold higher rate of MI and mortality in individuals younger 
than 40 years of age (Singh & Sen 2003). This has both health and economical implications on 
India due to loss of productive years of life. It is estimated that 17.9 million years of productive 
years of life will be lost in 2030, this is near to ten times that expected in the United States of 
America (Goyal & Yusuf 2006).  52% of all CVD deaths in India occur below the age of 50 years, 
whilst 25% of acute MIs occur under the age of 40 years (Sharma & Ganguly 2005). 
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 Greater severity 
Moreover, CAD has been demonstrated to be of a greater severity within an Indian population. 
CAD is typically present in a greater number of vessels, often occurring in three separate vessels 
(Singh & Sen 2003).  
 Conventional risk factors for CAD in the Indian population 
As stated, the conventional risk factors for CAD include smoking, Ht, abnormal lipid profile, 
diabetes mellitus, obesity and reduced level of physical activity. Most of these risk factors are of 
similar prevalence in India compared to other populations, with the exception of diabetes mellitus 
and thus they do not fully explain the increased risk (Bajaj & Banerji 2004, Bahl et al. 2001, 
Beckles et al. 1986). This suggests that the increased prevalence and greater severity of CAD may 
be partly attributable to genetic differences. It is thought that more than 60% of CAD among 
Indians cannot be explained by conventional risk factors. It is probable that unknown and novel 
risk factors may somewhat contribute to the 60% of unexplained CAD, but this will be alongside 
other genetic differences (Mohan & Deepa 2004). Sharma et al. (2005) reviewed multiple studies 
and confirmed that family history is an important CAD risk factor in Indians, finding it to be one of 
the strongest conventional risk factors (Sharma & Ganguly 2005). 
The amount of CAD that remains unaccountable for has shown variance between studies. In 
contrast, the interheart study predicted that up to 92% of risk could be explained by conventional 
risk factors, a number not dissimilar to other regions of the world and in fact was higher than 
European populations where only 86% could be explained (Yusuf et al. 2004). Goyal and Yusuf 
(2006) challenged the proposed South Asian ethnicity as a risk factor, they believe that the 
evidence from previous studies may be flawed due to a number of limitations, including few 
studies on South Asians living in their own countries, and limited data collected on characteristics 
such as dietary patterns and physical activity (Goyal & Yusuf 2006).  
The INTERHEART study by Yusuf et al. (2004) found that both smoking (OR = 2.43) and 
apolipoprotein B and A1 (OR =3.81) to be particularly prominent risk factors among South Asians.  
However, variances also existed when looking at hypertension, abdominal obesity and diabetes 
mellitus, with higher ORs present in South Asians compared to other population groups, 
challenging the previously found similar prevalence of conventional risk factors (Yusuf et al. 2004, 
Sharma & Ganguly 2005).   
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 Higher prevalence of Diabetes 
As stated diabetes mellitus is an important risk factor for CAD and is widely accepted to be at a 
greater frequency in an Indian population. A four to six fold increase has been found in Indians 
living abroad compared to indigenous populations (Sharma & Ganguly 2005, Barnett et al. 2006). 
Diabetes, central obesity and insulin resistance syndrome all show higher prevalence among 
Indians (Singh & Sen 2003).  A study on the global prevalence of diabetes predicted India to have 
the greatest prevalence of diabetes in 2030, projecting an increase from 31.7 million (2000) to 79.4 
million (2030), the magnitude of this increase was above and beyond any other country (Wild et al. 
2004). As an independent risk factor for the disease this may be a major contributor to the higher 
rates, although it is unlikely to be totally responsible.   
The prevalence of CAD globally and prominently among Indians is increasing. Currently the 
genetic heritability of the disease is yet to be fully understood. 
1.3.2 Hypertension 
The second disease to be incorporated in this study is hypertension (Ht). Ht is a well established 
risk factor for CAD (Grech 2003, Yusuf et al. 2004). However its vast prevalence has led it to be 
considered a health problem in its own entity (Whitworth 2003). Similarly to CAD Ht forms part 
of the group of disorders collectively known as CVD. The WHO states that in 1999 a third of 
deaths globally were caused by the CVD group. Ht is a global problem with no restrictions to 
gender, geographic, or socio-economic variables, it is becoming increasingly evident among 
developing countries with CVDs predicted to be the leading cause of death. The cause of this has 
been attributed to a change in lifestyle towards a more urban western manner 
(Http://www.who.int/cardiovascular_diseases/priorities/en/). More specifically Ht was estimated in 
the year 2000 to affect a total number of 972 million individuals worldwide with 639 million of the 
total number present in developing countries. The prevalence is increasing and is predicted to reach 
1.56 billion by 2025, an increase of around 60% (Kearney et al. 2005). 
1.3.2.1 Aetiology of Hypertension 
Ht is elevated blood pressure (BP), specifically this is the pressure at which the blood is under 
within the lumen of the vessels. Two measurements are taken for blood pressure; diastolic and 
systolic. The diastolic reading reflects the BP under the relaxation of the myocardium, and the 
systolic reading is the BP under the contraction of the myocardium. Essential Ht (also known as 
Chapter 1 – Background and Literature Review 
16 | P a g e  
 
 
primary Ht) accounts for 95% of all Ht cases and is responsible for all Ht cases where there is no 
identifiable cause. It is a result of both environmental and genetic factors. 
The commonly accepted definition of Ht provided in the guidelines by the International Society of 
Hypertension and WHO is an average (based on two or more readings) BP of diastolic BP ≥90 mm 
Hg and systolic ≥140mm Hg, beyond this there are further classifications denoted as mild, 
moderate and severe cases. There are also a number of patients that are defined as having isolated 
systolic; diastolic remains <90 mmHg but the systolic is above the threshold value (140mm Hg). 
(Whitworth 2003). 
Increases in BP have been shown to increase not only CVD risk but also the risk of renal failure 
(Cutler 1996, He & Whelton 1999a, He & Whelton 1999b, Carretero & Oparil 2000, Yusuf et al. 
2004). A history of Ht has been shown to be associated with CVD with an adjusted OR of 1.91 
(CI: 1.74-2.10), with ORs presenting more than twice the risk in some groups (such as young 
individuals) (Yusuf et al. 2004). Increases in BP as small as 2-3mmHg have been associated with a 
4-6% increased risk of coronary death and 6-9% for stroke related deaths (Dyer & Elliott 1989).  
Regulating BP is an intricate process involving multiple physiological systems. Heart rate, blood 
volume, blood viscosity and blood vessel resistance collectively contribute to an individual’s BP. 
The main system responsible for long term arterial BP regulation is the Renin-Angiotensin-
Aldosterone System (RAS). The RAS is a complex pathway where Renin is released from the 
kidneys into serum in response to various stimuli, this includes; a decrease in blood pressure, an 
increase in serum sodium levels or an increase in β adrenergic tone, it will also be released upon 
the release of Prostaglandin. The Renin carries out the conversion of angiotensinogen (produced by 
the liver) to Angiotensin I. Angiotensin I is then converted into Angiotensin II through catalysation 
by the angiotensin converting enzymes (ACE). The Angiotensin II stimulates aldosterone to be 
released and promotes the retention of sodium, this retention of sodium and water subsequently 
increases BP and feedback is provided to regulate the kidneys release of Renin. This is the primary 
effect of Angiotensin II, however the effects of Angiotensin II go beyond this and result in 
vasoconstriction of the blood vessels subsequently reducing the lumen diameter of the blood vessel 
(the area enabling the blood flow) resulting in an increase in BP (Lavoie & Sigmund 2003).  
1.3.2.2 Risk Factors for Hypertension 
Similarly to CAD, Ht has a number of well established risk factors. These can be classified as 
modifiable and non-modifiable (Table 2).  
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Table 2-Hypertension risk factors separated into modifiable and non-modifiable 
Modifiable Non-modifiable 
Smoking (active and secondary) Family History/Genetics 
Being overweight/obese Ethnicity 
Reduced physical activity Increased age 
Sodium intake  
Potassium intake  
Alcohol intake  
Stress  
1.3.2.3 Genetics of Hypertension 
A positive family history/genetics is a well established Ht risk factor. The heritability of BP has 
been confirmed through multiple familial and twin studies, with concordance shown to be up to 
66% in the general population (Rafiq et al. 2010, Harrap 1994, Levy et al. 2000, Fuentes et al. 
2000, Hunt et al. 1989, Jedrusik et al. 2003, Butler 2010). Research into identifying the genetic 
basis of the disease has had mixed success. 
Successful identification has been made for examples of Ht that do not fall into multifactorial 
essential Ht. An example of this is Familial Primary Pulmonary Hypertension (FPPHT); an 
autosomal dominant disorder that can result in death and is characterised by raised pulmonary 
arterial pressure. The prevalence of FPPHT is estimated to be between 1 in 100,000 and 1 in 
1,000,000 and a mutation in the BMPR2 gene has been successfully identified as a significant risk 
factor for the disorder (Http://www.ncbi.nlm.nih.gov/omim/178600). The identification of these 
rare cases of complex diseases exhibiting an autosomal dominant pattern can enhance biological 
understanding of Ht and act as targets for research for essential Ht.    
Successful identifications have also been made directly for essential Ht. Bonnardeaux et al. (1994) 
identified one of the first associations; the Angiotensin II type 1 receptor gene on chromosome 
3q21-q25. These findings have now been replicated in a number of studies (Bonnardeaux et al. 
1994, Jiang et al. 2001, Dzida et al. 2001, Hu et al. 1999, Stankovic et al. 2003, Wang et al. 
1997a). 
A number of mutations have been identified in genes involved in renal salt handling such as 
SLC12A3, SLC12A1 and KCNJ1, which have been studied in large numbers of individuals. These 
mutations have been confirmed in studies undertaken by Ji et al. (2008) through the Framingham 
Heart Study and similarly by Tobin et al. (2008) (Tobin et al. 2008, Ji et al. 2008). However these 
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have not been confirmed in a small number of more recent genome wide studies (Rafiq et al. 2010, 
Wellcome Trust Case Control Consortium 2007). 
A meta-analysis of previous GWASs undertaken by Koivukoski et al. (2004) found association for 
chromosome 3p14.1-q12.3 amongst Caucasians (Koivukoski et al. 2004). Other findings from 
GWASs include the successful identification of the novel genes CDH13, STK39, MTHFR, and 
CYP17A1. Rafiq et al. (2010) provides a good overview of the GWAS successes in Ht to date 
(2010) (Rafiq et al. 2010).  
 The RAS genes have been one of the most extensively studied for association with Ht due to their 
integral role in the aetiology of Ht. Included in this system is the Angiotensin I converting enzyme 
(ACE) gene (Http://www.ncbi.nlm.nih.gov/gene/1636). Genetic mutations within this gene and 
others in this pathway associated with Ht have been successfully identified and demonstrated in 
case control studies (Zintzaras et al. 2008). However, the heritability of Ht remains incompletely 
understood. 
1.3.2.4 Hypertension in Indians 
The WHO provides data on the global prevalence of a number of risk factors for CVD including 
Ht. Data based on 2008 showed the standardised average systolic BP in men and women was 
123.9mmHg and, 123.2mmHg respectively. An age adjusted estimate showed 23.1% and 22.6% of 
men and women were considered to have raised BP (http://apps.who.int/ghodata/?vid=2464, 
http://apps.who.int/ghodata/?vid=2464). Other studies have shown percentages to be as high as 
40% among urban population groups and there are apparent differences in the prevalence present 
between urban and rural adults (Gupta 2004).  Estimates made for the year 2000, predicted 60.4 
million men and 54.3 million women to be hypertensive in India. Predictions for future prevalence 
show a similar pattern to CAD, with significant elevations reaching 107.3 million men and 106.2 
million women by 2025 almost double over a period of 25 years (Kearney et al. 2005).  
Although Ht shows a significant problem in India, the magnitude of the problem is more similar to 
levels in other population groups. For example 22.9% of Indian men and 23.5% of Indian women 
are estimated be hypertension in 2025, but levels in china were 27% for both men and women and 
around the same for middle-eastern and sub-Saharan Africa, thus this is not in excess of other 
countries (Kearney et al. 2005). 
South Asians although not having excessive levels of Ht, may have a greater risk associated with 
this disease. Yusuf et al.(2004) found Ht to be a stronger risk factor for CVD than in other 
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population groups, finding an OR value of 2.89 (CI: 2.31-3.60), which is a higher value than the 
global CVD risk of Ht (Yusuf et al. 2004).  
1.3.3 Type 2 Diabetes Mellitus 
The third and final disease to be incorporated in this research is Diabetes. Diabetes has reached a 
status of a global epidemic; attributed to the global vast increases in overweight and obesity 
(Http://www.who.int/features/factfiles/diabetes). The WHO predict that the number of deaths 
attributable to diabetes will more than double in the next decade, with the global prevalence 
estimated to rise from 2.8% in 2000 to 4.4% in 2030, this is a projected increase of 171 million 
people to 366 million in 2030 (Wild et al. 2004). Estimations based on data from 2005 predicted 
1.1 million deaths attributable to diabetes. This is likely to be an underestimate, with recorded 
deaths often attributed to diabetes’ complications, such as CVD and kidney failure.  Around 80% 
of global mortality is present in lower and middle income countries, which includes India 
(http://www.who.int/mediacentre/factsheets/fs312/en/). The large increase in diabetes prevalence 
has been attributed to changes in lifestyle.  The current modern lifestyle sees a dual effect; a 
change in a diet towards higher calorie foods, alongside a lifestyle that has a decreasing energy 
expenditure. Modern technologies at more affordable prices have resulted in reduced physical 
activity levels (Leahy 2005). Altering the transitions has thus far not been entirely successful. 
Greater understanding of the pathogenesis of the disease, specifically the genetic components is 
crucial in reducing the impact of this problem. 
Diabetes is a complex disease in its physiology. Under normal circumstances following 
carbohydrate ingestion, glucose will be absorbed into the intestines and released into circulation in 
the blood flow. For a short period of time, approximately an hour, the blood will contain elevated 
glucose levels. The glucose is ultimately removed from the blood and taken up by muscle, fat and 
liver tissue, where it is stored in the form of glycogen and lipid. In the case of diabetes the blood 
glucose levels remain elevated; this is termed hyperglycemia and is a result of impaired disposal 
mechanisms (Müller 2010).  The uptake of glucose is controlled by the hormone insulin, which is 
released from beta cells of the pancreas. The action of insulin is controlled by a multitude of 
enzymatic pathways and intracellular signalling, thus can be affected on many levels through from 
the production, secretion, or utilisation of insulin by the subsequent tissues (Müller 2010). 
The consequences of the elevated blood glucose are common, severe and can be fatal, with twice 
the risk of death associated with diabetes. Among the severe consequences include: diabetic 
retinopathy (adult blindness), diabetic nephropathy (kidney failure) and lower limb amputation 
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(http://www.who.int/mediacentre/factsheets/fs312/en/). Moreover, diabetes is a major risk factor 
for cardiovascular disease, so can indirectly result in the adverse complications including strokes 
and myocardial infarctions (Yusuf et al. 2004). Nearly three times the risk of CVD has been 
observed in some groups, and the presence of diabetes (independent of sex or age) has been 
consistently shown to cause more than double the risk of CVD (Yusuf et al. 2004).  
Diabetes encompasses a group of disorders all categorised by hyperglycemia (elevated blood 
glucose), insulin insensitivity and altered lipid metabolism. There are three main sub categories of 
diabetes: Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM) and Maturity-onset 
diabetes of the young (MODY).  
T2DM is the most common form of diabetes, responsible for more than 90% of adult diabetes 
cases throughout the world (Müller 2010). It is a multifactorial disease, shown to be influenced by 
both genetic and environmental factors (Poulsen et al. 1999, Ling & Groop 2009). T2DM is 
becoming increasingly present at an earlier onset (Http://www.who.int/features/factfiles/diabetes). 
The contribution of T2DM to the total diabetes burden, its increasing prevalence, alongside a clear 
genetic link has led to focus within the current research on this subtype only. 
1.3.3.1 Aetiology of Type 2 Diabetes Mellitus 
The hyperglycaemia present in T2DM has three key characterising features: β cell dysfunction, 
overproduction of glucose by the liver, and reduced insulin sensitivity. This reduced insulin 
sensitivity known as insulin resistance is defined as impairment in insulin regulated glucose 
clearance into skeletal muscle (Leahy 2005, Mandrup-Poulsen 1998). 
Both insulin resistance and β cell dysfunction precede T2DM and identify an individual as pre-
diabetic, consequently the disease is considered to be a dual defect disease (Leahy 2005).   
1.3.3.1.1 Β Cell Dysfunction in T2DM 
β cells are pancreatic cells responsible for insulin production and β -cell dysfunction is a key 
characteristic preceding clinical T2DM. Under normal circumstances insulin is released in 
oscillations every 11 to 14 minutes, the purpose of the insulin release is to control hepatic 
endogenous glucose production. It is also released in larger short bursts (known as ultraradian 
oscillations) this occurs after the consumption of a meal to provide nutrient clearance  (Polonsky et 
al. 1998, Porksen 2002). In diabetes the pulsatile releases of insulin are impaired and studies have 
shown the pulsatile actions to be almost entirely eliminated in first degree relatives of T2DM 
individuals; concluding it to be a very early feature of T2DM (O'Rahilly et al. 1988). β cell 
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dysfunction is a complex process that has been attributed to a reduced β cell mass, glucose toxicity, 
β cell exhaustion, impaired proinsulin biosynthesis and lipotoxicity (Leahy 2005). 
1.3.3.1.2 Insulin Resistance 
Insulin resistance is defined as an ‘impaired insulin mediated glucose clearance into target tissues’ 
and affects multiple sites. Under normal insulin sensitivity insulin serves a dual role; firstly insulin 
acts by clearing the glucose load into skeletal muscle and secondly insulin prevents hepatic glucose 
production (Leahy 2005). The causes of insulin resistance are complex and have been attributed to 
serine phosphorylation of insulin receptor substrate (IRS-1), excess glucosamine, defective 
mitochondria, fatty acids and inflammation (Leahy 2005). 
The complete pathophysiology of T2DM is complex with multiple tissues contributing to the 
diabetes metabolic environment. Figure 2 from Jin and Patti (2009) provides an overview of this 
contribution. 
 
 
 
Figure 2-The contributions of various tissues in type 2 diabetes mellitus (Source: Jin & Patti 2009) 
1.3.4 Risk Factors for T2DM 
There are a number of known risk factors predisposing an individual’s risk for T2DM 
development. These risk factors include a suboptimal intrauterine environment, low birth weight, 
obesity, physical inactivity, gestational diabetes and advancing age (Jin & Patti 2009). Figure 3 
shows a schematic from Jin and Patti (2009) representing the multiple risk factors implicated in β 
cell dysfunction and insulin resistance and the development of clinically defined diabetes. 
. 
 
 
Figure 3-Schematic demonstrating the multiple risk factors implicated in type 2 diabetes mellitus (Source: 
Jin & Patti 2009) 
Figure 2 removed, please see: Figure 2 from: Jin, W. & Patti, M.E. 2009, "Genetic 
determinants and molecular pathways in the pathogenesis of Type 2 diabetes", Clinical 
science (London, England : 1979), vol. 116, no. 2, pp. 99-111.  
Figure 3 removed, please see: Figure 1 from: Jin, W. & Patti, M.E. 2009, "Genetic 
determinants and molecular pathways in the pathogenesis of Type 2 diabetes", Clinical 
science (London, England : 1979), vol. 116, no. 2, pp. 99-111. 
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1.3.4.1 Genetics of T2DM 
A strong genetic basis of T2DM has been demonstrated through multiple twin studies. In one study 
of monozygotic twins in the United Kingdom, concordance was shown to be near 100% (Barnett et 
al. 1981). Further twin studies have shown concordance to be around 90% (Gottlieb & Root 1968, 
Medici et al. 1999).  In contrast, other studies have supported a greater role for environmental 
factors alongside the genetic influence (Poulsen et al. 1999).  A strong genetic basis to the disease 
is now firmly accepted and studies among the general population has shown a positive family 
history to increase diabetes risk by 40% and 70% (for one and two affected parents respectively), 
whilst the presence of an affected sibling is associated with a 3-fold increased disease risk (Müller 
2010). The genetic findings for T2DM have thus far exhibited many successes, but cannot account 
for all of the genetic contribution to the disease (Vimaleswaran & Loos 2010, Barnett et al. 1981). 
MODY is a Mendelian subtype of diabetes resulting in the same phenotypic effects, with an 
alternate genetic cause. Contributing genes to MODY have been identified for the Hepatocyte 
nuclear factor-4α (HNF4A), Hepatocyte nuclear factor-1α (HNF1A) and Glucokinase (GCK) genes 
(Http://www.ncbi.nlm.nih.gov/omim/606391). Although MODY represents only a small 
percentage of all diabetes cases, these discoverys have aided research into T2DM. These same 
disease causing genes may potentially influence the progression of the more polygenic T2DM. 
Their identification can also aid the understanding of T2DM physiology, however its benefits do 
not go much beyond this in terms of understanding the genetic basis of T2DM. 
A number of successful indentifications have been made for susceptibility genes directly influening 
T2DM (Jin & Patti 2009). Consistent association has been found for the KCNJII gene (glu23lys 
variant), and the PPRAPG gene (TCF7L2 variants and the Pro12Ala variants), which are now 
established T2DM risk factors, shown to affect insulin sensitivity (Altshuler et al. 2000, Gloyn et  
al. 2003, Cauchi et al. 2007). 
Initial GWASs investigating T2DM have proved to be successful, providing insight and 
highlighting some novel genes that had previously shown no association for the disease. The 
GWASs undertaken to date have identified susceptibility loci in CDKAL1, CDKN2A, CDKN2B, 
TCF7L2 and IGF2BP2 genes (Müller 2010, Zeggini et al. 2007, Scott et al. 2007).  The main 
GWASs investigating T2DM have been undertaken by the Diabetes Genetics Initiative, the 
Wellcome Trust Case Control Consortium, and Finland-United States Investigation of non-insulin 
dependent diabetes mellitus (FUSION) (Jin & Patti 2009). A recent review stated a total of 18 loci 
for T2DM had been successfully identified through GWASs (Vimaleswaran & Loos 2010). 
Chapter 1 – Background and Literature Review 
23 | P a g e  
 
 
Although considerable success has been made in indentifying genetic variants associated with 
T2DM, the heritability cannot be fully explained and further genetic variants remain undiscovered 
(Wheeler & Barroso 2011).  
1.3.4.2 Diabetes in India 
A study estimating the global prevalence of diabetes in 2030 projected an increase from 31.7 
million (2000) to 79.4 million (2030), the magnitude of this increase was above and beyond any 
other country, resulting in India having almost double the prevalence of China who were the most 
closely ranked (2
nd
) in these estimates (Wild et al. 2004).  The burden of diabetes in India has been 
increasingly worsening; estimates show prevalence of 32 million, 57.2million and 80 million for 
2000, 2025 and 2030 respectively (Wild et al. 2004, Ramachandran et al. 1997, King et al. 1998). 
The increased prevalence of T2DM in migrant South Asians, including Indians is particularly 
marked when comparing individuals of this ethnicity to the respective indigenous populations 
(Jenum et al. 2005, McKeigue et al. 1993, Mohanty et al. 2005, McKeigue et al. 1991).  
There are variations in these estimates; however India’s estimated prevalence is consistently shown 
to be in excess of other populations. The prevalence also varies within areas of India itself; 1972 
and 1975 saw the first study investigating prevalence of T2DM in India conducted by the Indian 
Council of Medical Research, using a sample size of 35,000, the prevalence was found to be 5% in 
urban areas and 2.8% in rural areas for individuals above 40 years of age. It is now widely 
accepted that urban prevalence exceeds that of rural areas of India (Mohan et al. 2007). 
Similarly to CAD the occurrence of T2DM has also been shown to be present at a younger age in 
this population group. The majority of the adverse consequences of the disease are attributable to 
the duration of the disease, thus this is further worsening the problem within this population 
(Barnett et al. 2006).  
There are some differences found in the prevalence of the risk factors such as slightly raised blood 
pressure, although as seen in section 1.3.2.4 (hypertension in Indians) this has shown mixed 
results, with some studies showing this to be on par with other population groups (Kearney et al. 
2005).  Along with Ht, smoking also shows similar prevalence to white Caucasians. Overall, the 
variance that is present in these risk factors does not fully explain the four to six fold increased risk 
of T2DM in this population group (Barnett et al. 2006). Therefore there is likely to be a 
predisposed genetic risk factors present among this population. 
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There are a number of hypothesised reasons for the increased prevalence of T2DM, these include 
the thrifty genotype and the thrifty phenotype hypotheses. 
 The thrifty genotype and thrifty phenotype hypotheses 
In 1962 Neel et al. introduced the thrifty genotype hypothesis, which states that previously 
advantageous genetic variants under different circumstances (environmental or increased age) may 
have detrimental effects (NEEL 1962). For example, previously a predisposition to insulin 
resistance could enhance glucose availability for vital organs such as the brain, which requires 
glucose in an insulin independent manner (Bajaj & Banerji 2004, NEEL 1962). Further to this, 
some genes that have been found to be protective in Europeans have not shown similar 
protectiveness among Indians (Radha et al. 2006). 
A sub-optimum intrauterine environment has been identified as an established risk factor for 
T2DM, this forms the thrifty phenotype hypothesis. A low birth weight has consistently been 
shown to be associated with the development of impaired glucose tolerance and T2DM in later life 
(Bajaj & Banerji 2004, Hales et al. 1991, Hales & Barker 1992, Phillips 1996).  High rates of low 
birth weights have been identified in this population (35.68%) 
(http://www.bhj.org/journal/2003_4503_july/lowbirth_413.htm). The effects of this are likely to be 
enhanced when present in a genetically predisposed population, such as India. 
1.4  What is Nitric oxide and what is it’s role in CAD, T2DM and Ht? 
1.4.1 Nitric Oxide Role and Function  
Nitric Oxide (NO) is a simple gas containing one atom of nitrogen and one atom of oxygen per 
molecule (Butler & Nicholson 2003). NO is synthesised by the NO synthase (NOS) family which 
is made up of three separate enzymes, coded by three different genes. NO is an endothelium-
derived relaxation factor (EDRF) responsibile for smooth muscle cell relaxation (Palmer et al. 
1987, Ignarro et al. 1987). Since this discovery NO has also been found to limit a number of other 
processes, this includes: leukocyte adhesion, platelet interaction, smooth muscle cell proliferation 
and the oxidation of atherogenic low-density lipoproteins (Bath et al. 1991, Kubes et al. 1991, 
Radomski et al. 1991, Sarkar et al. 1996, Scott-Burden & Vanhoutte 1993, Hogg et al. 1993, 
Rubbo et al. 2002).   
 
 
Chapter 1 – Background and Literature Review 
25 | P a g e  
 
 
1.4.2 Nitric Oxide as an Endothelium Derived Relaxation Factor 
The role of NO as an EDRF was first discovered through the investigation of acetylcholine. It was 
observed that relaxation only occurred under the conditions of a present and intact vascular 
endothelium (Furchgott & Zawadzki 1980).  Acetylcholine activates a receptor on the vascular 
endothelium causing a change in calcium levels, signalling the release of NO by the endothelium. 
NO induces muscle relaxation through the activation of an enzyme known as enzyme-soluble 
guanylate cyclise (sGC). NO attaches to the haem component (an iron atom positioned in the 
centre of a porphyrin ring) of sGC. The attachment of the NO breaks the bond to histidine at 
position 105 causing the iron to move out of the porphyrin ring, resulting in a change in the three 
dimensional shape of the enzyme, consequently changing sGC from an inactive to an active state 
through the exposure of the catalytic site of the enzyme. This enables the activated sGC enzyme to 
catalyse the conversion of guanosine-5- triphosphate (GTP) into cyclic guanosine-3, 5-
monophosphate (cGMP) (Butler & Nicholson 2003).  
As cGMP levels within the cell increase this inhibits the entry of calcium and reduces intracellular 
calcium levels, secondly it activates myosin light chain phosphatise which is through a cGMP-
dependent kinase, finally the cGMP activates K+ channels which causes hyperpolarisation. Each of 
these contributes to smooth muscle relaxation. This reaction is dependent on a number of factors 
including Mg
2+
 ions.  The Mg
2+
 ions bind to sGC providing the rigidity needed to expose the 
catalytic site of the sGC (Butler & Nicholson 2003). This role of NO as a powerful vasodilator 
means NO is responsible for the maintenance of the diameter of the lumen of the vessel and a key 
regulator of blood pressure and blood flow.  
1.4.3 Nitric Oxide and Platelets 
A second of NO’s key roles within the body is its ability to prevent platelet aggregation. Platelets 
contain guanylate cyclise (the same enzyme found in smooth muscle). NO has the ability to 
activate this enzyme (a process that has been previously described), the activation initiates the 
conversion of GTP into cGMP and results in an alteration of the concentration of calcium ions 
within the platelet (Butler & Nicholson 2003). The alteration of the calcium concentration affects 
the platelets ability to adhere to one another and thus NO exhibits anti-aggregating properties. 
NO’s ability to inhibit platelet aggregation had been known prior to 1986 and has been valuable in 
confirming the role of NO as an EDRF (Moncada & Higgs 2006). 
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1.4.4 Nitric Oxide and Leukocyte Adhesion 
NO has the ability to alter the adherence of leukocytes to the vascular endothelial cells. Kubes et 
al. (1991) found NO inhibitors to increase leukocyte adhesion by 15 fold (Kubes et al. 1991).  
Whilst Lefer et al. (1999) observed a 10 fold increase in leukocyte adherence in eNOS deficient 
mice (Lefer et al. 1999). 
1.4.5 Nitric Oxide and Smooth Muscle Cell Proliferation and Migration 
A fourth role of NO is the ability to inhibit vascular smooth muscle cell proliferation and migration 
(Sarkar et al. 1996, Scott-Burden & Vanhoutte 1993).  This role has been supported by a number 
of studies which have shown eNOS gene knockout mice (the gene responsible for NO synthesis) to 
exhibit greater proliferation of vascular smooth muscle cells in response to induced vessel injury 
(Huang 2000). 
1.4.6 Nitric Oxide and Lipoprotein Oxidisation 
NO exhibits antioxidant activity in LDL oxidation. NO is capable of diffusing into the LDL 
particle, where NO can react with carbon-centered alkoxyl and peroxyl radicals. These are able to 
compete with LDL oxidations and consequently act as a scavenger of LOO a key component of the 
oxidation process (Hogg et al. 1993). 
1.4.7 Nitric Oxide and Superoxide Scavenging 
Superoxide (O2
-
) is an example of reactive oxygen species (ROS), it is generated for the large part 
in most cell types within the vascular wall. NO is an example of a reactive nitrogen species (RNS) 
and is able to react with O2
-
 through the unpaired electrons to form the stable peroxynitrite 
(ONOO
-
) (Guzik et al. 2002, Gryglewski et al. 1986). Under normal circumstances the body 
inactivates O2
-
 through superoxide dismutase (SOD), however the reaction of NO with O2
-
 has the 
ability to remove O2
-
 six times faster than SOD (White et al. 1994, Beckman & Koppenol 1996). 
The reaction occurring between the O2
-
 and NO has negative consequences rendering NO 
unavailable for its other important roles such as an EDRF (Gryglewski et al. 1986). Both ROS and 
RNS can be both beneficial and harmful (Fatehi-Hassanabad et al. 2010). The harmful effects 
occur in situations of oxidative and nitrosative stress which is the over production of ROS and 
RNS under conditions of a deficiency in antioxidants.  ROS can inhibit DNA, lipids and protein 
function (Pongnimitprasert 2009, Fatehi-Hassanabad et al. 2010).  Sources of ROS include: 
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mitochondria, NADPH oxidases (NOX), xanthine oxidase cytochromoe P450 and uncoupled NOS 
(Pongnimitprasert 2009, Fatehi-Hassanabad et al. 2010).  
1.4.8 Nitric Oxide and Coronary Artery Disease 
The roles of NO suggest it may inhibit multiple steps of the atherosclerotic process. NO is the key 
molecule released by the endothelium and critical in the maintenance of vascular homeostasis. BP 
control is among the key roles of the endothelium, the endothelium controls BP by producing both 
vasodilating and vasoconstricting substances in response to physiological and pathophysiological 
stimuli. NO is the major vasodilator produced by the endothelium and consequently key in 
maintaining BP. Other vasodilators released by the endothelium include prostacyclin and 
endothelium derived hyperpolarizing factor (Grover-Paez & Zavalza-Gomez 2009, Moncada et al. 
1977). Among the vasoconstrictive substances produced by the endothelium are endothelins and 
angiotensin II. Increases in BP damage the endothelium initiating CAD progression (Butler & 
Nicholson 2003). 
A second of NO’s key roles implicated in CAD is through its anti aggulation properties. NO acts 
alongside prostacylin (PGI2) in preventing platelet adhesion.  Under certain conditions such as 
turbulent blood flow (such as in the presence of an atherosclerotic plaque) platelet aggulation will 
occur and platelets may become activated. The platelet activation causes the platelets to release 
adhesion proteins, growth factors, chemokines and coagulation factors. These substances alter the 
proteolytic, chemotactic and adhesive properties of the endothelial cells. They also interact with 
one another to accelerate; the inflammatory process, smooth muscle cell proliferation and cell 
recruitment, all key factors in the progression of atherosclerosis (Gawaz et al. 2005, Gawaz 2006). 
NO is fundamental in preventing these processes, and consequently limits the inflammatory 
response characteristic of atherosclerosis, helping to prevent thrombus formation (Butler & 
Nicholson 2003). 
Leukocytes are a major contributing factor in the inflammatory process associated with 
atherosclerosis. NO has also been shown to inhibit the adherence of leukocytes to the endothelial 
cell (Lefer et al. 1999). NO’s ability to reduce the rate of this provides a further protective role 
against the development of CAD. Vascular smooth muscle cells are also a key component of the 
atherosclerotic plaque, helping to maintain the plaque in advanced lesions by promoting stability 
(Clarke & Bennett 2006). The ability of NO to inhibit vascular smooth muscle cell proliferation 
and migration limits the contribution of vascular smooth muscle cells in atherosclerotic plaque 
development (Sarkar et al. 1996, Scott-Burden & Vanhoutte 1993). 
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As stated NO can help limit LDL oxidations, this is a necessary step of the atherosclerosis 
hypothesised to act as a trigger for endothelial dysfunction (Hogg et al. 1993).  Consequently this 
is further protective role of NO against CAD. 
There is a complex relationship between NO and ROS. O2
- 
and other ROS have been shown to be 
elevated under CAD conditions (Pongnimitprasert 2009). As discussed, NO readily reacts with O2
- 
to form the stable peroxynitrite (ONOO
-
) (Gryglewski et al. 1986, Guzik et al. 2002). This reaction 
has multiple consequences on the atherosclerotic process. The ability of NO to act as a scavenger 
of ROS has one major vasoprotective effect through its limitation of LDL oxidation. LDL 
oxidation is an early and important step affecting both the initiation and progression of 
atherosclerosis (Witztum & Steinberg 1991, Witztum & Horkko 1997). The oxidisation of LDL is 
a required step to enable the recruited macrophages to engulf the LDL in the process of 
atherosclerosis (see section1.3.1.1.1). However, the reaction occurring between the O2
-
 and NO 
renders NO unavailable for the other important roles such as an EDRF (Gryglewski et al. 1986).  
Whilst the ONOO
-
 that is formed from this reaction, independently causes further negative 
vascular consequences, collectively contributing to a disruption of vascular homeostasis. For 
example ONOO
-
 will increase the rate of LDL oxidation a key step in the atherosclerosis 
physiology (White et al. 1994, Guzik et al. 2002). However, ONOO
-
 also has indirect effects that 
provide vasorelaxation and inhibit platelet aggregation (two vasoprotective affects), this occurs 
through the generation of nitrosylated thiols (Wu et al. 1994, Moro et al. 1994). Figure 4 
summarises the key roles of NO implicated in CAD progression. 
 
Figure 4-The key roles of nitric oxide in CAD 
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Numerous studies have confirmed the importance of NO in CAD. As stated, NO is the key 
vasodilator released by the endothelium and critical among its functions. When the function of the 
endothelium is impaired and vascular homeostasis is lost, this is termed endothelial dysfunction 
(Pasyk & Jakobczak 2004, Risau 1995).  The presence of endothelial dysfunction has been used as 
a tool for establishing the importance of NO in disease due to it being characterised by a reduction 
in the bioavailability of NO and a reduced ability to respond to acetylcholine (Grover-Paez & 
Zavalza-Gomez 2009, Moncada & Higgs 2006, Deanfield et al. 2007, Poredos 2002).  
Endothelial function (NO production) can be tested through multiple methods including; cardiac 
catherisation, venous occlusion plethysmograph, and flow mediated dilation (FMD) (Deanfield et 
al. 2007). FMD is the most common method adopted, measuring endothelium dependent 
relaxations through brachial artery reflow (Corretti et al. 2002). Numerous studies have 
demonstrated a reduced bioavailability of NO through impaired endothelium dependent 
vasodilations under atherosclerosis and related conditions (Ludmer et al. 1986, Forstermann 1988, 
Quyyumi et al. 1997, Chowienczyk et al. 1992, Katz et al. 1992). In addition a number of risk 
factors for CAD have been shown to be independently associated with impaired EDRs including 
Ht and diabetes (Vanhoutte & Boulanger 1995, Creager et al. 1990, Harrison 1997, Johnstone et al. 
1993, McVeigh et al. 1992, Hogikyan et al. 1998, Williams et al. 1996). Endothelial dysfunction is 
thought to be the first step in the aetiology of atherosclerosis and an early marker for the disease. 
This has been found to be present before disease manifestations are observable (Reddy et al. 1994, 
Zeiher et al. 1991). 
Reduced NO synthesis is thought to lead to an increased risk of CVDs,  however conversely higher 
NOx levels have been observed in CVD patients compared to controls, this is thought to be a result 
of compensatory pathways stimulating NO production from inducible NOS (Yoon et al. 2000). 
The eNOS gene is responsible for NO synthesis and eNOS knockout animal studies have provided 
a useful tool in determining if endothelial dysfunction is a result of a reduced synthesis or 
increased utilisation/degradation of NO. ENOS knockout mice have been repeatedly shown to 
become hypertensive and have raised blood pressure, a key risk factor predisposing a higher CAD 
risk (Huang et al. 1995, Shesely et al. 1996). More so,  Knowles et al. (2000) found that crossing 
atherosclerotic apolipoprotein (apo) E mice with hypertensive eNOS knock out mice further 
increased the progression of atherosclerosis and further increased BP (Knowles et al. 2000).  
Increasing eNOS enzyme function has shown to be beneficial and protective against CAD. For 
example supplementation of tetrahydrobiopterin (BH4) an important cofactor of the eNOS enzyme 
has been suggested to improve the development of endothelial dysfunction in atherosclerosis 
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(Tiefenbacher et al. 2000). Whilst supplementation of L-arginine (the substrate required by eNOS) 
has been shown to inhibit atherosclerosis progression in animal studies (Aji et al. 1997, Boger et 
al. 1997). 
There is clear evidence for the role of NO in CAD. The eNOS gene (responsible for NO synthesis) 
therefore stands as a good candidate gene for the disease. With a decreased NO production and 
reduced activity of eNOS thought to be one of the earliest signs of atherosclerosis (Davignon & 
Ganz 2004).   
1.4.9 Nitric oxide and Hypertension 
The role of NO in Ht is acts through its EDR properties. The vasodilatory properties of NO play a 
key role in the maintenance of blood pressure through the changes in lumen size of the blood 
vessel (Huang et al. 1995). Numerous studies have confirmed the importance of NO in Ht. 
Hypertensive rat studies have demonstrated endothelium dependent vasodilation to be impaired 
(Lockette et al. 1986, Winquist et al. 1984, Crabos et al. 1997, Bouloumie et al. 1997, Pourageaud 
& Freslon 1995). These findings have also been replicated in multiple studies in hypertensive 
patients (Calver et al. 1992, Cardillo et al. 1998, Cardillo et al. 1998, Panza et al. 1990, Panza et 
al. 1995, Panza et al. 1995, Higashi et al. 1995, Brush et al. 1992, Treasure et al. 1992, Treasure et 
al. 1993, Panza et al. 1993).  
There are a small number of studies that have failed to support these findings, with hypertensive 
rats also shown to have no differences in endothelium dependent vasodilations in response to 
acetylcholine (Tschudi et al. 1994, Fuchs et al. 1996).  These findings have been hypothesised to 
be due to the presence of other vasodilators or factors, or due to a lack of concordance between 
animals and humans. 
The numerous studies showing impaired EDRs strongly suggest a role for NO in Ht. ENOS 
knockout mice have been studied to determine if endothelium dependent relaxations are altered; 
this will help to decipher if the effect in hypertensive human and animal models are a result of 
reduced synthesis of NO or increased utilisation. Inconsistent results have been found in eNOS 
knockout mice with respect to endothelium dependent relaxations; these have been shown to 
exhibit no difference, become reduced, or be completely dimished (Lamping et al. 2000, Ding et 
al. 2002,Chataigneau et al. 1999).  The unchanged results found by Lamping et al. (2000) were 
hypothesised to be a result of compensation from other pathways in the absence of adequate eNOS 
function (Lamping et al. 2000). Further animal studies involving eNOS knockout mice have 
provided evidence for mice to exhibit elevated BP, become hypertensive, have reduced basal NO 
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production and reduced eNOS expression (in hypertensive animal models) (Huang et al. 1995, 
Shesely et al. 1996,Crabos et al. 1997, Millette et al. 2000). 
Human studies have also provided evidence from a variety of techniques, demonstrating the 
relationship between eNOS, NO production and BP. eNOS inhibition in humans through 
endogenous inhibitors; NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine methyl 
ester (L-NAME), have been demonstrated to result in increased BP (Sander et al. 1999). 
There is replicated evidence supporting a key role of NO in the development and severity of Ht and 
genetic polymorphisms within the eNOS gene have been demonstrated to increase Ht risk 
(Miyamoto et al. 1998, Yasujima et al.1998, Srivastava et al. 2008). Collectively this evidence 
supports the eNOS gene to be strong candidate gene for this disease. 
1.4.10 Nitric Oxide and Type 2 Diabetes Mellitus 
The eNOS enzyme plays a key role in normal insulin signalling through its role as an EDRF; 
eNOS increases vasodilation and facilitates the uptake of glucose in skeletal muscle (Baron et al. 
1995). Normal insulin signalling results in the initiation of two parallel pathways; the PI3 Kinase 
(PI3K)-Akt pathway and the Ras/Raf/MAP kinase pathway. The PI3k-Akt pathway is responsible 
for bringing about vasodilation; Akt kinase activates the eNOS enzyme through phosphorylation at 
serine 1177 (S1177). Akt kinase also stimulates GLUT4 (a glucose transporter) which increases the 
uptake of glucose, facilitated by the increased vasodilation brought about by eNOS (Figure 5) 
(Huang 2009).  
 
 
 
Figure 5-Insulin signalling in endothelial cells activating the PI3-Akt and RAS/RAF/MAP kinase 
pathways (Source: Adapted from Huang 2009) 
In the presence of insulin resistance there is a decreased effect of insulin due to a reduced 
sensitivity (Kim et al. 2006, Semenkovich 2006). The PI3 Kinase (PI3K)-Akt pathway is shown to 
be altered in the presence of insulin resistance, resulting in a diminished blood flow, whilst the the 
Ras/Raf/MAP kinase pathway remains unaffected (Huang 2009, Federici et al. 2002, Cusi et al. 
2000b). Under hyperglycemic conditions similar findings of disruption in this pathway have been 
observed (Gupta et al. 2002).   
Figure 5 removed, please see: Figure 2 from: Huang, P.L. 2009, "eNOS, metabolic 
syndrome and cardiovascular disease", Trends in endocrinology and metabolism: 
TEM, vol. 20, no. 6, pp. 295-302 
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There is a complex relationship between insulin resistance and endothelial dysfunction; insulin 
resistance is a known cause of endothelial dysfunction and conversely endothelial dysfunction also 
leads to insulin resistance perpetuating the problem (Huang 2009). Endothelial dysfunction is an 
established common feature of T2DM (Hadi & Suwaidi 2007, Rask-Madsen & King 2007, Bitar et 
al. 2005, McVeigh et al. 1992, De Vriese et al. 2000).  
Endothelium dependent relaxations have been investigated in this disease group to determine the 
role of NO. Endothelium dependent relaxations have been found to be significantly impaired in the 
diabetic rat (Durante et al. 1988, Pieper & Gross 1988, Meraji et al. 1987, Abiru et al. 1990, 
Mayhan 1989, Oyama et al. 1986, Pieper et al. 1997, Henry et al. 2004, Van De Ree et al. 2001). 
Animal studies by Pieper at al. (1997) also using the diabetic rat showed an inability to utilise L-
arginine by eNOS suggesting this as a potential causal pathway for the impaired endothelium 
relaxations (Pieper et al. 1997). 
Human studies using T2DM patients have also looked at endothelium dependent relaxations as a 
reflection of NO levels. Numerous studies have supported the hypothesis of reduced NO 
bioavailability in these individuals; finding impaired endothelium-dependent relaxations 
(Johnstone et al. 1993, Williams et al. 1996, Calver et al. 1992). The impaired endothelium 
dependent relaxations have been attributed to enhanced O2
-
 formation under hyperglycemic 
conditions (Gupta et al. 2002, Ceriello 2000, Graier et al. 1999).  In contrast there is evidence from 
both animal models and studies on T2DM patients that have failed to observe reduced NO 
production (Sobrevia & Mann 1997, Catalano et al. 1997). 
The involvement of eNOS in stimulating glucose uptake in skeletal muscle and the evidence of a 
reduced bioavailability of NO under T2DM conditions has led to the investigation of the eNOS 
gene with T2DM and associated conditions. Although the reduced NO availability has been 
hypothesised to be a result of increased NO utilisation/degradation through the elevated levels of 
ROS
 
under T2DM conditions, differences in the eNOS gene may also play apart in this 
progression. A number of studies have been conducted investigating the effect of eNOS gene 
polymorphisms on T2DM and its associated conditions and eNOS polymorphisms have been 
reported as a significant T2DM risk factor (Monti et al.2003, Ezzidi et al. 2008). ENOS gene 
knock out mice have also provided evidence for the role of the eNOS gene in T2DM with eNOS 
knockout mice reported to become insulin resistant and have reduced (40%) insulin stimulated 
uptake of glucose (Shankar et al. 2000, Duplain et al. 2001, Roy et al. 1998, Cook et al. 2004).  
There is strong evidence supporting the role of endothelial dysfunction in T2DM and thus the 
eNOS gene serves as a good candidate gene for a possible role in T2DM. It has been suggested that 
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increasing the bioavailability of NO and/or enhancing specifically eNOS activity could be 
beneficial under hyperglycaemic conditions (Chatterjee & Catravas 2008). Therefore further 
identification of the role of eNOS could be a beneficial tool in treatment.  
1.5 Nitric Oxide Synthase 
The important roles of NO within the body and their evident role in disease have highlighted this 
molecule as an important target for research. The bioavailability of NO is a result of the utilisation, 
sensitivity of the target tissue and ultimately NO production itself (Rush et al. 2005). As stated, 
NO is produced by the NO synthase (NOS) family of enzymes. There are three separate enzymes 
each coded by a separate gene, with clear contrasts in location, regulation, catalytic properties, and 
sensitivity to inhibitors (Alderton et al. 2001).  The three NOS isoforms are named accordingly to 
their position within the human body; NOS found in the endothelium is known as endothelial nitric 
oxide synthase (eNOS) (also known as Type III, NOS-III, NOS3 and ecNOS) and is constiutively 
expressed, NOS found in macrophages is known as inducible nitric oxide synthase (iNOS) (also 
known as Type II, NOS-II and NOS2) and the final type is neuronal nitric oxide synthase (nNOS) 
(also known as Type I, NOS-I and NOS1) (Alderton et al. 2001). Table 3 summarises the key 
characteristics of the three NOS isoforms. Due to the location and direct implications of the eNOS 
enzyme, focus will be on this NOS isoform only. 
Table 3- Key characteristics of iNOS, nNOS and eNOS 
Function iNOS nNOS eNOS 
Chromosome Chromosome 17 Chromosome 12 Chromosome 7 
Chromosomal position 17q11.2-q12 12q24.2-12q24.3 7q35-7q36 
Size of gene 37kbp 200kbp 21-22kbp 
Number of exons 26 29 26 
Number of introns 25 28 25 
Number of amino acids 1153 1434 1203 
Protein size 131kDa 161kDa 133kDa 
Source: adapted from Alderton et al. 2001 
The discovery of the NO synthase enzyme being responsible for NO production was in 1989 by 
Moncada et al. they discovered that NO synthase could generate NO and L-citrulline from L-
arginine and referred to the pathway as the Larginine: NO pathway (Moncada & Higgs 2006). This 
reaction can be seen in Figure 6 (Stuehr et al. 2001, Daff 2010).  
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Figure 6 Schematic demonstrating arginine to NO conversion (Source: Stuehr et al. 2001) 
1.5.1 Regulation of eNOS 
Enzyme activity and NO production are regulated through a multitude of mechanisms at both 
transcription and posttranslational levels, from gene expression to enzymatic function. Moderations 
in essential cofactors, the presence of endogenous eNOS inhibitors, eNOS gene expression and 
ultimately eNOS enzymatic activity collectively contribute to NO production (Strijdom et al. 2009, 
Kolluru et al. 2010). Figure 7 summarises a number of key elements known to affect eNOS 
enzyme function.  
 
Figure 7- The multiple contributors to eNOS enzyme function and NO production 
To extensively discuss all the contributing factors is not possible therefore an overview of the key 
identified factors affecting eNOS function is provided below. 
 
 
Figure 6 removed, please see Figure 1 from: Stuehr, D., Pou, S. & Rosen, G.M. 
2001, "Oxygen reduction by nitric-oxide synthases", The Journal of biological 
chemistry, vol. 276, no. 18, pp. 14533-14536 
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1.5.2 L-arginine 
L-arginine is the required substrate for the eNOS enzyme and the presence of adequate L-arginine 
is integral to NO production and consequently can act as a limiting factor (Sakuma et al. 1988, 
Palmer et al. 1988). Inadequate availability of L-arginine results in eNOS becoming uncoupled and 
the formation of O2
-
 . The effects of O2
-
 have been discussed in section 1.4.7, these are detrimental 
and render NO unavailable (Stuehr et al. 2001, Stuehr 2004). There are a number of known 
inhibitors of L-arginine including Asymmetric dimethylarginene (ADMA) and N (G)-
monomethyl-L-arginine (L-NMMA). The presence of these known inhibitors plays a key role in L-
arginine availability, aiding research into eNOS enzyme function and effects (Cooke 2000, Rees et 
al. 1990). L-arginine may also be limited through Arginase; Arginase is an enzyme that also 
requires L-arginine as a substrate and therefore may act as a down regulator of eNOS through its 
utilisation of L-arginine (Morris Jr 2000, Morris Jr 2002).   
1.5.3 eNOS Cofactors 
The eNOS enzyme also has a number of well established cofactors responsible for facilitating NO 
production. Tetrahydrobiopterin (BH4) is one example, it is responsible for stabilizing the 
enzyme’s dimeric structure, it also helps facilitate the binding of the substrate L-arginine. BH4 
mediates the coupling of the oxidative and reductive domains of the enzyme (Cosentino & Luscher 
1999). It has been shown, when BH4 bioavailability is limited uncoupling of eNOS can occur and 
thus the formation of O2
-
 (Stroes et al. 1998). When BH4 levels have been increased this has shown 
positive results; reducing eNOS uncoupling under high levels of eNOS expression (Bevers et al. 
2006). BH4 requires Guanosine 5’triphosphate cycohydrolase, this may act as a limiting factor 
causing the unpaired electron transport producing once again these unwanted superoxide anions 
(Cosentino et al. 1998). Other cofactors include Haem, which is necessary for eNOS dimerisation 
enabling the two subunitsw to act together (Klatt et al. 1996), and Heat shock protein (Hsp90) 
which interacts with eNOS increasing activity levels (Garcia-Cardena et al. 1998, Kolluru et al. 
2010). Variations in Hsp90 are also a known cause of eNOS uncoupling and O2
- 
production 
(Pritchard et al. 2001). 
1.5.4 eNOS Inhibitors 
In addition to the required cofactors, the eNOS enzyme has a number of known inhibitors that can 
also alter eNOS function, these include: Asymmetric dimethylarginene (ADMA), N-nitro-L-
arginine methyl ester (L-NAME) and N (G)-monomethyl-L-arginine (L-NMMA) (Rees et al. 
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1990, Vallance & Leiper 2004). ADMA will compete for L-arginine rendering the vital substrate 
unavailable and thus limits NO production through this action (Cooke 2000, Vallance & Leiper 
2004). L-NMMA a second endogenous competitor inhibitor of eNOS has been shown to inhibit 
EDRs and NO release, L-NMMA also acts through the inhibition of L-arginine the required 
substrate (Moncada & Higgs 2006, Rees et al. 1990).  
1.5.5 Uncoupled eNOS 
Under normal conditions the eNOS enzyme will produce NO and citrulline through the 
catalyzation of electron transport. As seen, this is dependent on a number of substrates and 
cofactors. Consequently under certain conditions, such as insufficient or absent L-arginine or BH4 
levels eNOS becomes ‘uncoupled’. eNOS uncoupling causes eNOS  to produce O2
-
 and hydrogen 
peroxide as a by product (Fatehi-Hassanabad et al. 2010, Deanfield et al. 2007, Bevers et al. 2006, 
Cosentino et al. 1998, Vásquez-Vivar et al. 1998). Therefore, although the eNOS enzyme provides 
the upmost benefial effects through the production of NO, under certain conditions eNOS can 
quickly turn from a NO producing enzyme to a O2
-
 producing enzyme causing a number of adverse 
effects. Consequently increasing eNOS gene expression/eNOS enzymatic activity may not always 
be advantageous as a therapeutic treatment. 
1.5.6 eNOS Gene Structure 
Functional production is controlled primarily by the eNOS gene itself which acts as a strong 
candidate gene for each of the three diseases. The organisational structure of the eNOS gene was 
first determined by Marsden et al. (1993). It was discovered to contain 26 exons incorporating 21 
kb of genomic DNA, encoding for 1,203 amino acids in the form of a 135-kD protein.  It contains 
around 1,500 base pairs of upstream promoter sequence, and encodes for an mRNA of 4,052 
nucleotides in size. Fluorescence in situ hybridization and southern blot hybridization revealed the 
location of the eNOS gene to be chromosome 7 within the 7q35-7q36 region (Marsden et al. 1993). 
Robinson et al. (1994) then localised this to 7q36 (Robinson et al. 1994).  
1.6 eNOS Gene Variation 
The eNOS gene has been shown to exhibit variation; a total of 303 variations have been identified, 
which included numerous single nucleotide polymorphisms (SNP), a variable number of tandem 
repeat (VNTR) in Intron 4 and a CA repeat microsatellite marker in intron 13 
(http://www.ncbi.nlm.nih.gov/gene/4846). The functional implications and influences of these 
variations on eNOS function and consequently disease is still disputed.The hypothesis is that the 
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presence of the variation(s) within the eNOS gene may individually or collectively reduce eNOS 
function and subsequently NO synthesis. To date research into the eNOS gene has primarily been 
focussed on three putatively functional variations; T-786C a 27 base-pair (bp) repeat within Intron 
4, and the Glu298Asp. There is limited research into the interaction between the variants. These 
variants will be discussed in greater detail below.  
1.6.1  Glu298Asp (rs17999983) 
The most widely studied of all the eNOS gene variants is the Glu298Asp variant, also referred to as 
G894T, E894D and rs17999983. It is the only common variation that leads to an amino acid 
substitution in the mature protein of the eNOS enzyme. Glu298Asp is an SNP; a guanine to 
thymine substitution in exon 7 in nucleotide 894 of the gene.  This results in a substitution in codon 
298 of glutamate (Glu) to aspartate (Asp) (Nassar et al. 2001). The three genotypes for this variant 
are: homozygote for the wild type G allele (GG), heterozygote for the mutant T allele (GT), or 
homozygote for the mutant T allele (TT) this is how they will be referred to throughout this 
research. 
The Glu298Asp variant has been shown to have a direct effect on enzymatic activity; Tesauro et al. 
(2000) showed the T allele to cause variation in enzyme cleavage and present a shorter half life in 
endothelial cell culture (Tesauro et al. 2000). One proposed mechanism for the increased 
susceptibility to degradation is a tight turn in the alpha helix secondary structure of the protein 
(Tesauro et al. 2000). Variations in mRNA and protein levels have also been associated with this 
variant (Wang et al. 2000, Senthil et al. 2005, Dosenko et al. 2006). In some instances a 
relationship has been observed but statistical significance has not been reached, for example Wang 
et al. (2000) found a non significant relationship between the mutant T allele and reduced enzyme 
activity (Wang et al. 2000) . 
A number of studies on enzymatic activity have failed to provide evidence towards a functional 
effect of this variant (Hingorani 2001, Golser et al. 2003, McDonald et al. 2004).  A possible 
reason for the contradictory results may be due to an alternative mechanism responsible for the 
enzyme activity changes that is independent of eNOS gene controls, it is evident that eNOS has 
multiple influencers (Casas et al. 2006).  Alternatively, it may be due to the location of the variant; 
this variant is located within a loop on the external surface, subsequently it does not contact either 
the dimerization interface or the active site of the enzyme (Hingorani 2001). 
NO has powerful vasodilatory properties. Consequently, the functional effects of the variant have 
been investigated through their effect on endothelium dependent vasodilations. Godfrey et al. 
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(2007) found that the Glu298Asp variant contributes to variability in endothelial dependent 
vasodilation, carrying the T mutant allele reduced endothelium-dependent vasodilation in healthy 
individuals (Godfrey et al. 2007). Paradossi et al. (2004) found similar findings, homozygosity for 
the T mutant allele (TT individuals) showed reduced endothelium dependent vasodilation yet 
exhibited no difference  between endothelium-independent vasodilations suggesting that there was 
a direct effect on NO as a result of this mutation (Paradossi et al. 2004).   
Alternatively, a number of studies have failed to find any overall influence of the Glu298Asp 
variant on endothelial function (Guzik et al. 2001, Leeson et al. 2002, Dell'Omo et al. 2007).  
Among these was a study undertaken by Leeson et al.(2002),  although failing to find an influence 
of the Glu298Asp variant on endothelial function, their findings did show an association with 
smoking, the asp variant increased the effect of smoking on the reduction of endothelium-
dependent vasodilations (Leeson et al. 2002). In contrast Wang et al. (2000) also investigated the 
effect of smoking upon this variant and failed to find any interaction (Wang et al. 2000).  
Some of the mixed findings may be attributable to differences in study methods. Godfrey et al. 
(2007) hypothesised that the negative findings may be due to their study populations; patients with 
increased cholesterol levels will have increased oxidised low-density lipoprotein levels, which is 
known to alter endothelial function itself and so therefore may mask the effects of the asp variant 
(Godfrey et al. 2007). 
Finally, direct effects on NO levels have been observed. Measuring NO through plasma 
nitrate/nitrite measurements (NOx) levels has shown this variant to be associated with reduced 
basal NO production (Veldman et al. 2002, Sofowora et al. 2001). However, although Sofowora et 
al. (2001) found a functional consequence on NO production of the Glu298Asp variant, they found 
no consequences in terms of vascular responses within the same study. As with the other methods 
of analysis, the effects of this variant remain inconclusive; Jeerooburkhan et al. (2001) also 
measured NO levels through plasma nitrate/nitrite measurements and failed to find any association 
with this variant (Jeerooburkhan et al. 2001). 
Overall, it is clear that there is a distinct contradiction within these results, what remains to be seen 
is if it is a result of differences between study methods, lack of control for other influencing factors 
for example smoking, or perhaps a lack of functional effect. 
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1.6.2 T-786C (rs2070744.) 
A second variant within the eNOS gene is the T-786C variant, also known as rs2070744. The T-
786C variant is located in the promoter region of the gene at position -786. It is a SNP resulting in 
a single base change of thymine (T) to cytosine (C) (Nakayama et al. 1999). There are three 
different genotypes for this variant; firstly, homozygote for the wild type T allele (TT), 
heterozygote for the mutant C allele (TC) or homozygote for the mutant C allele (CC). This is how 
the three genotypes will be referred to through the current research. 
This variant has been shown to affect both eNOS protein expression and eNOS activity; Nakayama 
et al. (1999) showed the C allele to be associated with a significant reduction of 50% in eNOS 
promoter activity (Nakayama et al. 1999). Focus on research into the functional consequences of 
this variant have been on eNOS expression levels due to its position in the promoter region of the 
gene. It has been discovered that individuals with this variant have lower eNOS, mRNA and serum 
nitrite/nitrate levels (Miyamoto et al. 2000). Dosenko et al. (2006) found homozygotes for the 
variant to have significantly lower eNOS activity (Dosenko et al. 2006).  However, prior to this 
Sim et al. (1998) found the T-786C variant to have no affect on plasma nitrate and nitrite levels, 
this study was in healthy subjects only (Sim et al. 1998). Jeeroburkhan et al. (2001) and Rossi et 
al. (2006) also failed to find a relationship between this variant and nitrate/nitrite levels 
(Jeerooburkhan et al. 2001, Rossi et al. 2006). Rossi et al. (2006) hypothesised that the reason for 
an ‘absence’ of a relationship from their study could be caused by the effect of dietary factors and 
NO production from other NOS enzymes masking the effect at this level (Rossi et al. 2006). 
As discussed any functional effect on NO is likely to affect an individual’s EDRs, as this is such a 
prominent role of NO. Bilsborough et al. (2003) found homozygotes for the variant to have a 
decreased maximal forearm blood flow in response to acetylcholine (Bilsborough et al. 2003). In 
contrast Dell’Omo et al. (2007) also used the same technique of the forearm blood flow measuring 
vasodilation as a reflection on NO activity and found responses to acetylcholine to exhibit no 
differences (Dell'Omo et al. 2007).  
The functional consequence of this variant again shows inconsistency, there are less studies 
investigating this variant compared to the Glu298Asp variant and consequently less supportive 
evidence. However, there is evidence that this variant may affect NO synthesis. 
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1.6.3 Intron 4 27bp Repeat 
The third variant of the eNOS gene to show a functional consequence is a 27 bp variable number of 
tandem repeat (VNTR) polymorphism, in Intron 4 of the eNOS gene. Predominantly two different 
alleles have been identified for this variant; the larger is known as eNOS 4b which is made up by a 
five tandem 27-bp repeats. The smaller is known as eNOS 4a and consists of four tandem repeats. 
However, a small number of studies have found a third allele with six repeats, but this is very rare 
(Howard et al. 2005). The 4b allele is considered the wild type allele. Typically there are three 
different genotypes found; homozygote for the 4b wild type allele (4bb), heterozygote for the 4a 
mutant allele (4ab) and homozygote for the 4a mutant allele (4aa).  
The functional consequences of this variant should be expected to be less apparent due to the 
intronic location. Research has shown findings suggesting a functional impact of this variant 
however once again this remains inconclusive and in some cases conflicting.  Dosenko et al. 
(2006) found eNOS activity to be 1.7 times lower for homozygotes of the 4a allele compared to 
homozygotes for the 4b allele (Dosenko et al. 2006). Zhang et al. (2005) found that human aortic 
cells showed a reduction of 63% in eNOS transcription, this was alongside decreased mRNA and 
protein levels. The effect is thought to be through the 27bp repeat providing a source of small 
nuclear RNA, able to regulate eNOS expression through a cis-acting role in respect to promoter 
activity. Interestingly to this research is the effect was specific and was able to be reversed through 
stimulation by vascular endothelial growth factor a known upregulator of eNOS, this could provide 
a useful intervention if the negative suppression is confirmed (Zhang et al. 2005). 
A number of studies have shown carriers of this variant to have both reduced protein expression 
and lower NO levels (Wang et al. 2000, Tsukada et al. 1998).  For example NO levels were found 
to be almost 20% lower in homozygotes for the 4a allele (Tsukada et al. 1998). However, other 
studies have failed to replicate these findings for plasma NO levels (Yoon et al. 2000, 
Jeerooburkhan et al. 2001, Salimi et al. 2008).  
The functional impact of this variant may be a result of linkage disequilibrium with other variants 
within the coding region of the eNOS gene.  Yoshimura et al. (2000) found that the Intron 4 variant 
was in disequilibrium with the T-786C variant and Wang et al. (2002) found this variant to 
coordinate with the T-786C and regulate transcriptional efficiency, this may explain the 
inconsistency (Yoshimura et al. 2000, Wang et al. 2002).   
EDRs have again been investigated for this variant. Significantly impaired EDRs have been 
observed in carriers for the variant compared to the wild type (Rittig et al. 2008). Conversely, 
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Dell’Omo et al. (2007) also measured EDRs as a reflection of NO levels and reported no 
significant differences between any genotypes for this variant (Dell'Omo et al. 2007). 
The eNOS 4ab genotype has been shown to have significantly lower mRNA and protein levels, 
compared to the 4bb genotype yet the enzyme activity was found to be higher in the 4ab 
individual’s compared to the 5bb genotype. This study by Wang et al. (2000) found an association 
of the 4a allele with increased NO production, their findings also provided evidence that in 
smokers this ability was compromised, yet smoking did not have the same effects on the wild type 
4b allele (Wang et al. 2000). These mixed findings even within one single study demonstrate the 
complexity in establishing the effect a variant exhibits. Currently there is clear evidence for a 
functional effect of the 4a mutant yet the directional implications of this are less clear. 
1.7 eNOS Gene Polymorphisms-Disease Association Studies  
The eNOS gene exhibits multiple variations (http://www.ncbi.nlm.nih.gov/omim/163729).  It 
remains unclear is these variations result in changes in NO bioavailability and subsequently a 
varying degree of disease susceptibility (Wang et al. 2000, Zhang et al. 2005, Tsukada et al. 1998, 
Wang et al. 2002, Wang et al. 1997b).  A comprehensive literature review was undertaken to 
further investigate the association of the eNOS gene with CAD, Ht and T2DM. This was 
undertaken primarily using the medical journal archive ‘PubMed’ and was done over a continuous 
period from October 2007 to May 2010. To compare studies odds ratios (ORs) were independently 
determined (where these were not available). 
To determine CAD association, it was important to include all studies which investigated 
associated cardiovascular disease (CVD) maladies such as myocardial infarction (MI), Ischemic 
heart disease (IHD) and Ischemic Stroke (IS). The vast literature has revealed multiple names for 
various CVDs and the definition of the disease has been provided as stated in the original paper. It 
should remain to be considered that there is much overlap between these definitions, thus when 
drawing overall conclusions, the CVD studies have been seen as a whole, independent of the 
presented divisions. Ht however has been included separately (although this falls within this 
category) as it is subsequently being investigated in its own entirety in the current research. All 
studies identified through the literature review investigating eNOS and diabetes (T1DM and 
T2DM) have been included. A number of other studies investigating T2DM complications have 
been included but this is not an extensive list. 
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1.7.1 Glu298Asp and Cardiovascular Disease 
There were an extensive number of studies investigating CVD association at this locus.  The first 
study to identifiy genetic association was undertaken by Yoshimura et al. (1998) who investigated 
genetic variation of the eNOS gene in patients with coronary artery spasm, Their group found the 
Glu298Asp variant  to be present in three out of ten patients and absent in all nine controls 
(Yoshimura et al. 2000). Since 1998, this polymorphism has been implicated as a risk factor for 
cardiovascular disease (CVD) (five studies) (Heltianu et al. 2005, Ameno et al. 2006, Lee et al. 
2006, Lin et al. 2008, Kerkeni et al. 2009) Ischemic Heart Disease (IHD) (two studies) (Casas et 
al. 2004, Tamemoto et al. 2008) Coronary Artery Disease (CAD) (15 studies) (Hingorani et al. 
1999, Lembo et al. 2001, Gardemann et al. 2002, Wei et al. 2002, Colombo et al. 2003b, Colombo 
et al. 2003a, Hirashiki et al. 2003, Agema et al. 2004, van Onna et al. 2004, Berdeli et al. 2005, 
Cam et al. 2005, Wolff et al. 2005, Kim et al. 2007, Rios et al. 2007, Salimi et al. 2010), 
Hypertension (Ht) (seven studies) (Miyamoto et al. 1998, Yasujima et al.1998, Shoji et al. 2000, 
Jáchymová et al. 2001, Periaswamy et al. 2008, Srivastava et al. 2008, Tang et al. 2008), Ischemic 
Stroke (IS) (five studies) (Elbaz et al. 2000, Szolnoki et al. 2005, Berger et al. 2007 Saidi et al. 
2009, Tao & Chen 2009) Myocardial Infarction (MI), (eight studies) (Shimasaki et al. 1998, Hibi 
et al. 1998, Hingorani et al. 1999, Poirier et al. 1999, Gardemann et al. 2002, Sobstyl et al. 2002, 
Antoniades et al. 2005, , Odeberg et al. 2008) and related coronary conditions (Yoshimura et al. 
2000, Chang et al. 2003, Gorchakova et al. 2003, McNamara et al. 2003, Fatini et al. 2004, Park et 
al. 2004, Gulec et al. 2007, Iturry-Yamamoto et al. 2007, Colomba et al. 2008). 
The first study to report highly significant CVD associations at this locus was undertaken by 
Hingorani et al. (1999). Their group found the TT mutant genotype to incur over four times the 
risk of homozygotes for the wild type GG genotype, with reported OR values of 4.2 for CAD and 
2.5 for MI. This study is likely to have been a key contributor to the continued research of this 
variant. However in the last 10 years the majority of studies have failed to replicate association on 
this level, subsequently it is more likely that this polymorphism is contributing a smaller effect 
than first believed, or this association may be limited to a UK population group only.  
The reported association has been inconsistent with mixed results even among the same 
populations. The literature review revealed a number of studies that failed to replicate/confirm any 
association of this variant for CVD and CHD (two studies) (Zhang et al. 2006, Mucenic et al. 
2009), CAD  (20 studies) (Liyou et al. 1998, Cai et al. 1999, Granath et al. 2001, Nassar et al. 
2001, Wang et al. 2001, Aras et al. 2002, Paolo Rossi et al. 2003, Schmoelzer et al. 2003, Wu et 
al. 2003, Afrasyap & Ozturk 2004, Rios et al. 2005, Jaramillo et al. 2006, Kara et al. 2006, Kim et 
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al. 2007, Andrikopoulos et al. 2008, Vasilakou et al. 2008, Alp et al. 2009, Nishevitha et al. 2009, 
Pacanowski et al. 2009, Jaramillo et al. 2010), Ht (13 studies) (Lacolley et al. 1998, Kato et al. 
1999, Benjafield & Morris 2000, Karvonen et al. 2002, Kishimoto et al. 2004, Wolff et al. 2005, 
Ma et al. 2006, Moe et al. 2006, Zintzaras et al. 2006, Khawaja et al. 2007, Ormezzano et al. 2007, 
Colomba et al. 2008, Kingah et al. 2009), IS (seven studies) (MacLeod et al. 1999, Akar et al. 
2000, Howard et al. 2005, Grewal et al. 2007, Henskens et al. 2007, Guldiken et al. 2009, Cheng 
et al. 2008a), Myocardial infarction (MI) (six studies) (Cai et al. 1999, Poirier et al. 1999, Chen et 
al. 2005, Jo et al. 2006, Andrikopoulos et al. 2008, Gluba et al. 2009) and coronary conditions 
(Markus et al. 1998, Ghilardi et al. 2002, Hassan et al. 2004, Alioglu et al. 2009, Caglayan et al. 
2009). 
The use of large sample sizes is invariably beneficial in the search for true/causal association, and 
the lack of association reported in a number of studies may be in part attributable to a restricted 
sample size. Meta-analyses provide a key tool in increasing the power of association studies 
through the amalgamation of multiple studies, creating a new outcome from the combined results.  
Two meta-analysis studies were found for the Glu298Asp variant and CVD, in both instances a 
significant overall association was reported, providing strong evidence for the role of this variant 
(Casas et al. 2004, Tao & Chen 2009). The first of the meta-analyses was undertaken by Casas et 
al. (2004), this study included 6036 Ischemic Heart Disease (IHD) cases and 6,106 controls from 
14 different studies. IHD was defined as MI or angiographic CAD. The combined power of a 
larger sample size produced significant association of the TT genotype, finding an OR of 1.31 (CI: 
1.13-1.51, p<0.001) (Casas et al. 2004). The second meta-analysis found was undertaken by Tao 
and Chen (2009), this study investigated IS, a CVD outcome that was excluded in the meta-
analysis by Casas et al. (2004), it was also undertaken more recently and consequently will have 
included a number of different studies.This study also reported an overall association, however 
access to this article was limited and subsequently further analysis and information cannot be 
provided beyond this. Another study that had considerable sample size was the study by Wolff et 
al. (2005), who used a sample population of 2,448 participants, their group reported the TT 
genotype to be significantly associated with carotid atherosclerosis in common carotid arteries, 
reporting an OR of 1.57 (1.05-2.34), p=0.025.  This study, alongside the agreement of both meta-
anlyses provides strong evidence for true association of this variant in the presence of an adequate 
sample size, supporting the suggestion it could be small sample size responsible for the failed 
replication in other studies. 
Among the studies that failed to show association, small sample sizes do appear to be the main 
contributor. However, in larger sample size studies such as Hirashaki et al. (2003) (1011 patients 
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and 650 controls) and Pacanowsk et al. (2009) (256 patients and 769 controls) other factors like 
genetic drift and linkage disequilibrium may be the main factors for the absence of the association. 
Agema et al. (2004) also used large sample sizes (755 patients and 574 controls) in Caucasian men 
and although their group reported association of the variant with CAD, this was found to be in an 
opposite manner to the other studies (T allele to be protective). Agema et al. (2004) postulated this 
could be attributable to linkage disequilibrium with other variants that may be present in their 
study and absent in other ethnic groups (Agema et al. 2004).  The protective association of this 
variant was also reported by Poirier et al. (1999) among a French white Caucasian population 
group (Poirier et al. 1999). This provides evidence that this locus may exhibit populational specific 
effects. There was a large variance in the frequency of this variant at the current locus, with the 
reported frequency of the TT mutant genotype varying from 0% to nearly 20% across populations. 
The literature review also revealed a possible interactive effect of this variant with smoking status. 
For example, Lee et al. (2006) found association to be present among smokers only (Lee et al. 
2006). Similarly, Rios et al. (2007) also found association in smokers, specifically in African 
Brazilians, finding no association among the Caucasian Brazilians group (Rios et al. 2007). This 
association further affirms a possible population specific effect that may have been masked if 
ethnicity had not been considered. An association with smoking has also been found amongst other 
variants of the eNOS gene and thus will be of a high importance to consider this factor in the 
current research analysis. 
Overall, the role of the Glu298Asp variant in CVD remains inconclusive, there have been a 
number of studies to report an associated increased CVD risk of this variant, however the 
association has not been consistently replicated. There is evident populational differences and with 
a complete absence of studies within a South Asian population group the role of this variant 
requires clairification within this high risk group. 
1.7.2 Glu298Asp and Hypertension 
Hypertension (Ht) is a well established risk factor for CAD and a number of studies have 
documented an association of the Glu298Asp variant with Ht. It may be that the association found 
in the CAD studies could be attributable to association specifically with Ht. The association with 
Ht is postulated to be a result of the vasodilator properties of NO. The first study to report this 
variant as a possible risk factor for Ht was undertaken by Miyamoto et al. (1998), their group 
investigated a Japanese population and found strong associations to be present. This study 
incorporated two different Japanese groups both separately and collectively and association was 
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reported to be present in all three groupings, with ORs of 2.35, 2.40 and 2.32 for total, Kyoto and 
Kumamoto respectively (Miyamoto et al. 1998). In the same year and once again in a Japanese 
population the T allele was found to be associated with Ht with a reported OR value of 1.8 (CI:1.1-
3.2) (Yasujima et al.1998). Since this time a number of other studies have been conducted and 
have replicated the possible increased risk associated with this variant (Shoji et al. 2000, 
Jáchymová et al. 2001, Periaswamy et al. 2008, Srivastava et al. 2008, Tang et al. 2008). This 
includes two comparable studies investigating an Indian population. The first, undertaken by 
Srivastava et al. (2008) found a strong association with Ht among a North Indian population, 
finding an OR of 2.10 after adjustments for both age and sex (Srivastava et al. 2008). The second 
study was undertaken by Periaswamy et al. (2008), this study was within a South Indian 
population, incorporating a large sample size (400 patients and 400 matched controls). Independent 
statistical evaluation found an association assuming a dominant model with an OR of 1.35 p=0.05. 
This was on the border of statistical significance, however subgroup analysis by gender revealed 
strong reported association for this variant among females (Periaswamy et al. 2008).  
The reported association remains inconclusive with a number of studies reporting no relationship 
for Ht at this locus, including a meta-analysis (Wolff et al. 2005, Colomba et al. 2008, Zintzaras et 
al. 2006, Lacolley et al. 1998, Ormezzano et al. 2007, Karvonen et al. 2002, Khawaja et al. 2007, 
Kato et al. 1999, Kishimoto et al. 2004, Kingah et al. 2009, Benjafield & Morris 2000, Ma et al. 
2006, Moe et al. 2006). 
The literature review revealed the association may be populational specific; of the seven studies to 
report the Glu298Asp variant as a significant risk factor nearly half (three) were of Japanese 
ethnicity, one Chinese, two Indian with the other unknown. There was no reported association of 
this variant among any European, American or African populations, nearly half (five) of the 
negative association studies were undertaken in European population groups (Benjafield & Morris 
2000, Karvonen et al. 2002, Wolff et al. 2005, Ormezzano et al. 2007, Colomba et al. 2008). The 
association may therefore be restricted to Asians and South Asians only, with only a small number 
of studies reporting no association in Asians, only one of which was in south Asians (Pakistan) 
(Kato et al. 1999, Kishimoto et al. 2004, Ma et al. 2006, Moe et al. 2006 Khawaja et al. 2007). 
Among the studies that failed to find an association was a meta-analysis, this was undertaken by 
Zintzaras et al. (2006) and included 35 studies (7779 patients and 10,498 controls). Overall ORs 
were found to be in close proximity to 1 indicating no overall association of this variant with Ht 
(Zintzaras et al. 2006). 
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The available literature suggests that the Glu298Asp may be associated with Ht in Asians only, 
however this remains inconclusive with a number of studies failing to replicate the findings, 
including a meta-analysis by Zintzaras et al. (2006). With only two studies available for an Indian 
population as with the wider CVD group further analysis is required to confirm or reject a possible 
association. 
1.7.3 Glu298Asp and Diabetes Mellitus 
The literature review identified a total of ten studies investigating a possible association of this 
variant with diabetes and its related traits. Of these ten studies, five reported an association or 
relationship (Li et al. 2001, Maruyama et al. 2003, Monti et al.2003, Ahluwalia et al.2008, Ezzidi 
et al. 2008). Whilst five studies failed to replicate these findings (Ohtoshi et al. 2001, Ukkola et al. 
2001, Conen et al. 2008, Odeberg et al. 2008, Thameem et al. 2008). Six of the ten studies looked 
at a direct relationship between T2DM and the Glu298Asp variant (Ohtoshi et al. 2001, Ukkola et 
al. 2001, Monti et al.2003 , Conen et al. 2008, Ezzidi et al. 2008, Odeberg et al. 2008). Two of 
which reported association, the remaining associations identified were with diabetic complications 
(Monti et al.2003, Ezzidi et al. 2008). 
The Glu298Asp variant has been shown to be associated with T2DM under dominant, recessive 
and allelic models and following independent calculations, with both the T mutant allele and TT 
mutant genotype showing a higher frequency among patients compared to controls. This study 
undertaken by Ezzidi et al. (2008) used a strong study sample size (900 cases and almost 750 
controls) and also investigated the diabetic complication diabetic nephropathy (Ezzidi et al. 2008).  
Similarly, Monti et al. (2003) also reported a higher frequency of the TT mutant genotype in 
T2DM patients (27.7%) than controls (14.0%) identifying a highly significant association of the T 
allele with T2DM (Monti et al. 2003). 
However, Odeberg et al. (2008) failed to replicate the association of the Glu298Asp variant finding 
no significant association under any model in a Swedish population. Their group used a large 
sample size of 403 patients and 799 controls, however their presented results were separated by 
gender; this would have considerably reduced the sample size and could explain the lack of 
significant association identified (Odeberg et al. 2008).  Conen at al. (2008) also failed to find 
association among a Caucasian population. Their study followed a prospective cohort design, 
24,309 women were involved in the study over a follow up period of 10.2 years, in this time 999 
women developed T2DM (Conen et al. 2008). The lack of association within this study may be 
attributable to the study design, firstly with any prospective study the longer the length of time the 
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more accurate the study. Given more time it is likely that more women would have developed the 
disease and subsequently would have been classified incorrectly at this time. Secondly the original 
study group was made up of healthy women only, it is possible that individuals potentially at a 
higher risk (through carrying this variant) may have already developed the disease at the time of 
inception and would have been excluded; this could have contributed towards the lack of identified 
association. 
The remainder of studies found, as stated examined complications or related factors, such as 
insulin levels and diabetic nephropathy. These results are not thought to be directly relevant but 
may be involved in pathways associated with diabetes. With only six studies directly investigating 
T2DM it is difficult to draw any conclusions. There is evidence that the Glu298Asp variant may be 
associated with T2DM and its related conditions but this needs further investigation. There is a 
complete absence of studies in a South Asian population.  
1.7.4 Overall Conclusions for the Glu298Asp Variant and Disease Association 
There have been a substantial number of studies investigating the possible association of this 
variant with disease, more so than for any other eNOS gene variants. The reason for this is likely to 
be due to its exonic location and the functional implications of an amino acid change in the 
resulting protein.  
To conclude, the possible association of the Glu298Asp variant remains inconclusive. It may be 
showing a specific role in certain population groups, however this also remains unclear with both 
association and a lack of association found within the same population groups, possibly a result of 
study design issues, sampling or sample size.  There are some population groups that remain un-
researched, specifically there is a distinct lack of association studies amongst South Asian 
populations groups, despite the significant problem of these diseases in this area of the world, a 
situation set to worsen. Secondly to this, the majority of the studies that have been undertaken in 
this population group report association, supporting the the requirement for research in this 
population.  
1.7.5 T-786C and Cardiovascular Disease  
The literature review identified a number of studies investigating a possible association of the T-
786C variant and CVD. Within these studies the T-786C variant has been reported to be associated 
with CAD (12 studies) (Alvarez et al. 2001, Colombo et al. 2003a, Colombo et al.2003b, Hirashiki 
et al. 2003, Paolo Rossi et al. 2003, Rios et al. 2005, Nassar et al. 2006, Tangurek et al. 2006, Jia 
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et al. 2007, Kim et al. 2007, Rios et al. 2007, Han et al. 2010), Ht (two studies) ( Hyndman et al. 
2002, Augeri et al. 2009) , IS (three studies) (Howard et al. 2005, Lee et al. 2006, Cheng et al. 
2008a)  MI (one study) (Jo et al. 2006), cardiovascular mortality (one study) (Rossi et al. 2006), 
ACS (two studies) (Fatini et al. 2004, Ciftci et al. 2008), coronary spasm (one study) (Nakayama et 
al. 1999), Internal carotid artery stenosis (one study) (Ghilardi et al. 2002) and carotid plaque 
atherosclerosis (one study) (Asakimori et al. 2003). However, the literature review also revealed a 
number of studies that failed to replicate the association. The variant was reported not to be 
association with CVD, IHD, CHD (five studies) (Casas et al. 2004, Ameno et al. 2006, Zhang et 
al. 2006, Ciftci et al. 2008, Pacanowski et al. 2009), CAD (eight studies) (Sim et al. 1998, Granath 
et al. 2001, Agema et al. 2004, Kara et al. 2007, Alp et al. 2009, Kincl et al. 2009, Meluzin et al. 
2009, Jaramillo et al. 2010), Ht (six studies) (Kajiyama et al. 2000, Ma et al. 2006, Moe et al. 
2006, Zintzaras et al. 2006, Colomba et al. 2008, Pacanowski et al. 2009), MI (two studies) ( Chen 
et al. 2005, Gluba et al. 2009) and cerebral small vessel disease (one study) (Hassan et al. 2004).  
Specifically the literature review revealed the T-786C variant may be associated with not only the 
occurrence of CAD but also the severity. One study by Rios et al. (2005) directly investigated the 
severity of CAD by considering patients with >75% stenosis separately to those with less severe 
stenosis (<75%). They reported significant association of the T-786C variant with severe CAD, 
independent analyses comparing the two patients groups (>75% vs. <75% stenosis) also revealed 
significant association, finding under a domninant model finding an OR value of 1.90 (CI: 1.22-
2.294), p=0.006 (Rios et al. 2005).  Colombo et al. (2003) also found a similar association, finding 
the T-786C variant to be associated with both the occurrence and severity of the disease (Colombo 
et al. 2003b).  
The T-786C varaint was shown to be interactive with other genetic variants. Two studies that 
reported such association were undertaken by Jia et al. (2007) and Nassar et al. (2006). Both 
studies  incorporated age of onset into their study design (this can reduce the effect of other risk 
factors such as increased weight, which are associated with an increase in age). Jia et al. (2007) 
found an interaction between the T-786C variant with the ADH2 arg47his variant (Jia et al. 2007). 
Whilst Nassar et al. (2006) found an OR of 2.78 when combined with four other variants, 
including one of the APOE gene (Nassar et al. 2006). Alvarez et al. (2001) also support an additive 
interactive effect of this variant, they found an association between the CC mutant genotype and 
CAD ,with an OR value of 1.6 which was shown to increase to an OR of 2.82 when the CC mutant 
genotype was combined with the DD genotype of the ACE gene (Alvarez et al. 2001). The 
replication in multiple studies of a combined interactive effect is plausible due to the polygenic and 
multifactorial nature of CVD.  
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The T-786C variant has also showed association with CVD risk factors. For example the 
association reported by Alvarez et al. (2001) consisted of only male smokers (two well established 
risk factors) (Alvarez et al. 2001). The association among smokers was also observed in the study 
by Rios et al. (2007) who found more than three times the associated risk for the T-786C variant 
(OR=3.162) to be present among smokers (Rios et al. 2007).   
The reported association of the T-786C variant was particularly evident when investigating 
ischemic stroke (IS), for example Chen et al. (2008) found an OR of 3.8 following adjustment for 
other classical risk factors and Lee et al. (2006) reported an adjusted relative risk ratio of 4.05 for 
the C allele when combined with a history of smoking (>20 packs per year), supporting the 
interaction reported by Rios et al. (2007) and Alvarez et al. (2001) (Lee et al. 2006, Cheng et al. 
2008a). Adjustment for risk factors is absent among some studies and may contribute towards the 
inconsistent results and false positives, with the effects of the variant possibly masked by more 
prominent risk factors such as obesity.  
This variant was also found to be strongly associated with coronary spasm, where there was an 
observed increased risk of nearly six times. This was a very early study undertaken in 1999 by 
Nakayama et al., as with the study in the UK for the Glu298Asp variant by Hingorani et al. (1999), 
this may have been an initiating factor for the multitude of studies to occur since this date 
(Nakayama et al. 1999). Effect sizes on this scale have not been replicated in the more recent 
studies. For example Hirashiki et al. (2003) analysed a Japanese population using a strong case 
control study design (1,011 cases and 650 controls), their group identified a moderate effect size 
only (OR=1.5 (CI: 1.0-2.2)) (Hirashiki et al. 2003).   
Casas et al. (2004) carried out a meta-analysis study on all three major eNOS variants including a 
total of 2377 patients and 7702 controls for the T-786C variant. The C risk allele was not found to 
be associated with IHD with an OR=1.06. Out of the three eNOS variants incorporated in the study 
this was the only one that failed to be associated with IHD when the multiple studies were 
incorporated.  However, only seven studies were used for this variant compared to 16 studies for 
the Intron 4 variant and 14 for the Glu298Asp variant, thus the power of this study was reduced 
and could explain the lack of association of this variant, slight variances in ethnicities could also 
account for the lack of association. 
Amongst the studies that failed to find association, sample sizes were generally small. For example 
Ciftci et al. (2008) used only 20 CHD patients and 31 controls (Ciftci et al. 2008). However 
exceptions included the studies by Kincl et al. (2009) and Agema et al. (2004), both of which had 
reasonable sample sizes yet failed to confirm an association among European populations. It is 
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likely that in European populations, population origins are a common factor for this lack of 
association, but further studies are warranted. 
The association of the T-786C variant with CVD is unclear it may not act as an independent risk 
factor or is likely to have a more moderate effect size. The literature review revealed the reported 
association of this variant may be a result of interactions with other genetic variants and CVD risk 
factors, in particuarlar smoking. Association may also be present in specific CVD groups only, 
such as severe CAD and coronary spasm. No clear populational specific association was identified 
and no comparable studies were found to investigate a South Asian population.  
1.7.6 T-786C and Hypertension 
Nine published studies were found to investigate the possible association of the T-786C variant and 
Ht. The T-786C variant was reported to be associated with Ht in two studies (Hyndman et al. 2002, 
Augeri et al. 2009).  The study carried out by Augeri et al. (2009) followed an unusual study 
design using three different treatment conditions for Ht; their group reported an interactive effect 
of the variant with exercise (a known upregulator of eNOS), finding carriers of the C allele to 
respond more favourably to the condition of antihypertensive exercise (Augeri et al. 2009). 
However, this study consisted of only 49 patients and therefore should be interpreted with caution 
(Augeri et al. 2009). Hyndman et al. (2002) reported association following a cohort study design, 
this study incorporated a strong sample using 705 men all considered to be a healthy population. 
Of the 705 men, 106 were found to be hypertensive and 599 normotensive. The CC genotype was 
reported to be significantly associated with higher systolic BP (OR=2.16 (CI 1.3-3.7)), presenting 
double the risk for individuals of this genotype (Hyndman et al. 2002). 
The association of the T-786C variant remains unclear with the majority (six) of the identified 
studies failing to observe any association with Ht (Kajiyama et al. 2000, Ma et al. 2006, Moe et al. 
2006, Zintzaras et al. 2006, Colomba et al. 2008, Pacanowski et al. 2009). This included a meta-
analysis  undertaken by Zintzaras et al. (2006)  which combined a total of 2491 patients and 3913 
controls and  found no statistically significant differences between cases and controls (Zintzaras et 
al. 2006). The remainder of studies that reported no association (with the exception of Pacanowski 
et al. (2009)) all have relatively small sample sizes, thus the lack of association found could be 
explained by this.  
Although the majority of studies failed to report an effect of the T-786C variant with Ht, with a 
complete absence of any studies within a South Asian population its role in this population needs 
to be clarified.  
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1.7.7 T-786C and Diabetes Mellitus 
Only five studies have been published investigating an association of the T-786C variant with 
diabetes or diabetic complications ( Zanchi et al. 2000, Ohtoshi et al. 2002, Ahluwalia et al. 2008, 
Ezzidi et al. 2008, Thameem et al. 2008). Only two studies directly investigated T2DM association 
(Ohtoshi et al. 2002, Ezzidi et al. 2008). The earliest study was undertaken by Ohtoshi et al. (2002) 
who reported no significant association between the T-786C variant and T2DM; their group 
reported the CC genotype to be at a frequency of 3.0% and 4% in patients and controls 
respectively. Independent statistical analysis also revealed no association under any model 
(Ohtoshi et al. 2002). Conversely, a more recent study undertaken by Ezzidi et al. (2008) found 
association of this variant at a recessive, dominant and allelic level.  The differences in association 
may be a result of a population specific effect; Ohtoshi et al. (2002) investigated a Japanese 
population, whilst Ezzidi et al. (2008) investigated a Tunisian population thus this is plausible. 
However, due to the limited published research investigating the possible association with diabetes, 
and with no comparable studies in any South Asian populations no true conclusions can be drawn. 
1.7.8 Overall Conclusions for the T-786C variant and Disease Association 
There are only a limited number of studies investigating disease association with this variant, 
possible reasons for the lack of investigations could be the location of this variant, population 
differences or a lack of functional role. There is evidence for an association of this variant; 
specifically interactive effects with risk factors and other genetic variants have been reported. 
1.7.9 Intron 4 and Cardiovascular Disease 
A total of 59 studies investigating a possible association of the eNOS intron 4 variant with CVD 
were found in the published literature. As with the other eNOS variants the studies reported mixed 
results. Overall 28 studies showed association with CVDs, with association reported for IHD, CHD 
(two studies) (Fowkes et al. 2000, Casas et al. 2004), CAD (seven studies) ( Wang et al. 1996, Lee 
et al. 2001, Agema et al. 2004, Matyar et al. 2005, Salimi et al. 2006, Kim et al.2007, Kincl et al. 
2009), Ht (seven studies) (Uwabo et al. 1998, Mustafina et al. 2001, Rodriguez-Esparragon et al. 
2003, Heltianu et al. 2005, Moe et al. 2006, Colomba et al. 2008, Jemaa et al. 2009), IS (three 
studies) (Hou et al. 2001, Shi et al. 2008, Tao & Chen 2009), MI (five studies) (Wang et al. 1996, 
Ichihara et al. 1998, Kunnas et al. 2002, Cine et al. 2002, Jemaa et al. 2007), ACS (two studies) 
(Fatini et al. 2004, Park et al. 2004), carotid plaques (one study) (Asakimori et al. 2003) and 
cerebral small vessel disease (one study) (Hassan et al. 2004). 
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However, there was an almost an equal number of studies (31) that did not support an association 
with CVD sub groups.  For CVD (one study) (Lin et al. 2008), CAD (16 studies) ( Nakagami et al. 
1999, Sigusch et al. 2000, Alvarez et al. 2001, Lembo et al. 2001, Granath et al. 2001, Gardemann 
et al. 2002, Hwang et al. 2002, Kunnas et al. 2002, Frost et al. 2003, Wu et al. 2003, Letonja 2004, 
Milutinovic & Hruskovicova 2005, Rios et al. 2007, Vasilakou et al. 2008, Meluzin et al. 2009, 
Jaramillo et al. 2010), Ht  (six studies) (Miyamoto et al. 1998, Yasujima et al. 1998, Shoji et al. 
2000,Yokoyama et al. 2000, Ma et al. 2006, Deng et al. 2007), IS (four studies) ( Yahashi et al. 
1998, Howard et al. 2005, Saidi et al. 2009, Tao & Chen 2009), MI ( two studies) ( Hibi et al. 
1998, Gardemann et al. 2002), coronary artery lesions  (one study) (Khajoee et al. 2003) and 
restenosis (one study) (Volzke et al. 2004).  
A meta-analysis by Casas et al. (2004) was included among the studies that reported association, 
this meta-analysis included all three of the major eNOS variants; Glu298Asp, T-786C and Intron 4 
combining a total of 16 studies. The Intron 4a allele incorporated 6036 cases and 6106 controls and 
was found to be associated with a small increased risk of IHD (OR=1.34 (CI: 1.03-1.75)). 
However, a second meta-analysis undertaken more recently by Tao and Chen (2009) failed to find 
an overall association when combining multiple studies. However this meta-analysis did report 
association among East Asians only, finding the variant to be associated with nearly three times 
disease risk (OR=2.74) among this group (Tao & Chen 2009). These meta-analyses support a role 
for the intron 4 variant in CVD risk that may be of a moderate level or exhibiting a populational 
specific effect.  
The Intron 4 variant has been reported to be interactive with CVD risk factors; Wang et al. (1996), 
Fowkes et al. (2000) and Kim et al. (2007) all failed to observe an overall association, but 
supported the role of an interactive effect of the variant with smoking (Wang et al. 1996, Fowkes 
et al. 2000, Kim et al. 2007). Fowkes et al. (2000) reported particularly strong association among 
smokers in a Scottish population (OR =2.47 (1.42-4.34)) (Fowkes et al. 2000). Kincl et al. (2009) 
found an association of the variant among diabetic and obese groups (Kincl et al. 2009).  
Overall there seems to be no apparent relationship between associations found among different 
population groups, there is a small amount of evidence supporting a possible Asian only 
association as seen in the Meta-analysis by Tao et al. (2009), but this requires replication. No 
studies were found directly investigating a South Asian population. 
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1.7.10 Intron 4 and Hypertension 
The literature review identified a total of 13 stuides which investigated a possible association of the 
Intron 4 variant with Ht.  Of these studies seven reported a significant association between the 
eNOS Intron 4 variant and Ht across multiple populations (Uwabo et al. 1998, Mustafina et al. 
2001, Rodriguez-Esparragon et al. 2003, Heltianu et al. 2005, Moe et al. 2006, Colomba et al. 
2008, Jemaa et al. 2009).  The strength of the association identified remains unclear with limited 
access to the full reported results and independent analyses revealing only small association. 
In addition a number of studies (six) were found that did not replicate the association. Four of 
which were among Japanese populations and two were in Chinese population groups (Miyamoto et 
al. 1998, Yasujima et al. 1998, Shoji et al. 2000, Yokoyama et al. 2000, Ma et al. 2006, Deng et 
al. 2007). Of these studies all sample sizes were small with none greater than 250. This could 
solely be the reason that association was not observed.  
There is limited evidence for an association of this variant with Ht, with the reported findings 
suggesting an absence of a relationship among Asian populations, however the combination of 
small sample sizes and the apparent low frequency of this variant among these populations means 
replication is required with larger sample sizes. Specifically the role of this variant among South 
Asians should be investigated with the literature review failing to identify a single study.   
1.7.11 Intron 4 and Diabetes Mellitus 
Thirteen studies were identified to have investigated a possible association of Intron 4 variant and 
diabetic traits. Only a small number of these studies (four) directly investigated T2DM disease risk. 
These studies strongly support an association between this variant and T2DM risk; three out of the 
four found a significant association with disease risk (Ksiazek et al. 2003, Ezzidi et al. 2008, 
Galanakis et al. 2008). 
The first study to observe the association was undertaken by Ksiazek et al. (2003), their group 
adopted a case control study design using 410 patients and 330 matched controls. The frequency of 
the 4aa genotype was found to be at a frequency of 8% in patients and 1.2% in controls, the 4a 
allele was found to be strongly related to T2DM with an OR of 2.24 (CI:1.12-3.40).  
A recent study undertaken by Ezzidi et al. (2008) also reported this association. Their study 
investigatied all three eNOS variants (Glu289Asp, T-786C and Intron 4) and found association in 
all instances.  Their group reported significant linkage disequilibrium between the Glu298Asp (T 
allele) and the Intron 4 (4a allele) among T2DM patients (p=0.021). It remains unclear if the 
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association found in all three variants is a result of linkage disequilibrium between the variants, 
possibly  present in one or two of the variants only, with the other(s) exhibiting a indirect effect. 
This would be more likely to be a population specific effect if this is the case. 
The one study directly investigating T2DM association that failed to identify any statistically 
significant differences in genotype frequencies between patients and controls was carried out by 
Lee et al. (2003) using a case control study design. Although no statistically significant results 
were reported, further independent statistical analysis identified under a recessive model an OR 
value of 7.07 that was just outside statistical significance (p=0.055) (Lee et al. 2003). 
The available studies strongly suggest that the Intron 4 variant may be associated with diabetes. 
However, with such a limited number of published studies this requires replication across multiple 
populations. It is unclear if association is present in a population specific manner, once again there 
is a complete absence of any studies in a South Asian population group thus this high risk 
population requires further research. 
1.7.12 Overall Conclusions for the Intron 4 Variant and Disease Association 
The Inton 4 variant is the second most extensively studied variant of the eNOS gene, second to the 
Glu298Asp variant.  This is perhaps surprising considering its intronic location, therefore any 
associations observed may be the product of linkage disequilibrium with another locus in the gene.  
1.7.13 Other Variants 
A number of other polymorphisms have been identified within the eNOS gene. The literature 
review revealed only a small number of studies investigating their association with disease. There 
is limited evidence for a functional effect of the variants and the majority of the identified studies 
do not provide strong evidence for a role of these eNOS variants in disease (appendix 1, section 
8.1). 
1.7.14 eNOS Haplotypes and Disease 
Haplotype analysis can provide a clearer picture than investigating single genetic variants; 
incorporating potential interaction among variants, this interaction within a haplotype can be a key 
determinant of disease risk. There are a small number of studies investigating eNOS haplotypes 
that have found an association with disease, in some cases this was identified when no association 
was found for individual eNOS variants (Sandrim et al. 2006, Gonzalez-Sanchez et al. 2007, Rios 
et al. 2007, Ahluwalia et al. 2008, Cheng et al. 2008a, Kitsios & Zintzaras 2010). A small number 
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of studies have also identified significant differences with respect to NOx levels, Metzger found 
the G-C-4b haplotype of the Glu298Asp, T-786C and Intron 4 variants respectively to be 
significantly associated with lower plasma nitrite levels (Metzger et al. 2007, Sandrim et al. 2007). 
These studies demonstrate the clear requirement for this type of analysis and consequently this will 
be incorporated as an aim of the current study. 
1.8 Conclusions from eNOS Literature Review 
The literature review has provided clear insights for the inclusion criteria to consider in the current 
research and there are some overall conclusions that can be drawn. Firstly, although invariably 
some benefits have been gained from altering the study designs, the literature review has further 
supported the requirement for a case control study design; it is well established and enables better 
comparisons between studies. Secondly, sample size is an issue; of the published studies many 
have inadequate sample sizes to draw accurate conclusions from, with both false positives and lack 
of association often a consequence of a biased sample. Recently the importance of sample size has 
been acknowledged with more recent samples reflecting this with increased sample sizes. Sample 
size in this current study will be as great as possible within the respective constraints to ensure that 
all conclusions based on the data can be accurate. Thirdly, there are only a small number of studies 
directly investigating South Asian population groups, considering the overwhelming evidence of 
the magnitude of the problem within this population group there is a requirement for further 
research to confirm the effects of these eNOS gene variants within this ethnic group. Ht has been 
investigated only for the Glu298Asp variant, and diabetes has not been investigated for any of the 
variants in this population group. Fourthly, many studies that have shown association indentified 
this following sub group analysis only. Sub group analysis should include the traditional high risk 
groups; smoking status, gender and age at a minimum and extended beyond this where possible. 
This should be undertaken with caution as this results in a restricted sample size and often contains 
large confidence intervals and significantly smaller sample sizes. 
There are also a number of specific conclusions that can be drawn with respect to diabetes. The 
literature review on T2DM and eNOS association revealed fewer studies compared to the numbers 
found for CAD and Ht. However, the majority of the available studies are more recent. This is 
likely to be due to the complex nature of the disease which remains somewhat unknown. The 
proposed pathway for NO’s role in the physiology is a more recent discovery that has recently 
received wider documentation by Authors such as Huang (2009) (Huang 2009). Research has been 
largely run through cardiovascular diseases and cancers and it is only more recently that these 
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related risk factors such as Ht, T2DM and metabolic syndrome are gaining more focus and 
attention.  
1.9 ACE Gene 
The literature review revealed that eNOS association may be influenced by other genes. One gene 
hightlighted to have a possible interactive/synergistic effect with eNOS is the Angiotensin 
Converting Enzyme (ACE) gene. 
There are multiple types of variations that exist, a few examples of these have been discussed such 
as SNPs and VNTRs, this list is far from extensive and there are many others. Another type of 
variation are short interspersed elements (SINEs) made up by the Alu family. There are around 
500-2000 Alu elements which are around 300bp in length, the Alu family are typical to 
homosapiens and are widespread throughout the human genome. The name Alu represents the 
common endonucleases Alu1 recognition site which is characteristic of this type of variation. The 
ACE insertion/deletion variant (rs4646994) is one example of the Alu polymorphisms, this specific 
variant is characterised as either an insertion/presence of a 489bp fragment or a deletion/absence of 
the polymorphism, where a 189bp fragment is viewed following polymerase chain reaction (PCR).  
The ACE gene is responsible for synthesising ACE, ACE is an enzyme responsible for converting 
angiotensin I to angiotensin II (Section 1.3.2.1). Angiotensin is an important vasoconstrictor, 
contrasting of the vasodilatory properties of the eNOS product NO (Davis & Roberts 1997). In 
addition ACE degrades bradykinin which is a second vasodilator. 
The role of ACE as an important vasoconstrictor has led to this variant being implicated as a 
possible risk factor for Ht and CAD. A number of studies have investigated the role of the ACE 
deletion with CVD risk, this includes a meta-analysis undertaken by Zintzaras et al. (2008), which 
included 118 studies and a total of 43,733 CAD patients and 82,606 controls. Their group found an 
overall significant increased risk associated with the ACE deletion variant (OR=1.25 (CI: 1.16-
1.35)) (Zintzaras et al. 2008). These effects of the ACE deletion variant have also been 
demonstrated among North Indian populations (Agrawal et al. 2004). 
The vasoconstrictive effects of the ACE gene provide a contrast to those of the eNOS gene, 
subsequently there is a close link between the two systems and a plausible synergistic/interactive 
effect. Alvarez et al. (2001) support this idea, finding an OR value of 1.6 for the T-786C CC 
mutant genotype to increase to 2.82 when combined with the DD genotype of the ACE gene 
(Alvarez et al. 2001). 
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The RAS system has also been associated with insulin resistance (Tikellis et al. 2004, Carlsson et 
al. 1998). The association with insulin resistance is thought to be a result of an increase in 
angiotensin II levels. The ACE gene may be evident in diabetes patients through its role in lipid 
and lipoprotein metabolism and has been implicated in the development of diabetes; ACE 
inhibitors have been demonstrated to reduce the risk of diabetes (Singh et al. 2006, Malik 2000). 
Previous studies have shown inconclusive results with respect to diabetes (Feng et al. 2002, 
Stephens et al. 2005, Thomas et al. 2001).  For example, Conen et al. (2008) investigated six 
variants of the eNOS and RAS genes in a prospective large cohort in Caucasian women and failed 
to find any association with T2DM (Conen et al. 2008). Conversely, association was found by 
Singh et al. (2006) who reported the ACE insertion/deletion DD mutant genotype and the D mutant 
allele to be associated with T2DM with ORs of 1.90 and 1.58 respectively. This study was 
undertaken in a North Indian population group and therefore provides evidence for a role of this 
variant in this population group (Singh et al. 2006). 
The previous literature suggest a role of the ACE deletion variant in CAD, Ht and T2DM, there is 
also a plausible interactive/synergistic effect between the ACE gene insertion/deletion 
polymorphism and the eNOS gene polymorphisms in a North Indian population. Consequently this 
will be investigated as a secondary aim to the current research.
Chapter 1 – Background and Literature Review 
58 | P a g e  
 
 
1.10 Aims and Objectives of this PhD 
The eNOS gene is responsible NO synthesis in the human body, the background has provided an 
overview of the key roles of NO in the human body and it is evident to have a clear role in a 
variety of diseases. Figure 8 summarises the rationale behind the choice of diseases being 
investigated in the current research. 
 
Figure 8-A summary of the key factors contributing to the disease choice in the current study 
The literature review has provided an overview of the studies published thus far that have 
investigated the role of eNOS polymorphisms in the three chosen diseases. There are a number of 
studies that provide strong evidence for a role of each of the variants in these diseases. The 
evidence remains inconclusive and there are very few studies investigating North Indian 
populations. Collectively this has led to the following aims and objectives of this research. 
1.10.1 Aims and Objectives of the Study 
To analyse through a case control study three different  polymorphisms of the eNOS gene and the 
deletion variant of the angiotensin-converting enzyme (ACE) gene for possible association with 
Coronary Artery Disease (CAD), Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) in 
North Indian population groups.  
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H0= The Glu298Asp, T-786C and Intron 4 variants of the eNOS gene and the ACE deletion of the 
ACE gene are not significantly associated with CAD, Ht or T2DM in North Indian population 
groups. 
H1= The Glu298Asp, T-786C and Intron 4 variants of the eNOS gene and the ACE deletion of the 
ACE gene are significantly associated with CAD, Ht or T2DM in North Indian population groups. 
To statistically evaluate descriptive statistics including; age, gender, smoking, dietary behaviours 
and lipid parameters for possible influence on disease and potential interaction with the 
polymorphisms. 
To undertake haplotype analysis of the eNOS gene, in the diseases and work out haplotype risk. 
To evaluate a possible linkage disequilibrium between the 3 eNOS variants 
To determine a possible synergistic/interactive effect of the eNOS polymorphisms with the ACE 
deletion polymorphism. 
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2 Chapter 2-Methods 
2.1 Ethical Considerations 
Full written consent was gained from all participants involved in this research project and the 
research protocol was approved by Loughborough University Ethical Advisory Committee under 
the generic protocol GP04/05. The permission for usage of DNA samples was also provided by the 
collaborators (Prof S. Agrawal and late Prof S.S.Papiha). The researchers were fully trained to use 
these techniques and samples under the above protocol by the protocol leader (Dr. Sarabjit 
Mastana).  All Samples were made anonymous through the allocation of an identification number 
to ensure confidentiality. 
2.2 Samples 
All samples were provided for the current study in the form of DNA (~100ng/ml), below outlines 
further information regarding the sampling process and clinical and demographic information 
where relevant.   
2.2.1 CAD Samples 
The CAD samples were collected in collaboration with and approved by the Sanjay Gandhi 
Postgraduate Institute of Medical Sciences (SGPIMS), Lucknow, Uttar Pradesh, North India.  
A total of 469 CAD patients and 301 controls were available for genotyping in the current study. 
The samples all came from Uttar Pradesh in North India; these were collected by Prof.  S. Agrawal, 
Head of the Department of Medical Genetics, SGPIMS, as part of the ongoing collaborative studies 
on genetics of CAD in Indian populations.  The samples were collected in the form of whole blood 
and the DNA was extracted from the whole blood using organic extraction or salting out methods.  
Angiographic classification of CAD was determined by the detection of 50% or more stenosis in 
one or more of the coronary arteries, this was done through coronary angiography performed by a 
trained cardiologist in the Department of Cardiology within the SGPIMS. The healthy case 
controls had no known history of ischemic heart disease, hypertension, diabetes, endocrine or 
metabolic disorders. They were selected after undergoing a treadmill test to ensure they were 
cardiovascular disease free. Exclusion criteria for CAD patients stated they could not be less than 6 
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weeks post myocardial infarction. Both patients and controls were matched for sex, age and 
ethnicity and lived in similar environments. Ethnicity was confirmed via a detailed questionnaire, 
including only individuals who had resided in Uttar Pradesh for a minimum of 5 generations. 
Other information collected during this time included age, gender, diet, smoking behaviour,  
apolipoprotein B (APO B) and a full lipid profile (determined using a chemistry auto analyser, 
Technicon RX-XT). 
2.2.2 Ht Samples 
The samples were collected from individuals residing in urban and rural areas of the Patiala, 
Kapurthala and Hoshiarpur Districts of Punjab and Ambala District of Haryana and were Lobana 
Sikhs. Lobana Sikhs have prominently settled in these districts after the independence of India in 
1947. Participants were all voluntary and local advertisements (via range of sources, local temple 
announcements, village and town councils, schools) invited them to participate at primary medical 
health centres in the area. The Lobanas are primarily vegetarians, with low prevalence of smoking 
and alcohol consumption. Hypertension diagnosis was determined based on the World health 
Organisation/ International society of hypertension guidelines (Whitworth 2003). Blood pressure 
measurements were taken on the left arm at the level of the heart, the cuff was placed on the 
subjects in the supine position. Three separate measurements were taken at the interval of 5 
minutes, on three different occasions. An average was then taken, and subjects were defined as 
hypertensive if they showed (1) systolic blood pressure>140 mmHg, and diastolic blood pressure> 
90mmHg on at least three separate occasions and (2) no presence of any clinical signs for 
secondary hypertension. Normotensive diagnosis was given if (1) resting systolic blood pressure 
<140mmHg and diastolic blood pressure <90mmHg on three different occasions, (2) no history of 
hypertension and (3) no antihypertensive medications or other blood pressure effecting 
medications. Exclusion criteria for the subjects were no cases with any known heart conditions and 
excluded all individuals with any disease condition. 
A number of lifestyle characteristics were also collected at this time. Blood samples were taken, 
and information was gained on age, sex, dietary habits and medical histories. This was collected by 
one of the study supervisors. DNA was available for genotyping from a total of 210 patients and 
162 controls. 
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2.2.3 T2DM Samples 
The T2DM samples were collected in collaboration with Late Prof S.S.Papiha as part of on going 
studies on genetic architecture of type 2 diabetes in Punjabi populations. These collections were 
approved by local health authorities and participating hospitals (medical colleges) in Punjab, India.     
A total of 628 individuals took part in the study, of these 319 were positive for T2DM and 307 
were non-diabetic and unrelated controls. All individuals were residing in urban and rural areas of 
the Patiala, Kapurthala and Hoshiarpur Districts of Punjab and Ambala District of Haryana and 
were Lobana Sikhs. Lobana Sikhs have prominently settled in these districts after the   
independence of India in 1947.  Participants were all voluntary and advertisement invited them to 
participate at primary medical health centres in the area.  
2.2.3.1 Type 2 Diagnosis 
T2DM diagnosis was based on clinical records, current medication and the oral glucose tolerance 
test. The guidelines for diagnosis followed the criteria set out by the American Diabetes 
Association (2004) as follows: A medical record indicating either a fasting plasma glucose (FPG) 
levels ≥7.0 mmol/l or ≥126 mg/dl after a minimum 12-hour fast or 2-hour post glucose level (oral 
glucose tolerance test or 2-h OGTT) ≥11.1 mmol/l or ≥200 mg/dl on more than one occasion with 
symptoms of diabetes. The impaired glucose tolerance (IGT) was defined as the FPG levels 100 
mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 mmol/l) or 2-h OGTT of ≥140 mg/dl (7.8 mmol/l) but 
<200 mg/dl (11.1 mmol/l). The 2-h OGTTs were performed following WHO criteria (75 mg oral 
glucose load). 2-h OGTT was performed on those subjects who were either borderline diabetic or 
previously reported hyperglycemic and were currently maintaining glycemic control with diet 
and/or exercise. The controls were matched with the patients on gender, age and ethnicity and lived 
in similar environments. They were given a 2-h OGTT to rule out the presence of IGT.  
2.2.3.2 Anthropometric Measurements 
Standardised techniques were adopted for anthropometric measurements of the following; weight, 
height, waist and hip circumferences. Blood pressure was also measured during this time and 
hypertension was defined as systolic blood pressure of ≥140 mmHg and diastolic blood pressure of 
≥90mmHg or if taking blood pressure medication.  Body mass index was also determined from 
weight and height measurements calculated as weight (kg)/(height (m))
2
. 
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2.2.3.3 Biochemical Measurements 
Fasting (overnight, 12 hours) blood samples were taken in EDTA coated plain vials. The blood 
samples were centrifuged to obtain the plasma, serum and buffy coat. Samples were stored at -
35ºC. The following tests were then undertaken on the blood sample. 
Total Cholesterol (TC), Triglycerides (TG) and HDL-C levels were estimated in serum using 
standard kits (Roche Diagnostics). LDL was calculated LDL=TC-(HDL – (TG/5)) 
Serum insulin was determined by means of radioimmunoassay (diagnostic products inc. USA). 
Glycosylated haemoglobin (HbA1c) was measured in the whole blood by turbidometric inhibition 
immunoassay. 
A fasting blood glucose level was measured from the whole blood by use of a glucometer. All the 
quantitative parameters were measured by use of Hitachi-912 Autoanalyser (Hitachi, Germany) 
following the instructions provided. HOMA-IR and HOMA-BF insulin resistance indices were 
used to evaluate insulin resistance and beta-cell functions. The following equations were used. 
HOMA-IR= (fasting insulin (µU/ml) x Fasting blood glucose (mmol/L))/22.5 
HOMA-BF= (20x fasting insulin (µU/ml))/fasting blood glucose (mmol/L) 
2.2.3.4 Other Clinical Information 
A standardised collection questionnaire was used to collect the following information; diabetic 
status, age and date of birth, family history of diabetes, metabolic syndrome presence, duration of 
T2DM and age of onset, physical activity, education, alcohol consumption and medical 
complications: neuropathy, nephropathy, cataract, familial cataract, diabetic foot, and amputations. 
2.3 Polymerase Chain Reaction (PCR) Overview 
A standard end-point PCR process was used for the three out of the four polymorphisms; the 
Glu298Asp, the Intron 4 27bp repeat variant and the ACE deletion polymorphism. The Polymerase 
chain reaction (PCR) is a process used to amplify DNA. The requirements are: target DNA, two 
specific oligonucleotide primers, a thermostable DNA polymerase, deoxynucleotide triphosphates 
(dNTPs), magnesium, reaction buffer and a thermal cycler. The PCR process uses three main steps 
to amplify the DNA; denaturing, annealing and extension. Theoretically each PCR cycle of the 
three steps will double the amount of the target DNA resulting in millions of copies of the original 
DNA within hours. The three main steps are outlined below: 
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 Denaturing 
This is the initial step in the PCR process, which denatures the target DNA by raising the 
temperature within the thermal cycler to 94-96°C for a period of time between 15 seconds to two 
minutes. This will separate the two strands of DNA from one another by breaking the hydrogen 
bonds. This produces two complementary strands of single stranded DNA templates for the next 
step known as annealing. 
 Annealing of the primers 
This step  involves lowering the temperature of the thermocycler  to 40-65°C for approximately 
15-60 seconds, the two specific oligonucleotide primers can then anneal to the denatured (single 
stranded) complementary sequence of the target DNA.  
 Extension phase 
The final step of the PCR process involves the synthesis for the new (copied) DNA. This step 
requires Taq polymerase, the temperature is raised to 70-74°C and will remain for a duration of 
approximately 1-2 minutes; the raised temperature allows the DNA polymerase to attach to the 
newly annealed primers. The new DNA is then synthesised based on the complimentary base 
pairing nature of DNA, and the target DNA is built up using the free deoxynucleotide triphosphates 
(dNTPs). Following this step the temperature of the thermal cycler will be raised back to 94-96°C 
to begin the denaturing step once again repeating the three step cycle. 
Following the final extension phase, the DNA will be incubated for five minutes at about 72°C to 
fill in the protruding ends of the synthesised PCR product. 
The specific temperatures at each step are optimised for each primer pair combination. The number 
will vary from 20 to 40 total cycles. Following this the amplified target DNA may be analysed 
using further experimental procedures such as gel electrophoresis or restriction fragment length 
polymorphism (RFLP) analysis. 
References: 
Williams 1989,  
http://www.dnalc.org/resources/animations/pcr.html, 
http://irc.igd.cornell.edu/MolecularMarkers/PCR%20basics.pdf 
2.3.1 Materials-PCR-RFLP 
 2X ReddyMixTM PCR Master Mix (2.5mM MgCl2) stored at -20°C containing: 
 2.5MgCl2, 1.25 units Thermoprime Plus DNA Polymerase, 75mM Tris-HCI (Ph 8.8 at 
25°C), 20mM (NH4)2SO4, 0.01% (v/v) Tween 20, 0.2mM each of dATP, dCTP, dGTP and 
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dTTP. It also contained precipitant and red dye to visually aid gel loading during the 
electrophoresis experimental phase. (Thermoscientific) 
 Forward and Reverse Primers (specific to reaction) (Invitrogen) 
 Ban II Restriction enzyme (10,000 U/ml) (New England BioLabs) 
 Buffer 4 (1x containing: high50mM potassium acetate, 20mM Tris-acetate, 10mM 
magnesium acetate, 1 mM DTT.) (New England BioLabs) 
 Agarose (Webscientific iberose high specification agarose for electrophoresis)  
 1X TBE buffer containing: Tris base FW= 121.14, Boric Acid FW= 61.83  and EDTA 
FW=292.25 (Fisher scientific) 
 Sybr®safe DNA gel stain (10,000 x concentrate in DMSO, Invitrogen) 
 Safeview nucleic Acid stain (NBS biologicals) 
 Reddy run 100bp superladder (50mg/ml) (Thermoscientific) 
 Ethidium bromide general purpose grade store at 4ºC (10mg/ml) (fisher scientific) 
2.3.2 Instruments-PCR 
 96 semi skirted well plate 
 Scales-(Mettler Toledo, PB3002-5 Delta Range® (monoBlock inside weighing 
technology)) 
 PCR thermocyclers: 
o GeneAmp® PCR system 9700 
o Eppendorf master cycler 
o Applied biosystems 2720 thermal cycler 
 Electrophoresis tank- (Fisher of Owl Scientific plastics submarine electrophoresis 
apparatus electrophoresis tank) 
 Electrophoresis power supply: 
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o Power pack LKB GPS 200/400, Pharmacia 
o Fisher Scientific power 300 electrophoresis power supply 
o Pharmacia Biotec electrophoresis power supply-EPS 300 
 Oven-Hybri Maxi oven (Hybaid) 
 Microwave- (Matsui 1755 sensor) 
 CD70 WPA pH meter 
 4RT Rocking table (genetic research instrumentation Ltd) 
 UV illuminator, Videographic printer, Camera (Sony UP-860) 
2.3.3 Primer Details 
The purchased oligonucleotide/primers were diluted to 100µMol to make a stock solution. The 
primers were then centrifuged at 12,000rpm for 1 minute, prior to use the primers were stored in 
the refrigerator at 4°C for at least 24 hours. The details of the specific primers are provided in the 
table below Table 4. 
Table 4-Primer details and preparation 
Variant Sequence Purchased 
concentration 
DNA/RNA 
free water 
added 
Final 
concentration 
Glu298Asp 
Forward 
primer 
5’- TCC CTG AGG AGG GCA TGA GGC 
T-3’ 
48.9nmol 480.9 µl 100 µMol 
Reverse 
Primer 
5’-TGA GGG TCA CAC AGG TTC CT-3’ 67.3nmol 673.0 µl 100 µMol 
Intron 4 
Forward 
primer 
5’-AGGCCCTATGGTAGTGCCTTT-3’ 38.9nMol 389.0 µl 100 µMol 
Reverse 
Primer 
5’- TCTCTTAGTTGCTGTGGTCAC-3’ 45.3nmol 453.0 µl 100 µMol 
This stock solution was further diluted to 10µMol working solution, for use in the PCR reactions. 
 
 
Chapter 2 – Methods 
67 | P a g e  
 
 
2.3.4 Tris Boric Acid EDTA (TBE) Buffer Preparation 
A 1X Tris Boric Acid EDTA (TBE) buffer was required for use in the standard PCR method, this 
was made from a stock solution of 5X TBE buffer. The details have been outlined below: 
1. 5X TBE buffer preparation 
5X TBE buffer was prepared by firstly adding 800ml of nuclease free water to a 2L glass beaker, 
to this the following were added to the beaker beginning with the largest quantity first: 
Tris base FW= 121.14     =54g 
Boric Acid FW= 61.83     =27.5g 
EDTA FW=292.25    =2.92g 
A magnetic stirrer flease was then placed into the 2l glass beaker containing the reagents, this was 
then placed onto the magnetic stirring machine. The speed was built up slowly beginning with 
350rpm and increasing to around 700rpm, this was maintained until the buffer was completely 
clear and the reagents were fully dissolved. Following this, whilst maintaining the stirring action 
on a rotation of approximately 550rpm the pH value was recorded using a pH meter. With the 
desired pH being 8.3, the pH was altered by adding hydrochloric acid to increase acidity (lower the 
pH) or by adding sodium hydroxide to make the solution more alkaline (increase the pH). This was 
done slowly until pH 8.3 was reached. Finally the buffer was made up to a total volume of 1000ml, 
by transferring the solution into a 1000ml measuring cylinder and topped up with DNA/RNA free 
water to the desired quantity. The solution was then transferred into a Duran bottle dated and 
labelled 5X TBE buffer.  
 1X TBE buffer preparation 
A concentration of 1x was required to prepare the agarose gel, this was done by adding 200ml of 
5X TBE buffer (measured using a measuring cylinder) to a Duran bottle labelled 1x TBE buffer, 
800ml of nuclease free water was measured using a 100ml measuring cylinder and added to the 
same Duran bottle, this was shaken well. This was a sufficient amount for preparation of 
approximately 5 electrophoresis gels. 
2.4 Glu298Asp (rs17999983) Method 
For the Glu298Asp variant a process of polymerase chain reaction followed by restriction fragment 
digestion (PCR-RFLP) was required. These steps were determined through a process of 
standardisation.  
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2.4.1 Glu298Asp PCR Protocol 
2.4.1.1 Preparing the Mastermix 
The first step in the PCR process was to make up a mastermix to which the target DNA would be 
added. The final quantities were determined through standardisation and were finalised as to make 
up a total of 19µl per sample. 
2X Reddymix
TM
 PCR mastermix                            =10µl 
Nuclease free water           =7.4µl 
Glu298Asp Forward primer (10µmol)     =0.8µl 
Glu298Asp Reverse primer (10µmol)     =0.8µl 
The mastermix solution was prepared by multiplying the quantities for the requisite number of 
samples (+10% of total sample number to account for potential pipetting errors) and adding them 
to a 2.0ml eppendorf tube (dated and labelled with the variant name) the resulting mastermix was 
then homogenised by firstly vortexing for 10 seconds and then secondly spinning using the 
centrifuge machine for a further 10 seconds at approximately 7000rpm. A total of 19µl of 
mastermix was required per sample. Depending on the number of samples being amplified in any 
one experiment, the choice of 0.2ml tubes (labelled on the side and lid with a number irrespective 
of the sample identification number) or a 96 semi-skirted well plate was made. 19µl of mastermix 
was then added to each tube/well. 1µl of DNA was then added to the tubes/wells containing the 
mastermix. In the case of the 0.2ml eppendorf tubes they were placed into the centrifuge and spun 
for 10 seconds on a speed of 9000rpm. In the case of the 96 well plate this was placed into the 
centrifuge at 12,000rpm for 1 minute. The tubes/plate now containing the mastermix and DNA 
were/was then loaded into the thermocycler and set to the following conditions. 
2.4.1.2 Glu298Asp PCR Conditions 
PCR was performed in a thermocycler and underwent a total of 30 cycles. Prior to the 30 cycles 
was a 5 minute hold at 94°C. Each cycle contained three steps; an initial 1 minute at 94°C (the 
denaturing of the DNA), Secondly was 1 minute at 61°C (the annealing of the primers), finally 1 
minute at 72°C (the extension phase). Following the 30 cycles the samples were held at 72°C for 7 
minutes then ∞ 4°C until they were removed.  
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The PCR product was 427bp in size, to determine the success of the PCR process a PCR check gel 
was required to detect the presence of a band of this size. The gel was prepared using the following 
gel electrophoresis protocol.  
2.4.2 Gel Electrophoresis Protocol 
Following a process of standardisation, in all cases a 2% agarose gel was the desired concentration 
for all gel runs. This was prepared as follows: The first step was using digital scales, 2g of agarose 
was measured and then added to a 250ml beaker. 100 ml of 1x Tris Boric Acid EDTA (TBE) 
buffer solution was measured using a 100ml cylindrical flask, this was then added to the 250ml 
beaker already containing the 2g agarose. The beaker was covered with cling film and pierced 
using scissors. The beaker was then placed into a microwave oven and heated for 2 minutes at 70% 
power, the contents were swirled and then heated for a further minute at 100% power. The contents 
were then viewed to determine if any bubbling had occurred and if the mixture was clear, if not 
further heating was undertaken at 20 second intervals, until the mixture bubbled and a clear 
solution was attained. The beaker was removed from the microwave ensuring oven gloves were 
worn to prevent any burning from the heat. The cling film was removed and using a thermometer 
the temperature was monitored and the agarose solution was allowed to cool at room temperature 
to around 65°c, cooling could be promoted at this point by carefully swirling the solution. 10µl of 
SybrSafe (or safeView) was added to the cooled gel and mixed thoroughly through a swirling 
action. 
During the cooling period, the gel cassettes were prepared by taping both ends to fully enclose the 
container, two gel combs were placed inside the cassette, separated evenly. The specific combs 
used varied dependent on how many samples were being analysed at the time. The container was 
then placed into a fume cupboard on a level surface verified by a spirit level to ensure an even 
spread of the solution. Once the agarose solution cooled to ~65°c it was poured into the container, 
pouring into the centre as quickly as possible. The gel was then left to set for half an hour within 
the fume cupboard with the fan on, if after this time the gel was not used immediately it was placed 
into the refrigerator until required, ensuring this was for no longer than a period of two hours. If 
this time was exceeded a fresh gel would be required. 
The tape was removed carefully and discarded; the container was then placed horizontally into the 
electrophoresis tank. 1x TBE buffer was added to the electrophoresis tank to ensure the gel wells 
were submersed by 3-5mm below the TBE buffer level, being careful not to fill above the 
designated fill line. The combs were removed with great care to prevent any splitting of the wells. 
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Note: in the case of the Glu298Asp variant, initially the gel preparation used ethidium bromide 
solution, however Sybrsafe was used as an alternative for safety reasons. Preparation included 
adding 10mg/ml of Ethidium bromide solution (stored at 4°C) to the 1X TBE buffer upon 
preparation, subsequently there was no addition of the sybrsafe during the cooling phase of the gel 
preparation. 
2.4.3 PCR Product Gel Loading 
The PCR product was removed from the machine and centrifuged on pulse for 10 seconds. Using a 
p20 micropipette 10µl of PCR product was added to each of the wells excluding wells 1 on each 
row, recording which sample went into each well. Tips were changed every time to prevent cross 
contamination. Following the loading of PCR product, 4µl of DNA superladder was added to well 
number 1 of each row, this is required as a reference for the judgement of the length of the bands. 
The electrophoresis tank power pack was attached to the anode and cathode of the gel tank lid 
accordingly, which was placed onto the tank, ensuring the cathode attachment occurred at the end 
where the PCR product was added. DNA has a negative charge so movement will be towards the 
positive anode.  Voltage was set to 125 volts and the electrophoresis machine was left to run for 
the specific length of time required. After the gel ran the machine was switched off and the gel 
removed with gloves, using a tray lined with blue towel, this was carried to the infra-red room 
where it could be viewed under an ultraviolet light on a UVP Transilluminator. A protective face 
mask was worn at all times to prevent any damage from the ultraviolet light. The sybrsafe allowed 
bands to be viewed on the gel under UV illumination of 254nm, a photograph was taken using the 
Videographic printer, and the imaged saved to disk for later reference. 
In the case of Glu298Asp PCR check gel the gel was run for approximately 30 minutes. PCR 
success was determined by the presence of a band at 457bp fragment. A sample gel can be seen in 
Figure 9. 
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Figure 9-Glu298Asp PCR product check gel 
The presence or absence of a visible band at 457bp in size indicated which samples would proceed 
to the RFLP phase of the study. An absence of a visible band indicated no DNA amplification had 
occurred during PCR, and therefore digesting these products would be wasteful of the expensive 
enzyme and buffer. 
2.4.4 Restriction Enzyme Digestion Protocol (Glu298Asp only) 
A mastermix was made up in a separate 2ml tube clearly labelled and kept on ice. The mastermix 
contained: 
Nuclease free water  =7.2µl 
Buffer 4    =2.0µl 
Enzyme BAN II   =0.8µl 
 
10µl of mastermix was required per 10µl of PCR product.  The amounts were multiplied by the 
number of samples being analysed, adding 10% to account for any possible pipetting errors that 
may occur. Each was added in the order stated above, using the smallest micropipette possible to 
increase accuracy. The mastermix was then centrifuged on pulse for 10 seconds. The enzyme BAN 
II cleaves the DNA at specific recognition sites, allowing determination of genotypes based on the 
presence or absence of these recognition sites thus the determination of genotype for the 
Glu298Asp variant. 
10µl of the mastermix was then added to each successful sample using a p10 micropipette, tips 
were changed each time to prevent contamination. All samples were centrifuged on pulse for 10 
seconds and placed into an oven at 37°c overnight for 20 hours. 
457bp 
indicates 
successful PCR 
amplification 
100bp 
ladder 
absent/too little 
amplification 
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2.4.5 Restriction Product Electrophoresis 
The gel was prepared following the ‘2% agarose gel protocol’ previously stated (section 2.4.2), the 
combs used for this gel were no larger than 16 wells per comb to ensure adequate separation 
occurred. 10µl of each restriction product was added using a p20 micropipette, tips were changed 
with every sample to avoid contamination. 4µl of a 100 base pair ladder was added to lane one of 
each row to use as a reference when comparing band size.  The electrophoresis machine was 
attached as before described in PCR product loading and run on 125volts for 45 minutes, or until 
adequate separation had occurred. Once more, the gel was photographed under ultraviolet light and 
the image saved. A sample gel is given in Figure 10. The genotypes were then scored, in the 
presence of no mutation one restriction site existed for the Ban II enzyme, subsequently 
fragmenting the PCR 457bp product into two fragments of 320bp and 137bp in size respectively. 
In the presence of the guanine to thymine SNP this restriction site was not present and therefore the 
PCR product was not cleaved, leaving the 457bp in its entirety. Thus the following genotypes were 
identified by bands of the following sizes; TT: one band at 457bp, GT: 3 bands, 457bp, 320bp and 
137bp, and GG: 2 bands 320bp and 137bp (Figure 10). 
 
Figure 10-Glu298Asp restriction digestion products 
 
2.5 Intron 4 Method 
In the case of the Intron 4 variant genotyping was possible immediately following PCR, no 
restriction digestion step was required for this variant. A VNTR polymorphism will result in 
different sized PCR amplified products, thus genotype can be determined following PCR. The 
materials and instruments and PCR mastermix were identical to those outlined in the Glu298Asp 
method with slight variations in the quantities, as well as different specific forward and reverse 
primers. 
100bp ladder 
TT genotype  
GG genotype  
GT genotype 
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2.5.1 Intron 4 PCR Protocol 
2.5.1.1 PCR Mastermix Preparation 
The final concentrations for the mastermix for this variant were determined following a process of 
standardisation and were as follows: 
2X Reddymix
TM
 PCR mastermix    =10µl 
Nuclease free water     =6µl 
Intron 4 Forward primer    =1µl 
Intron 4 Reverse primer     =1µl 
The total mastermix excluding the DNA totalled 18µl per sample. Note: The final PCR mastermix 
(including the DNA) was made up to a volume of 20µl, although only 10µl was required for the 
resulting agarose gel this allowed an additional 10µl in case a repeat run was required in the 
occurrence of problems viewing the gel. 
The stated amounts were multiplied by the number of samples adding 10% to account for any 
possible pipetting errors that may occur. Each was added in the order stated above, using the 
smallest micropipette possible to increase accuracy. The mastermix was vortexed for 5 seconds and 
centrifuged on pulse for 10 seconds. 18µl was added to each sample. The choice of 0.2ml tubes vs. 
a 96 well plate was determined as before based on the number of samples in the current reaction. 
2µl of the specific DNA was added to each well/tube carefully. In the case of the 0.2ml tubes they 
were placed into the centrifuge and spun for 10 seconds on a speed of 9000rpm in the case of the 
96 well plate this was placed into the plate centrifuge at 12,000rpm for 1 minute. The tubes/plate 
was then loaded into the thermocycler set to the following conditions for the Intron 4 variant. 
2.5.1.2 Intron 4 PCR Conditions 
PCR was performed in a thermocycler and underwent a total of 35 cycles. Prior to the 35 cycles an 
initial hold at 94 °C was undertaken. Each cycle contained the following three steps, an initial 30 
seconds at 94°c, 1 minute at 56°c and finally, 1 minute at 72°c. Following the 35 cycles the 
samples were held at 4°c until they were removed. 
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The PCR product was 420bp in size in the presence of the 5 27bp repeat (4b allele) or 393bp in the 
presence of the 4 27bp repeat (4a allele). To determine genotype the PCR products were run on a 
2% agarose gel. This was made up as before (2.4.2 Gel Electrophoresis Protocol) 
2.5.2 Intron 4 Electrophoresis 
The PCR product was loaded as stated in PCR Product Gel Loading (section 2.4.3) for the 
Glu298Asp variant. In the case of the Intron 4 variant the gel was run for approximately 1 hour 15 
minutes. The resulting genotypes for each DNA sample were viewed under the UV 
transilluminator as stated in the Glu298Asp PCR loading protocol. The genotypes were scored as 
4aa in the presence of one band at 393bp, 4ab in the presence of two bands at 393bp and 420bp or 
4bb in the presence of one band at 420bp only. Figure 11 shows an example of a typical gel from 
this variant. 
Figure 11-Intron 4 PCR products 
 
 
 
2.6 ACE (rs4646994) 
The ACE genetic variant was also genotyped using a standard PCR method, as with the Intron 4 
variant no RFLP step was required. This variant was genotyped prior to this study and the 
genotypes were made available. The details of this have been listed in appendix 2, section 8.2. 
2.7 T-786C (rs2070744) Method 
A small number of samples were genotyped using an alternative method (PCR-RFLP method) to 
that stated below, details of the original method can be found in the appendix 3, section 8.3.  
4ab 
genotype 
4bb 
genotype 
4aa genotype 100bp 
ladder 
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2.7.1 Q-PCR Overview 
The majority of the T-786C variant was determined using a different genotyping method to the 
other variants. In this case the DNA was amplified and genotyped using a real-time PCR method 
(qPCR). qPCR works by amplifying the target DNA much like a normal PCR reaction but the 
TaqMan® SNP genotyping assays utilises the minor groove binder (MGB) technology. The 
specific TaqMan® MGB probe (~13bp) will anneal to the specific complementary sequence 
between the forward and reverse primer sites. The VIC® reporter dye is linked to the allele 1 probe 
and will attach in the presence of the C allele. The FAM
TM 
dye is linked to the 5’ allele 2 probe and 
will attach in the presence of the T allele. As the AmpliTaq Gold® DNA polymerase extends the 
template DNA during the extension phase of PCR, the specific hybridised probe (allele 1 or 2) that 
has attached between the forward and reverse primer sites will be cleaved. The cleavage of the 
hybridised probes separates the quencher dye from the reporter dye, this results in an increase in 
the fluorescence signal of the reporter dye. Therefore the presence of an allele will be determined 
based on the intensity of the fluorescent signal of the respective reporter dye from the well 
(http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/real-time-
pcr/taqman-and-sybr-green-chemistries.html). 
qPCR has a number of advantages over standard PCR, it measures the PCR amplification as it 
occurs, as appose to at the end point of the experiment and subsequently it is a quantitative method. 
It is a more sensitive technique; detection may occur with as little as a 2-fold change. It is a highly 
automated technique and thus doesn’t require manual post-PCR processing therefore limiting the 
occurrence of general human error. This also means that it doesn’t require the use of an agarose gel 
and therefore limits the potential use of harmful substances such as ethidium bromide, and this also 
makes the whole process much faster due to the lack of a gel run and no requirement of a 
restriction digestion step (http://www.appliedbiosystems.com/absite/us/en/home/applications-
technologies/real-time-pcr/real-time-pcr-vs-traditional-pcr.html?ICID=EDI-Lrn2). 
2.7.2 Materials- qPCR 
 TaqMan® 2 X Universal PCR Master Mix, No AmpErase UNG (Stored at 4°C in the dark, 
Applied Biosystems) 
 TaqMan® SNP Genotyping Assay (20X) (Stored at -20°C, in the dark, Applied 
Biosystems): 
o Two specific primers – 
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required to amplify the target region containing the polymorphism very similar to 
stand PCR primers 
o Two specific allele TaqMan MGB probes containing: 
 A reporter dye at the 5’ end 
 A minor groove binder MGB  
 A non-fluorescent quencher (NFQ) at the 3’ end  
2.7.3 Instruments-qPCR 
 Applied Biosystems StepOnePlusTM Real-Time PCR System (StepOnePlusTM system)- 96 
well 
 Applied Biosystems StepOneTM Real-Time PCR System (StepOneTM system)- 48 well 
 MicroAmpTM Fast Optical 48-well reaction Plate 
 MicroAmpTM48-well Optical Adhesive Film 
 MicroAmpTM Fast Optical 96-well reaction Plate 
 MicroAmpTM 96-well Optical Adhesive Film 
 Magnetic stirrer- Fisher Scientific ISOtemp 
2.7.4 Pre PCR set up 
The TaqMan® SNP Genotyping Assay was custom made, following a comprehensive search no 
previous records were found of the real time PCR process being used for this variant. Prior to 
preparing the PCR reaction the TaqMan® SNP Genotyping Assay was of a medium scale at a 
concentration of 40x. The reaction required a 20x concentration, the 40x was diluted to 20x with 
1X TE buffer (10mM tris-HCL. 1Mm EDTA, pH8). The 1 x TE buffer was prepared from 100x TE 
buffer (49.5ml of 100 x TE buffer and 500µl of DNA free water), 625µl of 40X SNP genotyping 
assay was then added to 625ul of 1X TE buffer to make a final concentration of 20x. This was 
vortexed and aliquotted into quantities of 50µl into 1.5ml eppendorf tubes pre- labelled T-786C 
and dated, ready for use in the PCR reaction. 
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2.7.5 Setting up the PCR Mastermix 
For each reaction the following quantities were required: 
2XTaqMan® Universal PCR Mastermix Mix, No AmpErase      =5ul 
20X TaqMan® Drug Metabolism T-786C SNP Genotyping Assay     =0.5ul 
DNA free water                                   =3.5ul 
DNA (100ng/ml)                                                                      =1µl 
The designated quantities were increased relative to the requisite number of samples. Each reagent 
was added to a 1.5ml eppendorf and vortexed for 10 seconds then centrifuged on pulse for 10 
seconds.  
2.7.6 Preparing the Reaction Plate 
9µl of the reaction mix was added to each well of either the MicroAmp
TM 
Fast Optical 48-well 
reaction Plate or the MicroAmp
TM 
Fast Optical 96-well reaction Plate depending on the number of 
samples. Two negative controls were placed in position A1 and A2, three known positive controls 
(one representing each of the possible genotypes) were also run with each set up (determined 
following the first run). The positive controls were all from the diabetes samples DNA 6, 12 and 15 
corresponding to CC, TT and TC respectively. 1µl of DNA was then added to the remaining wells 
using a P2 micropipette.  
The plate was then covered using the appropriate MicroAmp
TM
 96-well Optical Adhesive Film or 
MicroAmp
TM
 46-well Optical Adhesive Film. 
2.7.7 Experiment set up  
The PCR thermal cycling steps were as followed: 
1. 60°C             30 seconds    
2. 95°C       10 minutes            
3. 92°C         15 Seconds      
4. 60°C             1 minute  
5. 60°C             30 seconds 
X 40 cycles of steps 3 and 4 
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The process began at step one and continued through, when reaching step 4, steps 3 and 4 were 
repeated a further 39 times. Following the total 40 cycles, the cycle proceeded onto step 5 for a 
post-PCR read of 30 seconds at 60ºC. 
To set the experiment up either the Applied Biosystems StepOnePlus
TM
 Real-Time PCR System 
(StepOnePlus
TM
 system) for 96 sample reaction or the Applied Biosystems StepOne
TM
 Real-Time 
PCR System (StepOne
TM
 system) for the 48 well reaction. A laptop was attached to the appropriate 
StepOne
TM 
machine via a modular connector plug. The experiment conditions were then set up 
following the flow diagram steps seen below (Figure 12-Figure 20). 
Figure 12- Experiment set up 1 
The experiment was 
named accordingly with 
the variant identification, 
which in this case was T-
786C, followed by the 
batch number and finally 
the date of the run. The 
appropriate instrument 
was selected in most 
cases this was the 
StepOnePlus 
TM
 96 well 
machine unless a smaller 
number of samples were 
being used, in which case 
the StepOne 
TM 
 48 well 
machine was used. Finally the type of experiment was selected which was in all cases 
‘Genotyping’. 
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Figure 13- experiment set up 2 
In all instances at this 
point the pre-
programmed choices 
were accepted which 
can be seen circled in 
red and next was then 
selected. 
 
 
 
 
 
Figure 14- experiment set up 3 
The number of SNP 
assays being run was 
entered as ‘1’ because 
only the T-786C variant 
was being analysed in 
this reaction. 
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Figure 15- experiment set up 4 
The number of samples 
was entered as ‘94’ (two 
negative controls were 
run in each 96 well plate 
reaction), this number 
was reduced accordingly 
if the plate was not full. 
The number of 
replicates was entered as 
‘1’, the number of 
negative controls was 
then entered as ‘2’ and 
these were automatically 
positioned in A1 and 
A2. Finally at this stage 
of the programming the 
number of positive 
controls was entered as ‘0’ as to control the positioning of these if in the case mastermix was 
limited or the plate was not entirely complete. ‘Next’ was then selected to proceed. 
Figure 16- experiment set up 5 
At this stage the 
specific run 
requirements 
were altered, 
under ‘Reaction 
Volume Per 
Well’ 10µl was 
entered (9µl 
PCR mastermix, 
1µl DNA). Then 
the temperature 
was altered to 
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‘92°C’ for the second step of the Cycling Stage. To proceed ‘Next’ was then selected. 
Figure 17- experiment set up 6 
This step was a 
reminder of the 
required reaction 
mix for the specified 
programme. 
Reaction volume 
was changed to 10µl 
solely for 
consistency. To 
proceed ‘Next’ was 
then selected. 
 
 
 
Figure 18- experiment set up 7 
This step provides 
information on how 
to order new 
materials, nothing 
was needed to be 
altered and ‘Finish 
Designing 
Experiment’ was 
selected. 
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Figure 19- experiment set up 8 
Following the 
selection of ‘Finish 
Designing 
Experiment’ this 
opened a new 
window to review 
the plate layout at 
which point ‘Edit 
Plate Layout’ was 
selected to enter the 
positioning of the 
three positive 
controls which were 
run with every 
batch. 
 
Figure 20- experiment set up 9 
This window shows 
the options for editing 
the plate layout and 
was done accordingly 
to each specific batch. 
In most cases well 9H 
corresponded to 
‘Positive Control 
/Allele 1/ Allele 1’ 
10H corresponded to 
‘Positive Control/ 
Allele 2/ Allele 2’ and 
11H corresponded to 
‘Positive Control / 
Allele 1/ Allele 2’. 
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The well was highlighted on the plate layout view and the respective choice was selected from the 
drop down menu beneath ‘Task’. When all three positive controls were identified ‘Start Run’ was 
selected, initiating the run.  
Prior to the start of the run, an option to save the experiment appeared and this was saved into a 
specific file on the laptop. The instrument was then left to run for approximately 1 hour 15 
minutes. The exact time remaining was displayed on the machine. After this time, the results could 
be viewed on a discrimination plot Table 5 summarises how this works.  
Table 5- T-786C discrimination plot key 
Genotype Result 
TT Increase in FAM
TM 
 fluorescence only 
TC Increases seen in both  FAM
TM 
and VIC® fluorescent signals 
CC Increase in VIC® fluorescence only 
 
Figure 21 provides an example of the output T-786C discrimination plot. 
 
 
Figure 21-T-786C discrimination plot 
 
TT genotype 
TC 
genotype 
CC 
genotype 
Undetermined result 
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2.8 Considerations 
2.8.1 General Considerations 
2.8.1.1 Waste Disposal 
All materials considered sharp, including pipette tips and eppendorf tubes were disposed of in the 
sharps bin. Any other clinical waste was disposed in clinical waste bags.  All clinical waste was 
then incinerated. 
2.8.1.2 Dilution of DNA 
Where possible the DNA was diluted to be conservative with materials this was done by adding 
5µl of neat DNA into 45µl of nuclease free water into a 2ml eppendorf tube clearly labelled on the 
side and top of the tube with the corresponding identification number. 
2.8.1.3 Accuracy of Results 
 Sample identification 
All DNA samples were given an identification number to protect the privacy of the participants. 
The disease status was ideally unknown to help prevent any possible strategic genotyping. Finally 
all additional information provided for the samples was not given until all samples had been 
genotyped, as to prevent any possible influence. 
 No result 
In the case of either no result or an ambiguous result there was a requirement for a repeat run. For 
the specific sample the quantity of DNA was increased initially to 2µl and if a further repeat was 
necessary then 3µl. The increase in DNA was subsequently accounted for by a corresponding 
reduction in nuclease free water within the mastermix.  
 Staining with Ethidium Bromide 
In a number of cases during the use of the agarose gel, viewing the presence or absence of the 
bands could be difficult, due to a faintness of the bands. In this case it was required to stain the gels 
with ethidium bromide. This was done by adding 10µl of ethidium bromide (10mg/ml, stored at 
4°C) and 90µl of nuclease free water. This was added to a tuppawear box labelled toxic and the gel 
was placed into this with then the box was secured with a lid. This was then placed onto a 4RT 
rocking table to fully stain the subsequent bands for a duration of 10 minutes. The gel was then 
viewed again under the transilluminator and rescored. 
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 Second genotyping 
The genotyping was scored independently in a small number of cases to ensure this was done 
correctly. In most cases scoring of the genotypes was done directly when viewing the gel under the 
UV transilluminator because this was deemed to provide the clearest result and a second individual 
would not be available in this situation. 
 Repeat samples 
A number of samples were repeated blindly through the entire PCR genotyping process to ensure 
consistency in the scored genotypes.  
 Excess volumes 
Excess volumes were included during the reaction preparation within calculations to allow for any 
possible loss that may occur during the reagent transfer through pipetting. As a standard this was 
done by increasing the multiplication process by 10% of the sample size being dealt with at that 
particular stage.  The smallest pipette size possible was used this increased pipetting accuracy and 
subsequently helped limit the loss of material during reagent transfer. 
2.8.1.4 Contamination Prevention 
 Separate pre and post PCR areas 
PCR is a highly sensitive technique a great deal of care was taken to prevent contamination, and 
ensure the amplification was of the specific unknown DNA only. Separate pre-PCR preparation 
and post PCR areas were used to limit this. 
 Autoclaving 
The process used a number of eppendorf tubes, and pipette tips, therefore offering multiple 
entrances for foreign material. To avoid contamination through these means autoclaving was used 
to sterilise the materials. 
 DNA away and ultra violet light 
All surfaces were wiped down with DNA away both before and after the PCR set up preparation. 
Further to this although materials were autoclaved they were placed for 10 minutes under an 
ultraviolet light as an extra precaution prior to use. 
 Gloves and lab coats 
Gloves and lab coats were worn throughout all laboratory based work for two main reasons; firstly 
to prevent contamination and secondly to provide an initial physical barrier between direct skin 
contact with materials. 
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 Negative controls 
Finally to determine if contamination had occurred with every batch of samples run, at least one 
negative control was included. This was done by adding nuclease free water for the required 
amount (1-3µl) instead of an unknown DNA sample. A presence of a PCR product in this sample 
would then indicate that contamination of DNA had occurred.  
2.8.2 PCR Specific Considerations (Glu298Asp and Intron 4 only) 
 Target DNA 
The amount of target DNA for PCR should be between 0.1 and 1µg in a total reaction volume of 
100µl. If the quantity is too small there will be inadequate amplification for the remaining 
experimental procedures. If the DNA quantity is too great this may yield non-specific PCR 
products. 
 Oligonucleotide primers 
The length of the primer should be between 10 and 24 base pairs. The specific amount of guanine 
and cytosine should be between 40-60%. It is most important that the primers are not self 
complimentary, and complimentary base pairing is only occurring between the primer and the 
specific corresponding region of the target DNA. The primers have specific melting temperatures 
corresponding to the base component and the primer melting temperatures (the temperature at of 
annealing of 50% of the primer molecules to their complimentary sequence) need to be within 5°C 
of one another. The specific primer melting temperature (Tm) can be worked out using one of the 
two following equations: Tm=4(G+C)+S(A+T) or  Tm= 81.5 + 16.6 × (log10[Na
+
]) + 0.41 × 
(%G+C) – 675/n where [Na+] is the molar salt concentration and n = number of bases in the 
oligonucleotide primer. The annealing temperature is based on the Tm and should be 
approximately 5°C below that of the Tm.  
 Mg+ ions 
MgCl2 because Mg
+ 
ions are necessary to form complexes with the dNTPs, oligonucleotide primers 
and the target DNA, all these factors affect the amount of free Mg
+ 
ions available. The Mg
+
 ions 
are required for DNA polymerase enzyme activation; if there are too many Mg
+ 
ions this can result 
in non specific PCR products.  However, if the Mg
+
 ions are too few then this may result in a low 
yield of PCR product. Typically a concentration of 1 to 3mM is required. 
 Taq DNA polymerase 
If the concentration of DNA polymerase is too high once more this can result in the formation of 
non-specific products. Promega recommend 1-1.25 units of DNA polymerase for a standard 50µl 
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reaction. Further increasing the concentration of DNA polymerase will increased the formation of 
non specific PCR products and result in smearing on the agarose gels during post PCR procedure. 
 Buffer considerations 
The buffer is required for PCR to regulate the pH of the reaction. This affects both the enzyme 
activity and fidelity. KCL can increases the DNA polymerase activity by 50-60% in comparison to 
reactions without KCL, an amount of 50mM KCL is considered ideal for most PCR reactions. 
References: 
http://www.dnalc.org/resources/animations/pcr.html 
http://irc.igd.cornell.edu/MolecularMarkers/PCR%20basics.pdf 
2.8.3 Real time PCR Considerations (T-786C only) 
 The assay mix was protected from light and stored in the freezer at -20°C to prevent excess 
exposure to light which could affect the fluorescent probes. 
 A non-fluorescent quencher (NFQ) at the 3’ end which allows the detection of the reporter 
dye fluorescence with better intensity than if a fluorescent quencher were used. 
 TaqMan® 2 X Universal PCR Master Mix, No AmpErase UNG contains a chemical 
hazard and can cause eye and skin irritation. Extra precaution was taken when handling 
this. 
2.9  Statistical Analysis 
Statistical analysis was carried out using the computer packages EXCEL and PAWS statistics 
(version 18.0).  
2.9.1 Genotype and Allele Frequencies 
Genotypes were determined by viewing the presence or absence of bands. The genotypes were 
scored, allele frequencies were calculated by allele counting. Genotypes were presented as both a 
count and a percentage. In all cases there were three possible genotypes, and allele frequencies (p 
or q) were calculated using the following equation: 
Allele frequency (p) = ((2*homozygotes) + heterozygotes)/(2*N) 
Where N is the total number of individuals. 
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2.9.2 Tests for Hardy-Weinberg Equilibrium 
All samples were tested for deviation from Hardy-Weinberg equilibrium (HWE). It has the 
following basic assumptions; firstly that the allele frequencies remain constant overtime through 
the following considerations: there is no considerable mutation, individuals with all genotypes 
have the capability to mate and thus pass on their genes, there is no significant immigration of 
individuals with varying allele frequencies from other population groups into the endogenous 
population. Secondly that the population is large and there is random mating with respect to the 
locus in question (Nussbaum et al. 2004). HWE investigates if the three possible genotypes are in 
relation to the binomial expansion:  
(p+q)
2
 = p
2
+2pq+q
2
 
The equation is used to calculate the expected numbers and then a chi-square test compares the 
observed numbers with the expected numbers, with respect to the degrees of freedom.  
Degrees of freedom =number of genotypes-number of alleles. 
This analysis was done using an online programme (http://ihg.gsf.de/cgi-bin/hw/hwa2.pl.). 
Providing a pearson’s goodness-of-fit-chi-square (degree of freedom=1), a Log-likelihood ratio 
chi-square (degree of freedom=1) and P value for the exact test. 
This programme also calculated an F value representing the inbreeding coefficient. This describes 
the level of heterozygosity in a population, measuring the reduction in heterozygotes compared to 
the levels evaluated through HWE. 
2.9.3 Differences Between Groups 
Independent samples t-test using PAWS statistics 18.0 software was used to analyse differences 
between the means of continuous variables. Two-tailed p values of <0.05 were taken to be 
statistically significant. Discrete variables were evaluated for significant differences using cross 
tabulation analysis.  
2.9.4 Genetic Association Analysis Tests 
To assess the association of disease risk between variables, odds ratios (OR) were calculated using 
a contingency programme with 95% confidence intervals (CI). The basic equation used to 
determine an OR is: 
OR=(ad)/(bc) 
a=number of patients positive for the marker 
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b=number of controls with the marker 
c= number of patients with the marker 
d=number of controls without the marker 
The OR can then be interpreted by the following: 
 OR value=1 if the genetic marker has no influence on the disease 
 OR>1 then the genetic marker is positively associated with the disease (increased 
susceptibility) 
 OR<1 then the genetic marker is negatively associated with the disease (protective) 
The genotype ORs were calculated using a contingency chi-square programme in excel under the 
following models: 
Dominant: A single copy of the risk allele increases the risk of disease 
Recessive: two copies of the risk allele are required for an increased risk  
A second method provided by the Institute of Human Genetics accessed via the link: 
http://ihg.gsf.de/cgi-bin/hw/hwa1.pl enables ORs to be calculated under a number of difference 
models full details can be found on the website. Listed below is a summary of the main ORs 
calculated. 
Calculations were done using the following equations with allele 1 being the wild type allele and 
allele 2 being the polymorphism: 
 Heterozygous: (Case_12 * Control_11) / (Case_11 * Control_12) 
 Homozygous: (Case_22 * Control_11) / (Case_11 * Control_22) 
 Allele positivity: ((Case_12+Case_22) * Control_11) / (Case_11 * 
(Control_12+Control_22)) 
 Armitage’s common trend: (Case_12*Control_11/N01 + Case_22*Control_12/N12 + 
4*(Case_22*Control_11/N02))/(Case_11*Control_12/N01 + Case_12*Control_22/N12 + 
4*(Case_22*Control_11*Case_11*Control_22)*0.5/N02) 
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2.9.5 Logistic Regression 
Logistic regression was run to incorporate multiple covariates and adjust ORs, determining the 
significance of each covariate as an independent predictor variable. This was run using the PASW 
statistics version 18 software. Covariates were always made dichotomous by recoding into a new 
variable if multiple groups were used. The reference group was always coded 0 and was dedicated 
as such based on the literature. Details of this are provided in the text. The logistic regression was 
always run twice, once considering a dominant model and then again considering a recessive 
model. 
2.9.6 Haplotype Analysis 
Haplotype analysis was run using the online programme SNPSTATs web tool for SNP analysis 
provided by Institut Català d'Oncologias and accessed through: 
http://bioinfo.iconcologia.net/snpstats/start.htm. When analysing multiple SNPs of the same gene, 
as is the case in the current study it will perform, linkage disequilibrium statistics, haplotype 
frequency estimations, and analysis of haplotype association with disease outcome. 
2.9.7 Linkage Disequilibrium Analysis 
Linkage disequilibrium is used when two alleles at two loci are inherited together more frequently 
than expected with independent assortment.  In other words, linkage disequilibrium describes the 
correlation between two variants located on the same chromosome. During recombination sections 
of different copies of chromosome pairs are interchanged. This results in different combinations of 
the maternal and paternal chromosomes. Recombination (crossing over) is less likely to happen 
when the variants are located closer together (they are more likely to be inherited together). This 
results in the variants closely located to those causal of disease to be identified as associated with 
the disease.  
The combination of variants that are transmitted together in all the resultant chromosomes is 
referred to as a haplotype. Linkage disequilibrium has been calculated using the online web based 
SNP analysis SNPStats accessed through the link: http://bioinfo.iconcologia.net/en/SNPStats_web. 
This website determined linkage disequilibrium through the D statistic which analyses the expected 
haplotype frequency’s deviation (assuming zero association) from the observed frequency.  
D= 12p - 1p 2p  
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Where P1 and P2 are the probabilities of two alleles. And P12 is the observed probability of them 
both. The D’ statistic is also provided which is equal to D scaled in [-1,1] , finally the correlation 
between the alleles by a r correlation coefficient . A value of 0 implies independence of the alleles, 
whilst a value of 1 implies that the two copies of the rare allele will always occur with one of the 
alleles in the second locus.  
2.9.8 Bonferroni Correction 
When doing multiple comparisons and statistical tests on the same individuals, there is a possibility 
that 1 in 20 would be statistically significant by chance alone. The Bonferroni corrected p value is 
an adjusted p value to reflect this issue. To correct for this the total number of chi-square related 
tests on each sample was calculated. To minimise the effect of multiple comparisons the corrected 
p values is adjusted by dividing the nominal p value (0.05) by the total number of comparisons.   
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3 Chapter 3-CAD in North Indians 
3.1 Introduction 
Coronary artery disease (CAD) was the first disease evaluated for its association with eNOS gene. 
The literature review revealed a number of studies reporting association of the eNOS gene with 
CAD and other CVDs. However, the association remains inconclusive with a number of studies 
failing to replicate these findings (see Chapter 1, section 1.7). 
The aim of this study is to document genetic variation at the Glu298Asp, T-786C and Intron 4 loci 
of the eNOS gene and their role in CAD within a North Indian population. The deletion variant of 
the Angiotensin-converting enzyme (ACE) gene was also analysed for a possible association with 
CAD and its interactive effect with the eNOS gene variants. The guiding hypothesis for this work 
was:  
H0= The Glu298Asp, T-786C, Intron 4 and ACE variants are not significantly associated with 
CAD in a North Indian population. 
H1= The Glu298Asp, T-786C, Intron 4 and ACE variants are significantly associated with 
CAD in a North Indian population. 
3.2 Samples and Methods 
The full methodology and individual genotyping protocols have been described in Chapter 2. The 
Glu298Asp variant was successfully genotyped for 443 patients and 218 controls. The T-786C 
variant was genotyped for a total of 437 patients and 212 controls using a combination of real time 
and PCR-RFLP, and 384 patients and 187 controls for the real time method only. Finally, the 
Intron 4 variant was successfully genotyped in 457 patients and 220 controls. The ACE 
polymorphism information was available for all samples. For details of statistical analyses see 
section 2.9. 
3.3 Results  
The result section is initially organised according to individual locus analysis followed by analysis 
at all loci level. This was done to understand the spectrum of genetic variation and its contribution 
to the disease.  
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3.3.1 Glu298Asp Results 
3.3.1.1 Baseline Characteristics for the Glu298Asp Variant 
The CAD and control groups were significantly different in nearly all of the continuous variables 
(Table 6). The CAD group were significantly older than the control group with a mean age of 
50.803 years compared to 44.225 years  in the control group (t=6.270, p<0.001).  Age was matched 
at the time of sampling, however some individuals were excluded due to poor quality of DNA 
leading to non-amplification, this may have led to this imbalance. 
Significant differences (p<0.001) were also seen between the CAD and control groups for all but 
one of the lipid parameters (TC, HDL, LDL and VLDL).  There was no significant difference 
between mean TG levels (t=0.288, p=0.773). 
Table 6- Glu298Asp baseline characteristics and independent samples t-test for continuous variables between CAD 
patients and controls 
Variable Disease status N Mean 
Std. 
Deviation 
Std. Error 
Mean t value 
Mean 
difference 
p 
value 
Age (years) 
Control 218 44.225 13.255 .898 6.270 -6.578 <0.001 
Patient 441 50.803 12.374 .589       
TC (mg/dl) 
Control 211 139.735 33.367 2.297 *10.577 -36.554 <0.001 
Patient 420 176.288 52.920 2.582       
TG (mg/dl) 
Control 211 138.393 66.515 4.579 *0.288 -2.056 0.773 
Patient 421 140.449 112.263 5.471       
HDL (mg/dl) 
Control 211 30.052 10.876 .749 *12.748 -49.815 <0.001 
Patient 421 79.867 78.693 3.835       
LDL (mg/dl) 
Control 210 83.586 25.706 1.774 *7.135 -20.793 <0.001 
Patient 415 104.379 47.099 2.312       
VLDL (mg/dl) 
Control 174 28.718 12.157 .922 *6.251 -7.732 <0.001 
Patient 414 36.450 16.783 .825       
APOB (mg/dl) 
Control 174 107.292 46.882 3.554 8.191 -40.328 <0.001 
Patient 174 147.620 44.947 3.407       
 
        
*equal variances not assumed 
The categorical variable results are presented in Table 7. Significant differences were found 
between gender (χ2=17.074, p<0.001), smoking (χ2=9.148, p<0.001), age distribution (χ2=52.583, 
df=2, p<0.001) and Ht (χ2=12.695, p<0.001). 
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The categorical variables were then tested for CAD association and odds ratios (ORs) were 
calculated with a 95% confidence interval (95% CI) (Table 7). Male gender was shown to be 
associated with an increased CAD risk (OR=2.36 (CI: 1.58-3.54), p<0.001). Smoking was also 
confirmed as a significant risk factor for CAD (OR=1.69 (CI: 1.21-2.37), p=0.002). A Non-
Vegetarian diet was not found to be associated with CAD (OR=1.30 (CI: 0.91-1.84), p=0.179) in 
this population. 
Table 7- Glu298Asp categorical variables in CAD patients and controls and Odds Ratios (ORs) for CAD 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 382 (86.4%) 159 (72.9%) 2.36 (1.58-3.54) 17.074 <0.001 
Female 60 (13.6%) 59 (27.1%) 0.42 (0.28-0.63)    
Total 442 (100.0%) 218 (100%)       
Smoking          
Smoker 218 (54.4%) 90 (41.3%) 1.69 (1.21-2.37) 9.148 0.002 
Non smoker 183 (45.6%) 128 (58.7%) 0.59 (0.42-0.82)    
Total 401 (100%) 218 (100%)      
Diet          
Non vegetarian 235(55.3%) 85 (48.9%) 1.30 (0.91-1.84) 1.809 0.179 
Vegetarian 190 (44.7%) 89 (51.1%) 0.77 (0.54-1.10)    
Total 425 (100.0%) 174 (100.0%)      
Age (years)          
≤39 (1) 69 (15.6%) 90 (41.3%) 3 vs.1+2 52.583 (DF=2)  <0.001 
40-54 (2) 171 (38.6%) 62 (28.4%) 1.92 (1.37-2.72) 13.55 <0.001 
>55 (3) 201 (45.4%) 66 (30.3%) 3+2 vs. 1    
  443 (100%) 218 (100%) 3.79 (2.62-5.50) 50.99 <0.001 
Family History        
absent 114 (72.2%) 44 (100%) Not possible *15.665 <0.001 
present 44 (27.8%) 0 (0%)     
Total 158 (100%) 44 (100%)      
Hypertension          
absent 127 (76.5%) 44 (100%) Not possible *12.695 <0.001 
present 39 (23.5%) 0 (0%)     
Total 166 (100%) 44 (100%)      
*cell with less than 5 (χ2 values not valid) 
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3.3.1.2 eNOS Glu298Asp Genotype and Allele Frequencies 
Table 8 shows the distribution of the genotypes and alleles among the CAD patient and control 
groups. The CAD patient genotype frequencies were 63.43%, 32.51% and 4.06% for GG, GT and 
TT respectively while the control genotype frequencies were 69.72%, 27.52% and 2.75% 
respectively. The G allele and GG genotype showed the highest frequencies in both groups. 
There was no significant departure from HWE (Table 8), using three tests: Pearson’s goodness of 
fit chi square, log likelihood ratio chi square or P exact test, (p>0.05). The inbreeding coefficient F 
(the fixation statistic) was also determined; this value was found to be low at 0.0397 and 0.00183 
for patients and controls respectively. 
Table 8- Glu298Asp genotype frequencies, allele frequencies and Hardy-Weinberg equilibrium tests for 
the CAD patient and control groups 
  CAD Patients (n=443) CAD controls (n=218) 
Genotype frequencies 
GG  281 (63.43%) 152 (69.72%) 
GT 144 (32.51%) 60 (27.52%) 
TT 18 (4.06%) 6 (2.75%) 
Total 443 (100%) 218 (100%) 
Allele frequencies   
Allele G 0.797 0.835 
Allele T 0.203 0.165 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.004 0.002 
P-Pearson's goodness of fit χ2 (DF=1) 0.933 0.978 
P-Log likelihood ratio χ2 (DF=1) 0.934 0.978 
P Exact test 1 1 
3.3.1.3 Association between the Glu298Asp polymorphism and CAD Risk 
The Glu298Asp variant was assessed for possible CAD association and ORs were calculated. 
These are presented firstly for the T allele as the risk factor (Table 9), and secondly for the G allele 
as the risk factor (Table 10). None of the ORs achieved statistical significance though some were 
above 1. However there was a general association towards the T allele and an increased risk of 
CAD in a non significant manner. This was most prominent under the TT vs. GG+ GT model 
(recessive) (OR=1.623 (CI: 0.631-4.174), p=0.311) (Table 9). At an allelic level the T allele 
showed an increased risk of CAD (OR=1.289 (CI: 0.95-1.74), p=0.098) whilst the G allele 
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suggested a protectiveness against CAD (OR=0.766 (CI: 0.57-1.05), p=0.098), neither result 
reached statistical significance. 
Table 9- Glu298Asp Odds Ratios (ORs) for CAD association (T risk allele) 
Glu298Asp CAD association  OR 95% CI χ2 P 
T vs. G 1.289 0.95-1.74 2.74 0.098 
GT vs. GG 1.298 0.91-1.86 1.03 0.155 
TT vs. GG+ GT 1.623 0.63-4.17 1.03 0.311 
TT + GT vs. GG 1.328 0.94-1.88 2.56 0.110 
Armitage's trend test 1.290   2.74 0.098 
 
Table 10- Glu298Asp Odds Ratios (ORs) for CAD association (G risk allele) 
Glu298Asp CAD association  OR 95% CI χ2 P 
G vs. T 0.766 0.57-1.05 2.74 0.098 
GT vs. TT 0.800 0.30-2.11 0.20 0.652 
GG vs. TT+GT 0.616 0.24-1.59 1.03 0.311 
GG+GT  vs. TT 0.668 0.26-1.71 0.72 0.397 
Armitage's trend test 0.777   2.74 0.098 
3.3.1.4 Glu298Asp Logistic Regression 
Logistic regression was performed to calculate the effect of the Glu298Asp variant on CAD status 
while adjusting for other covariates. 341 samples were included in analysis and 320 were excluded 
due to missing data on some of the covariates. 
Table 11 presents the reference groupings for the categorical variables included in the analysis. 
Table 11-Reference groupings for the categorical variables included in the Glu298Asp CAD logistic 
regression analysis 
 Covariate Reference Group Parameter 1 
Glu298Asp (dominant) GG GT+TT 
Glu298Asp (recessive) GG+GT TT 
Gender Female Male 
Smoking Non smoker Smoker 
Diet Vegetarian Non-vegetarian 
Occupation Heavy moderate +sedentary 
3.3.1.4.1 Logistic Regression for a Dominant Model  
The classification table revealed 50.9% of patients were correctly predicted without considering 
any other variables. Model 1 included the Glu298Asp variant only, this model successfully 
predicted 52.8% of CAD cases correctly. Model 1 was not a significant predictor of disease 
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outcome (χ2=0.918, 1df, p=0.338), this was confirmed by the Hosmer and Lemershow test 
(p<0.001).  The Wald test revealed that the Glu298Asp variable was not an independent risk factor 
(OR=1.245 (CI: 0.795-1.950), p=0.338). 
The model was then rerun to include diet, sex smoking and age (Model 2). The omnibus test of 
model coefficients revealed the Model to significantly predict CAD status (χ2=21.949, df=5, 
p=0.001), this was confirmed by the Hosmer and Lemeshow test (p=0.556).  The Glu298Asp 
variant had a slightly increased associated risk but remained non significant (OR=1.350 (CI: 0.846-
2.152), p=0.208). Smoking and age were both found to be independent risk factors for CAD 
(p<0.05) in this population. 
Table 12- Model 2: Glu298Asp dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age and diet 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp  0.300 0.238 1.585 0.208 1.350 0.846 2.152 
Gender  -0.234 0.317 0.543 0.461 0.791 0.425 1.474 
Smoking status  0.486 0.241 4.067 0.044 1.626 1.014 2.609 
AGE (in years) 0.032 0.009 12.875 <0.001 1.033 1.015 1.051 
Diet  -0.310 0.231 1.804 0.179 0.733 0.466 1.153 
Constant -1.594 0.513 9.661 0.002 0.203     
The Model was then extended to include lipid parameters (Model 3). This Model was the best 
predictor of disease status, (χ2=151.236, df=11, p<0.001), the Hosmer and Lemeshow test 
confirmed this to be significant (p=0.311). Model 3 was shown to successfully predict 78.6% of 
CAD status correctly. The Glu298Asp variant was found to have an increased OR value (OR=1.44 
(CI: 0.806-2.585), p=0.217). This was the highest OR of the variables included in the Model 
closely followed by smoking status. The only variables identified as independent predictors in the 
final model were age, VLDL cholesterol and APOB each with very low effect sizes.  
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Table 13- Model 3: Glu298Asp dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age, diet and lipid parameters. 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp  .367 .297 1.527 0.217 1.444 .806 2.585 
Gender  -.394 .405 .947 0.330 .674 .305 1.491 
Smoking status .330 .304 1.178 0.278 1.391 .766 2.526 
AGE (in years) .045 .011 15.208 <0.001 1.046 1.022 1.069 
Diet  .037 .290 .016 0.898 1.038 .588 1.833 
TC (mg/dl) .013 .007 3.118 0.077 1.013 .999 1.027 
TG (mg/dl) -.002 .003 .254 0.614 .998 .992 1.005 
HDL (mg/dl) .024 .016 2.164 0.141 1.024 .992 1.058 
LDL (mg/dl) .008 .007 1.270 0.260 1.008 .994 1.023 
VLDL (mg/dl) .057 .018 10.361 0.001 1.059 1.023 1.096 
APOB (mg/dl) .012 .003 14.770 <0.001 1.012 1.006 1.018 
Constant -8.844 1.117 62.735 <0.001 .000     
The logistic regression was also undertaken assuming a recessive model (GG+GT as the reference 
category); the complete data has not been included due to the similarity with the dominant model 
results. Table 14 summarises the key findings of both a dominant and a recessive model of the 
Glu298Asp variant. 
Table 14- Key findings of the CAD Glu298Asp logistic regression analysis for the three models 
Dominant Model 1 Model 2 Model 3 
Goodness of fit chi square 0.918 21.949 151.236 
significance 0.338 0.001 <0.001 
Hosmer and Lemershow <0.001 0.556 0.311 
Percentage correctly predicted 52.80% 58.70% 78.60% 
Glu298Asp  1.245 (0.795-1.950) 1.33 (0.836-2.123) 1.44 (0.806-2.585) 
Recessive Model 1 Model 2 Model 3 
Goodness of fit chi square 0.141 20.41 149.77 
Significance 0.707 0.001 <0.001 
Hosmer and Lemershow <0.001 0.602 0.33 
Percentage correctly predicted 51.30% 60.40% 77.70% 
Glu298Asp 1.260 (0.377-4.208) 1.158 (0.331-4.049) 1.237 (0.274-5.582) 
The Glu298Asp variant failed to be a significant independent risk factor for CAD following 
adjustment for the classical risk factors. Around 80% of CAD cases were successfully predicted by 
these risk factors. 
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3.3.1.5 Relationship of Genotypes with Lipid Parameters  
Pairwise comparisons of genotypes (TT vs. GG, TT vs. GT and GT vs. GG) for various lipid 
parameters did not reveal any statistically significant differences.  The TT genotype was generally 
found to have higher values for TC, TG, HDL, LDL, VLDL with the exception of APOB which 
was found to be lower. The individual tables are presented in appendix 4 (section 8.4). 
3.3.1.6 eNOS Glu298Asp Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Glu298Asp variant had disease association 
in high risk groups, these are presented in Table 15. The Glu298Asp variant was shown to be a 
significant risk factor for CAD under a dominant model amongst individuals who have ever 
smoked, (OR=2.84 (CI: 1.61-5.00), p<0.001) and amongst individuals who were current smokers 
(OR=2.48 (CI: 1.40-4.41), p=0.002.) No significant effects were found for this variant under 
gender or age group analysis (p>0.05). 
 
Table 15- Glu298Asp genotype frequencies and CAD association in subgroup analysis by gender, smoking 
behaviour and age 
 Controls Patients Model OR (95%CI) χ2 P 
Gender 
Males only            
GG 110 (69.2%) 239 (62.6%) TT vs. GT+GG 1.26 (0.45-3.52) 0.036 0.85 
GT 44 (27.7%) 128 (33.5%) TT+GT vs. GG 1.34 (0.90-1.99) 1.868 0.172 
TT 5 (3.1%) 15 (3.9%)         
 Total  159 (100%)  382 (100%)         
Females only          
GG 42 (68.9%) 42 (72.4%) TT vs. GT+GG 3.05 (0.31-30.22) *0.242 0.623 
GT 16 (26.2%) 15 (25.1%) TT+GT vs. GG 1.12 (0.49-2.53) 0.003 0.957 
TT 3 (4.9%) 1 (1.7%)         
Total  61 (100%)  58 (100%)         
Smoking habit 
Ever smoked            
GG 71 (78.9%) 137 (56.8%) TT vs. GT+GG 1.71 (0.36-8.06) *0.114 0.735 
GT 17 (18.9%) 95 (39.4%) TT+GT vs. GG 2.84 (1.61-5.00) 12.707 <0.001 
TT 2 (2.2%) 9 (3.7%)         
Total 90 (100%) 241 (100%)         
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 Controls Patients Model OR (95%CI) χ2 P 
Current smoker            
GG 71 (78.9%) 131 (60.1%) TT vs. GT+GG 1.68 (0.35-8.05) *0.089 0.765 
GT 17 (18.9%) 79 (26.2%) TT+GT vs. GG 2.48 (1.40-4.41) 9.156 0.002 
TT 2 (2.2%) 8 (3.7%)         
Total 90 (100%) 218 (100%)         
AGE groups           
≤39 years            
GG 59 (65.6%) 46 (66.7%) TT vs. GT+GG 1.31 (0.18-9.57) *0.058 0.81 
GT 29 (32.2%) 21 (30.4%) TT+GT vs. GG 0.95 (0.49-1.85) 0.000 0.982 
TT 2 (2.2%) 2 (2.9%)      
Total 90 (100%) 69 (100%)         
40-54years           
GG 47 (75.8%) 108 (63.2%) TT vs. GT+ GG 1.47 (0.30-7.13) *0.014 0.906 
GT 13 (21.0%) 55 (32.2%) TT+GT vs. GG 1.83 (0.95-3.53) 2.726 0.099 
TT 2 (3.2%) 8 (4.7%)      
Total 62 (100%) 171 (100%)         
≥55 years            
GG 46 (69.7%) 127 (63.2%) TT vs. GT+ GG 1.3 (0.27-6.41) *0.000 0.983 
GT 18 (27.3%) 66 (32.8%) TT+ GT vs. GG 1.34 (0.74-2.44) 0.66 0.42 
TT 2 (3.0%) 8 (4.0%)      
Total 66 (100%) 201 (100%)         
*cell with less than 5 (χ2 values not valid) 
3.3.1.7 Patient Only Analysis 
A small number of samples had information for the presence of hypertension (Ht). Table 16 shows 
the results for Glu298Asp association with this disease. In patients only the Glu298Asp did not 
show an association with Ht under either a dominant or a recessive model (p>0.05).  
Table 16- Glu298Asp Odds Ratios (ORs) calculations for Ht association in the CAD Patient group only 
CAD 
Patients 
only 
Controls Patients Model OR (95%CI) χ2 P 
Ht             
GG 81 (63.8%) 28 (71.8%) TT vs. GT+GG 2.23 (0.36-13.88) 0.121 0.728 
GT 43 (33.9%) 9 (23.1%) TT+GT vs. GG 0.69 (0.32-1.52) 0.532 0.466 
TT 3 (2.4%) 2 (5.1%)         
Total 127 (100%) 39 (100%)         
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3.3.2 T-786C 
The T-786C was analysed using two methods (PCR-RFLP and QPCR), both methods showed high 
concordance in genotype calls and gave confidence in genotyping methods used. Therefore the 
larger sample size was used in further statistical analyses.  
3.3.2.1 Baseline Characteristics for the T-786C Variant 
Table 17 shows that the CAD patient and control groups were significantly different in nearly all of 
the continuous variables. The CAD group were significantly older (51.085 years) than the control 
group (44.226 years) (t=6.523, p<0.001). Significant differences were also seen between the 
groups for all but one of the lipid parameters (p<0.001). There was no significant difference 
between mean TG levels. (p=0.835). 
Table 17- T-786C baseline characteristics and independent samples t-test for continuous variables 
between CAD patients and controls 
Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
difference 
P 
Age  (years) 
Control 212 44.226 12.914 0.887 6.523 -6.859 <0.001 
Patient 434 51.085 12.366 0.594       
TC (mg/dl) 
Control 204 138.966 33.045 2.314 *10.784 -37.840 <0.001 
Patient 417 176.806 53.872 2.640       
TG (mg/dl) 
Control 204 139.167 67.021 4.692 *0.209 -1.506 0.835 
Patient 418 140.672 112.080 5.482       
HDL 
(mg/dl) 
Control 204 29.647 10.989 0.769 *12.871 -49.343 <0.001 
Patient 418 78.990 76.784 3.756       
LDL 
(mg/dl) 
Control 203 83.066 25.624 1.798 *7.491 -22.266 <0.001 
Patient 413 105.332 48.092 2.366       
VLDL 
(mg/dl) 
Control 166 29.151 12.643 0.981 *5.762 -7.537 <0.001 
Patient 411 36.688 17.535 0.865       
APOB 
(mg/dl) 
Control 166 106.619 47.624 3.696 8.675 -44.419 <0.001 
Patient 170 151.038 46.238 3.546       
*Equal variances not assumed  
Non continuous variables are shown in Table 18. Significant differences were found between 
gender (χ2=21.212, df=1, p<0.001), smoking (χ2=9.968, df=1, p<0.001), age groups (χ2=46.100, 
df=2, p<0.001) and hypertension (χ2=12.921, df=1, p<0.001). Male gender was shown to be 
associated with an increased CAD risk (OR=2.62 (CI: 1.74-3.94), p<0.001). Smoking was also 
confirmed as a significant risk factor for CAD (OR=1.75 (CI: 1.25-2.45), p=0.002), as was 
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increased age ≥40 years (OR=8.51 (CI: 5.83-12.44), p<0.001). Eating meat was not associated with 
CAD (OR=1.497 (CI: 0.89-1.84), p=0.206). 
Table 18-T-786C categorical variables in CAD patients and controls and Odds Ratios (ORs) for CAD 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 378 (86.9%) 152 (71.7%) 2.62 (1.74-3.94) 21.212 <0.001 
Female 57 (13.1%) 60 28.3%) 0.38 (0.25-0.57)    
Total 435 (100%) 212 (100%)      
Smoking          
smoker 214 (54.87%) 87 (41.04%) 1.75 (1.25-2.45) 9.968 0.002 
non smoker 176 (45.13%) 125 (58.96%) 0.57 (0.41-0.80)    
Total 390 (100%) 212 (%)     
Diet          
non vegetarian 236 (56.2%) 83 (50.0%) 1.28 (0.89-1.84) 1.597 0.206 
vegetarian 184 (43.8%) 83 (50.0%) 0.78 0.54-1.12)    
Total 420 (100%) 166 (100%)     
Age (years)        
≤39 67 (15.4%) 83 (39.2%) 3 vs.1+2 46.10 (total)  <0.001 
40-54 166 (28.2%) 66 (31.1%) 2.04 (1.44-2.89) 15.55 <0.001 
>55 201 (46.3%) 63 (19.7%) 3+2 vs. 1    
Total 434 (100%) 212 (100%) 8.51 (5.83-12.44) 136.83 <0.001 
Family History      
absent 115 (74.2%) 46 (100%) Not possible *14.820 <0.001 
present 40 (25.8%) 0 (0%)     
Total 155 (100%) 46 (100%)     
Hypertension          
absent 127 (77.0%) 46 (100%) Not possible *12.921 <0.001 
present 38 (23.0%) 0 (0%)     
Total 165 (100%) 46 (100%)     
*cell with less than 5 (χ2 values not valid) 
3.3.2.2 eNOS T-786C Genotypes and Allele Frequencies 
Table 19 presents the T-786C genotype and allele distribution among the CAD patient and control 
groups. The CAD patient group’s genotype frequencies were 59.27%, 36.16% and 4.58% for TT, 
TC and CC respectively. The control group’s genotype frequencies were 62.74%, 33.02% and 
4.25% respectively. The T wild type allele and TT genotype showed the highest frequencies in 
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both groups. There was no significant departure from HWE. The inbreeding coefficient was found 
to be 0.032 and 0.004 for cases and controls respectively. 
Table 19-T-786C genotype frequencies, allele frequencies and Hardy-Weinberg equilibrium tests for the 
CAD patient and control groups 
  CAD Patients (n=437) CAD controls (n=212) 
Genotype frequencies 
TT 259(59.27%) 133(62.74%) 
TC 158 (36.16%) 70 (33.02%) 
CC 20 (4.58%) 9 (4.25%) 
Total 437 (100%) 212 (100%) 
Allele frequencies   
Allele T 0.773 0.792 
Allele C 0.227 0.208 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.032 0.004 
P-Pearson's goodness of 
fit χ2 (DF=1) 
0.507 0.956 
P-Log likelihood ratio χ2 
(DF=1) 
0.503 0.956 
P Exact test 0.586 1 
3.3.2.3 Association between the T-786C Polymorphism and CAD Risk 
ORs were calculated for the T-786C variant to assess possible CAD association.  These have been 
presented firstly for the C allele as the hypothesised risk allele (Table 20) and secondly for the T 
allele as the risk allele (Table 21). Overall, values found were relatively close to 1 indicating no 
association in either direction, and there was no statistically significant results found under any 
model (p>0.05). The OR was marginally increased for the C allele (OR= 1.118 (CI: 0.843-1.484), 
p=0.439). The largest effect was seen under the heterozygous model TC vs. TT (Table 20) but this 
was still very small and remained non significant effect, (OR=1.159 (CI: 0.816-1.646), p=0.409).  
Table 20-T-786C Odds Ratios (ORs) for CAD association (C risk allele) 
T-786C CAD association OR 95%CI χ2 P 
C  vs. T 1.118 0.843-1.484 0.6 0.439 
TC vs. TT 1.159 0.816-1.646 0.68 0.409 
CC  vs. TT+ TC 1.141 0.506-2.575 0.1 0.750 
CC + TC vs. TT 1.157 0.826-1.622 0.72 0.397 
Armitage's trend test 1.106   0.61 0.433 
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Table 21- T-786C Odds Ratios (ORs) for CAD association (T risk allele) 
T-786C CAD association OR 95%CI χ2 P 
 T vs. C 0.894 0.674-1.187 0.60 0.439 
TC vs. CC 1.016 0.440-2.342 0.00 0.971 
TT vs. CC +TC 0.876 0.388-1.978 0.10 0.750 
TT + TC vs. CC 0.924 0.414-2.066 0.04 0.848 
Armitage's trend test 0.904   0.261 0.433 
3.3.2.4 T-786C Logistic Regression 
Logistic regression was performed to calculate the effect of the T-786C variant on CAD status 
when adjusting for other covariates. There were 328 samples included in the analysis and 320 were 
excluded due to missing data. Table 22 presents the reference groupings for the categorical 
variables included in the analysis. 
Table 22-Reference groupings for the categorical variables included in the T-786C CAD logistic 
regression analysis 
 Covariate Reference Group Parameter 1 
T-786C (dominant) TT TC+CC 
T-786C  (recessive) TT+TC CC 
Gender Female Male 
Smoking Non smoker Smoker 
Diet Vegetarian Non-vegetarian 
Occupation heavy moderate +sedentary 
3.3.2.4.1 Logistic regression for a dominant model  
Firstly logistic regression was run assuming a dominant model of inheritance. The classification 
table revealed the percentage of cases correctly predicted was 50.6% without considering any other 
variables. Model one, only considering the T-786C variant, was shown not to be significantly 
better (χ2=0.392, 1df, p=0.531). The Hosmer and Lemershow test also showed this model not to be 
a good predictor of disease outcome, (p<0.001). Overall the model successfully predicted 51.8% of 
cases correctly. The Wald test revealed that the T-786C variable didn't significantly contribute to 
the model (OR=1.155 (CI: 0.735-1.814), p=0.532). 
Model 2 included diet, sex, smoking and age variables in addition to the genotypes.  The omnibus 
test of model coefficients revealed Model 2 to significantly predict CAD status (χ2=19.487, df=5, 
p=0.002); this was confirmed by the Hosmer and Lemeshow test (p=0.593). The OR for T-786C 
adjusted for these covariates remained non significant and very close to 1 (OR= 1.052 (CI: 0.659-
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1.680), p=0.831). The only covariate to be a significant independent risk factor for CAD was age 
with a small effect (OR=1.036 (CI: 1.017-1.056), p<0.001). 
Table 23- Model 2: T-786C dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age and diet. 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
T-786C  .051 .239 .046 0.831 1.052 .659 1.680 
Gender  -.195 .323 .366 0.545 .823 .437 1.548 
Smoking status  .391 .244 2.559 0.110 1.479 .916 2.387 
AGE (in years) .036 .009 14.429 <0.001 1.036 1.017 1.056 
Diet  -.197 .234 .707 0.401 .821 .519 1.300 
Constant -1.699 .554 9.413 0.002 .183     
The Model was then extended to include lipid parameters (Model 3). This Model was the best 
predictor of disease status, (χ2=151.869, df=11 p<0.001). The Hosmer and Lemeshow test 
confirmed this to be significant (p=0.208). Model 3 was shown to successfully predict 77.1% of 
CAD status correctly. The T-786C variant was found to have a decreased OR (OR=0.884 (CI: 
0.489-1.597), p=0.683). The final model showed the only variables to be independent predictors 
were age, VLDL cholesterol and APOB with relatively small effects. 
Table 24-Model 3: T-786C dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age, diet and lipid parameters. 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
T-786C  -.123 .302 .167 0.683 .884 .489 1.597 
Gender  -.532 .424 1.577 0.209 .587 .256 1.347 
Smoking status  .284 .314 .817 0.366 1.329 .717 2.461 
AGE (in years) .046 .012 13.995 <0.001 1.047 1.022 1.073 
Diet  -.007 .296 .001 0.981 .993 .555 1.775 
TC (mg/dl) .017 .008 5.044 0.025 1.017 1.002 1.033 
TG(mg/dl) -.001 .003 .102 0.749 .999 .993 1.005 
HDL (mg/dl) .015 .017 .777 0.378 1.015 .982 1.049 
LDL (mg/dl) .007 .007 .889 0.346 1.007 .992 1.022 
VLDL (mg/dl) .048 .017 8.458 0.004 1.049 1.016 1.084 
APOB (mg/dl) .012 .003 14.300 <0.001 1.012 1.006 1.018 
Constant -8.614 1.139 57.239 <0.001 .000     
The logistic regression was then re-run with a recessive model with TT+TC as the T-786C 
reference category, the complete table of results is not given due to similarity between the this and 
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dominant analyses above.  Table 25 summarises the key findings under both genetic models for 
logistic regression. 
Table 25-Key findings of the CAD Glu298Asp logistic regression analysis for the three models 
Dominant Model 1 Model 2 Model 3 
Goodness of fit chi square 0.392 19.832 151.869 
Significance 0.531 0.001 <0.001 
Hosmer and Lemershow <0.001 0.77 0.208 
Percentage correctly predicted 51.80% 60.10% 77.10% 
T-786C 1.155 (0.735-1.814) 1.052 (0.659-1.680) 0.884 (0.489-1.597) 
Recessive Model 1 Model 2 Model 3 
Goodness of fit chi square 0.317 19.794 152.092 
Significance 0.573 0.001 <0.001 
Hosmer and Lemershow 0.000 0.429 0.621 
Percentage correctly predicted 51.20% 59.10% 77.10% 
T-786C 1.336 (0.485-3.677) 1.041 (0.363-2.986) 0.665 (0.185-2.393) 
The T-786C variant failed to be a significant independent risk factor for CAD following 
adjustment for the classical risk factors.  Less than 80% of CAD could be predicted by these risk 
factors. 
3.3.2.5 Relationship of Genotypes with Lipid Parameters  
Pairwise comparisons of genotypes (CC vs. TC, CC vs. TT and TC vs. TT) for various lipid 
parameters did not reveal any statistically significant differences.  The CC genotype was observed 
to have higher values for TC, TG, VLDL, LDL and lower HDL compared to the two alternate 
genotypes in all cases. The individual comparative tables are given in appendix 4, section 8.4. 
3.3.2.6 eNOS T-786C Disease Association in High Risk Groups 
Sub-group analysis (Table 26), did not reveal any significance for the T-786C variant with CAD in 
any combinations (gender, smoking or age sub-group analysis (all p>0.05)). 
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Table 26- T-786C genotype frequencies and CAD association in subgroup analysis by gender, smoking 
behaviour and age 
CAD association Controls Patients Model OR (95%CI) χ2 P 
Gender 
Males only             
TT 97 (63.8%) 229 (60.6%) CC vs. TC +TT 1.53 (0.50-4.68) *0.24 0.624 
TC 51 (33.6%) 134 (35.4%) CC+TC vs. TT 1.15 (0.78-1.69) 0.352 0.553 
CC 4 (2.6%) 15 (4.0%)         
Total 152 (100%) 378 (100%)         
Females only             
TT 36 (60.0%) 30 (45.5%) CC vs. TC +TT 1.06 (0.29-3.87) 0.06 0.806 
TC 19 (31.7%) 22 (38.6%) CC+TC vs. TT 1.35 (0.65-2.81) 0.381 0.537 
CC 5 (8.3%) 5 (8.%)         
Total 60 (100%) 57 (100%)         
Smoking Habits      
Ever smoked             
TT 53 (60.9%) 236 (71.73%) CC vs. TC+TT 0.79 (0.25-2.50) *0.009 0.923 
TC 30 (34.5%) 81 (24.62%) CC+TC vs. TT 0.61 (0.38-1.01) 3.3 0.069 
CC 4 (4.6%) 12 (3.65%)         
Total 87 (100%) 329 (100%)         
Current smoker            
TT 53 (60.9%) 135 (63.1%) CC vs. TC+TT 1.12 (0.35-3.63) *0.009 0.923 
TC 30 (34.5%) 68 (31.8%) CC+TC vs. TT 0.91 (0.55-1.52) 0.049 0.826 
CC 4 (4.6%) 11 (5.1%)         
Total 87 (100%) 214 (100%)         
AGE groups             
≤39 years             
TT 57 (68.7%) 38 (56.7%) CC vs. TC+TT 5.21 (0.57-47.74) *1.34 0.25 
TC 25 (30.1%) 25 (37.3%) CC+TC vs. TT 1.67 (0.86-3.27) 1.80 0.18 
CC 1 (1.2%) 4 (6.0%)      
Total 83 (100%) 67 (100%)         
40-54years             
TT 37 (56.1%) 95 (57.2%) CC vs. TC+TT 0.70 (0.23-2.17) 0.10 0.75 
TC 24 (36.4%) 62 (37.3%) CC+TC vs. TT 0.95 (0.53-1.69) 0.00 0.99 
CC 5 (7.6%) 9 (5.4%)      
Total 66 (100%) 166 (100%)         
≥55 years             
TT 39 (61.9%) 126 (62.7%) CC vs. TC+TT 0.72 (0.18-2.88) *0.01 0.93 
TC 21 (33.3%) 68 (33.8%) CC+TC vs. TT 0.97 (0.54-1.73) 0.00 0.97 
CC 3 (4.8%) 7 (3.5%)      
Total 63 (100%) 201 (100%)         
*cell with less than 5 (χ2 values not valid) 
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3.3.2.7 Patient Only Analysis 
A small number of samples had information for the presence of Hypertension (Ht). Table 27 
presents the results for T-786C association with these variables. The T-786C did not show an 
association Ht under either a dominant or a recessive model (p>0.05). 
Table 27- T-786C Odds Ratio (OR) calculations for Ht association in the CAD patient group only 
Hypertension Ht controls Ht patients Model OR (95%CI) χ2 P 
TT 72 (56.7%) 22 (57.9%) CC vs. TC +TT 0.83 (0.09-7.67) *0.141 0.707 
TC 51 (40.2%) 15 (39.5%) CC+TC vs. TT 0.95 (0.46-1.98) 0.003 0.956 
CC 4 (3.1%) 1 (2.6%)         
Total 127 (100%) 38 (100%)         
*cell with less than 5 (χ2 values not valid) 
3.3.3 Intron 4 
3.3.3.1 Baseline Characteristics for the Intron 4 Variant 
Table 28 shows that the CAD and control groups were significantly different in nearly all of the 
continuous variables. The CAD group were significantly older than the control group with a mean 
of 51.002 years compared to 44.905 years  in the control group (t=5.899,  p<0.001). Similar to 
Glu289asp and T-786C loci, significant differences were also present between the CAD and 
control groups (p<0.001) for all but one of the lipid parameters (TC, HDL, LDL and VLDL).  
Table 28- Intron 4 baseline characteristics and independent samples t-test for continuous variables 
between CAD patients and controls 
Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
differen
ce 
p value 
Age  
(years) 
Control 220 44.905 13.105 0.884 
5.899 6.098 <0.001 
Patient 455 51.002 12.332 0.578 
TC (mg/dl) 
Control 213 138.441 32.498 2.227 
*-11.301 38.340 <0.001 
Patient 434 176.781 53.324 2.560 
TG (mg/dl) 
Control 213 136.756 65.264 4.472 
*-0.068 -0.471 0.946 
Patient 435 136.285 111.350 5.339 
HDL 
(mg/dl) 
Control 213 29.596 10.989 0.753 
*13.491 54.824 <0.001 
Patient 435 84.421 83.288 3.993 
LDL 
(mg/dl) 
Control 212 82.918 25.142 1.727 
*7.811 22.440 <0.001 
Patient 430 105.358 47.610 2.296 
VLDL 
(mg/dl) 
Control 173 28.763 12.174 0.926 
*6.242 7.848 <0.001 
Patient 428 36.611 17.603 0.851 
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Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
differen
ce 
p value 
APOB 
(mg/dl) 
Control 173 107.323 45.706 3.475 
8.792 44.012 <0.001 
Patient  166 151.335 46.453 3.605 
Categorical variables for patients and controls are presented in Table 29. Significant differences 
were found between gender (χ2=2.062, p<0.001), smoking (χ2=8.596, p=0.003), age (χ2=41.885, 
df=2, p<0.001) and Hypertension (χ2=12.865, df=1, p<0.001). No significant differences were 
found between dietary choices (χ2=1.249, p=0.264). Table 29 also shows the ORs for CAD risk 
calculated for the categorical variables. 
Male gender was shown to be associated with an increased CAD risk (OR=2.60 (CI: 1.75-3.87), 
p<0.001). Smoking was also confirmed as a significant risk factor for CAD (OR=1.66, (CI: 1.19-
2.32), p=0.003). Finally an increased age (≥40 years) was associated with CAD, (OR=3.28 (CI: 
2.26-4.75), p<0.001). Eating meat was not associated with CAD, (OR=1.24 (CI: 0.87-1.77), 
p=0.264). 
Table 29- Intron 4 categorical variables in CAD patients and controls and Odds Ratios (ORs) for CAD 
association  
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 395 (86.6%) 157 (71.4%) 2.60 (1.75-3.87) 22.062 <0.001 
Female 61 (13.4%) 63 (28.6%) 0.38 (0.26-0.57)    
Total 456 (100%) 220 (100%)      
Smoking           
smoker 217 (53.06%) 89 (40.45%) 1.66 (1.19-2.32) 8.596 0.003 
non smoker 192 (46.94%) 131 (59.55%) 0.60 (0.43-0.84)    
Total 409 (100%) 220 (100%)     
Diet          
non vegetarian 247 (56.3%) 88 (50.9%) 1.24 (0.87-1.77) 1.249 0.264 
vegetarian 192 (43.7%) 85 (49.1%) 0.80 (0.57-1.15)    
Total 439 (100%) 173 (100%)     
Age (years)          
≤39 71 (15.5%) 83 (37.7%) 3 vs.1+2 41.885 (total) <0.001 
40-54 174 (38.1%) 68 (30.9%) 1.88 (1.34-2.63) 12.77 <0.001 
>55 210 (46.05) 69 (31.4%) 3+2 vs. 1    
 Total 455 (100%) 220 (100%) 3.28 (2.26-4.75) 39.97 <0.001 
Family history        
absent 130 (72.6%) 47 (100%) Not possible *16.428 <0.001 
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present 49 (27.4%) 0 (0%)     
Total 179 (100%) 47 (100%)     
Hypertension          
absent 145 (77.5%) 47 (100%) Not possible *12.865 <0.001 
present 42 (22.5%) 0 (0%)     
Total 187 (100%) 47 (100%)     
*cell with less than 5 (χ2 values not valid) 
3.3.3.2 eNOS Intron 4 Genotypes and Allele Frequencies 
Table 30 shows the distribution of the genotypes and alleles among the CAD patient and control 
groups. The CAD’s group genotype frequencies were 71.12%, 27.13% and 1.75% for 4bb, 4ab and 
4aa respectively. The control group’s genotype frequencies were 69.55%, 26.36% and 4.09% for 
4bb, 4ab and 4aa respectively. The 4b allele and 4bb genotype showed the highest frequencies in 
both groups.  Table 30 also presents the tests for deviation from Hardy-Weinberg equilibrium 
(HWE). There was no significant departure from HWE for either patients or controls, finding no 
significant departure using three tests. The inbreeding coefficient F (the fixation statistic) was 
found to be 0.046 and 0.078 for cases and controls respectively. 
Table 30-Intron 4 genotype frequencies, allele frequencies and Hardy-Weinberg equilibrium tests for the 
CAD patient and control groups 
 CAD Patients (n=457) CAD controls (n=220) 
Genotype frequencies 
4bb 325(71.12%) 153 (69.55%) 
4ab 124(27.13%) 58 (26.36%) 
4aa 8 (1.75%) 9 (4.09%) 
Total 457 (100%) 220 (100%) 
Allele frequencies   
Allele 4a 0.847 0.827 
Allele 4b 0.153 0.173 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.046 0.078 
P-Pearson's goodness of fit χ2 (DF=1) 0.326 0.250 
P-Log likelihood ratio χ2 (DF=1) 0.311 0.266 
P Exact test 0.469 0.241 
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3.3.3.3 Association between the Intron 4 Polymorphism and CAD Risk 
The ORs were calculated for CAD firstly under the 4a as the risk allele (Table 31) and secondly 
under the 4b allele as the risk allele (Table 32). There were no significant results found under any 
model (p>0.05), although there were a number of differences in the ORs calculated. Under the 
hypothesised 4a risk allele overall there were reduced ORs (below 1) suggesting a possible 
protective effect, this was most prominent under the recessive 4aa vs. 4bb+4ab (OR=0.418 (CI: 
0.158-1.106), p=0.07). Conversely, the hypothesised 4b risk allele (Table 32), suggested an 
increased risk of CAD. This was most prominent under the heterozygous 4ab vs. 4aa model, 
(OR=2.405 (CI: 0.883-6.552), p=0.079) and the recessive 4bb vs. 4aa+4ab model, (OR=2.39 (CI: 
0.904-6.314), p=0.071). 
Table 31-Intron 4 Odds Ratios (ORs) for CAD association (4a risk allele) 
Intron 4 CAD association OR 95% CI χ2 P 
4a vs. 4b 0.866 0.638-1.176 0.85 0.357 
4ab vs. 4bb 1.006 0.698-1.452 0.00 0.972 
4aa vs. 4bb+4ab 0.418 0.158-1.106 3.27 0.071 
4aa + 4ab vs. 4bb 0.927 0.653-1.318 0.18 0.674 
Armitage's trend test 0.828   0.825 0.357 
Table 32- Intron 4 Odds Ratios (ORs) for CAD association (4b risk allele) 
3.3.3.4 Intron 4 Logistic Regression 
Logistic regression was performed to calculate the effect of the Intron 4 variant on CAD status 
with adjustments for other covariates. 333 samples were included in analysis and the remainder 
were excluded due to missing data. Table 33 presents the reference groupings for the categorical 
variables included in the analysis. 
 
 
Intron 4 CAD association OR 95% CI χ2 P 
 4b vs. 4a 1.154 0.850-1.567 0.85 0.357 
4ab vs. 4aa 2.405 0.883-6.552 3.09 0.079 
4bb vs. 4aa+4ab 2.39 0.904-6.314 3.27 0.071 
4bb + 4ab vs. 4aa 2.394 0.911-6.292 3.32 0.068 
Armitage's trend test 1.247   0.85 0.357 
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Table 33- Reference groupings for the categorical variables included in the Intron 4 CAD logistic 
regression analysis 
Covariate Reference Group Parameter 1 
Intron 4 (dominant) 4bb 4ab+4aa 
Intron 4  (recessive) 4bb+4ab 4aa 
Gender Female Male 
Smoking Non smoker smoker 
Diet Vegetarian Non-vegetarian 
Occupation heavy moderate +sedentary 
3.3.3.4.1 Logistic Regression for a Dominant Model  
The classification table revealed the percentage correctly predicted was 52% without considering 
any other variables. The Hosmer and Lemershow test also showed this model not to be a good 
predictor of disease outcome, (p<0.001) The Wald test revealed that the Intron 4 variable didn't 
significantly contribute to the model (OR=1.011 (CI: 0.635-1.608), p=0.964). 
Model 2 included the covariates: diet, sex smoking and age. This Model significantly predicted 
CAD status in 58.7% of subjects (χ2 =16.745, df=5, p=0.005); this was confirmed as significant by 
the Hosmer and Lemeshow test (p=0.93). The OR for Intron 4 when adjusted for these covariates 
decreased fractionally but remained non significant (OR= 0.988 (CI: 0.614-1.591), p=0.961). The 
only variable confirmed as a significant independent predictor of CAD was age, but this effect was 
minimal. 
Table 34-Model 2: Intron 4 dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age and diet. 
Variable B S.E. Wald df p OR 
95% C.I. 
Lower Upper 
Intron 4  -.012 .243 .002 1 0.961 .988 .614 1.591 
Gender  -.126 .317 .157 1 0.692 .882 .474 1.642 
Smoking status  .402 .242 2.768 1 0.096 1.495 .931 2.401 
AGE (in years) .032 .009 11.873 1 0.001 1.032 1.014 1.051 
Diet  -.134 .231 .334 1 0.563 .875 .556 1.376 
Constant -1.658 .538 9.493 1 0.002 .190     
The model was then extended to include lipid parameters (Model 3). This model was the best 
predictor of disease status, (χ2=155.782, df=11 p<0.001). The Hosmer and Lemeshow test 
confirmed this to be significant (p=0.169). Model 3 was shown to successfully predict 78% of 
CAD status correctly. The Intron 4 variant was found to have a decreased OR value (OR=0.915 
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(CI: 0.498-1.681), p=0.774). The final model showed age, VLDL cholesterol and APOB to be the 
only significant independent risk factors. 
Table 35-Model 3: Intron 4 dominant model CAD logistic regression analysis adjusting for gender, 
smoking, age, diet and lipid parameters 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Intron 4  -.089 .311 .083 0.774 .915 .498 1.681 
Gender  -.453 .418 1.174 0.279 .636 .280 1.442 
Smoking status   .286 .312 .840 0.359 1.331 .722 2.454 
AGE (in years) .040 .012 11.110 0.001 1.041 1.017 1.066 
Diet  -.019 .295 .004 0.949 .981 .551 1.749 
TC (mg/dl) .014 .007 3.573 0.059 1.014 .999 1.029 
TG (mg/dl) .000 .003 .006 0.937 1.000 .994 1.006 
HDL (mg/dl) .024 .019 1.613 0.204 1.024 .987 1.062 
LDL (mg/dl) .008 .007 1.064 0.302 1.008 .993 1.022 
VLDL (mg/dl) .052 .017 9.754 0.002 1.054 1.020 1.089 
APOB (mg/dl) .013 .003 15.554 <0.001 1.013 1.006 1.019 
Constant -8.722 1.141 58.433 <0.001 .000     
The logistic regression was then re-run under a recessive model with 4bb+4ab as the reference 
category. All other covariates were shown to exhibit similar effects to those present under a 
dominant model subsequently the complete data has not been included. Table 36 summarises the 
key findings of the logistic regression under each model. 
Table 36- Key findings of the CAD Intron 4 logistic regression analysis for the three models 
 Model 1 Model 2 Model 3 
Dominant    
Goodness of fit chi square 0.002 16.745 155.782 
significance 0.964 0.005 <0.001 
Hosmer and Lemershow <0.001 0.93 0.169 
Percentage correctly predicted 52.10% 58.70% 78.00% 
Intron 4 1.011(0.635-1.608) 0.988 (0.614-1.591)  0.915(0.498-1.681) 
Recessive    
Goodness of fit chi square 2.02 18.994 157.963 
significance 0.155 0.002 <0.001 
Hosmer and Lemershow 0.000 0.312 0.927 
Percentage correctly predicted 52.10% 61.10% 78.30% 
Intron 4 0.397 (0.103-1.522) 0.364 (0.91-1.459) 0.293 (0.054-1.588) 
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3.3.3.5  Relationship of Genotypes with Lipid Parameters  
Pairwise comparisons of genotypes (4aa vs. 4ab, 4aa vs. 4bb  and 4ab vs. 4bb) for various lipid 
parameters revealed the 4aa genotype to have a significantly lower HDL mean, 34.471mg/dl 
compared to 67.730mg/dl in the 4bb sample (t=-4.284, p<0.001).  This was also present when 
comparing to the 4ab heterozygotes (p<0.05). The 4aa genotype was also found to have lower TG 
and LDL mean levels, and higher TG levels, but these were not statistically significant. No other 
statistically significant results were observed following this analysis (p>0.05). The individual 
tables are presented in appendix 4 section 8.4. 
3.3.3.6  eNOS Intron 4 Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Intron 4 variant had CAD association in 
high risk groups, these are presented in Table 37. The Intron 4 variant was found to be significantly 
associated with CAD among current smokers. Under a dominant model 4aa+4ab vs. 4bb there was 
a significant protective association with CAD (OR=0.56 (0.33-0.96), p=0.046).      
Table 37-Intron 4 genotype frequencies and CAD association in subgroup analysis by gender, smoking 
behaviour and age 
CAD association Controls Patients Model OR (95%CI) χ2 P 
Gender       
Males only             
4bb 109 (69.4%) 279 (70.6%) 4aa vs. 4ab +4bb 0.63 (0.20-1.95) 0.249 0.618 
4ab 43 (27.4%) 108 (27.3%) 4aa + 4ab vs. 4bb 0.94 (0.63-1.41) 0.031 0.86 
4aa 5 (3.2%) 8 (2.0%)         
Total 157 (100%) 395 (100%)         
Females only            
4bb 44 (69.8%) 45 (73.8%) 4aa vs. 4ab +4bb not possible     
4ab 15 (23.8%) 16 (26.2%) 4aa + 4ab vs. 4bb 0.82 (0.38-1.80) 0.082 0.775 
4aa 4 (6.3%) 0 (0%)         
Total 63 (100%) 61 (100%)         
Smoking Habits      
Ever smoked           
4bb 57 (64.0%) 184 (74.8%) 4aa vs. 4ab +4bb 0.42 (0.12-1.41) 1.199 0.273 
4ab 27 (30.3%) 56 (22.76%) 4aa + 4ab vs. 4bb 0.60 (0.36-1.01) 3.229 0.072 
4aa 5 (5.6%) 6 (2.44%)         
Total 89 (100%) 246 (100%)         
Current smoker           
4bb 57 (64.0%) 165 (76.0%) 4aa vs. 4ab +4bb 0.48 (0.14-1.61) 0.773 0.379 
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4ab 27 (30.3%) 46 (21.2%) 4aa + 4ab vs. 4bb 0.56 (0.33-0.96) 3.975 0.046 
4aa 5 (5.6%) 6 (2.8%)         
Total 89 (100%) 217 (100%)         
AGE              
≤39 years             
4bb 61 (73.5%) 47 (66.2%) 4aa vs. 4ab +4bb 6.21 (0.70-54.48) *2.10 0.15 
4ab 21 (25.3%) 19 (26.8%) 4aa + 4ab vs. 4bb 1.42 (0.71-2.83) 0.66 0.42 
4aa 1 (1.2%) 5 (7.0%)      
Total 83 (100%) 71 (100%)         
40-54years             
4bb 41 (60.3%) 125 (71.8%) 4aa vs. 4ab +4bb 0.14 (0.03-0.77) *4.67 0.03 
4ab 22 (32.4%) 47 (27.0%) 4aa + 4ab vs. 4bb 0.60 (0.33-1.07) 2.51 0.11 
4aa 5 (7.4%) 2 (1.1%)      
Total 68 (100%) 174 (100%)         
≥55 years             
4bb 51 (73.9%) 151 (71.9%) 4aa vs. 4ab +4bb 0.32 (0.02-5.12) *0.001 0.979 
4ab 15 (21.7%) 58 (27.6%) 4aa + 4ab vs. 4bb 1.10 (0.60-1.05) 0.03 0.87 
4aa 3 (4.3%) 1 (0.5%)      
Total 69 (100%) 210 (100%)         
*cell with less than 5 (χ2 values not valid) 
3.3.3.7  Patient Only Analysis 
A small number of samples had information for the presence of hypertension (Ht). Table 38 shows 
the results for Intron 4 association with these variables. Table 38 shows the Intron 4 did not show 
an association Ht under either a dominant or a recessive model (p>0.05). 
Table 38-Intron 4 Odds Ratio (OR) calculations for Ht association in CAD patients only 
Patients only Controls Patients Model OR (95%CI) χ2 P 
Ht             
4bb 105 (72.4%) 31 (73.8%) 4aa vs. 4ab +4bb not possible     
4ab 38 (26.2%) 11 (26.2%) 4aa + 4ab vs. 4bb 0.93 (0.43-2.03) 0 0.938 
4aa 2 (1.4%) 0 (0%)         
Total 145 (100)% 42 (100%)         
3.3.4 eNOS Gene Data Analysis 
3.3.4.1 Synergistic Effect of eNOS Genotypes 
The genotypes were investigated for a possible synergistic effect on CAD status. Table 39 shows 
the frequency of each different combination as a count and a percentage. ORs were calculated to 
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determine if any eNOS genotype combination had an increased/decreased risk of CAD. Table 39 
demonstrates that the frequency of each combination was not uniform. A number of combinations 
were not observed in the data (not included in table) and some were at a very low frequency. There 
were no statistically significant effects present for any single eNOS genotype combination. The 
GG, CC and 4aa genotypes of the Glu298Asp, T-786C and Intron 4 respectively suggested a 
protective not significant association with CAD (OR=0.29 (0.10-0.91), p=0.052). Alternatively the 
GG, TC and 4ab combination suggested an increased CAD risk (OR=3.19 (0.93-10.93), again this 
was outside statistical significance (p=0.086). 
Table 39- Glu298Asp, T-786C and Intron 4 composite genotypes and Odds Ratios (ORs) for CAD 
association 
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Controls Patients 
OR (95% C.I) χ2 P 
n % n % 
TT CC 4ab 0 0.00 1 0.27 not possible     
TT CC 4bb 0 0.00 1 0.27 not possible     
TT TC 4ab 0 0.00 1 0.27 not possible     
TT TC 4bb 2 1.09 7 1.86 not possible     
TT TT 4bb 4 2.19 6 1.60 0.73 (0.20-2.60) 0.024 0.878 
GT CC 4aa 0 0.00 1 0.27 not possible     
GT CC 4ab 0 0.00 2 0.53 not possible     
GT CC 4bb 0 0.00 2 0.53 not possible     
GT TC 4ab 9 4.92 17 4.52 0.92 (0.40-2.10) 0 0.996 
GT TC 4bb 12 6.56 31 8.24 1.28 (0.64-2.56) 0.285 0.594 
GT TT 4ab 0 0.00 3 0.80 not possible     
GT TT 4bb 31 16.94 64 17.02 1.01 (0.63-1.67) 0.009 0.924 
GG CC 4aa 8 4.37 5 1.33 0.29 (0.10-0.91) 3.764 0.052 
GG CC 4ab 0 0.00 5 1.33 not possible     
GG CC 4bb 0 0.00 2 0.53 not possible     
GG TC 4ab 34 18.58 60 15.96 0.83 (0.52-1.32) 0.432 0.511 
GG TC 4bb 3 1.64 19 5.05 3.19 (0.93-10.93) 2.945 0.086 
GG TT 4ab 7 3.83 16 4.26 1.04 (0.42-2.58) 0.02 0.88 
GG TT 4bb 73 39.89 133 35.37 0.82 (0.57-1.19) 0.894 0.344 
Total     183 100 376 100       
Further OR calculations were undertaken, with a focus on the Glu298Asp and T-786C variant. No 
significant associations were found at different combinations. However, carrying the T risk allele 
of the Glu298Asp variant and being homozygote for the C allele of the T-786C variant was found 
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to be present in seven patients yet absent in all controls, this may have an association however it 
was not possible to calculate ORs for this combination. 
3.3.4.2 Linkage Disequilibrium Analysis  
Linkage disequilibrium analysis suggested the strongest correlation (r statistic) was found to be 
between the Intron 4 variant and the T-786C variant (r=0.661). D’ statistic and r statistic showed 
that there was very low linkage disequilibrium between Glu298Asp and T-786C loci,  while 
individually they were strongly in linkage disequilibrium with Intron 4 (D’ 0.8158 and 0.7998, all 
p values <0.05).  
Table 40- Linkage disequilibrium analysis between Glu298Asp, T-786C and Intron 4 variants.  D’ statistic 
above the diagonal, r statistics below the diagonal 
 D' statistic 
Glu298Asp T-786C Intron 4 r statistic  
Glu298Asp . 0.069 0.8158 
T-786C 0.0631 . 0.7998 
Intron 4 0.1766 0.661 . 
All values were significant p<0.05 and p<0.001 for the Intron 4 variant  
3.3.4.3 eNOS Haplotype Analysis 
Haplotypes were estimated using the online programme SNPStats. The most common haplotype 
was the G-T-4b alleles of the Glu298Asp, T-786C and Intron 4 variants respectively.  This was 
estimated to have a frequency of 0.614, with this as the reference haplotype ORs were calculated 
for each possible haplotype. The haplotypes 7 and 8 were estimated to be extremely rare and ORs 
were not possible. A statistically significant association with CAD was found for haplotype 5 (G-
C-4b), (OR=4.76 (CI: 1.43-15.78), p=0.011) which needs caution in interpretations as the relative 
frequencies are low leading to a wide confidence interval. 
Table 41-eNOS Glu298Asp, T-786C and Intron 4 haplotype estimations and Odds Ratios (ORs) for CAD 
association 
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Controls Patients Total OR  (95%CI) P value 
1 G T 4b 0.635 0.604 0.614 1 --- 
2 T T 4b 0.138 0.138 0.138 1.05 (0.71 - 1.55) 0.8 
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Controls Patients Total OR  (95%CI) P value 
3 G C 4a 0.160 0.118 0.132 0.80 (0.55 - 1.15) 0.23 
4 T C 4b 0.037 0.054 0.049 1.48 (0.75 - 2.91) 0.26 
5 G C 4b 0.010 0.049 0.036 4.76 (1.43 - 15.78) 0.011 
6 G T 4a 0.020 0.028 0.025 1.45 (0.59 - 3.56) 0.42 
7 T C 4a 0 0.010 0.007 Rare   
8 T T 4a 0 0 0 Rare   
3.3.4.4 The ACE Variant 
Information on the samples genotype for the ACE locus was already analysed in the lab and was 
available for further analyses on these samples.  The ACE gene was found to be significantly 
associated with CAD under all models. The control group was found to be in HWE, confirmed by 
three independent tests (Table 42). 
Table 42-ACE deletion allele and genotype frequencies in the CAD patient and control groups and Odds 
Ratio (OR) calculations  for CAD association 
Genotype Patients Controls 
II 64 (14.1%) 58 (26.4%) 
ID 248 (54.6%) 106 (48.2%) 
DD 142 (31.3%) 56 (25.5%) 
Total 454 (100%) 220 (100%) 
D allele 0.59 0.50 
I allele 0.41 0.50 
ACE CAD association Odds Ratio 95% CI χ2 P 
D vs. I 1.441 1.146-1.811 9.82 0.002 
ID vs. II 2.120 1.391-3.233 12.44 <0.001 
DD vs. II+ID 2.298 1.435-3.681 12.21 <0.001 
DD +ID vs. II 2.182 1.463-3.254 15.04 <0.001 
Armitage's trend test 1.495  10.49 <0.001 
Further analysis was carried out to evaluate if there was an interaction of ACE with eNOS loci. 
The ACE genotypes showed no significant association/interaction with any of the eNOS variants 
(Table 131, appendix 4, Section 8.4) 
 
Chapter 3 – CAD 
119 | P a g e  
 
 
3.3.4.5 Logistic Regression of all Genetic Variants Together 
Logistic regression was performed to calculate the effect of the all eNOS gene variants and 
including the ACE gene variant on CAD status when adjusting for each of the variants and other 
covariates. Only 282 samples were included in analysis due to missing data. Table 43 presents the 
reference groups for this analysis. 
Table 43-Reference groups for the categorical variables inputted in the CAD logistic regression analysis 
 Variable reference group Parameter 1 
Glu298Asp GG TT+GT 
T-786C TT CC+TC 
Intron 4 4bb 4aa+4ab 
ACE II DD+ID 
Diet vegetarian non vegetarian 
Smoking non smokers & ex smokers current smokers 
Gender female Male 
Logistic regression was performed only assuming a dominant effect of the genetic variants, the 
numbers were too small to run under a recessive effect. The Model was firstly run to include only 
the genetic variants. This model was not found to be a significant predictor of disease status (χ2 
=5.052, p=0.282) and predicted 53.2% of all cases correctly (Table 44).  None of the genetic 
variants were independent risk factors for CAD. The ACE variant had the highest OR value 
(OR=1.665 (CI: 0.961-2.882)) this was just outside statistical significance (p=0.069). 
Table 44-Model 1: CAD logisitic regression using the covariates Glu298Asp, T-786C, Intron 4 and ACE 
genetic variants only (dominant effect) 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp 0.160 0.269 0.356 0.551 1.174 0.693 1.987 
T-786C 0.302 0.325 0.868 0.351 1.353 0.716 2.556 
Intron 4 -0.152 0.347 0.191 0.662 0.859 0.435 1.697 
Ace 0.510 0.280 3.309 0.069 1.665 0.961 2.882 
Constant -0.543 0.279 3.773 0.052 0.581     
Logistic regression was then rerun to include age, diet, smoking, gender and lipid parameters, this 
Model was a significant predictor of disease status (χ2 =139.099, df=14, p<0.001). This was 
supported by the Hosmer and Lemershow calculation (p=0.63). 79.40% of cases were shown to be 
predicted correctly when including all these covariates. Table 45 shows the effect of all covariates 
on disease status. The only variables to be shown as independent risk factors were age, TC, VLDL, 
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APOB and ACE. However, the effect of these variables (indicated by the OR values) were small 
with the exception of ACE, which was found to have a high OR value (OR=2.399 (CI: 1.113-
5.172), p=0.026). The next highest effect was for the Glu298Asp variant but this was non 
significant (OR=1.675 (CI: 0.823-3.407), p=0.155). 
Table 45-Model 2: logistic regression analysis for CAD risk adjusting for the Glu298Asp, T-786C, Intron 
4 and ACE genetic variants (dominant effect) alongside age and lipid parameters 
Dominant B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp .516 .362 2.024 .155 1.675 .823 3.407 
T-786C .014 .412 .001 .973 1.014 .452 2.274 
Intron 4 .013 .437 .001 .976 1.013 .431 2.385 
ACE .875 .392 4.983 .026 2.399 1.113 5.172 
Age (years) .042 .014 9.563 .002 1.043 1.016 1.071 
TC (mg/dl) .016 .008 3.845 .050 1.016 1.000 1.032 
TG (mg/dl) .000 .003 .007 .935 1.000 .993 1.006 
HDL (mg/dl) .024 .021 1.298 .255 1.024 .983 1.066 
LDL (mg/dl) .010 .008 1.581 .209 1.010 .994 1.026 
VLDL (mg/dl) .051 .019 7.528 .006 1.053 1.015 1.092 
APOB (mg/dl) .011 .004 10.050 .002 1.011 1.004 1.018 
Diet -.148 .339 .190 .663 .863 .444 1.676 
Smoking .214 .349 .377 .539 1.239 .625 2.456 
Gender -.499 .455 1.202 .273 .607 .249 1.481 
Constant -9.763 1.316 54.999 <0.001 .000     
In this eNOS CAD analysis for each locus eight chi squares were carried out in the categorical data 
set, five in gene association analysis and 14 in sub group analysis, altogether 27 chi-square related 
p values were calculated. The bonferroni correction was applied and the nominal p value (0.05) 
was divided by the number of comparisons. In this case it would be 0.05/27 = 0.00185.   
3.4 Discussion 
This study analysed the frequency of the Glu298Asp, T-786C and Intron 4 27bp repeat 
polymorphisms in 443 patients and 218 controls (Glu298Asp), 437 patients and 212 controls (T-
786C) and 457 patients and 220 controls (Intron 4) within a North Indian population. CAD is a 
multifactorial disease affected by both genes and the environment (Shirodkar & Marsden 2011). 
Identification of genetic influencers will enhance the understanding of atherosclerosis and its 
progression, it will also enable the identification of high risk individuals. The eNOS gene has been 
examined through a number of different studies due to a possible association with CAD and other 
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related CVDs. CAD association of the eNOS polymorphisms has been based on the putative 
mechanism that the polymorphisms influence NO levels. Further analysis was undertaken on a 
number of conventional risk factors to determine if there was any association or interaction with 
any of the eNOS variants.  
3.4.1 Glu298Asp CAD Association 
The first variant of the eNOS gene analysed in this study was the Glu298Asp variant; a guanine to 
thymine SNP resulting in an amino acid substitution in the mature protein of the eNOS gene. This 
study has rejected the null hypothesis and confirmed there to be a significant difference between 
CAD patients and controls within smokers only. This suggests that within this population group 
this variant affects an individual’s risk of CAD in a smoking dependent manner. 
The CAD patient and control groups were found to be in accordance with HWE, (Table 8), and the 
genotype frequencies were comparable to previous studies (Berdeli et al. 2005, Cam et al. 2005, 
Nishevitha et al. 2009). The current study found the percentage of homozygotes for the Asp 
polymorphism (genotype TT) within the CAD controls to be at 2.75%, this was within the range of 
frequencies reported in previous studies (0.00-16%) (appendix 5, section 8.5). 
The TT mutant genotype frequency range is large between populations; the current study was very 
low within this range. A meta-analysis revealed this variant to be significantly lower in Asians 
(p=0.0006), thus it is important to assess the values directly against South Asians (Casas et al. 
2004). There are a small number of studies on South Asians and the 2.75% TT genotype frequency 
is very similar to that found in a Tamilian population  of Southern India (Nishevitha et al. 2009), 
and a North Indian population (Shankarishan et al. 2011, Srivastava et al. 2005).  The percentage 
of homozygotes for the Asp polymorphism (genotype TT) within the CAD patients was also low, 
at a frequency of 4.06%, however again this was comparable to previously reported findings, 
falling within the range of frequencies found (0-39.9%) (appendix 5, section 8.5). This suggests 
that the low frequency found in the current study within both case and control groups are likely to 
be due to population differences rather than small sample size.     
This Glu298Asp variant was tested under multiple models (Table 9) to investigate a possible 
influence on CAD disease status, the evidence in the literature has suggested the asp (T) allele to 
be associated with reduced NO production and an increased susceptibility to disease including 
CAD and Ht (Srivastava et al. 2008, Hingorani et al. 1999).  
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Although no significant differences were found between patients and control groups, there were 
increased ORs (>1) under all models for the hypothesised mutant T allele suggesting a possible 
increased risk associated with this variant. The effect of this variant on disease status was most 
prominent when considering a recessive model. The model (TT vs. GG+GT) revealed a non 
significant OR of 1.623, yet this effect remained when also considering a dominant effect (TT +GT 
vs. GG), OR=1.33 NS.  
This non significant effect was in the same direction as the majority of previous studies supporting 
the alternative hypothesis that the substitution of the aspartate in place of the glutamate causes a 
functional change resulting in an increased CAD susceptibility. The current study is in keeping 
with the meta-analysis undertaken by Casas et al. (2004). This study included 6036 patients and 
6106 controls finding an overall OR of 1.31 (CI: 1.13-1.51), p=0.0003, this was almost identical to 
the OR found in the current study. This effect of the Glu298Asp variant as a risk factor for CAD is 
supported by a number of functional studies; Veldman et al. (2002) and Sofoworo et al. (2001) 
both found this variant to be associated with reduced basal NO production (Veldman et al. 2002, 
Sofowora et al. 2001). Tesauro et al. (2000) showed the T allele to cause variation in enzyme 
cleavage and present a shorter half life in endothelial cell culture, this was proposed to be caused 
by a tight turn in the alpha helix secondary structure of the protein (Tesauro et al. 2000).  
The lack of a statistically significant result in the current study may be due to the effect of this 
variant being smaller than first believed. For example, Hingorani et al. (1999) one of the first 
studies to highlight this variant as a possible risk factor for disease, reported an increased risk of 
2.9 times, (TT vs. GT+GG, OR=2.9, p>0.05), yet since this study the effect sizes observed have 
been much smaller. There are a few exceptions such as Tamemoto et al.(2008) and Berdeli et al. 
(2005) who found substantial increased risk for this variant; finding significant ORs under a 
recessive model of 8.26 (CI: 1.35-50.76) and 17 (CI: 3.952-73.125) respectively (Tamemoto et al. 
2008, Berdeli et al. 2005). More recently, a study by Syed et al. (2011) also mirrored a 
substantially increased CAD risk in a South Indian population, they found an OR of 2.590 (CI: 
1.34-9.64) following logistic regression adjusting for classical risk  factors, however this had a 
very small sample size (79 patients and 79 controls) (Syed et al. 2011).  
A second possibility is the effects of the variant may be interactive with/masked by other 
conventional risk factors. There were significant differences present between the patient and 
control groups in a number of variables including age, gender and smoking; three classical CAD 
risk factors. The basic ORs were adjusted for these risk factors and others using logistic regression. 
Under a dominant effect when adjusted for gender, smoking, age, diet and lipid parameters the OR 
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was found to increase to 1.44 (CI: 0.806-2.585) although this remained non-significant (p=0.217). 
The logistic regression revealed including all these factors still more than 20% of CAD was not 
explained and a proportion of this is likely to be due to genetic variants.   
Smoking is a well established risk factor for heart disease, stroke, emphysema and numerous 
cancers (Heitzer & Meinertz 2005). The INTERHEART study found smoking to influence CVD 
risk with an adjusted odds ratio of 2.87 (CI: 2.58-3.19) and was found to be one of the most 
important risk factors across all ethnicities (Yusuf et al. 2004). This was supported in this study, 
finding smoking to be a significant risk factor for CAD with an OR of 1.6 (CI: 1.21-2.37), 
p=0.002. This variant was significantly associated with CAD both in individuals who were current 
smokers and among individuals who had ever smoked. In individuals who have ever smoked the 
effect of the variant was statistically significant under a dominant model (TT+GT vs. GG) 
OR=2.84 (CI: 1.61-5.0), p<0.001, the effect was almost identical among current smokers.  This 
remains significant when considering the bonferroni corrected p value. 
This association amongst smokers is consistent with previously reported findings. Lee et al. (2006) 
found an adjusted hazard rate ratio of 2.07 (CI: 1.39-3.07) in a Caucasian population when 
comparing smokers carrying the variant to non smokers homozygote for the wild type (GG) (Lee et 
al. 2006). Rios et al. (2007) found similar association in smokers in an African- Brazilians 
population; OR=2.22 (CI: 1.11-4.47), p=0.024 (Rios et al. 2007). 
Similarly a relationship has been identified in functional studies. Leeson et al. (2002) investigated 
the effect of the Glu298Asp variant on endothelial function, individually they found the variant to 
have no association. However, their findings provided evidence for a relationship between the 
variant and smoking, with the asp variant causing a further reduction on the endothelium 
dependent vasodilation among smokers (Leeson et al. 2002). The interaction of the variant is 
unsurprising as smoking has been shown to reduce NO activity both indirectly and directly through 
a reduction in tetrahydrobiopterin (BH4) (lowe et al. 2005). BH4 is responsible for stabilizing the 
enzyme’s dimeric structure, it also helps facilitate the binding of the L-arginine (Cosentino & 
Luscher 1999). Smoking is a major risk factor for CAD known to increase triglyceride, LDL and 
homocysteine levels whilst reducing HDL levels, it causes a prothrombotic state, enhancing the 
formation of free radicals, for example, hydroxyl and superoxide part of the reactive oxidative 
species (ROS) family. ROS production readily reacts with NO, thus the presence of ROS will 
render nitric oxide unavailable further limiting the basal levels already previously shown to be 
reduced in functional studies, in the presence of the asp variant (Cengel & Sahinarslan 2006, 
Veldman et al. 2002, Sofowora et al. 2001). Secondly, ROS is known to be responsible for the 
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oxidisation of LDL cholesterol so further contributes to progression of atherosclerosis through this 
role. Smoking is an example of chemical damage, as well as being a source of free radicals, is 
likely to be a strong initiating factor for CAD, possibly initiating and enhancing the functional 
consequences of this variant.  
Overall, the Glu298Asp variant findings in the current study suggest that within this populational 
group this variant is likely to have a functional consequence resulting in an increased risk of CAD, 
which amongst smokers reached statistical significance. With large interethnic differences in the 
frequency of this variant, further assessment of the variant is required to confirm this association in 
North Indians  (Marroni et al. 2005). 
3.4.2 T-786C CAD Association 
The second variant of the eNOS gene analysed in this study was the T-786C variant. This study has 
accepted the null hypothesis and confirmed there to be no significant difference between CAD 
patients and controls. This suggests that within this population group this variant does not affect an 
individual’s risk of CAD.   
The control group was found to be in accordance with HWE, with a low inbreeding coefficient at 
just 0.0003 (Table 19). The current study control group had a low percentage of homozygotes for 
the mutant allele (CC genotype) at 4.25%. The percentage of homozygotes for the C mutant allele 
within the CAD patients was also found to be low at 4.58%. However, both frequencies were in 
keeping with the range found in world populations (0-26%) (appendix 5, section 8.5).  The current 
genotype frequencies fall between those previously reported in Asian studies, whilst the majority 
of the higher frequencies were found in the Caucasian studies. Unfortunately there are no studies 
on this variant in South Asian populations and thus no direct comparisons can be made. Overall, 
this information supports that both the control and patient sample are representative, thus 
conclusions drawn on this data should be applicable to a North Indian populations. 
The T-786C variant was tested under both recessive and dominant models to investigate a possible 
influence on CAD disease status, the evidence in the literature has suggested the mutant C allele of 
the T-786C variant may be associated with reduced NO production and an increased susceptibility 
to disease including CAD and more recently hypertension (Colombo et al. 2003a, Han et al. 2010). 
It was apparent when considering all models there is no effect of this variant on disease status. The 
ORs were remarkably similar under both the C hypothesised ‘risk’ allele and the T ‘risk’ allele. 
With the C vs. T allele revealing an OR value of 1.1 whilst the T vs. C allele an OR value of 0.9 
this proximity to 1 indicates no effect on disease status. Significant differences were present in the 
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majority of the lipid parameters, gender and smoking behaviours. Due to the presence of these 
differences, logistic regression analysis was run adjusting for these and other conventional risk 
factors. This was run assuming both a dominant and recessive effect of the variant, under both 
models the same effect was seen; the genotype OR decreased slightly, remaining very close to 1. 
This further indicates a lack of effect of this variant on disease status.  
The lack of association found in the current study was in keeping with the meta-analysis 
undertaken by Casas et al. (2004). This study amalgamated seven previously published studies and 
incorporated 2377 patients and 7702 controls (Casas et al. 2004). Agema et al. (2004) was another 
strong study (709 patients and 387 controls) in a Caucasian population and the reported findings 
were very similar to the current study (C allele OR=1.08 (CI: 0.90-1.30)) (Agema et al. 2004). A 
recent study by Kincl et al. (2009), again incorporating a large number of patients (939) and 
controls (222), also supported the current findings (Kincl et al. 2009). Therefore, although the 
literature review found this variant to show association in some studies, this study and other 
available literature support the argument this may be a result of these studies being weaker with 
respect to sample size.   
The previously found ‘association’ may be at a lesser extent or absent entirely. There are a number 
of functional studies that have failed to find a significant effect for this variant.  Sim et al. (1998) 
investigated plasma nitrate and nitrite levels as an indirect measure of NO levels in healthy 
subjects.  The TT, TC and CC genotypes were 35.9+/-3.1umol/L, 40+/-2.9umol/L and 37.7+/-
6.3umol/L respectively, showing no significant differences (Sim et al. 1998). Jeeroburkhan et al. 
(2001) and Rossi et al. (2006) undertook similar studies also investigating the relationship between 
this variant and nitrate/nitrite levels these studies also failed to find any functional effect 
(Jeerooburkhan et al. 2001, Rossi et al. 2006).  Dell’Omo et al. (2007) used the technique of the 
forearm blood flow vasodilation as a reflection on NO activity and found responses to 
acetylcholine to exhibit no differences between genotypes (Dell'Omo et al. 2007).  
There are no published studies found on South Asian population; therefore based on these findings 
alone, this variant is unlikely to have a direct functional role and consequently no influence on 
disease status. 
3.4.3 Intron 4 CAD Association 
The final variant of the eNOS gene analysed was the VNTR 27bp repeat in Intron 4. This study has 
accepted the null hypothesis and confirmed there is no significant difference between CAD 
patients and controls. This suggests that within this population group this variant is unlikely to 
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affect an individual’s risk of CAD.  There was a hint of this variant to be protective in smoking 
group (p=0.046) but this becomes non-significant when one takes multiple comparisons into 
consideration.  
The control and patient groups were in HWE and had low inbreeding coefficients (Table 30). The 
genotype frequencies were consistent with previous studies. The current study found the 
percentage of control individuals with the 4aa genotype to be 4.09%, this was in keeping with 
previous studies falling within the range found (0-6.4%). This is a relatively small range and when 
sorted by size there appeared to be a possible population specific effect with lower frequencies in 
Asian population groups and higher frequencies in Caucasians. This range was small so it is 
anticipated the population specific effects were less apparent than in other eNOS variants 
(appendix 5, section 8.5).  
The Intron 4 variant was tested under both recessive and dominant models to investigate a possible 
influence on CAD disease status, the evidence in the literature has suggested the 4a allele of the 
Intron 4 variant to be associated with reduced NO production and an increased susceptibility to 
disease (Colomba et al. 2008, Matyar et al. 2005). 
It was apparent when considering all models there is no significant independent effect of this 
variant on disease status. Yet there was a relationship towards the 4b wild type allele increasing 
CAD disease susceptibility, whilst the 4a allele was surprisingly exhibiting a ‘protective’ effect. 
The 4a allele was found to have an OR value of 0.418 and the effect of this variant was found to be 
most prominent under a recessive model. This ‘protective’ effect of 4aa genotype is contrary to 
previous studies in which an increased risk was associated with the 4a allele. These include a meta-
analysis undertaken by Casas et al. (2004) (Casas et al. 2004). Salimi et al. (2006) showed strong 
effects of this variant finding OR values beyond 3 under some models (Salimi et al. 2006).  
This surprising result of ‘protectiveness’ may be unique for this CAD sample, however, other 
studies have also suggested a similar effect in different diseases. Park et al. (2004) found a 
protective effect in acute coronary syndrome. Hassan et al. (2004) found the 4a allele to be 
protective against cerebral small vessel disease. (Hassan et al. 2004). Sigusch et al. (2000) was yet 
another study that found this trend of ‘protectiveness’;  this study was a strong study with respect 
to sample size investigating 630 patients and 413 controls and was investigating CAD (Sigusch et 
al. 2000). Kunnas et al. (2002) used MI death as a clear end point for diagnosis of 700 patients and 
found that men carrying the Intron 4a allele were at a lower risk of coronary thrombosis OR=0.43 
(CI: 0.18-1.01) (Kunnas et al. 2002). 
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These among others, support the fact that the effect, if present, of the 4a allele as a risk factor is 
firstly likely to be of a smaller nature than first anticipated, or secondly it may be a population 
specific effect (a result of linkage disequilibrium with an alternate variant), supported by effects 
not restricted to one direction. It should be considered that the previous studies of confounding 
mixed effects are not showing an apparent pattern within ethnicities. Thirdly, the Intron 4 variant 
may have an interactive effect with other conventional risk factors.  Finally, the small frequency of 
this variant seen in this study and nearly all of the previous literature, could increase the chance of 
false positive findings. The ‘association’ may not be due to a functional relevance of this variant, 
but to chance alone.  
The functional effect of this variant has been investigated in a number of studies, the effect of this 
variant was previously attributed to being in linkage disequilibrium with a second functional 
variant supporting the above possibility. More recently it has been hypothesized by Zhang et al. 
(2005) this 27bp repeat during pre-mRNA processing may provide a source of small or micro 
RNA. This production of microRNA is able to regulate eNOS expression in a reductive manner. It 
has previously been established that microRNA is a cause of gene silencing and it is thought when 
eNOS is over expressed this would act as a crucial control mechanism, specifically controlling the 
production of ROS, a negative and detrimental consequence of uncoupled eNOS (Zhang et al. 
2005). 
The current protectiveness is supported by functional studies including Wang et al. (2000) who 
found increased enzymatic activity and NO production to be increased by five times in 
heterozygote 4a allele carriers compared to homozygotes for the 4b wild type allele (Wang et al. 
2000). If the 4a allele is associated with increased NO production this would most likely result in a 
protective effect against CAD, as seen in the current study. If the 4a allele does result in a gain of 
function the opposite disease association in previous studies could be a result of the fine balance 
between optimum and detrimental increased enzymatic activity resulting in ROS production. 
Alternatively it may be a result of the 4a allele’s functional effect being indirect and thus 
populational specific. This is supported by a number of studies have failed to find any functional 
effect. Dell’Omo et al. (2007) measured endothelial dependent relaxations as a reflection of NO 
levels, finding no significant differences for this variant (Dell'Omo et al. 2007). Other studies 
looked at plasma NO indicators and found no difference in levels (Yoon et al. 2000, Jeerooburkhan 
et al. 2001, Salimi et al. 2008). This leaves both the functional presence and directional implication 
unclear.  The study by Wang et al. (2000) in contrast to the increased enzymatic function, found 
within the same study NO production to be greater in the 4ab genotype their findings suggested 
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mRNA and protein levels to be significantly lower in the 4ab genotype compared to the 4bb 
genotype (Wang et al. 2000).  
Logistic regression analyses showed no genotype effect under a dominant model. However under a 
recessive model a ‘protective’ relationship with CAD was retained but remained non significant. 
To assess other interactions the variant was analysed in subgroups and basic ORs were 
recalculated, comparing genotypes with CAD association by gender, smoking and age. There was, 
once again an association found when assessing smokers only. The ‘protective’ effect of the 
variant under a dominant model 4aa+4ab vs. 4bb reached statistical significance OR=0.56 (0.33-
0.96) p=0.046.  As stated Rios et al. (2007) has previously found an interaction between smoking 
and the eNOS gene for CAD susceptibility (Rios et al. 2007). The proposed mechanisms for this 
are similar to those discussed previously (Glu298Asp discussion, 3.4.1). The effect of smoking 
alongside this variant is, to my knowledge, unique to this study, with respect to disease status. 
Functional studies have also found a relationship between smoking and this variant. Wang et al. 
(2000) found smoking to reduce enzyme activity only in carriers of the 4a mutant allele, this effect 
was absent in homozygotes for the wild type allele (Wang et al. 2000). 
Overall the effect of the Intron 4 variant remains unclear. The current study suggests that within 
this population group this variant is not a significant independent risk factor for CAD, and suggests 
the role of this variant is more likely to be exhibiting protective properties. This is in contrast to the 
meta-analysis undertaken by Casas et al. (2004), and a recent meta-analysis which failed to find 
any significant association of this variant in either direction (Li et al. 2010a). Further assessment of 
the variant revealed a possible interaction with smoking behaviours. There is a small amount of 
evidence that suggests an increased basal NO production associated with this variant and 
supporting a functional interaction with smoking. Therefore, due to the apparent contradicting 
findings of this variant, the effects are most likely to be down to linkage disequilibrium with an 
alternative functional variant in eNOS gene. Confirmation is required to clarify the role of this 
variant in different population groups. 
3.4.3.1 Synergistic Effect of eNOS Gene Variants 
The three eNOS loci were assessed for a possible synergistic effect to identify a possible high 
‘risk’ or ‘protective’ genotype combination. The frequency of the different combinations showed a 
non uniform distribution, which was as expected considering the different frequencies in the alleles 
and genotypes at each locus. Analysis revealed a significant protective effect under the 
combination GG-CC- 4aa for Glu298Asp, T-786C and Intron 4 loci respectively, this showed an 
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OR 0.29 (CI: 0.10-0.91), p=0.05. This effect was likely to be caused by the ‘protectiveness’ of the 
Glu298Asp GG genotype, combined with the ‘protective’ effect seen of the 4aa genotype. There 
was also a relationship for a ‘risky’ combination, the combination GG-TC-4bb for Glu298Asp, T-
786C and Intron 4 respectively had an OR of 3.19 (CI: 0.93-10.93) but this combination failed to 
reach statistical significance p=0.086.  These OR values were of a larger effect than the OR values 
found under the each variant when analysed individually, and support a possible synergistic effect 
of the three eNOS variants.  
A synergistic effect has been investigated previously but in only a small number of studies, these 
are often limited to only two variants. Kara et al. (2007) is one such study, they looked at a 
synergistic effect of genotypes including only the Glu298Asp and T-786C variants. However, 
unlike the current study, no significant ORs were identified, although they were unable to calculate 
an OR for the CC-TT composite genotype due to it being absent entirely in patients (Kara et al. 
2007). Vasilakou et al. (2008) also investigated the Glu298Asp variant alongside this time the 
Intron 4 variants and found no synergistic effect on CAD status in a Greek population (Vasilakou 
et al. 2008). 
When different synergistic effects were further analysed, there was an increased OR value 
associated with being a carrier of the T-786C mutant C allele in combination with homozygosity 
for the Glu298Asp mutant T allele (OR=2.47 (CI: 0.54-11.40)), this did not reach statistical 
significance. This was a similar effect to that found by Colombo et al. (2003) who also investigated 
a synergistic effect just looking at two out of the three eNOS variants, they found a synergistic 
effect of the Glu298Asp TT genotype when present with one or two of the mutant C alleles of the 
T-786C variants an OR of 4 (CI: 1.7-9.1), p<0.001 was present (Colombo et al. 2003b). The effect 
found here is most likely to be a consequence of the functional relevance of the Glu298Asp variant 
previously discussed in individual sections. This would need to be confirmed with a larger sample 
size, the sample size was small for these calculations due to some samples failing to be 
successfully genotyped for one or more variants.  
3.4.3.2  Linkage Disequilibrium 
Linkage disequilibrium has been discussed as a possible mechanism for the lack of replicated 
association of the variants.  The current study supports the possibility for the Intron 4 variant to be 
in linkage disequilibrium with the T-786C variant. This is consistent with the previous findings by 
Tanus-Santos et al. (2001) who investigated the distribution of eNOS variants among different 
ethnicities, finding the T-786C C allele  and Intron 4 4a allele to be significantly associated in 
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Asians (p<0.0001) (Tanus-Santos et al. 2001).  Low linkage disequilibrium was also identified 
between the Glu298Asp and T-786C loci which was consistent with findings by Rios et al. (2007), 
who identified the same linkage disequilibrium (Rios et al. 2007).  
3.4.3.3  Haplotype Analysis 
Haplotype analysis can provide a clearer picture than investigating single genetic variants because 
it incorporates potential interaction among variants; this interaction within a haplotype can be a key 
determinant of disease risk. The G-C-4b haplotype was significantly associated with CAD 
(OR=4.76 (CI: 1.43-15.78), p=0.01). The mechanism for a haplotype specific effect is an 
understudied area, although highlighted in multiple studies (Rios et al. 2007, Kitsios & Zintzaras 
2010). Metzger et al. (2007) reported the G-C-4b haplotype to be at an estimated frequency of 16% 
in individuals with low NOx levels whilst present in only 4% of those with high NOx levels. These 
findings lend support to the current study which found the G-C-4b haplotype to be associated with 
increased CAD risk. It should be highlighted that Metzger study was very limited by a sample size 
of only 30 in each group. However, this provides good evidence for a possible future investigation 
(Metzger et al. 2007). 
Rios et al. (2007) subdivided  their sample by ethnicity and smoking behaviours and found the  
wild type haplotype (G-T-4b) frequency to be significantly lower in cases 46.15% compared to 
58.97%, in controls, p=0.0033 among African-Brazilian smokers. The same study found the 4a 
repeat allele to have a modified effect dependent on the haplotype combination, among Caucasian 
Brazilian smokers when in a haplotype with the G-C of the Glu98Asp and T-786C variants, there 
was an increased CAD risk whilst when in the haplotype G-T-4a the 4a allele was part of a 
protective effect (Rios et al. 2007). Cheng et al. (2008) undertook haplotype analysis incorporating 
2 out of the 3 eNOS variants included in the current study (the Glu298Asp and T-786C), they 
included the A-922G variant in addition to these. Their results revealed an increased risk of 
ischemic stroke for the G-C-G haplotype, found to be significantly higher in the patients with an 
OR of 1.547 (1.029-2.34), the G-C combination is comparable to the haplotype G-C-4b found to 
increase disease susceptibility in the current study (Cheng et al. 2008a). 
There is also some evidence against a haplotypic association of the eNOS variant for example, a 
very recent study undertaken by Majumdar et al. (2010) found no significant effects when looking 
at the same  3 eNOS variants within a South Indians population with  ischemic stroke (Majumdar 
et al. 2010). 
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3.4.4 The ACE Variant in CAD 
The ACE insertion/deletion variant was tested for association with CAD and secondly for a 
possible interaction with the 3 eNOS variants. The ACE deletion was confirmed as a risk factor for 
CAD, finding under a dominant effect this variant was associated with more than twice the risk of 
disease development. This was similar to the results found in the meta-analysis of ACE undertaken 
by Zintzaras et al. (2008), which included 118 studies, 43,733 CAD patients and 82,606 controls.  
Where overall they found a significantly increased risk of CAD, OR=1.25 (CI: 1.16-1.35) 
(Zintzaras et al. 2008). 
The ACE variant was tested for significant differences using a chi-square test for each of the three 
eNOS variants. Individually no significant differences were found. Including the ACE variant in 
the overall logistic regression analysis alongside the eNOS variants failed to modify any of the 
previous individual calculations.  
The relationship between the ACE deletion and eNOS variants has been investigated previously in 
a few studies. For example, Berdeli et al. (2005) investigated both the Glu298Asp variant and the 
ACE deletion variant, identifying both variants as independent risk factors for CAD following 
logistic regression. Their study also reported a synergistic effect between the TT and DD 
genotypes further increasing CAD risk in this Turkish population group (Berdeli et al. 2005). 
Szolnoki et al. (2004) found an increased risk of ischemic stroke for the TT genotype of the 
Glu298Asp variant when in combination with the DD genotype of ACE and the TT genotype of 
the MTHRF 677 variant (Szolnoki et al. 2005). Similarly, a synergistic effect was identified 
between the DD genotype of ACE and the CC genotype of the T-786C which was reported to 
result in an increased risk of premature CAD (Alvarez et al. 2001).  
The current study was comparable to that by Nakagami et al. (1999) who investigated the ACE 
deletion variant alongside the Intron 4 variant. Confirming, like this study the ACE variant as a risk 
factor but found under combined analysis no influence on risk of the Intron 4 variant (Nakagami et 
al. 1999). The small number of comparable studies and apparent populational specific effects of 
the eNOS gene highlights this area for future research.  
3.4.4.1  Interaction of Genetic Variants 
Logistic regression analysis of all eNOS and ACE loci revealed under the final model (including 
all four genetic variants alongside the conventional risk factors), that age, TC, VLDL, APOB and 
ACE are independent significant CAD risk factors. However the effect of the variables, although 
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significant, in all but one case was not meaningful. The only variable to have a meaningful effect, 
was the ACE variant OR=2.399 (CI: 1.11-5.17), p=0.026. The Glu298Asp variant was shown to 
have an OR=1.675 which was the second highest OR but this was still non-significant, p=0.155.  
This is supportive of the effects found in the individual Glu298Asp variant analysis. The OR 
increased when including the other genetic variants from the adjusted value previously found. The 
T-786C and Intron 4 variants revealed ORs very close to 1 indicating no effect.  
3.5 Overall Discussion and Conclusions 
Identifying the genetic basis of CAD is challenging, with genetic variations affecting multiple 
levels of the atherosclerosis process: arterial inflammation, thrombosis and endothelial function. 
The eNOS gene is a unique candidate gene for CAD susceptibility with NO influencing all of these 
levels (Damani & Topol 2007). This study successfully genotyped three variants of the eNOS gene 
in a group of CAD cases and controls from Uttar Pradesh, North India. This was undertaken with 
the aim to greater the understanding of the genetic basis of CAD. Deciphering the genetic basis to 
CAD is a challenging task, further complicated by the multiple risk factors for CAD each having 
an underlying genetic architecture (Padmanabhan et al. 2010). 
Retrospective power analysis was undertaken, this was done for the Glu298Asp variant only. This 
indicated (based on allele frequencies and OR (1.29) observed in the current CAD study) the 
analysis was under powered (39% power) to detect overall significant susceptible association. To 
achieve 80% power for the whole population, one would require 812 individuals in each group to 
detect a statistical significance for OR of 1.29 observed in this study. This is a large sample size 
and consequently would require further population sampling.  The lack of significance may be 
partly attributed to this or the effect of this variant being small. The association found in smokers 
was adequately powered (>90%) with the current sample size and allele frequencies.   
Among other challenges are the multiple phenotypes that CAD presents, in some cases there will 
be a complete absence of clinical features, in contrast there may be severe clinical symptoms, such 
as myocardial infarctions (Damani & Topol 2007). Although recently, it has been shown that 
phenotypic variance in CAD does not have a significant impact (Kitsios et al. 2011).  
The matching of cases and controls in any study is critical in determining true genetic 
susceptibility. This is particularly challenging with respect to CAD. Clinical diagnosis, due to this 
variance in clinical manifestations, is based on the degree of stenosis within the vessel. Typically, 
this is defined more than 50% occlusion. The procedure required to detect stenosis is an 
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angiogram, this is an invasive procedure. It is associated with some major risks including: arterial 
access complications (1 in 500 people), possible stroke (1 in 1000), and in the worst case, death (1 
in 1400) (Grech 2003). Consequently, an angiogram would not be performed in the absence of 
clinical manifestations, and will be unable to detect asymptomatic cases. The ‘ideal’ control is 
described by Damani et al. (2007) as ‘a 90 year old individual with completely normal coronary 
arteries on angiography and no prior history of MI’(Damani & Topol 2007). This is unachievable, 
and consequently imperfect matching is a limitation that should be considered in the current study.  
This aside there was some major findings within the current study. Among these include the 
interaction identified between the eNOS variants and smoking. A report undertaken in 2001 found 
the overall prevalence of tobacco use to be 34.6% in Uttar Pradesh. They also found a negative 
association between the prevalence of tobacco use and education (Chaudhry et al. 2001). This 
suggests that with appropriate interventions, the prevalence of tobacco use could be reduced within 
this region. Which in light of the interaction identified with the eNOS gene alongside the known 
increased CAD risk, would vastly aid the prevention of CAD among this population.  
More recently the role of environmental factors has become better understood, contributing to not 
only the protein function but also gene regulation. Epigenetics, which is primarily histone 
modification and DNA methylation, have been shown to regulate gene expression within the 
vascular endothelium. The mechanisms are controlled by stimulations such as hypoxia. Epigenome 
mapping has been advised amongst this disease group to aid the understanding of the relationship 
between genes and environmental influencers (Shirodkar & Marsden 2011). ENOS function has 
been shown to be repressed in atherosclerotic lesions. It has become apparent that eNOS is being 
actively repressed in vascular smooth muscle cells, it has been suggested that epigenetic studies 
should progress by studying cell types where the genes are not normally expressed.  The role of the 
epigenetic mechanisms and hemodynamic forces including hypoxia is a newer paradigm that have 
created a new vision for human cardiovascular disease and the role of genes involved in this 
disease (Shirodkar & Marsden 2011).  
3.5.1 Overall Conclusions 
The findings in the current study have enabled a number of conclusions with respect to the eNOS 
gene and CAD association. All the samples were shown to be in HWE and consistent with 
previous studies, thus are representative of a south Asian population. Overall the eNOS gene was 
found to influence CAD risk; with the Glu298Asp and Intron 4 variants showing a significant 
association with CAD in a smoking dependent manner. The T-786C variant showed no overall 
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influence on CAD risk. Whether the effects of these variants are direct or a result of linkage 
disequilibrium remains unclear, although the evidence supports a direct functional influence of the 
Glu298Asp variant, whilst the Intron 4 variant may be more likely to be in linkage disequilibrium 
due to the ‘protectiveness’ found in the current study. This study provided evidence for both 
synergistic and haplotypic effects of the eNOS gene on CAD status.  Male gender, smoking and 
increased age were confirmed as independent risk factors for CAD along with ACE deletion.  
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4 Chapter 4- Hypertension in North Indians 
4.1 Introduction 
The second disease to be evaluated for a possible association with the eNOS gene is Hypertension 
(Ht). The literature review revealed a number of studies reporting association of the eNOS gene 
with Ht. However, the association remains inconclusive with a number of studies failing to 
replicate these findings (see Chapter One, section 1.7). Currently, to my knowledge there are no 
studies published evaluating a possible association of Ht for all three variants in a North Indian 
population.  
The aim of this study was to document genetic variation at the Glu298Asp, T-786C and Intron 4 
loci of the eNOS gene and their role in Ht within a North Indian population. The deletion variant of 
the Angiotensin-converting enzyme (ACE) gene was also analysed for a possible association with 
Ht and its interactive effect with the eNOS gene variants. The working hypothesis was: 
H0= The Glu298Asp, T-786C, Intron 4 and ACE variants are not significantly associated with Ht 
in a North Indian population. 
H1= The Glu298Asp, T-786C, Intron 4 and ACE variants are significantly associated with Ht in a 
North Indian population. 
4.2 Samples and Methods 
The full methodology and individual genotyping protocols have been described in Chapter Two. 
Unfortunately the number of samples was limited and DNA was available for genotyping from a 
total of 210 patients and 162 controls. To overcome this, the control group was extended by adding 
in a number of the diabetic controls, who were from the same population and geographical area. 
Only those defined as normotensive were included, diagnosis was following the same criteria 
outlined in section 2.2.2. For details of statistical analyses please see section 2.9.  
4.3 Results 
The result section is initially organised according to individual locus analysis followed by analysis 
at all loci level. This was done to understand the spectrum of genetic variation and its contribution 
to the disease.  
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4.3.1 Glu298Asp Results 
4.3.1.1 Baseline Characteristics for the Glu298Asp Variant 
Table 46 shows that the Ht and control groups were significantly different in nearly all of the 
continuous variables. The Ht group were significantly older than the control group with a mean age 
of 56.188 years compared to 50.013 years in the control group (t=-4.815, p<0.001).  
Significant differences were also seen between the Ht and control groups for blood pressure, FBS, 
and WHR (p<0.001). No significant difference was found for BMI mean which was found to be 
25.7 kg/m
2
 and 25.8 kg/m
2
 in controls and patients respectively (t=-0.192, p=0.848). 
Table 46- Glu298Asp baseline characteristics and independent samples t-test for continuous variables 
between Ht patients and controls 
Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
difference 
p value 
Age  
Controls 240 50.013 12.255 0.791 -4.815 -6.175 <0.001 
Patient 128 56.188 10.627 0.939       
SBP 
Controls 240 120.200 8.981 0.580 *-17.050 -33.488 <0.001 
Patient 128 153.688 21.231 1.877       
DBP 
Controls 240 77.154 6.559 0.423 *-18.735 -20.049 <0.001 
Patient 128 97.203 11.120 0.983       
FBS 
Controls 121 113.959 49.629 4.512 -6.916 -61.440 <0.001 
Patient 128 175.398 86.585 7.653       
BMI 
Controls 240 25.738 4.811 0.311 -0.192 -0.107 0.848 
Patient 128 25.844 5.525 0.488       
WHR 
Controls 240 0.941 0.070 0.005 *-8.270 -0.055 <0.001 
Patient 128 0.995 0.054 0.005       
The categorical variables are presented in Table 47. As expected significantly more patients had a 
positive family history (23.4%) compared to controls (8.3%) (χ2=9.525, df=1, p=0.002). Significant 
differences were also found between age groups brackets (χ2=29.504, df=2, p<0.001). The largest 
difference was apparent in the number of subjects ≥55 years, 56.3% compared to 29.5% in patients 
and controls respectively. No significant differences were found between gender (χ2=0.633, df=1, 
p=0.426), occupation (χ2=3.06, df=2, p=0.217) or dietary choices (χ2=1.033, df=1, p=0.309). The 
categorical variables were tested for Ht association and ORs were calculated, these results are also 
shown in Table 47. Increased age was confirmed as a risk factor for Ht (≥55 years OR=3.07 (CI: 
1.96-4.80), p<0.001 and ≥40 years OR=4.85 (CI: 1.86-12.63), p<0.001). A positive family history 
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was also confirmed as a risk factor (OR=3.40 (CI: 1.58-7.31), p<0.001). No association was found 
between occupation, diet or gender (p>0.05). 
Table 47- Glu298Asp categorical variables in Ht patients and controls and Odds Ratios (ORs) for Ht 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 65 (50.8%) 110 (45.8%) 1.22 (0.79-1.87) 0.633 0.426 
Female 63 (49.2%) 130 (54.8%) 0.80 (0.534-1.0)    
Total 128 (100%) 240 (100%)     
Diet          
Non vegetarian 54 (42.2%) 116(48.3%) 0.78 (0.51-1.20) 1.033 0.309 
Vegetarian 74 (57.8%) 124 (51.7%) 1.28 (0.83-1.98)    
Total 128 (100%) 240(100%)     
Age (3 groups)          
 ≤39 years (1) 5 (3.9%) 39 (16.5%) 3 vs.1+2 29.504 (total, df=2) <0.001 
40-54years (2) 51 (39.8%) 128 (54.0%) 3.07 (1.96-4.80) 23.84 <0.001 
≥55 years (3) 72 (56.3%) 70 (29.5%) 3+2 vs. 1    
Total 128 (100%) 237 (100%) 4.85 (1.86-12.63) 11.19 <0.001 
Family History        
Absent 98 (76.6%) 111 (91.7%) 0.29 (0.14-0.63) 9.525 0.002 
Present 30 (23.4%) 10 (8.3%) 3.40 (1.58-7.31)    
Total 128 (100%) 121 (100%)    
Occupation        
Sedentary (1) 35 (27.3%) 22 (18.2%) 1 vs. 2+3  3.06 (total, df=2) 0.217  
Moderate (2) 75 (58.6%) 78 (64.5%) 1.69 (0.93-3.10) 2.462 0.117 
Heavy (3) 18 (14.1%) 21 (17.4%) 1+2 vs. 3     
Total 128 (100%) 121 (100%) 1.28 (0.65-2.55) 0.292 0.589 
4.3.1.2  eNOS Glu298Asp Genotypes and Allele Frequencies 
Table 48 shows the distribution of the genotypes and alleles among the Ht patient and control 
groups. The Ht patient genotype frequencies were 64.1%, 33.59% and 2.34% for GG, GT and TT 
respectively. The control group’s genotype frequencies were 57.5%, 35.8% and 6.5% for GG, GT 
and TT respectively. The G allele and GG genotype showed the highest frequencies in both groups 
(Table 48). There was no significant departure from HWE using three tests; Pearson’s goodness of 
fit chi square, log likelihood ratio chi square or P exact test (p>0.05).  
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Table 48-Glu298Asp genotype and allele frequencies and Hardy-Weinberg equilibrium tests for the Ht 
patient and control groups 
  Ht Patients (n=128) Ht controls (n=240) 
Genotype frequencies 
GG  82 (64.1%) 138 (57.5%) 
GT 43 (33.59%) 86 (35.8%) 
TT 3 (2.34%) 16 (6.7%) 
Total 128 (100%) 240 (100%) 
Allele frequencies   
Allele G 0.809 0.754 
Allele T 0.191 0.246 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.085 0.034 
P-Pearson's goodness of fit χ2 (DF=1) 0.335 0.603 
P-Log likelihood ratio χ2 (DF=1) 0.314 0.605 
P Exact test 0.565 0.603 
4.3.1.3 Association Between the Glu298Asp Polymorphism and Ht Risk 
Ht risk was assessed by calculating the odds ratios (ORs) of the genotypes under different models, 
ORs are expressed with a 95% confidence interval (CI). These are presented firstly for the T allele 
as the risk factor (Table 49), secondly for the G allele as the risk factor (Table 50). There were no 
significant associations observed under any model.  At an allelic level the T allele suggested a 
small reduced risk of Ht (OR=0.726 (CI: 0.499-1.056), p=0.09), whilst the G allele suggested a 
small increased risk of Ht (OR=1.377 (CI: 0.947-2.2002), p=0.09) both these results were non 
significant. These effects were most prominent under the recessive model (GG vs. TT+GT), 
(OR=3.169 (CI: 0.896-11.206), p=0.06), but was also present in the dominant model (GG + GT vs. 
TT), (OR=2.976 (CI: 0.851-10.413), p=0.074) (Table 50).  
Table 49-Glu298Asp Odds Ratios (ORs) for Ht association (T risk allele) 
Glu298Asp Ht association  OR 95% CI χ2 P 
T vs. G 0.726 0.499-1.056 2.82 0.093 
GT vs. GG 0.841 0.533-1.329 0.55 0.459 
TT vs. GG+ GT 0.316 0.089-1.116 3.52 0.061 
TT + GT vs. GG 0.759 0.488-1.181 1.5 0.221 
Armitage's trend test 0.69   2.82 0.093 
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Table 50- Glu298Asp Odds Ratios (ORs) for Ht association (G risk allele) 
Glu298Asp Ht association  OR 95% CI χ2 P 
 G vs. T 1.377 0.947-2.200 2.82 0.093 
GT vs. TT 2.667 0.737-9.652 2.38 0.123 
GG vs. TT+GT 3.169 0.896-11.206 3.52 0.061 
GG+GT  vs. TT 2.976 0.851-10.413 3.19 0.074 
Armitage's trend test 1.506   2.82 0.093 
4.3.1.4 Glu298Asp Logistic Regression 
Logistic regression was performed to calculate the effect of the Glu298Asp variant on Ht status 
when adjusting for other covariates. 249 samples were included in analysis and 119 were excluded 
due to missing data. Logistic regression was performed by first inputting the covariate Glu298Asp 
only (model 1), this model was then adjusted to also include the covariates; sex, age, FBS, BMI, 
occupation, diet and family history (model 2). Table 51 shows the reference groups used for the 
categorical covariates. 
Table 51- Reference groupings for the categorical variables included in the Glu298Asp Ht logistic 
regression analysis 
Covariate Reference Group Parameter 1 
Glu298Asp (dominant) GG GT+TT 
Glu298Asp (recessive) GG+GT TT 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Occupation Heavy moderate +sedentary 
Family History Absent Present 
4.3.1.4.1 Logistic Regression for a Dominant Model  
The classification table revealed the percentage of disease status correctly predicted was 51.4% 
without considering any other variables. Model 1, included the Glu298Asp variant only, this Model 
was not a significant predictor of disease status (χ2=0.004, 1df, p=0.947). This was confirmed by 
the Hosmer and Lemershow test (p<0.001). Overall, Model 1 predicted 52.8% of cases correctly. 
The Wald test revealed that the Glu298Asp variable didn't significantly contribute to the model 
(OR=1.018 (CI: 0.606-1.709), p=0.338) (Table 52). The Model was then extended to include sex, 
age, FBS, BMI, occupation, diet and family history (Model 2) The omnibus test of model 
coefficients revealed the model to significantly predict Ht status (χ2=85.136, df=8, p<0.001), this 
was confirmed by the Hosmer and Lemeshow test (p=0.272). Model 2 correctly predicted 76.70% 
of cases. The only significant variables were age and FBS but the effect size was negligible/small. 
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The logistic regression analysis was rerun under a recessive model, with GG+GT as the reference. 
The covariates all showed similar effects, the full details have not been included but are 
summarised in Table 52. 
Table 52- Key findings of Glu298Asp (dominant model) Ht logistic regression analysis adjusting for 
gender, age, fasting blood sugar (FBS), Body mass index (BMI), occupation, diet and family history 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Model 1 (dominant)        
Glu298Asp .017 .265 .004 .947 1.018 .606 1.709 
Constant .050 .158 .100 .752 1.051     
Model 2 (dominant)       
Glu298Asp  0.041 0.321 0.017 0.897 1.042 0.556 1.954 
Gender  0.361 0.333 1.175 0.278 1.434 0.747 2.753 
AGE  0.077 0.015 25.042 <0.001 1.080 1.048 1.114 
FBS 0.015 0.003 21.210 <0.001 1.015 1.009 1.022 
BMI 0.048 0.031 2.466 0.116 1.049 0.988 1.114 
Occupation 0.170 0.422 0.161 0.688 1.185 0.518 2.711 
Diet  -0.084 0.316 0.071 0.790 0.920 0.495 1.707 
Family History 0.273 0.472 0.335 0.563 1.314 0.521 3.313 
Constant -7.561 1.348 31.440 <0.001 0.001     
 Model 1 Model 2 
Dominant model   
Goodness of fit chi square 0.004 85.136 (df=8) 
Significance 0.947 <0.001 
Hosmer and Lemershow <0.001 0.272 
Percentage correctly predicted 51.40% 76.70% 
Glu298Asp 1.018 (0.606-1.709) 1.042 (0.556-1.954) 
Recessive model   
Goodness of fit chi square 3.656 (df=1) 88.172 (df=8) 
Significance 0.056 <0.001 
Hosmer and Lemershow <0.001 0.069 
Percentage correctly predicted 53.80% 77.10% 
Glu298Asp 0.299 (0.79-1.131) 0.255 (0.49-1.315) 
The Glu298Asp variant failed to be a significant independent risk factor for Ht following 
adjustment for the classical risk factors.  Less than 80% of Ht could be predicted by these risk 
factors. 
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4.3.1.5 Glu298Asp Genotype Association with Continuous Variables 
Pairwise comparisons of genotypes (TT vs. GG, TT vs. GT and GT vs. GG) for continuous 
variables did not reveal any statistically significant differences. The individual tables are presented 
in appendix 6, section 8.6. 
4.3.1.6 eNOS Glu298Asp Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Glu298Asp variant had association by 
gender or age, these are presented in Table 53. The Glu298Asp variant was not shown to be a 
significant risk factor for Ht under any gender, or age subgroup analyses (p>0.05). 
Table 53- Glu298Asp genotype frequencies and Ht association in subgroup analysis by gender and age 
Ht 
association 
Controls Patients Model OR (95%CI) Χ2 P 
Gender        
Males only           
GG 68 (61.8%) 41 (63.1%) TT vs. GT+GT 0.20 (0.02-1.63) *1.704 0.192 
GT 34 (30/9%) 23 (35.4%) TT+GT vs. GG 0.95 (0.50-1.79) 0.00 0.996 
TT 8 (7.3%) 1 (1.5%)      
 Total 110 (100%) 65 (100%)      
Females only            
GG 70 (53.8%) 41 (65.1%) TT vs. GT+GT 0.54 (0.11-2.62) *0.179 0.672 
GT 52 (40%) 20 (31.7%) TT+GT vs. GG 0.63 (0.34-1.17) 1.756 0.185 
TT 8 (6.2%) 2 (3.2%)      
Total 130 (100%) 63 (100%)         
AGE groups            
≤39 years             
GG 23 (59.0%) 4 (80.0%) TT vs. GT+GT 2.19 (0.19-24.68) *0.01 0.919 
GT 12 (30.8%) 0 (0%) TT+GT vs. GG 0.36 (0.004-3.52) 0.177 0.674 
TT 4 (10.3%) 1 (20%)      
Total 39 (100%) 5 (100%)         
40-54 years            
GG 75 (58.6%) 34 (66.7%) TT vs. GT+GT 0.35 (0.04-2.88) *0.39 0.053 
GT 46 (35.9%) 16 (31.4%) TT+GT vs. GG 0.71 (0.36-1.40) 0.688 0.407 
TT 7 (5.5%) 1 (12.5%)      
Total 128 (100%) 51 (100%)         
≥55 years             
GG 39 (55.7%) 44 (61.1%) TT vs. GT+GT 0.18 (0.02-1.61) *1.656 0.198 
GT 26 (37.1%) 27 (37.5%) TT+GT vs. GG 0.80 (0.41-1.56) 0.232 0.630  
TT 5 (7.1%) 1 (1.4%)      
Total 70 (100%) 72 (100%)         
*value less than 5 (χ2 not valid) 
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4.3.2 T-786C Results 
4.3.2.1 Baseline Characteristics for the T-786C Variant 
Table 54 shows that the Ht and control groups were significantly different in nearly all of the 
continuous variables. The patient group were significantly older than the control group with a 
mean of 55.34 years compared to 49.83 years  in the control group (t=-5.071, p<0.001).  
Significant differences were also seen between the Ht and control groups for blood pressure, FBS, 
and WHR (p<0.001). No significant difference was found for BMI mean, BMI=25.64 kg/m
2
 and 
25.21 kg/m
2
 in controls and patients respectively, (t=-1.134, p=0.257). 
Table 54-T-786C baseline characteristics and independent samples t-test for continuous variables between 
Ht patients and controls 
Variable 
Disease 
status 
N Mean SD SE T value 
mean 
difference 
p value 
Age  
(years) 
Controls 285 49.833 12.214 0.724 -5.071 -5.511 <0.001 
Patient 192 55.344 10.726 0.774       
SBP 
Controls 285 119.779 8.768 0.519 *-20.123 -33.409 <0.001 
Patient 192 153.188 21.849 1.577       
DBP 
Controls 285 76.702 6.520 0.386 *-23.323 -20.793 <0.001 
Patient 192 97.495 11.134 0.804       
FBS 
Controls 152 109.921 44.148 3.581 *-9.193 -68.626 <0.001 
Patient 192 178.547 90.762 6.550       
BMI 
Controls 285 25.644 4.958 0.294 -1.134 -0.566 0.257 
Patient 192 26.210 5.885 0.425       
WHR 
Controls 285 0.944 0.070 0.004 *-8.826 -0.049 <0.001 
Patient 192 0.993 0.052 0.004       
*Equal variances not assumed 
Family history showed significantly more patients had a positive family history 27.6% compared to 
6.6% in patients and controls respectively (χ2=23.683, p=<0.001) (Table 55). Significant 
differences were also found between age groups brackets, (χ2=34.505, df=2, p<0.001). No 
significant differences were found between gender (χ2=0.004, p=0.948), occupation (χ2=3.847, 
p=0.146) or dietary choices (χ2=0.895, p=0.344).  
The categorical baseline characteristics were then tested for Ht association and ORs were 
calculated (Table 55). A positive family history was confirmed as a risk factor (OR=5.41 (CI: 
0.265-11.07), p<0.001). Increased age was also confirmed as a risk factor for Ht for both ≥55 years 
(OR=2.82 (CI: 1.92-4.14), p<0.001) and for ≥40 years (OR=3.73 (CI: 1.84-7.58), p<0.001). No 
association with Ht was found for occupation, diet or gender (p>0.05). 
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Table 55- T-786C categorical variables in Ht patients and controls and Odds Ratios (ORs) for Ht 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 88 (45.8%) 131 (46.0%) 0.99 (0.69-1.44) 0.004 0.948 
Female 104 (54.2%) 154 (54.0%) 1.00 (0.69-1.45)    
Total 192 (100%) 285 (100%)     
Diet          
Non vegetarian 77 (40.1%) 128 (44.9%) 0.82 (0.57-1.19) .895 0.344 
Vegetarian 115 (59.9%) 157 (55.1%) 1.22 (0.84-1.76)    
Total 192 (100%) 285 (100%)     
Age (3 groups)         
 ≤39 years (1) 10 (5.2%) 48 (5.2%) 3 vs.1+2 34.505 (total) <0.001 
40-54years (2) 79 (41.1%) 152 (53.9%) 2.82 (1.92-4.14) 27.95 <0.001 
≥55 years (3) 103 (53.6%) 82 (29.1%) 3+2 vs. 1    
Total 192 (100%) 282 (100%) 3.73 (1.84-7.58) 13.763 <0.001 
Family History        
Absent 139 (72.4%) 142 (93.4%) 0.18 (0.09-0.38) 23.683 <0.001 
Present 53 (27.6%) 10 (6.6%) 5.41 (2.65-11.07)    
Total 192 (100%) 152 (100%)     
Occupation        
Sedentary (1) 56 (29.2%) 31 (20.4%) 1 vs. 2+3 3.847 (total) 0.146  
Moderate (2) 111 (57.8%) 95 (62.5%) 1.61 (0.97-2.66) 3.006 0.083 
Heavy (3) 25 (13.0%) 26 (17.1%) 1+2 vs. 3    
Total 192 (100%) 152 (100%) 1.38 (0.76-2.50) 0.821 0.365 
4.3.2.2 eNOS T-786C Genotypes and Allele Frequencies 
Table 56 shows the distribution of the genotypes and alleles among the Ht patient and control 
groups. The Ht’s group genotype frequencies were 58.3%, 33.3% and 9.4% for TT, TC and CC 
respectively. The control group’s genotype frequencies were 62.1%, 32.3% and 6.3% for TT, TC 
and CC respectively. The T allele and TT genotype showed the highest frequencies in both groups. 
There was a significant departure from HWE in patients only. For patients the results were 
significant for Pearson’s goodness of fit= 0.037, Log likelihood ratio chi square result= 0.042 and 
P exact test= 0.038. The Ht controls did not show any departure from HWE.  
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Table 56-T-786C genotype and allele frequencies and Hardy-Weinberg equilibrium tests for the Ht patient 
and control groups 
  Ht patients (n=192) Ht controls (n=285) 
Genotype frequencies 
TT 112 (58.3%) 177 (62.1%) 
TC 62 (32.3%) 90 (31.6%) 
CC 18 (9.4%) 18 (6.3%) 
Total 192 (100%) 285 (100%) 
Allele frequencies   
Allele T 0.745 0.779 
Allele C 0.255 0.221 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.151 0.083 
P-Pearson's goodness of fit χ2 (DF=1) 0.04* 0.161 
P-Log likelihood ratio χ2 (DF=1) 0.04* 0.170 
P Exact test 0.04* 0.169 
*significant  
4.3.2.3 Association between the T-786C Polymorphism and Ht Risk 
Table 57 shows the estimated ORs assuming the C allele as the Ht risk allele and Table 58 shows 
the ORs of the T allele as the Ht risk allele. There were no significant effects seen for this variant 
under any model for the either the C or T as the risk allele. The C allele has a small increased Ht 
risk (OR=1.207 (CI: 0.892-1.635)) whilst the T allele has a small reduced risk (OR=0.828 (CI: 
0.612-1.121)), however, the results were non significant (p=0.22). The slightly elevated disease 
risk associated with the C allele was most prominent under the recessive model (CC vs. TT+CT, 
OR=1.58 (CI: 0.789-3.166)), but again failed to reach statistical significance (p>0.05). 
Table 57- T-786C Odds Ratios (ORs) for Ht association (C risk allele) 
T-786C Ht association OR 95% CI χ2 P 
C  vs. T 1.207 0.892-1.635 1.49 0.222 
TC vs. TT 1.089 0.729-1.625 0.17 0.678 
CC  vs. TT+ TC 1.58 0.789-3.166 1.69 0.194 
CC + TC vs. TT 1.171 0.806-1.701 0.68 0.408 
Armitage's trend test 1.212   1.34 0.247 
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Table 58- T-786C Odds Ratios (ORs) for Ht association (T risk allele) 
T-786C Ht association  OR 95% CI χ2 P 
T vs. C 0.828 0.612-1.121 1.49 0.222 
TC vs. CC 0.689 0.332-1.428 1.01 0.315 
TT vs. CC +TC 0.633 0.316-1.268 1.69 0.194 
TT + TC vs. CC 0.652 0.330-1.287 1.54 0.215 
Armitage's trend test 0.604   8.4 0.247 
4.3.2.4 T-786C Logistic Regression 
Logistic regression was performed to calculate the effect of the T-786C variant on Ht status while 
adjusting for other covariates. 344 samples were included in this analysis and 133 were excluded 
due to missing data. Logistic regression was performed by first inputting the covariate T-786C 
only (Model 1), this Model was then adjusted to also include the covariates; sex, age, FBS, BMI, 
occupation, diet and family history (Model 2). Table 59 presents the reference groups used for the 
categorical covariates. 
Table 59- Reference groupings for the categorical variables included in the T-786C Ht logistic regression 
analysis 
 Variable Reference Group Parameter 1 
T-786C (dominant) TT TC+CC 
T-786C (recessive) TT+TC CC 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Occupation Heavy moderate +sedentary 
Family History Absent Present 
4.3.2.4.1 Logistic regression for a Dominant Model  
The classification table revealed the percentage of cases correctly predicted was 55.8% without 
considering any other variables. Model 1 included the T-786C variant only, this Model did not 
significantly predict disease status (χ2 =3.238 1df p=0.072). The Hosmer and Lemershow test also 
showed this model not to be a good predictor of disease outcome, (p<0.001). Overall, the Model 
remained at 55.8% of cases correctly predicted. 
The Wald test revealed that the T-786C variable didn't significantly contribute to the Model 
(OR=1.501 (CI: 0.962-2.343), p=0.480) (Table 60). The Model was then extended to include sex, 
age, FBS, BMI, occupation, diet and family history (Model 2). The omnibus test of model 
coefficients revealed the model to significantly predict Ht status (χ2=135.461, df=8, p<0.001), this 
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was confirmed by the Hosmer and Lemeshow test, (p=0.144). Model 2 correctly predicted 79.40% 
of cases correctly. The only significant variables were age and FBS but the effect was negligent. 
The highest OR values were seen for T-786C and family history. The logistic regression was then 
rerun with a recessive model with TC+TT as the reference category. All covariates showed a 
similar effect to that under a dominant model, these data have not been included. The key findings 
of the T-786C logistic regression analyses are summarised in Table 60. 
Table 60- Key findings of T-786C Ht logistic regression analysis adjusting for gender, age, fasting blood 
sugar (FBS), Body mass index (BMI), occupation, diet and family history 
Variable B S.E. Wald P OR 
95% C.I. 
Lower Upper 
Model 1 (dominant)       
T-786C .406 .227 3.205 .073 1.501 .962 2.343 
Constant .084 .137 .377 .539 1.087     
Model 2 (dominant)      
T-786C 0.507 0.279 3.296 0.069 1.661 0.960 2.872 
Gender  0.146 0.286 0.260 0.610 1.157 0.661 2.026 
AGE (in years) 0.073 0.014 27.928 <0.001 1.075 1.047 1.105 
FBS 0.019 0.003 30.277 <0.001 1.019 1.012 1.026 
BMI 0.065 0.026 6.569 0.010 1.068 1.016 1.122 
Occupation 0.121 0.370 0.107 0.743 1.129 0.546 2.332 
Diet  0.034 0.277 0.015 0.904 1.034 0.600 1.782 
Family History 0.482 0.439 1.208 0.272 1.619 0.685 3.826 
Constant -8.092 1.180 46.996 <0.001 0.000     
 Model 1 Model 2 
Dominant model   
Goodness of fit chi square 3.238 135.461 (df=8) 
Significance 0.072 0 
Hosmer and Lemershow 0 0.144 
Percentage correctly predicted 55.80% 79.40% 
T-786C 1.501 (0.962-2.343) 1.661 (0.960-2.872) 
Recessive model   
Goodness of fit chi square 0.508 (df=1) 132.161 (df=8) 
Significance 0.476 <0.001 
Hosmer and Lemershow <0.001 0.6 
Percentage correctly predicted 55.80% 76.70% 
T-786C 1.326 (0.606-2.899) 0.918 (0.353-2.388) 
The T-786C variant failed to be a significant independent risk factor for Ht following adjustment 
for the classical risk factors.  Less than 80% of Ht could be predicted by these risk factors. 
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4.3.2.5 T-786C Genotype Association with Continuous Variables 
Pairwise comparisons of genotypes (CC vs. TC, CC vs. TT and TC vs. TT) was undertaken to 
detect any significant difference between continuous variables. This analysis revealed the CC 
genotype had a significantly younger mean age of onset, 46.06 years compared to 52.3 years in the 
TT individuals, (p=0.022). The individual tables are given in appendix 6, section 8.6. 
4.3.2.6 eNOS T-786C Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the T-786C variant had association by gender 
or age, these are presented in Table 61. The T-786C variant was not a significant risk factor for Ht 
under any dominant or recessive model by gender, or age subgroup analysis in all cases p>0.05. 
There was a non-significant association with Ht under a recessive model (CC+TC vs. TT) 
(OR=2.67 (CI: 0.93-7.64) p=0.1). 
Table 61-T-786C genotype frequencies and Ht association in subgroup analysis by gender and age 
Variable Controls Patients Model OR (95%CI) Χ2 P 
Gender       
Males only             
TT 87 (66.4%) 54 (61.4%) CC vs. TC+TT 2.67 (0.93-7.64) 2.65 0.1 
TC 38 (29.0%) 24 (27.3%) CC+TC vs. TT 1.24 (0.70-2.18) 0.386 0.535 
CC 6 (4.6%) 10 (11.4%)      
Total 131 (100%) 88 (100%)      
Females only             
TT 90 (58.4%) 58 (55.8%) CC vs. TC+TT 0.99 (0.39-2.50) 0.043 0.835 
TC 52 (33.8%) 38 (36.4%) CC+TC vs. TT 1.12 (0.67-1.84) 0.088 0.766 
CC 12 (7.8%) 8 (3.1%)      
Total 154 (100%) 104 (100%)         
AGE groups             
≤39 years             
TT 32 (66.7%) 4 (40.0%) CC vs. TC+TT not possible     
TC 14 (29.2%) 6 (60.0%) CC+TC vs. TT 3.00 (0.74-12.17) 1.495 0.221 
CC 2 (4.2%) 0 (0%)      
Total 48 (100%) 10 (100%)         
40-54years             
TT 92 (60.5%) 47 (59.5%) CC vs. TC+TT 2.33 (0.81-6.69) 1.78 0.18 
TC 53 (58.9%) 24 (30.4%) CC+TC vs. TT 1.04 (0.60-1.82) 0 0.99 
CC 7 (4.6%) 8 (10.1%)      
Total 152 (100%) 79 (100%)         
≥55 years             
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Variable Controls Patients Model OR (95%CI) Χ2 P 
TT 50 (61.0%) 61 (59.2%) CC vs. TC+TT 0.87 (0.34-2.26) 0.001 0.97 
TC 23 (28.0%) 32 (31.1%) CC+TC vs. TT 1.07 (0.59-1.95) 0.008 0.93 
CC 9 (11.0%) 10 (9.7%)      
Total 82 (100%) 103 (100%)         
4.3.3 Intron 4 results 
4.3.3.1 Baseline Characteristics for the Intron 4 Variant 
Table 62 shows that the Ht and control groups were significantly different in nearly all of the 
continuous variables. The patients were significantly older than the control group with a mean of 
55.344 years compared to 49.485 years in the control group (t=-5.357, p<0.001).  
Significant differences were also seen between the Ht and control groups for blood pressure, FBS, 
and WHR (p<0.001). No significant difference was found for mean BMI values (25.54 and 26.296 
in controls and patients respectively). 
Table 62- Intron 4 baseline characteristics and independent samples t-test for continuous variables 
between Ht patients and controls 
Variable 
Disease 
status N Mean 
Std. 
Deviation 
Std. 
Error 
Mean t value 
mean 
difference p value 
Age  
(years) 
Controls 286 49.485 12.241 0.724 -5.357 -5.859 <0.001 
Patient 189 55.344 10.744 0.781       
SBP Controls 286 119.713 8.762 0.518 *-20.22 -33.657 <0.001 
Patient 189 153.370 21.747 1.582       
DBP Controls 286 76.766 6.496 0.384 *-22.944 -20.583 <0.001 
Patient 189 97.349 11.146 0.811       
FBS Controls 157 110.516 44.243 3.531 *-9.232 -71.373 <0.001 
Patient 189 181.889 94.551 6.878       
BMI Controls 286 25.544 4.959 0.293 -1.502 -0.752 0.134 
Patient 189 26.296 5.877 0.428       
WHR Controls 286 0.944 0.070 0.004 *-8.598 -0.049 <0.001 
Patient 189 0.993 0.055 0.004       
Family history showed significantly more patients had a positive family history 27.5% compared to 
6.4% in patients and controls respectively (χ2=24.649, p<0.001) (Table 63). Significant differences 
were also found between age groups (χ2=38.413, df=2, p<0.001). No significant differences were 
found between gender (χ2=0.286, p=0.593), occupation (χ2=32.762, df=2, p=0.251) or dietary 
choices (χ2=1.400, p=0.237).  
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The categorical characteristics were tested for Ht association and ORs were calculated. These 
results are also given in Table 63. Increased age was confirmed as a Ht risk factor (≥55 years 
OR=2.85 (CI: 1.94-4.19), p<0.001 and for ≥40 years OR=5.09 (CI: 2.36-10.99), p<0.001). Family 
history was also confirmed as a risk factor (OR=5.57 (CI: 2.72-11.41), p<0.001). No association 
was found between occupation, diet or gender and Ht (p>0.05). 
Table 63-Intron 4 categorical variables in Ht patients and controls and Odds Ratios (ORs) for Ht 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 83 (43.9%) 134 (46.9%) 0.89 (0.61-1.29) 0.286 0.593 
Female 106 (56.1%) 152 (53.1%) 1.12 (0.78-1.63)    
Total 189 (100%) 286 (100%)     
Diet          
Non vegetarian 76 (40.2%) 132 (46.2%) 0.78 (0.54-1.14) 1.400 0.237 
Vegetarian 113 (59.8%) 154 (53.8%) 1.27 (0.88-1.85)    
Total 189 (100%) 286 (100%)     
Age (3 groups)         
≤39 years (1) 8 (4.2%) 52 (18.4%) 3 vs.1+2 38.413 (total) <0.001 
40-54years (2) 81 (42.9%) 151 (53.4%) 2.85 (1.94-4.19) 28.13 <0.001 
≥55 years (3) 100 (52.9%) 80 (28.3%) 3+2 vs. 1    
Total 189 (100%) 283 (100%) 5.09 (2.36-10.99) 19.17 <0.001 
Family History        
Absent 137 (72.5%) 147 (93.6%) 0.18 (0.09-0.37) 24.649 <0.001 
Present 52 (27.5%) 10 (6.4%) 5.57 (2.72-11.41)    
Total 189 (100%) 157 (100%)    
Occupation        
Sedentary (1) 51 (27.0%) 31 (19.7%) 1 vs. 2+3  2.762 0.251 
Moderate (2) 112 (59.3%) 99 (63.1%) 1.50 (0.90-2.50) 2.101 0.147 
Heavy (3) 26 (13.8%) 27 (17.2%) 1+2 vs. 3     
Total 189 (100%) 157 (100%) 1.30 (0.72-2.34) 0.54 0.462 
4.3.3.2 eNOS Intron 4 Genotypes and Allele Frequencies 
Table 64 shows the distribution of the genotypes and alleles among the Ht patient and control 
groups. The patient’s group genotype frequencies were 70.90%, 26.46% and 2.65% for 4bb, 4ab 
and 4aa respectively. The control group’s genotype frequencies were 74.8%, 24.5% and 0.7% for 
4bb, 4ab and 4aa respectively. There was no significant departure from HWE in both groups which 
was tested with three tests. 
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Table 64-Intron 4 genotype and allele frequencies and Hardy-Weinberg equilibrium tests for the Ht 
patient and control groups 
 Patients (n=189) Controls (n=286) 
Genotype frequencies 
4bb 134 (70.9%) 214 (74.8%) 
4ab 50 (26.5%) 70 (24.5%) 
4aa 5 (2.6%) 2 (0.7%) 
Total 189 (100%) 286 (100%) 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.009 0.087 
P-Pearson's goodness of fit χ2 (DF=1) 0.897 0.143 
P-Log likelihood ratio χ2 (DF=1) 0.897 0.108 
P Exact test 0.790 0.192 
Allele frequencies 
Allele 4a 0.841 0.871 
Allele 4b 0.159 0.129 
4.3.3.3 Association between the Intron 4 Polymorphism and Ht Risk 
The Intron 4 variant was assessed for Ht risk and ORs were calculated. These are presented firstly 
for the 4a allele as the risk allele (Table 65) and secondly for the 4b allele as the risk allele (Table 
66).  The 4a allele increased risk of Ht (OR=1.27 (CI: 0.878-1.835), p=0.203) and the 4b allele was 
protective against Ht (OR=0.788 (CI: 0.545-1.138), p=0.203), neither result reached statistical 
significance (p>0.05). This effect was most prominent under the recessive (4aa vs. 4bb+4ab) model 
(Table 65) (OR=3.993 (CI: 0.764-20.872), p=0.077).  
Table 66 shows the 4b allele to be protective, this was most prominent under the recessive (4bb vs. 
4aa + 4ab) model, (OR=0.25 (CI: 0.048-1.309), p=0.077) and was also present under a dominant 
effect (4bb+4ab vs. 4aa) model, (OR=0.259 (CI: 0.050-1.350), p=0.085). 
Table 65- Intron 4 Odds Ratios (ORs) for Ht association (4a risk allele) 
Intron 4 Ht association OR 95% CI χ2 P 
4a vs. 4b 1.27 0.878-1.835 1.62 0.203 
4ab vs. 4bb 1.14 0.748-1.740 0.37 0.541 
4aa vs. 4bb+4ab 3.99 0.764-20.872 3.12 0.077 
4aa + 4ab vs. 4bb 1.22 0.808-1.842 0.9 0.344 
Armitage's trend test 1.40   1.69 0.193 
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Table 66-Intron 4 Odds Ratios (ORs) for Ht association (4b risk allele) 
Intron 4 Ht association OR 95% CI χ2 P 
 4b vs. 4a 0.788 0.545-1.138 1.62 0.203 
4ab vs. 4aa 0.286 0.053-1.532 2.39 0.122 
4bb vs. 4aa+4ab 0.25 0.048-1.309 3.12 0.077 
4bb + 4ab vs. 4aa 0.259 0.050-1.350 2.97 0.085 
Armitage's trend test 0.753   1.69 0.193 
4.3.3.4 Intron 4 Logistic Regression 
Logistic regression was performed to calculate the effect of the Intron 4 variant on Ht status while 
controlling for other covariates. 346 samples were included in the analysis and 129 were excluded 
due to missing data. Logistic regression was performed by first inputting the covariate Intron 4 
only (Model 1), this Model was then extended and adjusted for the covariates; sex, age, FBS, BMI, 
occupation, diet and family history (Model 2). Table 67 shows the reference groups used for the 
categorical covariates. 
Table 67- Reference groupings for the categorical variables included in the Intron 4 Ht logistic regression 
analysis 
 Variable Reference Group Parameter 1 
Intron 4 (dominant) 4bb 4ab+4aa 
Intron 4 (recessive) 4bb+4ab 4aa 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Occupation Heavy moderate +sedentary 
Family History Absent present 
4.3.3.4.1 Logistic regression for a Dominant Model  
The classification table revealed the percentage of disease status correctly predicted was 54.6% 
without considering any other variables. Model 1, considered only the Intron 4 variant was shown 
not to be significantly better (χ2 =1.696, 1df, p=0.193). The Hosmer and Lemershow test also 
showed this model not to be a good predictor of disease outcome, (p<0.001). Overall the model 
remained at 54.6% of cases correctly predicted. The Wald test revealed that the Intron 4 variable 
didn't significantly contribute to the model (OR=1.380 (CI: 0.848-2.245) p=0.195) (Table 68). The 
model was then extended to include sex, age, FBS, BMI, occupation, diet and family history 
(model 2) The omnibus test of model coefficients revealed the Model to significantly predict Ht 
status (χ2=138.741, df=8, p<0.001), this was not confirmed by the Hosmer and Lemeshow test, 
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(p=0.012). Model 2 correctly predicted 78.30% of cases correctly. The only significant variables 
were age and FBS but the effect was negligent (Table 68). 
Table 68- Key findings of Intron 4 (dominant model) Ht logistic regression analysis adjusting for gender, 
age, fasting blood sugar (FBS), Body mass index (BMI), occupation, diet and family history 
Model 1 B S.E. Wald P OR 
95% C.I. 
Lower Upper 
Intron 4 .322 .248 1.678 0.195 1.380 .848 2.245 
Constant .102 .125 .662 0.416 1.107     
Model 2       
Intron 4 0.474 0.310 2.346 0.126 1.607 0.876 2.949 
Gender  0.015 0.287 0.003 0.959 1.015 0.578 1.783 
AGE  0.073 0.014 29.186 <0.001 1.076 1.048 1.105 
FBS 0.019 0.003 32.309 <0.001 1.019 1.012 1.025 
BMI 0.071 0.026 7.568 0.006 1.074 1.021 1.129 
Occupation 0.033 0.368 0.008 0.928 1.034 0.503 2.125 
Diet  0.022 0.279 0.006 0.936 1.023 0.592 1.768 
Family History 0.402 0.443 0.820 0.365 1.494 0.627 3.564 
Constant -8.108 1.176 47.539 <0.001 0.000     
Dominant Model 1 Model 2 
Goodness of fit chi square 1.696 (df=1) 138.741 (df=8) 
Significance 0.193 <0.001 
Hosmer and Lemershow <0.001 0.012 
Percentage correctly predicted 54.60% 78.30% 
Glu298Asp 1.380 (0.848-2.245) 1.607 (0.876-2.949) 
The logistic regression was not rerun under a recessive model due to the low frequency of the 4aa 
genotype. The Intron 4 variant failed to be a significant independent risk factor for Ht following 
adjustment for the classical risk factors.  Less than 80% of Ht could be predicted by these risk 
factors. 
4.3.3.5 Intron 4 Genotype Association with Continuous Variables 
Pairwise comparisons of genotypes (4aa vs. 4ab, 4aa vs. 4bb and 4ab vs. 4bb) for other continuous 
variables revealed no significant differences. The individual tables are presented in the appendix 6, 
section 8.6. 
4.3.3.6 eNOS Intron 4 Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Intron 4 variant had association by gender 
or age, these are presented in Table 69. The Intron 4 variant was not shown to be a significant risk 
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factor for Ht under any dominant or recessive model by gender, or age subgroup analysis (p>0.05). 
The Ht association of the Intron 4 variant in most cases increased the Ht risk (OR>1) under a 
recessive effect. This possible association was largest in the 40-54 year age group but remained a 
non-significant effect, (OR=3.80 (CI: 0.34-42.53), p=0.58). 
Table 69- Intron 4 genotype frequencies and Ht association in subgroup analysis by gender and age 
Variable Controls Cases Model OR (95%CI) χ2 P 
Gender      
Males only           
4bb 99 (73.9%) 53 (63.9%) 4aa vs. 4ab+4bb not possible   
4ab 35 (26.1%) 29 (34.9%) 4aa+4ab vs. 4bb 1.60 (0.89-2.89) 2.001 0.157 
4aa 0 (0%) 1 (1.2%)      
Total 134 (100%) 83 (100%)       
Females only           
4bb 115 (75.7%) 81 (76.4%) 4aa vs. 4ab+4bb 2.94 (0.53-16.36) *0.755 0.385 
4ab 35 (23.05) 21 (19.8%) 4aa+4ab vs. 4bb 0.96 (0.54-1.72) 0.00 0.994 
4aa 2 (1.3%) 4 (3.8%)      
Total 152 (100%) 106 (100%)       
AGE groups           
≤39 years           
4bb 38 (73.1%) 5 (62.5%) 4aa vs. 4ab+4bb not possible     
4ab 14 (26.9%) 3 (37.5%) 4aa+4ab vs. 4bb 1.62 (0.34-7.73) 0.04 0.84 
4aa 0 (0%) 0 (0%)      
Total 52 (100%) 8 (100%)         
40-54 years           
4bb 116 (76.8%) 56 (69.1%) 4aa vs. 4ab+4bb 3.80 (0.34-42.53) *0.3 0.58 
4ab 34 (22.5%) 23 (28.4%) 4aa+4ab vs. 4bb 1.48 (0.81-2.71) 1.25 0.26 
4aa 1 (0.7%) 2 (2.5%)      
Total 151 (100%) 81 (100%)         
≥55 years             
4bb 57 (71.3%) 73 (73.0%) 4aa vs. 4ab+4bb 2.44 (0.25-23.95) *0.07 0.77 
4ab 22 (27.5%) 24 (24.0%) 4aa+4ab vs. 4bb 0.92 (0.48-1.77) 0.01 0.93 
4aa 1 (1.3%) 3 (3.0%)      
Total 80 (100%) 100 (100%)       
*value less than 5 (χ2 not valid) 
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4.3.4 eNOS Gene Data Analysis 
The genotypes were investigated for a possible synergistic effect on Ht status. Table 70 shows the 
frequency of each different genotype combination as a count and a percentage. ORs were then 
calculated to determine if any eNOS genotype combination had an increased risk of Ht. A perusal 
of Table 70 demonstrates that the frequency of each combination was not uniform. A number of 
combinations were not observed in the data (not included in table) and some were in very low 
frequency. There was a non significant protective association with the TT-TT-4bb genotypes of the 
Glu298Asp, T-786C and Intron 4 respectively (OR=0.29 (CI: 0.06-1.33), p=0.163). Alternatively 
the GG, CC and 4aa combination showed an association towards an increased risk of Ht, once 
again this was outside statistical significance (OR=3.70 (CI: 0.33-41.27), p=0.593). 
Table 70- Glu298Asp, T-786C and Intron 4 composite genotypes and Odds Ratios (ORs) for Ht 
association  
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TT CC 4bb 2 0.88 0 0.00 2 Not possible  -  - 
TT TC 4bb 2 0.88 1 0.81 3 0.91 (0.08-10.19) 0.285 0.593 
TT TT 4bb 12 5.29 2 1.61 14 0.29 (0.06-1.33) 1.948 0.163 
GT CC 4aa 1 0.44 0 0.00 1 not possible  -  - 
GT CC 4ab 7 3.08 3 2.42 10 0.78 (0.20-3.07) 0 0.982 
GT TC 4ab 12 5.29 11 8.87 23 1.74 (0.75-4.08) 1.148 0.284 
GT TC 4bb 20 8.81 5 4.03 25 0.43 (0.16-1.19) 2.093 0.148 
GT TT 4ab 0 0.00 1 0.81 1 not possible  -  - 
GT TT 4bb 43 18.94 20 16.13 63 0.82 (0.46-1.47) 0.261 0.609 
GG CC 4aa 1 0.44 2 1.61 3 3.70 (0.33-41.27) 0.285 0.593 
GG TC 4ab 34 14.98 19 15.32 53 1.03 (0.56-1.89) 0.005 0.944 
GG TC 4bb 5 2.20 3 2.42 8 1.10 (0.26-4.69) 0.06 0.807 
GG TT 4aa 0 0.00 1 0.81 1 not possible  -  - 
GG TT 4ab 5 2.20 1 0.81 6 0.36 (0.04-3.12) 0.285 0.559 
GG TT 4bb 83 36.56 55 44.35 138 1.38 (0.89-2.16) 1.727 0.189 
Total     227 100 124 100.0 351       
4.3.4.1 Linkage Disequilibrium Analysis 
Linkage disequilibrium analysis was run to determine any possible linkage disequilibrium between 
the three eNOS variants. The Intron 4 variant was found to be in strong linkage disequilibrium with 
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both the Glu298Asp variant (0.72) and the T-786C variant (0.88). The strongest correlation (r 
statistic) was found to be between the Intron 4 variant and the T-786C variant r=0.719 (Table 71).  
 Table 71-Linkage disequilibrium analysis between the Glu298Asp, T-786C and Intron 4 variants of the 
Ht sample.  D’ statistic above the diagonal, r statistics below the diagonal 
 D' statistic 
Glu298Asp T-786C Intron 4 r statistic  
Glu298Asp . 0.1645 0.721 
T-786C 0.1532 . 0.881 
Intron 4 -0.163 0.719 . 
All p values are below <0.001 and significant  
4.3.4.2 Haplotype Analysis 
Haplotypes were estimated using the online programme SNPStats. Table 72 presents these results. 
The most common haplotype was G-T-4b for the Glu298Asp, T-786C and Intron 4 variants 
respectively. This was estimated to have a frequency of 0.619, with this as the reference haplotype 
ORs were calculated for each possible haplotype. The haplotypes 7 and 8 (T-C-4a and T-T-4a) 
were estimated to be extremely rare and the OR calculation was not possible for haplotype 8. None 
of the haplotypes were found to be significantly associated with Ht. The strongest disease 
association was found to be haplotype 4 (T-C-4b) showing possible protectiveness for Ht, this was 
just outside statistical significance (OR=0.46 (CI: 0.21-1.01), p=0.054). 
Table 72- eNOS Glu298Asp, T-786C and Intron 4 haplotype estimations and Ht Odsd Ratio (OR) 
calculations 
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1 G T 4b 0.603 0.655 0.619 1 --- 
2 T T 4b 0.176 0.13 0.162 0.74 (0.46 - 1.19) 0.21 
3 G C 4a 0.118 0.128 0.124 1.15 (0.64 - 2.06) 0.65 
4 T C 4b 0.071 0.035 0.059 0.46 (0.21 - 1.01) 0.05 
5 G T 4a 0.012 0.016 0.014 1.29 (0.38 - 4.38) 0.68 
6 G C 4b 0.014 0.015 0.014 0.95 (0.22 - 4.10) 0.94 
7 T C 4a 0.006 0.020 0.009 1.66 (0.06 - 43.54) 0.76 
8 T T 4a NA 0.001 rare   
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4.3.4.3 The ACE Variant 
The ACE variant was analysed for a possible association with Ht. The ACE gene was found to be 
significantly associated with Ht under a recessive model (OR=1.96 (CI: 1.61-3.31), p=0.01).  This 
sample was found to be in agreement with HWE (Table 73). 
Table 73- ACE deletion allele and genotype frequencies in the Ht patient and control groups and Odds 
Ratios (ORs) for Ht association 
ACE  Patient (%) Control (%) 
II 39 (20.6%) 74 (26.2%) 
ID 87 (46.0%) 147 (52.1%) 
DD 63 (33.3%) 61 (13.0%) 
Total 189 (100%) 282 (100%) 
I allele 0.44 0.53 
D allele 0.56 0.48 
ACE Ht association Odds Ratio 95% CI χ2 P 
D vs. I 1.416 1.089-1.840 6.78 0.009 
ID vs. II 1.123 0.702-1.796 0.23 0.628 
DD vs. II+ID 1.960 1.161-3.309 6.40 0.011 
DD +ID vs. II 1.368 0.880-2.127 1.95 0.163 
Armitage's trend test 1.406  6.74 0.009 
The ACE genotypes were analysed by a χ2 test for association with the eNOS variants no 
significant differences were found with any of the eNOS variants (appendix 6, section 8.6). 
4.3.4.4 Logistic Regression with all Genetic Variants 
Logistic regression was performed to calculate the effect on Ht disease status of all three eNOS 
gene variants in addition to the ACE gene variant, whilst adjusting for other covariates. 239 
samples were included in analysis and 112 were excluded due to missing data. Logistic regression 
was performed only under a dominant model for all genotypes. The data presented below is 
following a dominant model only with the reference as the homozygote wild type of the variants 
(GG, TT, 4bb, II for Glu298Asp, T-786C, Intron 4 and ACE respectively). It was not possible to be 
run assuming a recessive effect of the variants, due to the values being too small with the limited 
data file. Logistic regression was run firstly including only the genetic variants (Model 1). Model 1 
was found to be a significant predictor of disease status (χ2 =12.856, p=0.012) and predicted 
61.10% of all cases correctly (Table 74). The ACE variant was found to be the only significant 
independent risk factor for Ht (OR=2.508 (CI: 1.39-4.52), p=0.002). 
Chapter 4 – Hypertension 
157 | P a g e  
 
 
This was then extended to include lifestyle parameters (Model 2). Model 2 was a significant 
predictor of disease status (χ2 =96.668, df=11, p<0.001). This was supported by the Hosmer and 
Lemershow calculation (p=0.178) and 78.70% of cases were shown to predicted correctly 
including all the covariates. Table 74 shows the effect of all covariates on disease status. The only 
variables to be shown as independent risk factors were age, FBS and ACE. However the effect of 
these variables (indicated by the OR values) were small with the exception of ACE (OR=3.09 (CI: 
1.45-6.58), p=0.003). The next highest effect was in the Intron 4 value, however this was not 
statistically significant (OR=1.892 (CI: 0.634-5.648), p=0.253). 
Table 74-Key findings for Ht logistic logistic regression analysis including the Glu298Asp, T-786C,  
Intron 4 and ACE deletion variants (dominant model) adjusting for gender, age, fasting blood sugar 
(FBS), body mass index (BMI), occupation, diet and family history 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Model 1        
Glu298Asp 0.073 0.296 0.060 0.806 1.075 0.602 1.922 
T-786C -0.397 0.433 0.842 0.359 0.672 0.288 1.570 
Intron 4 0.670 0.455 2.169 0.141 1.953 0.801 4.762 
ACE 0.920 0.301 9.347 0.002 2.508 1.391 4.522 
Constant -0.652 0.281 5.374 0.020 0.521     
Model 2       
Glu298Asp 0.034 0.359 0.009 0.924 1.035 0.512 2.092 
T-786C -0.225 0.534 0.178 0.673 0.798 0.280 2.275 
Intron 4 0.638 0.558 1.306 0.253 1.892 0.634 5.648 
ACE 1.128 0.386 8.550 0.003 3.089 1.450 6.579 
Gender  0.313 0.356 0.774 0.379 1.367 0.681 2.744 
AGE  0.080 0.017 23.332 <0.001 1.083 1.049 1.119 
FBS 0.015 0.003 20.502 <0.001 1.016 1.009 1.022 
BMI 0.061 0.032 3.562 0.059 1.063 0.998 1.133 
Occupation 0.116 0.460 0.064 0.801 1.123 0.456 2.764 
Diet  -0.104 0.334 0.097 0.755 0.901 0.469 1.734 
Family History 0.157 0.490 0.102 0.749 1.170 0.447 3.058 
Constant -8.879 1.524 33.941 <0.001 0.000     
In this eNOS Ht analysis for each locus 9 chi squares were carried out in the categorical data set, 5 
in gene association analysis and 10 in sub group analysis, altogether 24 chi-square related p values 
were calculated. The bonferroni correction was applied and the nominal p value (0.05) was divided 
by the number of comparisons. In this case it would be 0.05/24 = 0.00208. Therefore the corrected 
p value should be considered in making inferences about the associations.. 
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4.4 Discussion 
This study analysed the frequency of the Glu298Asp, T-786C and Intron 4 27bp repeat 
polymorphisms in 210 Ht patients and 206 matched controls from an endogamous Punjabi 
population. Ht is a multifactorial disease affected by both genes and the environment (Butler 
2010).  
The association of the eNOS gene variants with Ht has been based on the putative mechanism that 
the variants influence NO levels. The eNOS variants have been shown to impair endothelial 
dependent vasodilations. NO is an endothelial dependent relaxation factor resulting in vasodilation 
of the lumen of the blood vessels, it acts in response to acetylcholine (see section 1.4.2) (Palmer et 
al. 1987, Ignarro et al. 1987). Further investigation was undertaken on a number of conventional 
risk factors to determine if there was any association or interaction with any of the eNOS variants. 
4.4.1 Glu298Asp Ht Association 
The first variant of the eNOS gene analysed in this study was the Glu298Asp variant, this variant 
results in an amino acid substitution in the mature protein of the eNOS gene. This study has 
accepted the null hypothesis and confirmed this variant not to be significantly associated with Ht. 
This suggests that within this population group this variant does not affect an individual’s risk of 
Ht. The control group was found to be in accordance with HWE, determined by three independent 
methods and representative of South Asian populations (Table 75). The TT mutant genotype 
(6.7%) was within the range of frequencies previously reported (0.73-13.4%) but nearly three times 
higher than some Indian studies.  
Table 75- Glu298Asp Ht control genotype frequencies reported in previous studies 
Population Number  GG GT TT Study 
Asian Indians  200  77.0% 22.0% 1.0% (Srivastava et al. 2008) 
South Indian  444  72.7% 24.8% 2.5% (Periaswamy et al. 2008) 
Pakistani  186  70.0% 28.0% 2.0% (Khawaja et al. 2007)  
North Indian 240  57.5% 35.8% 6.7% Current Study 
Multiple 10,498  67.0% 28.0% 4.0% (Zintzaras et al. 2006) 
Caucasian 4219  49.2% 42.0% 8.8% (Wolff et al. 2005) 
Italian 67  28.0% 61.0% 11.0% (Colomba et al. 2008) 
Finnish 600  50.5% 41.4% 8.1% (Karvonen et al. 2002) 
Italian 67  28.0% 61.0% 11.0% (Colomba et al. 2008) 
Chinese (Hani) 
267  
71.4% 17.3% 11.3% 
(Tang et al. 2008)  
Chinese (Yi) 55.2% 31.3% 13.4% 
Japanese 513  84.41% 14.81% 0.7% (Kato et al. 1999) 
Japanese 789  86.1% 12.75% 1.3% (Kishimoto et al. 2004)  
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The patients were also in HWE, the percentage of homozygotes for the asp mutant allele (genotype 
TT) within the Ht patients was 2.34%, this was comparable to those previously found in Ht patients 
(0-9.5%), and was consistent with South Asians (Khawaja et al. 2007, Srivastava et al. 2008, 
Periaswamy et al. 2008). Overall, this information supports that both the patient and control 
samples are representative, thus conclusions drawn on this data would be applicable to a North 
Indian populations. 
The Glu298Asp was tested to investigate a possible influence on Ht disease status. The evidence in 
the literature has suggested the T mutant allele of the Glu298Asp variant may be associated with 
reduced NO production and an increased susceptibility to disease, including CAD and Ht 
(Hingorani et al. 1999, Tang et al. 2008). 
To assess this, ORs were calculated under multiple models (dominant, recessive and additive). 
Although no statistically significant results were found under any model, there was an apparent 
relationship towards the T allele being protective. The T allele OR value was found to be 0.726 
(CI:0.499-1.056), p=0.093. This ‘protective’ effect of the T allele is contrary to previous studies 
which reported the T allele to be associated with an increased Ht risk (Yasujima et al. 1998, 
Miyamoto et al. 1998, Shoji et al. 2000, Periaswamy et al. 2008, Srivastava et al. 2008). This may 
be a result of the control group having a higher frequency of homozygotes for the mutant T allele 
and requires confirmation. 
Despite the apparent contradictory findings of the current study, there are a small number of 
studies investigating this variant and Ht disease association that also support these findings of no 
association/protective association (Section 1.7.2). For example Khawaja et al. (2007) also provide 
evidence against the asp variant as a risk factor, their group found a protective OR value very 
similar to the current study of 0.44 (CI: 0.13-1.54) and was  also in a South Asian population. 
There are clear allele/genotype frequency differences among population groups, thus it is probable 
that the risk association found in previous studies may be populational specific. This is also 
supported in other CVD groups where the evidence contradicts an increased risk associated with 
this variant, finding protective effects among other CVDs (Elbaz et al. 2000, Poirier et al. 1999, 
Colomba et al. 2008, Park et al. 2004, Kara et al. 2006, Wang et al. 2001). Often these findings 
were unreported, perhaps due to their contradiction to the hypothesised mechanism and were 
detected only through independent analysis by the author. Consequently, this may be a source of 
publication bias. 
The protective effect identified under basic ORs was absent following adjustment for a number of 
conventional risk factors. Logistic regression analysis found no effect of genotype on Ht risk 
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(1.042 (CI: 0.556-1.954), p=0.897). Similarly, the Glu298Asp variant was not shown to be a 
significant risk factor for Ht under any dominant or recessive model by gender, or age subgroup 
analysis.   
These findings indicate the effects of this variant do not significantly increase Ht risk among North 
Indians. This may be a result of the T mutant allele having a smaller or absent effect on basal NO 
production. This is supported by functional studies undertaken by Hingorani et al. (2001), Golser 
et al. (2003) and McDonald et al. (2004) who all failed to detect any significant functional effect of 
the asp variant on enzymatic activity (Golser et al. 2003, Hingorani 2001, McDonald et al. 2004). 
The functional relevance may be more conservative due to the amino acid substitution sharing both 
the hydrophilic property, and a negatively charged R-group with the wild type. This similarity 
could possibly cause a smaller magnitude of change than anticipated in the face of an amino acid 
substitution on enzyme function. The location of the variant also provides possibility for a more 
conservative effect; it is positioned within a loop on the external surface, consequently there is no 
contact with either the dimerization interface or the active site of the enzyme (Hingorani 2001). 
Plasma nitrate/nitrite measurements have also failed to present significant differences between 
genotypes of this variant (Jeerooburkhan et al. 2001). Further more, this variant has been found to 
have no influence on endothelium dependent relaxations, finding the T mutant allele to have no 
significant effect on forearm mediated dilations (FMD) (Leeson et al. 2002). Guzik et al. (2001) 
once more, failed to find any overall functional consequence on endothelial function (Guzik et al. 
2001). 
In support of the protective effect found under basic ORs and providing evidence against this 
polymorphism as a risk factor, the analysis of BP by genotype revealed that the TT genotype had a 
lower mean value for both BP measures (SBP and DPB).  
This study accepted the null hypothesis finding no significant differences of the Glu298Asp variant 
between cases and controls. There was no evidence for an interaction between the variant and any 
of the classical Ht risk factors incorporated in the current research. A number of studies have 
supported these findings including functional studies which have failed to find a functional effect 
of the variant. These findings provide evidence that the hypothesised risk of this variant is unlikely 
to be present in this North Indian population. The protective effect due to the lack of statistical 
significance would need to be investigated further. 
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4.4.2 T-786C Ht Association 
The second variant of the eNOS gene analysed in this study was the T-786C variant, a thymine to 
cytosine change in the promoter region at the position -786. For the T-786C variant this study has 
accepted the null hypothesis and confirmed this variant not to be significantly associated with Ht. 
This suggests that within this population group this variant does not affect an individual’s risk of 
Ht.  
The control group was found to be representative and in accordance with HWE, determined by 
three independent methods. The frequency of the CC genotype in the controls was 6.3%, there 
were two comparable studies available in Ht controls (Table 76), neither was in South Asian 
populations and both reported higher frequencies. Hyndman et al. (2002) found a CC genotype 
frequency of 15%, this was substantially lower than the frequency found (29%) in a small sample 
(n =38) by Colomba et al. (2008). Similarly the current Ht patient group was low in comparison to 
previous reported findings; 9.38% compared to the 29% found by Colomba et al. (2008) (Table 
76). There are no studies in any South Asian population groups to make direct comparisons.  
Table 76-T-786C Ht control and patient genotype frequencies reported in previous studies 
Population Number TT TC CC Study 
Controls      
Canadian men only 705  39.0% 46.0% 15.0% (Hyndman et al. 2002) 
Italian 38  21.0% 50.0% 29.0% (Colomba et al. 2008) 
North Indian 285 62.1% 31.6% 6.3% Current Study 
Patients      
Italian 107 23.0% 48.0% 29.0% (Colomba et al. 2008) 
North Indian 192  58.33% 32.29% 9.38% Current Study 
The T-786C variant was tested for association with Ht. The results found a slight increased Ht risk, 
in a non significant manner associated with the C mutant allele, with the calculated ORs revealing 
values of 1.207 (CI: 0.892-1.635) and 0.828 (CI: 0.612-1.121) for the C allele and T allele 
respectively, p=0.22. This effect was most prominent in a recessive manner (under the CC vs. 
TT+CT model), where the OR suggested a 50% increased risk of Ht, OR=1.58 (CI: 0.789-3.166), 
but again failed to reach statistical significance (p>0.05). The current study with the slight 
increased risk weakly supports the finding by Hyndman et al. (2002), who found among healthy 
males the CC genotype was significantly associated with higher systolic blood pressure (OR=2.16, 
(CI: 1.3-3.7) (Hyndman et al. 2002). 
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The current study’s failure to reach statistical significance may be due to the restricted sample size 
(192 patients and 285 controls). Alternatively, these findings may be a result of the effect being 
absent, a result of chance alone. With only a small amount of published studies available, the effect 
of this variant, specifically on Ht remains unclear. Among these, a number of studies reported (like 
the current study) no significant association, this included meta-analyses by Zintzaras et al. (2006) 
(2491 patients and 3913 controls) and more recently Pereira et al. (2007) (Zintzaras et al. 2006, 
Pereira et al. 2007). 
One possible reason for a lack of statistical significance is differences in other baseline 
measurements between cases and controls. An independent samples t-test revealed that the Ht 
patient and control groups exhibited a number of differences; with the patients found to be 
significantly older than the control group by around five years, FBS, WHR and family history also 
revealed significant differences. These differences may mask the effect of the variant, consequently 
logistic regression was performed to adjust for multiple continuous and dichotomous covariates. 
Under a recessive model the OR was found to go down in value following adjustment for gender, 
age, FBS, BMI, occupation, diet, and family history (OR=0.918 (CI: 0.353-2.388)). Suggesting the 
increased risk may not have been a direct effect but caused by other factors. The dominant model 
showed smaller variance following adjustment, although an elevated risk was present, it remained 
non-significant. Equally no significant effects were found between the T-786C variant and disease 
status following sub group analysis under any dominant or recessive model (p >0.05).  
Genetic predisposition to a disease often has a key identifying characteristic of a premature onset. 
The information of age of onset among the patients was available, it was revealed that the CC 
genotype was found to have a significantly younger age of onset than the TT individuals, 46.06 and 
52.3 years respectively (p=0.022). This relationship was also present comparing the CC genotype 
to the TC genotype but the effect was smaller and less significant, typical of an additive effect. To 
my knowledge this is the first study to find an association of the variant with the age of onset of Ht, 
and would need to be confirmed in further studies.   
Therefore although this study failed to find this variant statistically significant as an independent 
risk factor for the presence of the Ht, the variant was associated with an earlier age of onset in 
homozygotes for the mutant C allele. The true effect of this variant remains unclear. It has been 
investigated through both endothelial dependent vasodilations and plasma nitrate/nitrite 
concentrations as a reflection of NO levels. These functional studies have also failed to clarify the 
true effect of this variant and have shown inconsistent results in the literature. For example 
homozygotes of the mutant C allele have been shown to have reduced eNOS enzymatic activity, as 
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well as reduced nitrite/nitrate levels (Dosenko et al. 2006, Miyamoto et al. 2000). Yet other studies 
have found no differences between the genotypes (Sim et al. 1998).  Unlike the Glu298Asp 
variant, the association studies although limited, seem to find an association of this variant in one 
direction only, or absent entirely.  
The current study does not provide strong evidence in clarifying the role of T-786C in Ht. The 
findings remain unclear; there was evidence of a possible increased Ht risk that may be more 
prominent in males, however these findings failed to reach statistical significance. To conclude 
these results suggest the effect of this variant within a North Indian population could be absent or 
at a smaller magnitude than previously reported, perhaps only affecting disease onset. 
4.4.3 Intron 4 Ht Association 
The Intron 4 27bp variant was successfully genotyped in 189 patients and 286 controls. This study 
found no significant differences between the patients and controls, however the body of results 
does support an association between this variant and Ht status, therefore further research is 
required to accept or reject the null hypothesis and understand if this variant is affecting an 
individual’s risk of Ht within a North Indian population.  
The control group were found to be representative and in keeping with HWE confirmed by three 
independent methods. The frequency of the homozygotes for the mutant 4a allele within the 
controls was found to be very low at 0.7%. A small number of studies were found for comparison 
(Table 77), the frequencies were almost identical to those found in this study by Colomba et al. 
(2008) and Deng et al. (2007). There were no available studies to make direct comparisons within 
a South Asian population group, so further replication is required within this area.  
The percentage of homozygotes for the mutant 4a allele (genotype 4aa) within Ht patients was 
found to be 2.65%. The current study is identical to the frequency found by Deng et al. (2007) and 
falls within the very small range of frequencies found, 0.4%-2.65% (Table 77). The 4bb and 4ab 
genotypes also showed consistency with other frequencies found. There are to my knowledge no 
studies available in a South Asian population group to enable more specific comparisons. The 
patients were also found to be in agreement with HWE.  
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Table 77-Intron 4 Ht control and patient genotype frequencies reported in previous studies 
Population Number 4bb 4ab 4aa Reference 
Controls      
Italian 31   77.0% 23.0% 0.0% (Colomba et al. 2008) 
North Indian 286   74.8% 24.5% 0.7% Current study 
Tunisian 395   69.4% 28.4% 2.3% (Jemaa et al. 2009) 
Kazakh Chinese 138   84.06 15.22% 0.72% (Deng et al. 2007) 
Patients      
Italian 119   72.5% 25.0% 2.5% (Colomba et al. 2008) 
North Indian 189   70.90% 26.46% 2.65% Current Study 
Tunisian 295   60.9% 32.7% 0.4% (Jemaa et al. 2009) 
Kazakh Chinese 151   81.46% 15.89% 2.65% (Deng et al. 2007) 
The Intron 4 variant was tested under both recessive and dominant models to investigate a possible 
influence on Ht disease status. The evidence in the literature has suggested the 4a allele of the 
Intron 4 variant to be associated with reduced NO production and an increased susceptibility to 
disease (Colomba et al. 2008, Matyar et al. 2005). 
The Intron 4 variant analysis suggested a relationship with an increased risk of Ht. Under all 
models there was an increased risk of Ht associated with the 4a allele, however it failed to reach 
statistical significance. The overall allelic risk of Ht associated with the 4a allele found an OR of 
1.27 (CI: 0.878-1.835), p=0.203. The effect of the 4a risk allele was most prominent under a 
recessive model (4aa vs. 4bb+4ab) with 3.9 times the risk, this was only just outside statistical 
significance (OR=3.993, p=0.077). The results found in the current study support the hypothesis of 
the 4a mutant allele to be associated with an increased Ht risk, this is to my knowledge the first 
study to support an effect of this variant on Ht risk in South Asians. These results are comparable 
to a number of previous findings including: Colomba et al. (2008), Jemaa et al. (2009), Uwabo et 
al. (1998), Mustafina et al. (2001) and a meta-analysis by Pereira et al. (2007). These studies like 
the current have found the association to be in different manners at an allelic, dominant and 
recessive level.    
The lack of significant effect in other studies and the current may be due to a masking by other 
independent Ht risk factors. A number of significant differences existed between the patient and 
control groups. For example the Ht group was significantly older p<0.001, whilst family history 
showed a 27.5% presence in patients compared to only 6.4% in controls, p<0.001. Family history 
implies a strong genetic link to the disease and was found to be significantly associated with Ht. 
Logistic regression found the Intron 4 OR value to increase, finding it to be the strongest 
independent risk factor even above family history reaching an OR of 1.607 (CI: 0.876-2.949), but 
remained a non significant effect. Equally the effect was shown to be present following subgroup 
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analysis. The OR value increased among females to 2.94 (CI: 0.53-16.36), however, due to the 
relatively limited data caused by any sub-group analysis and the small frequency of the variant, this 
did not achieve statistical significance.  Jemaa et al. (2009) found a similar gender specific effect 
of this variant (Jemaa et al. 2009).  
Genotype association revealed that the 4aa variant had a higher mean for systolic BP, 
149.571mmHg compared to 133.351mmHg in the 4bb individuals. This physiological effect is 
supportive of an increased risk, it is the primary basis of diagnosis so was unsurprising considering 
the elevated risk (OR values >1) at an unadjusted, adjusted and gender specific level. It should be 
noted that there were only 7 4aa individuals and a large standard deviation, consequently this result 
was just outside statistical significant p=0.069 and would need to be confirmed.   
The current available literature is limited, however, it was discovered that the studies that failed to 
find any statistically significant differences between patients and controls were all in Asian 
populations groups. The data was not available, or presented as a combined frequency of the 4aa 
and 4ab genotypes assuming only a dominant effect (Yasujima et al. 1998, Yokoyama et al. 2000, 
Miyamoto et al. 1998,  Deng et al. 2007, Ma et al. 2006, Shoji et al. 2000). This current study has 
shown that the associated risk is most prominent under a recessive effect so this could have 
influenced the apparent ‘lack’ of significant effect in these few studies. This variant is also present 
at a very low frequency, which appears to be even lower among Asians, with genotype frequencies 
often combined to enable analysis. The greater strength of the variant following adjustment, 
alongside the previous findings in sub group analysis in the current findings and those by Jemaa et 
al. (2009), suggest a plausible reason for the lack of effects among some previous studies, where 
adjustment and subgroup analysis have not been undertaken/reported (Jemaa et al. 2009).  
The association of this variant with Ht is possible, it’s been hypothesised (due to its intronic 
location) to be a result of an influence on alternative splicing. The functional effect of this variant 
has been supported by functional testing. Dosenko et al. (2006) found there to be a recessive effect 
of the 4a allele with 1.7 times lower eNOS activity compared to 4bb individuals (Dosenko et al. 
2006). Lower NO levels have also been associated with the variant (Wang et al. 2000, Tsukada et 
al. 1998). 
Zhang et al. (2005) hypothesized the 27bp repeat, during pre-mRNA processing provides a source 
of small or micro RNA. This production of microRNA is able to regulate eNOS expression in a 
reductive manner. It has previously been established that microRNA is a known cause of gene 
silencing and it is thought when eNOS is overexpressed this would act as a crucial control 
mechanism specifically controlling the production of ROS, a negative and detrimental consequence 
Chapter 4 – Hypertension 
166 | P a g e  
 
 
when eNOS becomes uncoupled. The reduced eNOS expression has been proposed by Zhang et al. 
(2005) among others, to act either through the inhibition of the binding of the transcriptional factor, 
or alternatively through modifications of the methylation of the nucleotide status, histone 
acetylation status or the splicing occurring at pre-mRNA (Zhang et al. 2005, Wang et al. 2002, 
Morris et al. 2004). The specific effect of the Intron 4 VNTR is that the number of repeats would 
alter the quantity of microRNA production. Interestingly, from this same research the reduced 
eNOS expression (through microRNA production) was able to be reversed through stimulation by 
vascular endothelial growth factor (VEGF). The VEGF is a known up-regulator of eNOS but was 
shown to do this without further enhancing microRNA production (Zhang et al. 2005). Therefore 
there is a possible intervention if this risk factor is widely accepted and supported in multiple 
population groups.  
Alternatively the functional impact of this variant and small inconsistency among previous studies 
may be a result of linkage disequilibrium with other variants within the coding region of the eNOS 
gene. Yoshimura et al. (2000) found that the Intron 4 variant was in disequilibrium with the T-
786C variant (Yoshimura et al. 2000). Wang et al. (2002) found this variant to coordinate with the 
T-786C variant and regulate transcriptional efficiency (Wang et al. 2002). The possibility of 
linkage disequilibrium and interaction with alternate eNOS variants will be discussed further in the 
overall effect of the eNOS gene on Ht disease status. 
Overall, this information suggests the Intron 4 ‘4a’ mutant allele may be associated with an 
increased susceptibility to Ht, particularly in a recessive manner. The extremely low frequency of 
this variant seen in Asians and within the current study requires a larger sample size to confirm the 
significance of these findings.  
4.4.4 eNOS gene and Ht Association 
4.4.4.1 Synergistic Effect of eNOS Gene Variants 
The genotype combinations at the three eNOS gene loci were assessed for a possible synergistic 
effect to identify any high ‘risk’ or ‘protective’ combinations. The frequency of the different 
composite genotypes did not show a uniform distribution, which was as expected considering the 
different frequencies in the alleles and genotypes at each locus. Analysis revealed no significant 
effect of any of the composite genotypes on Ht risk.  
Due to the small numbers within each genotype combination, statistical significance was 
challenging and subsequently was not met. However, there appeared to be a pattern towards the 
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TT, TT and 4bb genotypes of the Glu298Asp, T-786C and Intron 4 variants respectively 
collectively exhibiting a protective effect against disease status, OR=0.29 (CI: 0.06-1.33), p=0.163. 
Alternatively the GG, CC and 4aa combination showed a trend towards being at an increased risk 
OR=3.70 (CI: 0.33-41.27), once more this was outside statistical significance p=0.593. These 
results are likely to be acting through the additive effects of the GG, CC and 4aa increased risk, 
and are supportive of the relationships found individually at each variant. This would need to be 
confirmed in a larger sample to have confidence carrying all ‘risk’ variants caused an additive 
effect. Particularly with the controversial ‘opposite’ effects of the Glu298Asp variant found in the 
current study. The strength of this analysis is poor due to limited sample size, only 124 patients and 
227 controls were included for which all three variants had been successfully genotyped.  
A synergistic effect has been investigated previously but in only a small number of studies, these 
are limited often to only two variants, with a complete absence in Ht. 
4.4.4.2 Linkage Disequilibrium 
Linkage disequilibrium analysis was run to determine any possible linkage disequilibrium between 
the three eNOS variants. The Intron 4 variant was found to be in strong linkage disequilibrium with 
the T-786C variant, this was consistent with previous findings among Asians (Tanus-Santos et al. 
2001).  
4.4.4.3 Haplotype Analysis 
Haplotype analysis can provide a clearer picture than investigating single genetic variants because 
it incorporates potential interaction among variants, this interaction within a haplotype can be a key 
determinant of disease risk. Haplotypes were estimated using the online programme SNPStats. 
None of the haplotypes were found to be significantly associated with Ht, yet one haplotype T-C-
4b suggested a possible protectiveness for Ht, this was just outside statistical significance. 
(OR=0.46 (CI: 0.21-1.01), p=0.054).  
These findings are comparable to those found by Sandrim et al. (2006) who looked at the same 
three eNOS variants also using a case control study design investigating Ht. Their findings showed 
both the T-T-4b and the G-C-4b haplotypes of the Glu298Asp, T-786C and Intron 4 variants were 
at a significantly higher frequency in the controls, p<0.05. Unlike this study they found the T-C-4b 
haplotype to be more frequent in patients, again this was statistically significant, p<0.05 (Sandrim 
et al. 2007). Similarly, Kitsios et al. (2010) investigated eNOS haplotypes, again incorporating the 
same three variants this time in a Caucasian population. Their group found the G-T-4a haplotype to 
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be significantly higher among controls, indicating a possible protective effect of this rare haplotype 
(Kitsios & Zintzaras 2010). These studies demonstrate the clear requirement for this type of 
analysis, with the individual variant and genotype analysis failing to find an individual effect.  
Sandrim et al. (2007) also found the G-C-4b haplotype to be more frequent in controls, and 
identified an associated functional consequence with NOx levels found to be higher. The same 
haplotype showing association with an increased Ht risk presented lower NOx levels. This study 
readily supports both a plausible haplotypic effect of the three eNOS variants, but supports the 
original hypothesis that the variants’ increased disease risk is acting through direct reductions in 
NO levels (Sandrim et al. 2007). The current study did not support a protectiveness of the G-C-4b 
haplotype, the frequency was similar in both groups (0.014 in patients and 0.015 in controls) 
leading to a non-significant effect (OR 0.95 (CI: 0.22-4.10) p=0.94).   
4.4.5 ACE 
The ACE insertion/deletion variant was tested for association with Ht and a possible interaction 
with the three eNOS variants. This variant was confirmed as a risk factor for Ht in a recessive 
manner, (OR=1.96 (CI: 1.16-3.31), p=0.01). These findings are in agreement with others in South 
Asians (Das et al. 2008, Mastana & Nunn 1997). This includes Das et al. (2008) who found 
homozygosity for the deletion to have an increased risk of Ht (OR= 7.483 (CI: 1.746, 30.192) (Das 
et al. 2008). Similar findings have been found in meta-analyses and other population groups (Qiu 
et al. 1998, Qu et al. 2001). In contrast, Gupta et al. (2009) found no significant differences in the 
frequency of the ACE deletion between patients and controls. This was also in an Indian 
population in Haryana (Gupta et al. 2009). The ACE polymorphism did not show any significant 
association/interaction with any of the three eNOS variants analysed.  
4.4.5.1 Interaction of all Genetic Variants Analysed 
Logistic regression of all three eNOS variants and the ACE variant alone successfully predicted 
61.10% of all cases correctly, showing a significant contribution of these four genetic variants to 
the model. The ACE variant was a significant independent risk factor with an OR value of 2.509 
(CI: 1.391-4.522), p=0.002. When the other parameters were added the OR values and contribution 
to disease for all the genetic variants was altered. This was most prominent for the ACE variant, 
the OR value increased to 3.09 (1.450-6.579). The Model 2 (including genetic variants and other 
conventional risk factors) was now shown to successfully predict 78.70% of all cases. The only 
variables to be shown as independent risk factors were age, FBS and ACE. However the effect of 
these variables (other than ACE) was indicated by the OR values to be small, thus although 
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significant, may not be meaningful. The effect of each variant remained very similar to their 
independent contributions with the exception of the T-786C variant which was reduced when 
considering the other eNOS variants and the ACE gene, suggesting that the effect of this variant 
previously discussed may not be direct. A relationship between the T-786C variant and ACE 
deletion has been identified in previous studies, in other related disease groups. For example the 
CC-DD composite found to be significantly higher in CAD patients than controls (Alvarez et al. 
2001). 
4.5 Overall Discussion and Conclusions 
This study successfully analysed the frequency of three different genetic variants of the eNOS gene 
in a North Indian population among Ht patients and normotensive ethnically matched controls. 
This was undertaken with the aim to greater the understanding of the genetic basis of Ht. 
Deciphering the genetic basis to Ht is a challenging task, it is anticipated that multiple genetic 
variants will each contribute a small effect, collectively resulting in the 50% heritability associated 
with the disease (Butler 2010). 
For this sample retrospective power analysis based on Glu289Asp allele frequencies and OR 
observed for Ht sample, showed the sample had 68% power to detect significant association for 
overall genotypic effect. To achieve 80% power for the whole population, 230 individuals would 
be required in each group to detect a statistical significance for OR of 1.51 observed in this study. 
Within this sample a number of effects were seen that failed to reach statistical significance, this 
can in part be attributed to a reduced power and limited sample size. 
Among other challenges is the difficult definition of HT. The definition is based on a cut off point 
on a continuum and consequently borderline cases could be miss-classified as controls. There is 
also an apparent variance day to day, including ‘white coat syndrome’ which has resulted in this 
disease group being understudied despite the clear role of NO as an endothelium dependent 
vasodilator and key maintainer of BP. BP is also largely affected by medication and consequently 
Ht cases are often immediately treated with anti-hypertensive drugs and consequently would be 
either classified as controls or excluded from the study entirely-creating bias. Diet, specifically 
sodium has also been shown to greatly influence blood pressure, further adding to the variance 
from day to day (Midgley et al. 1996). This is further complicated by the epigenetic regulation of 
gene expression, which is complex and not well understood. Epigenetics regulates gene expression, 
through a number of mechanisms, one of which is DNA methylation. DNA methylation is greater 
when genes are ‘switched off’. Evidence has shown the same genetic polymorphisms to exhibit 
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varied responses to antihypertensive treatment. A recent review by Guang-Wei et al. (2010) 
highlights the relationship between DNA methylation and clinical Ht. With DNA methylation 
being potentially reversible, they propose this epigenetic regulation to have therapeutic 
implications among this disease group (Guang-Wei et al. 2010).  
These issues aside, there are a number of conclusions that can be drawn based on the current 
findings that will contribute towards a greater understanding of the genetic basic of Ht. Although 
Ht has not been shown to be at excessive levels such as CVD and T2DM in a North Indian 
population, this understanding will help to reduce its role as a risk factor for other disease groups 
(Kearney et al. 2005). 
4.5.1 Overall Conclusions 
The three eNOS gene variants analysed were found for the most part to be at a similar frequency to 
those found in previous studies and all control groups were in accordance to HWE. Family history 
was confirmed as a strong independent risk factor for Ht and supports a significant genetic basis to 
the disease. The genetic analysis revealed that the Glu298Asp variant provided evidence against an 
increased Ht risk, and even suggested within this population group the presence of a possible 
protective effect under a recessive model. The T-786C variant’s role in disease remained unclear 
with the findings showing an increased disease risk that was non-significant. This was also found 
to be absent when considering the two remaining eNOS variants and the ACE deletion variant. 
There was also evidence for a possible novel significant association of this variant with the age of 
onset of Ht. The final variant to be analysed, the Intron 4 variant was shown to increase Ht risk in a 
North Indian population. This variant was found at a very low frequency that was typical of a 
South Asian population, which created large confidence intervals, thus the effect was non 
significant and requires confirmation with larger sample sizes and studies on different populations.  
The combined analysis, using logistic regression and haplotype analysis revealed no significant 
associations, but there was a possible protective effect of the T-C-4b haplotype. 
Finally the ACE genetic variant was confirmed to be an independent risk factor for Ht among this 
population. The ACE gene is not thought to be interactive with any of the three eNOS variants 
incorporated in the current study.  
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5 Chapter 5- Diabetes in North Indians 
5.1 Introduction 
The final disease to be evaluated for a possible association with the eNOS gene was Type Two 
Diabetes Mellitus (T2DM). A review of published literature revealed only a small number studies 
have investigated the possible relationship between the eNOS variants and diabetes (Chapter 1, 
section 1.7, p41). An association has been reported for the Glu298Asp variant, the T-786C variant 
and the Intron 4 variant (Monti et al. 2003, Ohtoshi et al. 2002, Ezzidi et al. 2008, Galanakis et al. 
2008, Ksiazek et al. 2003). These associations require further confirmation in multiple populations 
to evaluate the role of the eNOS gene in diabetes.  The aim of this study will be to clarify the role 
of the three eNOS gene variants in T2DM within a North Indian population. Currently, to my 
knowledge this is the first study to investigate the association. The working hypothesis for this 
study was: 
H0= The Glu298Asp, T-786C, Intron 4 and ACE variants are not significantly associated 
with T2DM in a North Indian population group. 
H1= The Glu298Asp, T-786C, Intron 4 and ACE variants are significantly associated with 
T2DM in a North Indian population group. 
5.2 Samples and Methods 
The full methodology and individual genotyping protocols have been described previously in 
Chapter 2-Methods, p60. DNA was available for genotyping from a total of 321 patients and 309 
controls. For the Glu298Asp variant, 263 patients and 247 controls were successfully genotyped. 
For the T-786C variant, 294 patients and 293 controls were successfully genotyped. Finally for the 
Intron 4 variant, 278 patients and 270 controls were successful genotyped. All samples were 
genotyped without the knowledge of disease/control status. 
5.3 Results 
The result section is initially organised according to individual locus analysis followed by analysis 
at all loci level. This was done to understand the spectrum of genetic variation and its contribution 
to the disease.  
Chapter 5 – Diabetes 
172 | P a g e  
 
 
5.3.1 Glu298Asp Results 
5.3.1.1 Baseline Characteristics for the Glu298Asp Variant 
Table 78 shows that the T2DM and control groups to be significantly different in a number of the 
continuous variables. The T2DM group were significantly older than the control group with a 
mean of 61.713 years compared to 58.928 years  in the control group (t=2.551, p=0.011). Patients 
were taller, heavier and had higher levels of both blood pressure measurements. There were no 
significant differences between the T2DM and control groups for BMI, triceps skin folds, 
subscapula skin folds, TC and LDL cholesterol (p<0.05) . 
Table 78- Glu298Asp baseline characteristics and independent samples t-test for continuous variables 
between T2DM patients and controls 
 Variable 
Disease 
status 
N Mean SD T 
mean 
difference 
P Value 
Age (yrs) 
Controls 247 58.924 14.180 
*2.551 -2.789 0.011 
Patients 263 61.713 10.015 
Height (cm) 
Controls 247 159.067 8.811 
2.711 -2.194 0.007 
Patients 263 161.261 9.420 
Weight (Kg) 
Controls 247 68.359 13.099 
2.697 -3.169 0.007 
Patients 263 71.528 13.416 
BMI 
Controls 247 27.052 4.994 
1.033 -0.440 0.302 
Patients 263 27.492 4.621 
Triceps skin folds (mm) 
Controls 247 22.340 8.908 
-0.223 0.175 0.824 
Patients 263 22.165 8.843 
Sub scapula skin folds 
(mm) 
Controls 247 29.645 9.238 
*1.886 -1.464 0.059 
Patients 263 31.110 8.228 
Waist (inches) 
Controls 247 35.351 4.484 
4.943 -1.916 <0.001 
Patients 263 37.266 4.268 
Hip (inches) 
Controls 247 37.819 3.691 
2.308 -0.768 0.021 
Patients 263 38.587 3.811 
Systolic blood pressure 
(mmHg) 
Controls 247 138.425 26.598 
4.823 -10.484 <0.001 
Patients 263 148.909 22.420 
Diastolic blood pressure 
(mmHg) 
Controls 247 81.955 14.048 
2.479 -2.828 0.013 
Patients 263 84.783 11.660 
Glucose (mg/dl) 
Controls 247 96.883 8.338 
*21.735 -90.832 <0.001 
Patients 263 187.715 67.226 
TC (mg/dl) 
Controls 164 183.311 47.280 
0.428 -2.105 0.669 
Patients 245 185.416 49.632 
Glyceride (mg/dl) 
Controls 164 163.003 82.341 
1.850 -17.881 0.065 
Patients 245 180.884 103.813 
HDL (mg/dl) 
Controls 164 42.563 10.568 
*-3.066 3.508 0.002 
Patients 245 39.055 12.401 
LDL (mg/dl) 
Controls 164 106.882 37.632 
0.142 -0.577 0.887 
Patients 244 107.459 41.778 
Chapter 5 – Diabetes 
173 | P a g e  
 
 
 Variable 
Disease 
status 
N Mean SD T 
mean 
difference 
P Value 
VLDL (mg/dl) 
Controls 164 32.849 16.697 
*2.553 -5.549 0.020 
Patients 243 38.399 27.117 
Significant differences were found between gender (χ2=7.296, p=0.007), family history (χ2=58.372, 
p<0.001), hypertension (χ2=46.265, p<0.001) and coronary heart disease (χ2=24.923, p<0.001). No 
significant differences were found between dietary choices (χ2=0.179, p=0.672) or physical activity 
(χ2=2.64, p=0.267) (Table 79). The categorical variables were then tested for T2DM association 
and ORs were calculated. Male gender, positive family history, sedentary behaviours, 
hypertension, increased age  and coronary heart disease were all confirmed to be associated with 
T2DM with (OR>1, p<0.05). The most prominent effect was seen for a family history (Table 79).  
Table 79- Glu298Asp categorical variables in T2DM patients and controls and Odds Ratios (ORs) for 
T2DM association 
Variable 
Total Patient   (%) Total Control (%) OR (95%CI) χ 2 P 
Gender          
Male 140 (53.2) 101 (40.9) 1.65 (1.16-2.34) 7.296 0.007 
Female 123 (46.8) 146 (59.1) 0.61 (0.43-0.86)    
Total 263 (100%) 247 (100%)     
Dietary status          
Vegetarian 141 (53.6) 138 (55.9) 0.91(0.64-1.29) 0.179 0.672 
Non vegetarian 122 (46.4) 109 (44.1) 1.10 (0.77-1.55)    
Total 263 (100%) 247 (100%)     
Family 
History 
         
Yes 221 (84.0) 129 (52.2) 4.81 (3.18-7.28) 58.372 <0.001 
No 42 (16.0) 118 (47.8) 0.21 (0.14-0.31)    
Total 263 (100%) 247 (100%)    
Physical Activity         
Sedentary 19 (7.2) 12 (4.9) 2.58 (1.22-5.48) 5.557 0.018 
Normal 185 (70.3) 167 (67.6) 1.14 (0.78-1.65) 0.326 0.568 
Very Active 59 (22.4) 68 (27.5) 0.76 (0.51-1.14) 1.507 0.220 
Total 263 (100%) 247 (100%)  2.64 (total) 0.267 
Hypertension          
Present 175 (66.5) 89 (36.0) 1.85 (1.54-2.24) 46.265 <0.001 
Absent 88 (33.5) 158 (64.0) 0.28 (0.20-0.41)   
Total 263 (100%) 247 (100%)     
Coronary Heart Disease         
Present 69 (26.2) 22 (8.95) 3.64 (2.17-6.10) 24.923 <0.001 
Absent 194(73.8) 225 (91.1) 0.27 (0.16-0.46)    
Total 263 (100%) 247 (100%)      
Chapter 5 – Diabetes 
174 | P a g e  
 
 
Variable 
Total Patient   (%) Total Control (%) OR (95%CI) χ 2 P 
Age (years)          
≤39 (1) 1 (0.4%) 19 (7.9%) 3 vs.1+2 25.761 (total) <0.001 
40-54 (2) 67 (25.9%) 84 (34.7%) 2.08 (1.43-3.03) 14.08 <0.001 
>55 (3) 191 (73.7%) 139 (57.4%) 3+2 vs. 1    
Total 259 (100%) 242 (100%) 
21.98 (2.92-
165.52) 
16.3 <0.001 
5.3.1.2 eNOS Glu298Asp Genotype and Allele Frequencies and Hardy Weinberg 
Equilibrium Tests 
The T2DM group Glu298Asp genotype frequencies were 71.10%, 25.10% and 3.80% for GG, GT 
and TT respectively. The control group genotype frequencies were 55.47%, 40.08% and 4.45% for 
GG, GT and TT respectively. The G allele and GG genotype showed the highest frequencies in 
both groups (Table 80). There was no significant departure from HWE under any of the three 
independent tests; Pearson’s goodness of fit chi square, log likelihood ratio chi square or p exact 
test (p>0.05). The inbreeding coefficient F (the fixation statistic) was also determined, this value 
was 0.08 for both the patients and controls (Table 80). 
Table 80- Glu298Asp genotype and allele frequencies and Hardy-Weinberg equilibrium tests for the 
T2DM patient and control groups 
  
T2DM patients (n=263) T2DM controls  (n=247) 
Genotype frequencies 
GG  187 (71.10%) 137 (55.47%) 
GT 66 (25.10%) 99 (40.08%) 
TT 10 (3.80%) 11 (4.45%) 
Total 263 (100%) 247 (100%) 
Allele frequencies   
Allele G 0.837 0.755 
Allele T 0.163 0.245 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.083 0.084 
P-Pearson's goodness of fit χ2 (DF=1) 0.181 0.189 
P-Log likelihood ratio χ2 (DF=1) 0.198 0.179 
P Exact test 0.178 0.23 
5.3.1.3 Association between the Glu298Asp Polymorphism and T2DM Risk 
The Glu298Asp variant was assessed for T2DM association and ORs were calculated assuming 
different models. This is presented firstly for the T allele as the risk factor (Table 81) and secondly 
for the G allele as the risk factor (Table 82) There was a significant protective association with 
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T2DM under a dominant (GT+TT vs. GG) model (OR= 0.506 (CI: 0.351-0.730), p<0.001). At an 
allelic level the T allele was also found to be protective against T2DM, (OR=0.603 (CI: 0.442-
0.821), p=0.001). Conversely, the G allele was found to be associated with T2DM susceptibility 
(OR=1.66 (CI: 1.219-2.260), p=0.001).  
Table 81- Glu298Asp Odds Ratios (ORs) for T2DM association (T risk allele) 
Glu298Asp T2DM association OR 95% CI χ2 P 
T vs. G 0.603 0.442-0.821 10.45 0.001 
GT vs. GG 0.488 0.33-0.715 13.74 <0.001 
TT vs. GG+ GT 0.666 0.275-1.613 0.82 0.365 
TT + GT vs. GG 0.506 0.351-0.730 13.44 <0.001 
Armitage's trend test 0.648  10.45 0.001 
Table 82- Glu298Asp Odds Ratios (ORs) for T2DM association (G risk allele) 
Glu298Asp T2DM association OR 95% CI χ2 P 
 G vs. T 1.66 1.219-2.260 10.45 0.001 
GT vs. TT 0.733 0.295-1.824 0.45 0.504 
GG vs. TT+GT 1.501 0.620-3.635 0.82 0.365 
GG+GT  vs. TT 1.179 0.492-2.828 0.14 0.711 
Armitage's trend test 1.516  10.45 0.001 
5.3.1.4 Glu298Asp Logistic Regression 
Logistic regression was performed to calculate the effect of the Glu298Asp variant on T2DM 
disease status with adjustments for other covariates. 401 samples were included in analysis and 105 
were excluded due to missing data. Logistic regression was performed under three different 
models. Table 83 shows the reference groupings for the non-continuous variables. 
Table 83- Reference groupings for the categorical variables included in the Glu298Asp T2DM logistic 
regression analysis 
  Reference Group Parameter 1 
Glu298Asp (dominant) GG GT+TT 
Glu298Asp (recessive) GG +GT TT 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Alcohol intake never & light heavy & very heavy 
Physical Activity very active normal & sedentary 
Obesity BMI<25 BMI>25 
Hypertension Absent Present 
Family history Absent Present 
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5.3.1.4.1 Logistic Regression for a Dominant Model  
Model 1, considering only the Glu298Asp variant found this variant alone did not significantly 
predict disease outcome. Overall, Model 1 correctly predicted 59.5% (χ2=6.358, 1df, p=0.012). The 
Hosmer and Lemershow test confirmed this model not to be a good predictor of disease outcome, 
(p<0.001). The Wald test revealed that the Glu298Asp variable significantly influenced disease 
(OR=0.587 (CI: 0.387-0.888), p=0.012). 
The Model was then rerun, including the covariates; diet, sex, alcohol intake, physical activity, 
obesity, age, Ht and family history (Model 2). The omnibus test of model coefficients revealed the 
model to significantly predict T2DM status (χ2=89.358, df=9, p<0.001), this was confirmed by the 
Hosmer and Lemeshow test (p=0.385). Model 2 successfully predicted T2DM status in 71.6% of 
the sample. The OR for Glu298Asp increased when adjusted for these covariates and remained 
significant (OR= 0.590 (CI: 0.370-0.942), p=0.027) (Table 84). 
Table 84-Model 2: Glu298Asp (dominant model) T2DM logistic regression analysis adjusting for gender, 
age, diet, alcohol, physical activity, obesity, hypertension and family history 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp  -0.528 0.239 4.889 0.027 0.590 0.370 0.942 
Gender  0.340 0.251 1.833 0.176 1.405 0.859 2.297 
AGE (in years) -0.004 0.011 0.118 0.732 0.996 0.976 1.018 
Diet  -0.064 0.235 0.074 0.785 0.938 0.591 1.488 
Alcohol -0.223 0.438 0.259 0.610 0.800 0.339 1.887 
Physical Activity  0.387 0.274 1.983 0.159 1.472 0.859 2.521 
Obesity  -0.034 0.249 0.018 0.893 0.967 0.593 1.577 
Hypertension  1.328 0.250 28.199 <0.001 3.773 2.311 6.160 
Family history 1.496 0.256 34.273 <0.001 4.463 2.705 7.365 
Constant -1.302 0.701 3.452 0.063 0.272     
The model was then extended to include lipid parameters (Model 3). This Model was the best 
predictor of disease status, (χ2=104.646, df=14 p<0.001). The Hosmer and Lemeshow test 
confirmed this to be significant (p=0.013). Model 3 successfully predicted 72.6% of T2DM disease 
status correctly. The Glu298Asp variant was found to be significantly associated with a reduced 
risk of T2DM (OR=0.574 (CI: 0.355-0.927), p=0.023). The final Model showed the only variables 
to be independent predictors were Glu298Asp, Ht, family history and HDL cholesterol (p<0.05). 
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Table 85-Model 3: Glu298Asp (dominant model) T2DM logistic regression analysis adjusting for gender, 
age, diet, alcohol, physical activity, obesity, hypertension, family history and lipid parameters 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Glu298Asp  -0.555 0.245 5.146 0.023 0.574 0.355 0.927 
Gender  0.142 0.265 0.289 0.591 1.153 0.686 1.938 
AGE (in years) -0.004 0.011 0.152 0.696 0.996 0.974 1.017 
Diet  -0.095 0.242 0.155 0.694 0.909 0.566 1.462 
Alcohol -0.288 0.447 0.415 0.520 0.750 0.313 1.800 
Physical Activity  0.363 0.281 1.665 0.197 1.437 0.828 2.494 
Obesity  -0.220 0.261 0.709 0.400 0.803 0.481 1.339 
Hypertension  1.399 0.259 29.195 <0.001 4.050 2.438 6.726 
Family history 1.589 0.266 35.669 <0.001 4.898 2.908 8.250 
TC (mg/dl) -0.001 0.005 0.024 0.876 0.999 0.990 1.009 
Gly (mg/dl) -0.001 0.004 0.025 0.874 0.999 0.991 1.007 
HDL (mg/dl) -0.035 0.011 10.172 0.001 0.965 0.944 0.986 
LDL (mg/dl) 0.001 0.005 0.047 0.827 1.001 0.991 1.012 
VLDL (mg/dl) 0.016 0.021 0.614 0.433 1.016 0.976 1.058 
Constant -0.093 0.928 0.010 0.920 0.911     
Logistic regression was rerun under a recessive model with a GG+GT as the reference category, 
the effects of the covariates remained very similar with the exception of the Glu298Asp variant 
which was no longer found to be a significant covariate. Table 86 summarises the key findings of 
the logistic regression under each model of inheritance. 
Table 86- Key findings of the T2DM Glu298Asp logistic regression analysis for the three models 
 Model 1 Model 2 Model 3 
Dominant     
Goodness of fit chi square significance 0.012 <0.001 <0.001 
Hosmer and Lemershow significance <0.001 0.385 0.013 
Percentage correctly predicted 59.50% 71.60% 72.60% 
Glu298Asp 0.587 (0.387-0.888) 0.590 (0.370-0.942) 0.574 (0.355-0.927) 
Recessive     
Goodness of fit chi square 0.709 <0.001 <0.001 
Hosmer and Lemershow <0.001 0.571 0.02 
Percentage correctly predicted 59.50% 70.40% 74.10% 
Glu298Asp 1.234 (0.406-3.750) 1.245 (0.376-4.124) 1.137 (0.334-3.868) 
5.3.1.5 Glu298Asp Genotype Association with Continuous Variables 
Pairwise comparisons of genotypes (TT vs. GG, TT vs. GT and GT vs. GG) for various lipid 
parameters and other continuous variables revealed a significant difference between the GG and 
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GT genotypes, the GG genotype had a mean glucose level of 149.929mg/dl compared to 
130.903mg/dl  in the GT group, (p=0.003). A similar result was found for VLDL cholesterol, the 
GG genotype sample had statistically significant higher mean values; 37.570mg/dl compared to 
32.945mg/dl in the GT sample (p=0.031). There were no other statistically significant differences 
seen between any of the other variables (p>0.05). The individual tables are presented in appendix 
7, section 8.7. 
5.3.1.6 eNOS Glu298Asp Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Glu298Asp variant showed association in 
high risk groups, these are presented in Table 87. The Glu298Asp variant remained significantly 
protective for T2DM under a dominant model amongst both males and females, (males: OR=0.50 
(CI: 0.29-0.85), p=0.015 and females: OR=0.52 (CI: 0.31-0.86), p=0.014). Similarly the effect 
remained under age group analysis (p=0.017). 
Table 87- Glu298Asp genotype frequencies and T2DM association in subgroup analysis by gender and 
age 
T2DM 
association 
Controls Patients Model OR (95%CI) χ2 P 
Gender        
Males             
GG 56 (55.4%) 100 (71.4%) TT vs. GT+GG 1.47 (0.43-5.02) *0.101 0.751 
GT 41 (40.6%) 32 (22.9%) TT +GT vs. GG 0.50 (0.29-0.85) 5.884 0.015 
TT 4 (4.0%) 8 (5.7%)         
Total 101 (100%) 140 (100%)     
Females             
GG 81 (55.5%) 87 (70.7%) TT vs. GT+GG 0.33 (0.07-1.61) *1.209 0.272 
GT 58 (39.7%) 34 (27.6%) TT +GT vs. GG 0.52 (0.31-0.86) 5.988 0.014 
TT 7 (4.8%) 2 (1.6%)         
Total  146 (100%) 93 (100%)     
AGE groups            
≤39 years            
GG 9 (47.4%) 0 (0%) TT vs. GT+GG Not possible     
GT 10 (52.6%) 1 (100%) TT+GT vs. GG Not possible    
TT 0 (0%) 0 (0%)      
Total 19 (100%) 1 (100%)         
40-54years           
GG 47 (56.0%) 51 (76.1%) TT vs. GT+GG 0.49 (0.09-2.59) *0.223 0.637 
GT 32 (38.1%) 14 (20.9%) TT+GT vs. GG 0.40 (0.20-0.81) 5.800  0.016 
TT 5 (6%) 2 (3%)      
Total 84 (100%) 67 (100%)         
≥55 years           
GG 79 (56.8%) 134 (70.2%) TT vs. GT+GG 0.84 (0.28-2.57) <0.001 0.99 
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T2DM 
association 
Controls Patients Model OR (95%CI) χ2 P 
GT 54 (38.8%) 50 (26.2%) TT+GT vs. GG 0.56 (0.35-0.88) 5.671 0.017 
TT 6 (4.3%) 7 (3.7%)      
Total 139 (100%) 191 (100%)         
*Value less than 5 (χ2 not valid) 
5.3.1.7 Patient only analysis 
A small number of samples had information for the presence of hypertension (Ht), coronary heart 
disease (CHD), retinopathy, neuropathy and stroke. The Glu298Asp variant was found under a 
recessive effect to be significantly associated with retinopathy (OR=0.12 (CI: 0.01-0.93), p=0.036). 
No other significant associations were found with any of the diseases under either a dominant or a 
recessive model (p>0.05) (Table 88).  
Table 88-Glu298Asp Odds Ratio (OR) calculations for Hypertension, Coronary heart disease (CHD), 
diabetic neuropathy, stroke, and diabetic retinopathy in the T2DM patient group 
Patients only absent present Model OR (95%CI) χ2 P 
Ht             
GG 61 (69.3%) 126 (72%) TT vs. GT+GG 1.18 (0.30-4.68) *0.011 0.916 
GT 24 (27.3%) 42 (24.0%) TT +GT vs. GG 0.88 (0.50-1.54) 0.095 0.758 
TT 3 (3.4%) 7 (4%)         
Total 88 (100%) 175 (100%)         
CHD             
GG 141 (72.7%) 46 (66.7%) TT vs. GT+GG 0.30 (0.04-2.43) *0.678 0.41 
GT 44 (22.7%) 22 (31.9%) TT+GT vs. GG 1.33 (0.74-2.40) 0.627 0.428 
TT 9 (4.6%) 1 (1.4%)         
Total 194 (100%) 69 (100%)         
Retinopathy            
GG 93 (67.4%) 94 (75.2%) TT vs. GT+GG 0.12 (0.01-0.93) *4.410 0.036 
GT 36 (26.1%) 30 (24.0%) TT+GT vs. GG 0.68 (0.40-1.17) 1.585 0.208 
TT 9 (6.5%) 1 (0.8%)         
Total 138 (100%) 125 (100%)         
Neuropathy            
GG 83 (66.9%) 104 (74.8%) TT vs. GT+GG 0.37 (0.09-1.46) *1.329 0.249 
GT 34 (27.4%) 32 (23.0%) TT+GT vs. GG 0.68 (0.40-1.16) 1.618 0.203 
TT 7 (5.6%) 3 (3.3%)         
Total 124 (100%) 139 (100%)         
Stroke             
GG 179 (71.0%) 8 (72.7%) TT vs. GT+GG not possible   
GT 63 (25.0%) 3 (27.3%) TT+GT vs. GG 0.92 (0.24-3.56) *0.048 0.827 
TT 10 (4.0%) 0 (0.0%)         
Total 252 (100%) 11 (100%)         
*value less than 5 (χ2 not valid) 
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5.3.2 T-786C Results 
5.3.2.1 Baseline Characteristics for the T-786C Variant 
T2DM patient and control groups were significantly different in a number of the continuous 
variables (Table 89). The T2DM patient group were significantly older than the control group with 
a mean age of 61.701 years compared to 59.010 years  in the control group (t=-2.674, p=0.008). 
There were no significant differences between the T2DM patient and control groups for BMI, 
triceps skin folds, TC, glyceride and LDL cholesterol (p<0.05). 
Table 89-T-786C baseline characteristics and independent samples t-test for continuous variables between 
T2DM patients and controls 
Variable 
Disease 
Status 
N Mean 
Std. 
Deviation 
T 
mean 
difference 
P 
Value 
Age (yrs) 
Controls 293 59.010 13.809 
*-2.674 -2.691 0.008 
Patients 294 61.701 10.316 
Height (cm) 
Controls 293 159.105 8.986 
-2.970 -2.242 0.003 
Patients 294 161.348 9.302 
Weight (Kg) 
Controls 293 68.736 13.188 
-2.193 -2.395 0.029 
Patients 294 71.131 13.273 
BMI 
Controls 293 27.156 4.781 
-.423 -.164 0.673 
Patients 294 27.320 4.603 
Triceps skin folds 
(mm) 
Controls 293 22.360 8.674 
.437 .316 0.662 
Patients 294 22.044 8.853 
Sub scapula skin 
folds (mm) 
Controls 293 29.661 9.095 
*-1.969 -1.401 0.049 
Patients 294 31.062 8.120 
Waist (inches) 
Controls 293 35.459 4.371 
-4.707 -1.658 <0.001 
Patients 294 37.117 4.160 
Hip (inches) 
Controls 293 37.814 3.561 
-2.160 -.646 0.031 
Patients 294 38.460 3.682 
Systolic blood 
pressure (mmHg) 
Controls 293 139.273 26.417 
-4.688 -9.550 <0.001 
Patients 294 148.823 22.812 
Diastolic blood 
pressure (mmHg) 
Controls 293 82.154 13.787 
-2.571 -2.704 0.010 
Patients 294 84.857 11.599 
Glucose (mg/dl) 
Controls 293 97.031 8.627 
*-22.844 -89.755 <0.001 
Patients 294 186.786 66.812 
TC (mg/dl) 
Controls 194 184.082 45.428 
-.703 -3.139 0.482 
Patients 276 187.221 49.099 
Glyceride 
Controls 194 169.044 82.672 
*-1.828 -16.092 0.068 
Patients 276 185.136 107.953 
HDL (mg/dl) 
Controls 194 43.002 10.920 
3.566 3.955 <0.001 
Patients 275 39.047 12.432 
LDL (mg/dl) 
Controls 194 106.774 36.795 
-.591 -2.208 0.555 
Patients 274 108.982 41.809 
VLDL (mg/dl) 
Controls 194 34.002 16.698 
*-2.502 -5.080 0.013 
Patients 273 39.081 27.070 
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Significant differences were found between family history (χ2=67.415, p<0.001), Ht (χ2=46.495, 
p<0.001), coronary heart disease (χ2=19.947, p<0.001) and gender (χ2=8.13, p=0.004) (Table 90). 
No significant differences were found between dietary choices (χ2=0.507, p=0.477), stroke 
(χ2=0.80, p=0.371) or physical activity (χ2=2.64, p=0.267). The categorical baseline characteristics 
were tested for T2DM association and ORs were calculated (Table 90). Male gender, positive 
family history, hypertension and coronary heart disease were all confirmed to be associated with 
T2DM (OR>1, p<0.05). The most prominent effect was seen for a positive family history 
(OR=4.77 (3.25-6.99), p<0.001). 
Table 90- T-786C categorical variables in T2DM patients and controls and Odds Ratios (ORs) for T2DM 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 159 (54.1%) 123 (42.0%) 1.63 (1.17-2.26) 8.132 0.004 
Female 135 (45.9%) 170 (58.0%) 0.61 (0.44-0.85)   
Total 194 (100%) 193 (100%)      
Dietary status          
Vegetarian 160 (54.4%) 169 (57.7% 0.88 (0.63-1.21) 0.507 0.477 
Non vegetarian 134 (45.6%) 124 (42.3%) 1.14 (0.82-1.58)   
Total 194 (100%) 193 (100%)       
Family History          
Yes 245 (83.3%) 150 (51.2%) 4.77 (3.25-6.99) 67.415 <0.001 
No 49 (25.5%) 143 (48.8%) 0.21 (0.14-0.31)   
Total 294 (100%) 193 (100%)      
Physical Activity          
Sedentary 19 (7.2) 12 (4.9) 2.08 (1.02-4.25) 3.541 0.060 
Normal 185 (70.3) 167 (67.6) 1.14 (0.80-1.63) 0.43 0.051 
Very Active 59 (22.4) 68 (27.5) 0.69 (0.47-1.00) 3.439 0.064 
Total 263 (100%) 247 (100%)   2.64 0.267 
Hypertension          
Present 197 (67.0%) 113 (38.6%) 3.24 (2.31-4.54) 46.495 <0.001 
Absent 97 (33.0%) 180 (61.4%) 0.31 (0.22-0.43)   
Total 294 (100%) 293 (100%)      
Coronary Heart Disease         
Present 79 (26.9%) 35 (11.9%) 2.71 (1.75-4.19) 19.947 <0.001 
Absent 215 (73.1%) 258 (88.1%) 0.37 (0.24-0.57)   
Total 293 (100%) 293(100%)      
Stroke          
Present 15 (5.1%) 10 (3.4%) 1.58 (0.70-3.57) 0.800 0.371 
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Absent 279 (94.9%) 283 (96.6%) 0.63 (0.28-1.44)    
Total 294 (100%) 293(100%)      
Age (years)          
≤39 (1) 4 (1.4%) 21 (7.3%) 3 vs. 2+1 19.01 (total) <0.001 
40-54 (2) 74 (25.5%) 96 (33.4%) 1.87 (`.32-2.66) 11.79 <0.001 
>55 (3) 212 (73.1%) 170 (59.2%) 3+2 vs. 1    
 Total 290 (100%) 287 (1005) 5.64 (1.91-16.66) 10.88 0.001 
5.3.2.2 eNOS T-786C Genotype, Allele Frequencies and Hardy Weinberg 
Equilibrium 
The T2DM patient group T-786C genotype frequencies were 54.08%, 37.07% and 8.84% for TT, 
TC and CC respectively. The control group’s genotype frequencies were 53.92%, 37.88% and 
8.19% for TT, TC and CC respectively. The T allele and TT genotype showed the highest 
frequencies in both groups. There was no significant departure from HWE, under any of the three 
tests; Pearson’s goodness of fit chi square, log likelihood ratio chi square or P exact test (p>0.05) 
(Table 91).   
Table 91- T-786C genotype frequencies, allele frequencies and Hardy-Weinberg equilibrium tests for the 
T2DM patient and control groups 
  Patients (n=294)  Controls (n=293) 
Genotype frequencies 
TT 159(54.08%) 158 (53.92%) 
TC 109 (37.07%) 111 (37.88%) 
CC 26 (8.84%) 24 (8.19%) 
Total 294 (100%) 293 (100%) 
Allele frequencies   
Allele T 0.726 0.729 
Allele C 0.274 0.271 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.068 0.042 
P-Pearson's goodness of fit χ2 (DF=1) 0.246 0.473 
P-Log likelihood ratio χ2 (DF=1) 0.250 0.476 
P Exact test 0.243 0.462 
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5.3.2.3 Association between the T-786C Polymorphism and T2DM Risk 
The ORs for T2DM risk were calculated under firstly the C allele as the risk allele (Table 92) and 
secondly under the T allele as the risk allele (Table 93). There were no significant effects seen for 
this variant under any model, ORs were in all cases in close proximity to 1 indicating no 
association. No significant association was found for either the C allele (OR=1.013 (CI: 0.783-
1.309), p=0.924) or the T allele (OR=0.988 (CI: 0.764-1.277), p=0.924).  
Table 92- T-786C Odds Ratios (ORs) for T2DM association (C risk allele) 
T-786C T2DM association OR 95% CI χ2 P 
C  vs. T 1.013 0.783-1.309 0.01 0.924 
TC vs. TT 0.976 0.692-1.376 0.02 0.889 
CC  vs. TT+ TC 1.077 0.593-1.955 0.06 0.809 
CC + TC vs. TT 0.994 0.718-1.375 0 0.970 
Armitage's trend test 1.021   0.01 0.926 
Table 93- T-786C Odds Ratios (ORs) for T2DM association (T risk allele) 
T-786C T2DM association OR 95% CI χ2 P 
 T vs. C 0.988 0.764-1.277 0.01 0.924 
TC vs. CC 0.906 0.490-1.676 0.1 0.754 
TT vs. CC +TC 0.929 0.511-1.687 0.06 0.809 
TT + TC vs. CC 0.92 0.515-1.643 0.08 0.777 
Armitage's trend test 0.979   0.01 0.926 
5.3.2.4 T-786C Logistic Regression 
Logistic regression was performed to calculate the effect of the T-786C variant on T2DM disease 
status with adjustments for other covariates. 465 samples were included in analysis and 122 were 
excluded due to missing data. Logistic regression was run under three models. Table 94 shows the 
reference groupings for the categorical variables. 
Table 94- Reference groupings for the categorical variables included in the T-786C T2DM logistic 
regression analysis 
  Reference Group Parameter 1 
T-786C (dominant) TT TC+CC 
T-786c (recessive) TT +TC CC 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Alcohol intake never & light heavy & very heavy 
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  Reference Group Parameter 1 
Physical Activity very active normal & sedentary 
Obesity BMI<25 BMI>25 
Hypertension Absent Present 
Family history Absent Present 
5.3.2.4.1 Logistic Regression for a Dominant Model  
The classification table revealed the percentage of cases correctly predicted was 58.3% without 
considering any other variables. Model 1 included the T-786C variant only, this Model was not a 
good predictor of disease status (χ2=0.311, df=1, p=0.577), this was confirmed by the Hosmer and 
Lemershow test (p<0.001). The Wald test revealed that the T-786C variable didn't significantly 
contribute to the model (OR=1.111 (CI: 0.766-1.612), p=0.577). 
The model was then rerun, including the covariates; diet, sex, alcohol intake, physical activity, 
obesity and age (Model 2). The omnibus test of model coefficients revealed the model to 
significantly predict T2DM status (χ2=98.167, df=9, p<0.001), this was confirmed by the Hosmer 
and Lemeshow test (p=0.171). The new model successfully predicted T2DM status in 70.8% of the 
sample. The OR for T-786C variant increased slightly after adjustment for these covariates but 
remained non significant (OR=1.206 (CI: 0.794-1.832), p=0.379) (Table 95). 
Table 95-Model 2: T-786C (dominant model) T2DM logistic regression analysis adjusting for gender, age, 
diet, alcohol, physical activity, obesity, hypertension and family history 
Variable B S.E. Wald P OR 
95% C.I. 
Lower Upper 
T-786C 0.188 0.213 0.775 0.379 1.206 0.794 1.832 
Gender  0.366 0.233 2.470 0.116 1.442 0.913 2.277 
AGE (in years) -0.003 0.010 0.119 0.730 0.997 0.978 1.016 
Diet  -0.079 0.218 0.130 0.719 0.924 0.602 1.418 
Alcohol  -0.164 0.412 0.158 0.691 0.849 0.379 1.902 
Physical Activity  0.410 0.253 2.616 0.106 1.507 0.917 2.476 
Obesity  -0.220 0.231 0.910 0.340 0.802 0.510 1.261 
Hypertension  1.330 0.229 33.798 <0.001 3.782 2.415 5.923 
Family History 1.488 0.236 39.812 <0.001 4.427 2.789 7.028 
Constant -1.563 0.644 5.881 0.015 0.210     
The Model was then extended to include lipid parameters (Model 3). This Model was the best 
predictor of disease status (χ2=104.646, df=14 p<0.001). The Hosmer and Lemeshow test 
confirmed this to be significant (p=0.070). Model 3 was shown to successfully predict 73.5% of 
T2DM disease status correctly. The T-786C variant was found to have a further increased OR 
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value (OR=1.277 (CI: 0.830-1.964), p=0.266). The final model showed the only variables to be 
independent predictors were Ht, family history and HDL cholesterol. 
Table 96-Model 3: T-786C (dominant model) T2DM logistic regression analysis adjusting for gender, age, 
diet, alcohol, physical activity, obesity, hypertension, family history and lipid parameters 
Variable 
B S.E. Wald p OR 
95% C.I. 
Lower Upper 
T-786C 0.244 0.220 1.236 0.266 1.277 0.830 1.964 
Gender  0.203 0.244 0.694 0.405 1.225 0.760 1.976 
AGE (in years) -0.006 0.010 0.310 0.578 0.994 0.975 1.014 
Diet  -0.111 0.224 0.245 0.621 0.895 0.578 1.388 
Alcohol  -0.186 0.420 0.197 0.657 0.830 0.364 1.891 
Physical Activity  0.412 0.259 2.522 0.112 1.510 0.908 2.510 
Obesity  -0.374 0.240 2.414 0.120 0.688 0.430 1.103 
Hypertension  1.368 0.235 33.971 <0.001 3.926 2.479 6.219 
Family History 1.522 0.243 39.314 <0.001 4.582 2.847 7.374 
TC (mg/dl) 0.000 0.005 0.002 0.964 1.000 0.991 1.009 
Glyceride (mg/dl) -0.002 0.004 0.164 0.685 0.998 0.990 1.006 
HDL(mg/dl) -0.031 0.010 9.453 0.002 0.970 0.951 0.989 
LDL (mg/dl) 0.002 0.005 0.206 0.650 1.002 0.992 1.013 
VLDL (mg/dl) 0.020 0.021 0.965 0.326 1.021 0.980 1.063 
Constant -0.687 0.857 0.643 0.423 0.503     
The logistic regression analysis was also carried out assuming a recessive model with TT+TC as 
the reference category. Similar effects were present for all covariates, the effect of the T-786C 
variant was larger under this model, but also contained wider confidence intervals. Table 97 
summarises the key findings of the logistic regression under each model.  
Table 97- Key findings of the T2DM T-786C logistic regression analysis for the three models 
 Model 1 Model 2 Model 3 
Dominant    
Goodness of fit chi square (p) 0.577 <0.001 <0.001 
Hosmer and Lemershow 0.000 0.171 0.070 
Percentage correctly predicted 58.30% 70.80% 73.50% 
T-786C 1.111 (0.766-1.612) 1.206 (0.794-1.832) 1.277 (0.830-1.964) 
Recessive    
Goodness of fit chi square 0.18 <0.001 <0.001 
Hosmer and Lemershow 0 0.098 0.052 
Percentage correctly predicted 58.30% 71.40% 71.80% 
T-786C 1.610 (0.791-3.275) 1.725 (0.780-3.814) 1.691 (0.742-3.853) 
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5.3.2.5 T-786C Genotype Association with Continuous Variables  
Pairwise comparisons of genotypes (CC vs. TC, CC vs. TT and TC vs. TT) for various continuous 
variables revealed the mean age of the CC genotype to be significantly greater than the TT 
genotype. With a mean age of 64.484years, and 59.493years for the CC and TT groups 
respectively (t=2.786, p=0.006). There were no other statistically significant differences seen 
between any of the continuous variables (p>0.05). The individual tables are given in appendix 7, 
section 8.7. 
5.3.2.6 eNOS T-786C Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the T-786C variant had association in high risk 
groups, these are presented in Table 98. The T-786C variant did not show any significant 
association with T2DM following gender of age group analysis (p>0.05).  
Table 98-T-786C genotype frequencies and T2DM association in subgroup analysis by gender and age 
T2DM Controls Patients Model OR (95%CI) χ2 P 
Gender       
Males             
TT 68 (55.3%) 89 (56.0%) CC vs. CT+TT 0.96 (0.43-2.14) 0.013 0.91 
TC 43 (35.0%) 55 (34.6%) CC +TC vs. TT 0.97 (0.61-1.56) 0 0.996 
CC 12 (9.8%) 15 (9.4%)         
Total 123 (100%) 159 (100%)         
Females        
TT 90 (52.9%) 70 (51.9%) CC vs. CT+TT 0.72 (0.31-1.69) 0.295 0.587 
TC 68 (40.0%) 54 (40.0%) CC +TC vs. TT 1.04 (0.66-1.64) 0.005 0.94 
CC 12 (7.1%) 11 (8.1%)         
Total 170 (100%) 135 (100%)         
Age       
≤39 years           
TT 15 (71.4%) 2 (50.0%) CC vs. CT+TT not possible     
TC 6 (28.6%) 2 (50.0%) CC +TC vs. TT not possible     
CC 0 (0%) 0 (0%)         
Total 21 (100%) 4 (100%)         
40-54 years             
TT 44 (45.8%) 44 (59.5%) CC vs. CT+TT 0.86 (0.23-3.16) *0.009 0.923 
TC 46 (47.9%) 26 (35.1%) CC +TC vs. TT 0.58 (0.31-1.07) 2.59 0.108 
CC 6 (6.3%) 4 (5.4%)         
Total 96 (100%) 74 (100%)         
≥55 years             
Chapter 5 – Diabetes 
187 | P a g e  
 
 
T2DM Controls Patients Model OR (95%CI) χ2 P 
TT 94 (55.3%) 112 (52.8%) CC vs. CT+TT 0.93 (0.48-1.80) 0.002 0.961 
TC 58 (34.1%) 79 (37.3%) CC +TC vs. TT 1.10 (0.74-1.66) 0.142 0.706 
CC 18 (1.6%) 21 (9.9%)         
Total 170 (100%) 212 (100%)         
*Value less than 5 (χ2 not valid) 
5.3.2.7 Patient Only Analysis 
A small number of samples had information for the presence of Hypertension (Ht), Coronary heart 
disease (CHD), retinopathy, neuropathy and stroke. The T-786C variant did not show an 
association with any of the diseases under either a dominant or a recessive model (p>0.05) (Table 
99).  
Table 99-T-786C Odds Ratio (OR) calculations for Hypertension, Coronary heart disease (CHD), diabetic 
neuropathy, stroke, and diabetic retinopathy in the T2DM patient group 
Variable  Absent Present Model OR (95%CI) Χ2 P 
Ht             
TT 54 (55.7%) 105 (53.3%) CC vs. CT+TT 0.92 (0.40-2.15) 0.001 0.973 
TC 34 (35.1%) 75 (38.1%) CC +TC vs. TT 1.10 (0.67-1.79) 0.067 0.796 
CC 9 (9.3%) 17 (8.6%)         
Total 97 (100%) 197 (100%)         
CHD             
TT 116 (54.0%) 43 (54.4%) CC vs. CT+TT 1.23 (0.51-2.96) 0.057 0.812 
TC 81 (37.7%) 28 (35.4%) CC +TC vs. TT 0.98 (0.58-1.65) 0.004 0.953 
CC 18 (8.4%) 8 (8.8%)         
Total 215 (100%) 79 (100%)         
Neuropathy             
TT 75 (53.2%) 84 (54.9%) CC vs. CT+TT 0.46 (0.20-1.06) 2.746 0.097 
TC 49 (34.8%) 60 (39.2%) CC +TC vs. TT 0.93 (0.59-1.48) 0.031 0.86 
CC 17 (12.1%) 9 (5.9%)         
Total 141 (100%) 153 (100%)         
Stroke             
TT 150 (53.8%) 9 (60.0%) CC vs. CT+TT 3.04 (0.79-11.60) 1.467 0.226 
TC 106 (38.0%) 3 (20.0%) CC +TC vs. TT 0.78 (0.27-2.24) 0.043 0.837 
CC 23 (8.2%) 3 (20.0%)         
Total 279 (100%) 15 (100%)         
Retinopathy       
TT 81 (51.6%) 78 (56.9%) CC vs. CT+TT 0.69 (0.30-1.58) 0.443 0.506 
TC 60 (38.2%) 49 (35.8%) CC +TC vs. TT 0.81 (0.51-1.28) 0.639 0.424 
CC 16 (10.2%) 10 (3.4%)         
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Variable  Absent Present Model OR (95%CI) Χ2 P 
Total 157 (100%) 137 (100%)         
5.3.3 Intron 4 Results 
5.3.3.1 Baseline Characteristics Between the Intron 4 Patients and Controls 
The T2DM patient and control groups were significantly different in a number of the continuous 
variables (Table 100). The T2DM patient group were significantly older than the control group 
with a mean of 62.050 years compared to 58.782 years  in the control group (t=-3.088, p=0.002) . 
There were significant differences between the T2DM and control groups for BMI, triceps skin 
folds, TC, glyceride and LDL cholesterol. 
Table 100-Intron 4 baseline characteristics and independent samples t-test for continuous variables 
between T2DM patients and controls 
Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
difference 
p 
value 
Age (years) 
Control  272 58.782 14.224 0.862 *-3.088 -3.267 0.002 
Patient 281 62.050 10.275 0.613       
Height (cm)  
Control  272 159.340 8.976 0.544 -2.355 -1.828 0.019 
Patient 281 161.168 9.273 0.553       
Weight  (Kg) 
Control  272 68.430 13.255 0.804 -2.241 -2.526 0.025 
Patient 281 70.956 13.252 0.791       
Body Mass 
Index  (Kg/m
2
) 
Control  272 26.957 4.831 0.293 -0.900 -0.363 0.369 
Patient 281 27.320 4.654 0.278       
Triceps Skin 
folds  (mm)  
Control  272 22.193 8.695 0.527 0.185 0.139 0.853 
Patient 281 22.054 8.942 0.533       
Sub Scapula 
Skin folds 
(mm)  
Control  272 29.618 9.261 0.562 *-1.991 -1.478 0.047 
Patient 281 31.095 8.137 0.485       
Waist (inches) 
Control  272 35.314 4.506 0.273 -4.893 -1.835 <0.001 
Patient 281 37.148 4.313 0.257       
Hip (inches)  
Control  272 37.692 3.608 0.219 -2.542 -0.800 0.011 
Patient 281 38.492 3.784 0.226       
Systolic Blood 
Pressure 
(mmHg)  
Control  272 138.460 25.781 1.563 -5.202 -10.807 <0.001 
Patient 281 149.267 23.033 1.374       
Diastolic 
Blood Pressure 
(mmHg)  
Control  272 81.805 13.545 0.821 -2.912 -3.134 0.004 
Patient 281 84.940 11.725 0.699       
 Glucose Control  272 97.015 8.574 0.520 *-22.851 -90.199 <0.001 
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Variable 
Disease 
status 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t value 
mean 
difference 
p 
value 
(mg/dl)  Patient 281 187.214 65.592 3.913       
TC (mg/dl)  
Control  177 183.740 45.103 3.390 -0.891 -4.124 0.374 
Patient 264 187.864 49.288 3.033       
Glyceride 
(mg/dl)  
Control  177 168.060 83.891 6.306 *-1.717 -15.833 0.087 
Patient 264 183.894 109.289 6.726       
HDL (mg/dl)  
Control  177 43.331 10.790 0.811 3.606 4.157 <0.001 
Patient 263 39.175 12.523 0.772       
LDL (mg/dl)  
Control  177 106.504 35.951 2.702 *-0.734 -2.744 0.463 
Patient 261 109.248 41.726 2.583       
VLDL (mg/dl)  
Control  177 33.540 16.666 1.253 *-2.539 -5.371 0.011 
Patient 261 38.911 27.535 1.704       
The patient and control groups were also tested for differences between categorical variables 
(Table 101). Significant differences were found between gender (χ2=5.956, p=0.015), family 
history (χ2=71.33, p<0.001), physical activity (χ2=8.068, p=0.018), hypertension (χ2=46.778, 
p<0.001) and coronary heart disease (χ2=17.348, p<0.001). No significant differences were found 
between dietary choices (χ2=0.362, p=0.547) or stroke (χ2=0.971, p=0.324) (Table 101). The non-
continuous characteristics were then tested for T2DM association and Odds Ratios were calculated. 
Male gender, positive family history, sedentary behaviour, hypertension and coronary heart disease 
were all confirmed to be associated with T2DM (OR>1, p<0.05). The most prominent effect was 
seen for a family history (OR=5.31 (3.56-7.92) p<0.001) (Table 101). 
Table 101- Intron 4 categorical variables in Ht patients and controls and Odds Ratios (ORs) for T2DM 
association 
Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Gender          
Male 150 (53.4%) 116 (42.6%) 1.54 (1.10-2.15) 5.956 0.015 
Female 131 (46.6%) 156 (57.4%) 0.65 (0.46-0.91)    
Total 281 (100%) 272(100%)      
Dietary status          
Vegetarian 153 (54.4%) 156 (57.4%) 0.89 (0.64-1.24) 0.362 0.547 
Non vegetarian 128 (45.6%) 116 (42.6%) 1.13(0.80-1.57)    
Total 281(100%) 272(100%)      
Family History          
Yes 237 (84.3%) 137 (50.4%) 5.31 (3.56-7.92) 71.33 <0.001 
No 44 (15.7%) 135 (49.6%) 0.19 (0.13-0.28)    
Total 281 (100%) 272 (100%)      
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Variable Patient (%) Control (%) OR (95%CI) χ2 P 
Physical Activity          
Sedentary 20 (7.1%) 7 (2.6%) 2.90 (1.21-6.98) 5.205 0.023 
Normal 200 (71.2%) 189 (69.5%) 1.08 (0.75-1.56) 0.117 0.733 
Very Active 61 (21.7%) 76 (27.9%) 0.72 (0.49-1.05) 2.556 0.110 
Total 281 (100%) 272(100%)  8.068 0.018 
Hypertension          
Present 185 (65.8%) 99 (36.4%) 3.37 (2.38-4.77) 46.778 <0.001 
Absent 96 (34.2%) 173 (63.6%) 0.30 (0.21-0.42)    
Total 281 (100%) 272 (100%)      
Coronary Heart Disease        
Present 76 (27.0%) 33 (12.1%) 2.20 (1.53-3.17) 17.348 <0.001 
Absent 205 (73.0%) 239 (87.9%) 0.45 (0.32-0.66)    
Total 281 (100%) 272 (100%)       
Stroke          
Present 14 (5.0%) 9 (3.3%)  0.971 0.324 
Absent 267 (95.0%) 263 (96.7%)     
Total 281 (100%) 272 (100%)      
Age (years)          
≤39 (1) 2 (0.7%) 22 (8.3%) 3 vs.1+2 
 25.266 
(total) 
<0.001  
40-54 (2) 70 (25.5%) 89 (33.6%) 2.02 (1.41-2.91) 13.949 <0.001 
>55 (3) 202 (73.7%) 154 (58.1%) 3+2 vs. 1    
 Total 274 (100%) 265 (100%) 12.31 (2.87-52.90) 16.42 <0.001 
5.3.3.2 eNOS Intron 4 Genotypes and Allele Frequencies 
The T2DM’s group Intron 4 genotype frequencies were 64.75%, 31.65% and 3.60% for 4bb, 4ab 
and 4aa respectively. The control group’s genotype frequencies were 66.67%, 29.26% and 4.07% 
for 4bb, 4ab and 4aa respectively. The 4b allele and 4bb genotype showed the highest frequencies 
in both groups.  There was no significant departure from HWE under any of the three independent 
tests; Pearson’s goodness of fit chi square, log likelihood ratio chi square or p exact test (p>0.05) 
(Table 102). 
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Table 102-Intron 4 genotype frequencies, allele frequencies and Hardy-Weinberg equilibrium tests for the 
T2DM patient and control groups 
 T2DM patients (n=278) T2DM controls (n=270) 
Genotype frequencies 
4bb 180(64.75%) 180 (66.67%) 
4ab 88(31.65%) 79 (29.26%) 
4aa 10(3.60%) 11 (4.07%) 
Total 278 (100%) 270 (100%) 
Allele frequencies   
Allele 4a 0.806 0.813 
Allele 4b 0.194 0.187 
Hardy-Weinberg equilibrium tests 
F-inbreeding coefficient 0.01124 0.03787 
P-Pearson's goodness of fit χ2 (DF=1) 0.851 0.534 
P-Log likelihood ratio χ2 (DF=1) 0.851 0.540 
P Exact test 1 0.548 
 
5.3.3.3 Association Between the Intron 4 Polymorphism and T2DM Risk 
The Intron 4 variant was assessed for possible association with T2DM and ORs were calculated 
under different models.Table 103 presents the ORs with the 4a allele as the T2DM risk allele and 
Table 104 presents the ORs with the 4b allele as the T2DM risk allele. There were no significant 
effects seen for this variant under any model for the hypothesised 4a or 4b risk alleles (p>0.05). 
The OR values showed a close proximity to 1 indicating no significant disease association for 
either the 4a allele (OR=1.048 (CI: 0.775-1.417), p=0.761) or the 4b allele (OR=0.954 (CI: 0.706-
1.290), p=0.761).  
Table 103- Intron 4 Odds Ratios (ORs) for T2DM association (4a risk allele) 
Intron 4 T2DM association OR 95% CI χ2 P 
4a vs. 4b 1.048 0.775-1.417 0.09 0.761 
4ab vs. 4bb 1.114 0.771-1.608 0.33 0.565 
4aa vs. 4bb+4ab 0.909 0.377-2.194 0.04 0.832 
4aa + 4ab vs. 4bb 1.089 0.765-1.550 0.22 0.636 
Armitage's trend test 1.023   0.09 0.763 
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Table 104-Intron 4 Odds Ratios (ORs) for T2DM association (4b risk allele) 
Intron 4 T2DM association OR 95% CI χ2 P 
 4b vs. 4a 0.954 0.706-1.290 0.09 0.761 
4ab vs. 4aa 1.225 0.494-3.040 0.19 0.661 
4bb vs. 4aa + 4ab 1.1 0.456-2.654 0.04 0.832 
4bb + 4ab vs. 4aa 1.138 0.475-2.726 0.08 0.771 
Armitage's trend test 0.979   0.09 0.763 
5.3.3.4 Intron 4 Logistic Regression 
Logistic regression was performed to calculate the effect of the Intron 4 variant on T2DM disease 
status when adjusting for other covariates. 432 samples were included in analysis and 116 were 
excluded due to missing data.  Logistic regression was performed using three different Models. 
Table 105 shows the reference groupings for the categorical variables. 
Table 105- Reference groupings for the categorical variables included in the Intron 4 T2DM logistic 
regression analysis 
 Variable Reference Group Parameter 1 
Intron 4 (dominant) 4bb 4ab +4aa 
Intron 4 (recessive) 4bb +4ab 4aa 
Gender Female Male 
Diet Vegetarian Non-vegetarian 
Alcohol intake never & light heavy & very heavy 
Physical Activity very active normal & sedentary 
Obesity BMI<25 BMI>25 
Hypertension Absent Present 
Family history Absent Present 
5.3.3.4.1 Logistic Regression for a Dominant Model  
The classification table revealed the percentage of cases correctly predicted was 59.3% without 
considering any other variables. Model 1 considered only the Intron 4 variant and was not a 
significant predictor of disease outcome (χ2=0.354, 1df, p=0.552), this was confirmed by the 
Hosmer and Lemershow test (p<0.001). The Wald test revealed that the Intron 4 variable didn't 
significantly contribute to the model and had an (OR=1.133 (CI: 0.751-1.707), p=0.552). 
The Model was then rerun, including the covariates; diet, sex, alcohol intake, physical activity, 
obesity and age (Model 2). The omnibus test of model coefficients revealed the Model to 
significantly predict T2DM status (χ2=100.117, df=9, p<0.001), this was confirmed by the Hosmer 
and Lemeshow test (p=0.957). The new model successfully predicted T2DM status in 72% of the 
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sample. The OR for Intron 4 increased, but remained non-significant (OR= 1.136 (CI: 0.710-
1.817), p=0.595). 
Table 106-Model 2: Intron 4 dominant model T2DM logistic regression analysis adjusting for gender, 
age, diet, alcohol, physical activity, obesity, hypertension and family history 
Variable B S.E. Wald p OR 
95% C.I. 
Lower Upper 
Intron 4  0.127 0.240 0.282 0.595 1.136 0.710 1.817 
Gender  0.135 0.245 0.301 0.583 1.144 0.707 1.850 
AGE (in years) 0.003 0.010 0.071 0.789 1.003 0.983 1.023 
Diet  0.010 0.229 0.002 0.964 1.011 0.645 1.584 
Alcohol  -0.025 0.444 0.003 0.955 0.975 0.408 2.329 
Physical Activity  0.443 0.266 2.766 0.096 1.557 0.924 2.625 
Obesity  -0.217 0.243 0.796 0.372 0.805 0.500 1.296 
Hypertension  1.396 0.244 32.865 <0.001 4.039 2.506 6.511 
Family history 1.646 0.250 43.218 <0.001 5.186 3.175 8.471 
Constant -1.912 0.678 7.962 0.005 0.148     
The model was then extended to include lipid parameters (Model 3). This Model was the best 
predictor of disease status (χ2=119.642, df=14, p<0.001). The Hosmer and Lemeshow test 
confirmed this Model to be a significant predictor of disease outcome (p=0.256). Model 3 was 
shown to successfully predict 74.8% of T2DM disease status correctly. The Intron 4 variant’s OR 
remained very similar to Model 2 and was once again non significant (OR=1.126 (0.694-1.828), 
p=0.630). The final model showed the only variables to be independent risk factors were Ht, family 
history and HDL cholesterol. 
Table 107-Model 3: Intron 4 dominant model T2DM logistic regression analysis adjusting for gender, 
age, diet, alcohol, physical activity, obesity, hypertension, family history and lipid parameters 
Variable B S.E. Wald P OR 
95% C.I. 
Lower Upper 
Intron 4  0.119 0.247 0.233 0.630 1.126 0.694 1.828 
Gender  -0.005 0.260 0.000 0.984 0.995 0.598 1.655 
AGE (in years) 0.000 0.011 0.000 0.985 1.000 0.980 1.021 
Diet  -0.043 0.237 0.033 0.857 0.958 0.603 1.523 
Alcohol  -0.087 0.457 0.036 0.849 0.917 0.374 2.246 
Physical Activity  0.480 0.276 3.033 0.082 1.616 0.942 2.775 
Obesity  -0.351 0.252 1.934 0.164 0.704 0.429 1.155 
Hypertension  1.465 0.254 33.198 <0.001 4.327 2.629 7.122 
Family History 1.699 0.258 43.212 <0.001 5.467 3.294 9.072 
TC (mg/dl) -0.002 0.006 0.070 0.791 0.998 0.987 1.010 
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Variable B S.E. Wald P OR 
95% C.I. 
Lower Upper 
Gly (mg/dl) -0.018 0.016 1.164 0.281 0.983 0.952 1.014 
HDL (mg/dl) -0.033 0.011 8.900 0.003 0.968 0.947 0.989 
LDL (mg/dl) 0.004 0.006 0.430 0.512 1.004 0.992 1.017 
VLDL (mg/dl) 0.099 0.081 1.495 0.221 1.105 0.942 1.296 
Constant -0.888 0.897 0.981 0.322 0.411     
The logistic regression was then re-run with a recessive model 4bb + 4ab as the reference category. 
All covariates were shown to have a similar effect with the exception of the Intron 4 variant, which 
had greater OR values with wider confidence intervals. Table 108 summarises the key findings of 
the logistic regression under both models of inheritance. 
Table 108- Key findings of the T2DM Intron 4 logistic regression analysis for the three Models 
 Model 1 Model 2 Model 3 
Dominant    
Significance 0.552 <0.001 <0.001 
Hosmer and Lemershow 0.000 0.957 0.256 
Percentage correctly predicted 59.30% 72.00% 74.80% 
Intron 4 1.133 (0.751-1.707) 1.136 (0.710-1.817) 1.126 (0.694-1.828) 
Recessive Model 1 Model 2 Model 3 
Significance 0.173 <0.001 <0.001 
Hosmer and Lemershow <0.001 0.474 0.094 
Percentage correctly predicted 59.30% 70.10% 75.50% 
Intron 4 2.344 (0.636-8.643) 3.833 (0.844-17.403) 4.729 (0.918-24.366) 
5.3.3.5 Intron 4 Genotype Association Irrespective of Disease Status 
Pairwise comparisons of genotypes (4aa vs. 4ab, 4aa vs. 4bb and 4ab vs. 4bb) for various 
continuous variables revealed a significant difference for mean age between the 4aa and 4bb 
genotypes with values of  65.748 years, and 59.763 years for the 4aa and 4bb groups respectively 
(t=2.162, P=0.0031). Glyceride levels also showed a significant difference between the 4aa and 
4bb genotypes with mean values of 117.869mg/dl and 180.573mg/dl for 4aa and 4bb respectively 
(t=-2.321, p=0.021). There were no other statistically significant differences seen between any of 
the continuous variables (p>0.05). The individual tables are presented in the appendix 7, section 
8.7. 
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5.3.3.6 eNOS Intron 4 Disease Association in High Risk Groups 
Sub-group analysis was undertaken to determine if the Intron 4 variant had association with T2DM 
in high risk groups, these are presented in Table 109. The Intron 4 variant did not show a 
significant association with T2DM following gender or age group sub-analysis (p>0.05).  
Table 109- Intron 4 genotype frequencies and T2DM association in subgroup analysis by gender and age 
T2DM Controls Patients Model OR (95%CI) χ2 P 
Gender       
Males only             
4bb 81 (69.8%) 99 (66.0%) 4aa vs. 4ab +4bb 0.94 (0.28-3.15) 0.043 0.836 
4ab 30 (25.9%) 43 (28.7%) 4aa +4ab vs. 4bb 1.15 (0.68-1.93) 0.141 0.708 
4aa 5 (1.9%) 6 (4.0%)         
Total 116 (100%) 150 (100%)         
Females only       
4bb 99 (63.5%) 81 (62.3%) 4aa vs. 4ab +4bb 0.78(0.22-2.84) *0.003 0.96 
4ab 49 (31.4%) 45 (34.6%) 4aa +4ab vs. 4bb 1.09(0.67-1.770 0.049 0.825 
4aa 6 (3.8%) 4 (3.1%)         
Total 154 (100%) 130 (100%)         
Total 245 (100%) 39 (100%)         
AGE groups       
≤39 years             
4bb 16 (72.7%) 2 (100%) 4aa vs. 4ab +4bb not possible     
4ab 6 (27.3%) 0 (0%) 4aa + 4ab vs. 4bb not possible    
4aa 0 (0%) 0 (0%)      
Total 22 (100%) 2 (100%)         
40-54years             
4bb 60 (67.4%) 46 (65.7%) 4aa vs. 4ab +4bb 0.31 (0.03-2.82) *0.412 0.521 
4ab 25 (28.1%) 23 (32.9%) 4aa + 4ab vs. 4bb 1.08 (0.56-2.10) 0.003 0.955 
4aa 4 (4.5%) 1 (1.4%)      
Total 89 (100%) 70 (100%)         
≥55 years             
4bb 99 (64.3%) 129 (63.9%) 4aa vs. 4ab +4bb 0.98 (0.26-2.69) 0.047 0.828 
4ab 48 (31.2%) 64 (31.7%) 4aa + 4ab vs. 4bb 1.02 (0.66-1.58) 0.001 0.977 
4aa 7 (4.5%) 9 (4.5%)      
Total 154 (100%) 202 (100%)         
*Value below 5 (χ2 not valid) 
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5.3.3.7 Patient Only Analysis 
A small number of samples had information for the presence of Ht, coronary heart disease (CHD), 
retinopathy, neuropathy and stroke. The Intron 4 variant did not show any association with any of 
the diseases under either a dominant or a recessive model (p>0.05) (Table 110).  
Table 110-Intron 4 odds ratio (OR) calculations for Hypertension, Coronary heart disease (CHD), 
diabetic neuropathy, stroke, and diabetic retinopathy in the T2DM patient group 
Patients only Absent Present Model OR (95%CI) χ2 P 
Ht             
4bb 66 (68.8%) 114 (62.6%) 4aa vs. 4ab +4bb 1.24 (0.31-4.91) *0.001 0.975 
4ab 27 (28.1%) 61 (33.5%) 4aa +4ab vs. 4bb 1.31(0.78-2.22) 0.778 0.378 
4aa 3 (3.1%) 7 (3.8%)         
Total 96 (100%) 182 (100%)         
CHD             
4bb 132 (65.02%) 48 (63.2%) 4aa vs. 4ab +4bb 1.85 (0.51-6.75) *0.339 0.561 
4ab 65 (32.01%) 23 (30.3%) 4aa +4ab vs. 4bb 1.05 (0.60-1.820 0 0.986 
4aa 6 (2.9%) 4 (5.3%)         
Total 203 (100%) 75 (100%)         
Neuropathy             
4bb 88 (65.6%) 92 (63.9%) 4aa vs. 4ab +4bb 0.39 (0.10-1.52) *1.172 0.279 
4ab 39 (29.1%) 49 (34.0%) 4aa +4ab vs. 4bb 1.08 (0.66-1.77) 0.34 0.853 
4aa 7 (5.2%) 3 (2.1%)         
Total 134 (100%) 144 (100%)         
Stroke             
4bb 172 (65.1%) 8 (57.1%) 4aa vs. 4ab +4bb Not possible   
4ab 82 (31.0%) 6 (42.9%) 4aa +4ab vs. 4bb 1.40 (0.47-4.16) 0.105 0.746 
4aa 10 (3.7%) 0 (0%)         
Total 264 (100%) 14 (100%)         
Retinopathy             
4bb 99 (68.2%) 81 (60.0%) 4aa vs. 4ab +4bb 2.63(0.67-10.39) *1.224 0.269 
4ab 43 (29.6%) 45 (33.3%) 4aa +4ab vs. 4bb 1.38(0.84-2.26) 1.345 0.246 
4aa 3 (2.0%) 7 (5.2%)         
Total 145 (100%) 135 (100%)         
*Value below 5 (χ2 not valid)  
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5.3.4 Synergetic effects of eNOS Genotypes 
The genotypes were investigated for a possible synergistic effect on T2DM status (Table 111). The 
frequency of each combination was not uniform; a number of combinations were not observed in 
the data (not included in table) and some were in very low frequency.  The genotype combination 
of TT, TT and 4bb of Glu298Asp, T-786C and Intron 4 respectively was shown to be significantly 
protective against T2DM (OR=0.20 (CI: 0.04-0.92), p=0.046). Similar effects were seen for the 
combination GT, TC and 4ab and GT, TT 4bb (OR<1 p<0.05). The GG, TT and 4bb combination 
was found to be an increased risk of T2DM (OR 1.62 (CI: 1.09-2.39), p=0.02). 
Table 111- Glu298Asp, T-786C and Intron 4 composite genotypes and Odds Ratios (ORs) for T2DM 
association  
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TT CC 4ab 0 0.00 1 0.41 Not possible     
TT CC 4bb 1 0.00 5 2.05 4.62 (0.54-39.88) 1.249 0.264 
TT TC 4bb 1 0.45 1 0.41 0.91 (0.06-14.63) 0.413 0.521 
TT TT 4bb 9 4.05 2 0.82 0.20 (0.04-0.92) 3.966 0.046 
GT CC 4aa 2 0.90 0 0.00 Not possible     
GT CC 4ab 5 2.25 4 1.64 0.72 (0.19-2.73) 0.021 0.886 
GT CC 4bb 1 0.45 1 0.41 0.91 (0.06-14.63) 0.413 0.521 
GT TC 4ab 25 11.26 13 5.33 0.44 (0.22-0.89) 4.7 0.03 
GT TC 4bb 19 8.56 17 6.97 0.80 (0.40-1.58) 0.22 0.639 
GT TT 4bb 40 18.02 26 10.66 0.54 (0.32-0.92) 4.595 0.032 
GG CC 4aa 7 3.15 8 3.28 1.04 (0.37-2.92) 0.035 0.852 
GG CC 4ab 3 1.35 1 0.41 0.30 (0.03-2.91) 0.357 0.55 
GG TC 4ab 33 14.86 50 20.49 1.48 (0.91-2.39) 2.144 0.14 
GG TC 4bb 8 3.60 7 2.87 0.79 (0.28-2.22) 0.035 0.852 
GG TT 4ab 6 2.70 12 4.92 1.86 (0.69-5.05) 0.998 0.318 
GG TT 4bb 62 27.93 94 38.52 1.62 (1.09-2.39) 5.395 0.02 
Total     222 100 244 100       
Further OR calculations were undertaken, looking at combinations of carrying alleles of each 
variant (Table 112). Carrying the T allele of Glu298Asp variant or carrying the C allele of the T-
786C variant was found to be significantly protective against T2DM (OR=0.46 (CI: 0.32-0.68), 
p<0.001). 
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Table 112-eNOS genotype combination Odds Ratio (OR) calculations for T2DM risk 
Model OR (95%CI) χ2 p 
Carrying the T allele of Glu298Asp variant 
or carrying the C allele of the T-786C 
variant 
0.46 (0.32-0.68) 14.866 <0.001 
Homozygote for the T allele of the 
Glu298Asp variant and homozygote for the 
C allele of the T-786C variant 
5.57 (0.67-46.55) 1.957 0.162 
Carrying the T allele of Glu298Asp variant 
or being homozygote of the C alleleT-786C 
variant 
1.12 (0.45-2.75) 0.00 0.99 
TT genotype for the Glu298Asp variant and 
carrying the C allele of the T-786C variant 
0.73 (0.30-1.81) 0.198 0.656 
5.3.4.1 Linkage Disequilibrium Analysis 
Linkage disequilibrium analysis was run to determine any possible linkage disequilibrium between 
the three eNOS variants (Table 113). The largest linkage disequilibrium was found to be between 
the Intron 4 variant and the T-786C variant D’= 0.847. The strongest correlation (r statistic) was 
also found to be between the Intron 4 variant and the T-786C variant r=0.696.  
Table 113- Linkage disequilibrium analysis between Glu298Asp, T-786C and Intron 4 variants in the 
T2DM sample.  D’ statistic above the diagonal, r statistics below the diagonal 
 D' statistic 
Glu298Asp T-786C Intron 4 r statistic  
Glu298Asp . 0.1999 0.7553 
T-786C 0.1665 . 0.8473 
Intron 4 -0.1947 0.6963 . 
All values were significant p<0.001  
5.3.4.2 Haplotype Analysis 
Haplotype frequencies were estimated using the online programme SNPStats (Table 114). The 
most common haplotype was the G, T and 4b alleles of the Glu298Asp, T-786C and Intron 4 
variants respectively.  This was estimated to have a frequency of 0.575, with this as the reference 
haplotype ORs were calculated for each possible haplotype.  Haplotype 3 (T,T,4b) was found to be 
significantly protective for T2DM (OR=0.41(CI: 0.26-0.65), p=<0.001). None of the other 
haplotypes were found to be significantly associated with T2DM (Table 114). 
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Table 114- eNOS Glu298Asp, T-786C and Intron 4 haplotype estimations and T2DM Odds Ratio (OR) 
analysis 
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Total OR  (95%CI) 
P 
value 
1 G T 4b 0.5226 0.620 0.575 1 --- 
2 G C 4a 0.1694 0.163 0.165 0.89 (0.60 - 1.30) 0.53 
3 T T 4b 0.183 0.082 0.128 0.41 (0.26 - 0.65) <0.001 
4 T C 4b 0.0555 0.071 0.064 0.98 (0.57 - 1.67) 0.93 
5 G C 4b 0.0362 0.025 0.030 0.62 (0.27 - 1.40) 0.25 
6 G T 4a 0.0151 0.03 0.023 1.44 (0.53 - 3.96) 0.48 
7 T C 4a 0.0182 0.010 0.015 0.29 (0.04 - 1.91) 0.2 
5.3.4.3 The ACE Variant 
The ACE variant was found to be in agreement with HWE confirmed by three independent tests in 
the T2DM control sample.The ACE variant was found to be significantly associated with T2DM 
under all models (Table 115).  
Table 115- ACE deletion allele and genotype frequencies in the T2DM patient and control groups and 
Odds Ratios (OR) for T2DM association 
ACE Patients  Controls 
II 20 (6.8%) 47 (16.0%) 
ID 158 (53.7%) 145 (49.5%) 
DD 116 (39.5%) 101 (34.5%) 
Total 294 (100%) 293 (100%) 
I allele  0.34 0.41 
D allele 0.66 0.59 
ACE T2DM association OR 95% CI χ2 P 
D vs. I 1.357 1.07-1.720 6.35 0.012 
ID vs. II 2.561 1.449-4.527 10.92 <0.001 
DD vs. II+ID 2.699 1.500-4.856 11.43 <0.001 
DD +ID vs. II 2.617 1.509-4.541 12.39 <0.001 
Armitage's trend test 1.515  7.09 0.008 
Further analysis was carried to evaluate if there was an interaction of ACE with eNOS loci. The 
ACE genotypes showed no significant association/interaction with any of the eNOS variants 
(Appendix 7, section 8.8). 
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5.3.4.4 Logistic Regression of all Genetic Loci Analysed 
Logistic regression was performed to calculate the effect on T2DM status of all three eNOS gene 
variants and the ACE gene variant when adjusting for each of the genetic variants and other 
covariates. This was run firstly including just the genetic variants Glu298Asp, T-786C, Intron 4 
and ACE (Model 1). Then extended to include, gender, age, family history, diet, alcohol intake, 
physical activity, obesity, and hypertension (Model 2). Finally this was further extended to include 
lipid parameters (Model 3). 
The data presented below is following a dominant model with the reference as the homozygote 
wild type of the variants (GG, TT, 4bb, II for Glu298Asp, T-786C, Intron 4 and ACE respectively). 
Table 116 presents the results of the logistic regression including only the genetic variants (Model 
1) this Model was a significant predictor of T2DM disease status, (χ2=16.867, p=0.02). The 
Hosmer and Lemershow test confirmed these covariates to be significant (p=0.842) and this Model 
successfully predicted T2DM status in 63.30% of the sample. The Glu298Asp variant was shown 
to be a significant independent variable following adjustment for the other genetic variants 
(OR=0.503 (CI: 0.311-0.813), p=0.005). ACE was also shown to be a significant independent 
variable (OR= 2.66 (CI: 1.334-5.325), p=0.005). 
Table 116- Model 1: T2DM logisitic regression using the covariates Glu298Asp, T-786C, Intron 4 and 
ACE genetic variants only (dominant effect) 
Variable B S.E. Wald p OR 
95% CI 
Lower Upper 
Glu298Asp -.687 .245 7.851 .005 .503 .311 .813 
T-786C .334 .307 1.184 .277 1.396 .765 2.546 
Intron 4 -.336 .314 1.141 .285 .715 .386 1.324 
ACE .980 .353 7.713 .005 2.666 1.334 5.325 
Constant -.207 .353 .342 .559 .813     
Table 117 shows Model 2, (including key risk factors such as family history and gender) 
successfully predicted 73.90% of all T2DM disease status (χ2=94.132, p<0.001), the Hosmer and 
Lemershow test confirmed the Model to be significant (p=0.281). The Glu298Asp variant 
remained a significant independent protective factor (OR=0.455 (CI: 0.264-0.786), p=0.005). 
However, the ACE variant was no longer a significant risk factor (OR=2.03 (CI: 0.935-4.406), 
p=0.073). The Glu298Asp variant and hypertension were the only independent risk factors under 
this model. 
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Table 117- Model 2:  logistic regression analysis for T2DM risk adjusting for the Glu298Asp, T-786C, 
Intron 4 and ACE genetic variants (dominant effect) alongside gender, age, family history, diet, alcohol 
intake, physical activity, obesityand hypertension(Ht) 
Variable B S.E. Wald p OR 
95% CI 
Lower Upper 
Glu298Asp -.787 .279 7.972 .005 .455 .264 .786 
T-786C .501 .352 2.029 .154 1.651 .828 3.292 
Intron 4 -.510 .364 1.965 .161 .600 .294 1.225 
ACE .708 .395 3.208 .073 2.030 .935 4.406 
Gender .197 .273 .521 .471 1.217 .713 2.077 
Age -.004 .011 .148 .701 .996 .973 1.018 
Family History 1.600 .279 32.967 <0.001 4.952 2.868 8.549 
Diet -.029 .256 .013 .908 .971 .588 1.603 
Alcohol intake -.052 .476 .012 .913 .950 .374 2.412 
Physical Activity .417 .292 2.039 .153 1.517 .856 2.690 
Obesity .068 .269 .065 .799 1.071 .632 1.813 
Ht 1.396 .270 26.783 <0.001 4.038 2.380 6.851 
Constant -1.883 .821 5.264 .022 .152     
Table 118 presents the results from Model 3 (extended to include lipid parameters). Model 3 was 
found to be the best predictor of T2DM status successfully predicting 73.10% of all subjects 
correctly, this was significant (χ2 =112.128, p<0.001). However, the Hosmer and Lemershow did 
not support this Model to be significant. The Glu298Asp variant, family history, Ht and HDL 
cholesterol were all significant covariates when adjusting for these covariates. 
Table 118-Model 3: T2DM risk adjusting for the Glu298Asp, T-786C, Intron 4 and ACE genetic variants 
(dominant effect) alongside gender, age, family history, diet, alcohol intake, physical activity, obesity, 
hypertension (Ht) and lipid parameters 
Variable B S.E. Wald p OR 
95% CI 
Lower Upper 
Glu298Asp -.898 .289 9.682 0.002 .407 .231 .717 
T-786C .707 .369 3.674 0.055 2.027 .984 4.175 
Intron 4 -.636 .377 2.847 0.092 .529 .253 1.108 
ACE .572 .410 1.947 0.163 1.771 .793 3.955 
Gender .023 .292 .006 0.937 1.023 .577 1.814 
Age -.007 .012 .322 0.570 .993 .971 1.017 
Family History 1.700 .291 34.058 <0.001 5.475 3.093 9.691 
Diet -.076 .264 .082 0.775 .927 .553 1.555 
Alcohol intake -.191 .491 .152 0.697 .826 .315 2.163 
Physical Activity .455 .303 2.262 0.133 1.577 .871 2.854 
Obesity -.145 .284 .261 0.609 .865 .496 1.509 
Ht 1.537 .286 28.929 <0.001 4.650 2.656 8.141 
TC -.005 .007 .566 0.452 .995 .982 1.008 
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Variable B S.E. Wald p OR 
95% CI 
Lower Upper 
Gly -.021 .017 1.468 0.226 .980 .947 1.013 
HDL -.034 .013 7.455 0.006 .966 .943 .990 
LDL .006 .007 .775 0.379 1.006 .992 1.020 
VLDL .119 .086 1.927 0.165 1.126 .952 1.332 
Constant -.428 1.081 .157 0.692 .652     
Table 119- Key findings for T2DM logistic logistic regression analysis including the Glu298Asp, T-786C,  
Intron 4 and ACE deletion variants (dominant model) adjusting for gender, age, family history, diet, 
alcohol intake, physical activity, obesity, hypertension (Ht) and lipid parameters 
 model 1 model 2 model 3 
Dominant    
Goodness of fit chi square 16.867 94.132 112.128 
significance 0.02 <0.001 <0.001 
Hosmer and Lemershow 0.842 0.281 0.002 
Percentage correctly predicted 63.30% 73.90% 73.10% 
Glu298Asp 0.503 (0.311-0.813) 0.455 (0.264-0.786) 0.408 (0.231-0.717) 
T-786C 1.396 (0.765-2.546) 1.651 (0.828-3.292) 2.027 (0.984-4.175) 
Intron 4 0.715 (0.386-1.324) 0.600 (0.294-1.225) 0.529 (0.253-1.108) 
ACE 2.666 (1.334-5.325) 2.030 (0.935-4.406) 1.771 (0.793-3.955) 
Recessive model 1 model 2 model 3 
Goodness of fit chi square 4.409 87.421 112.128 
significance 0.354 <0.001 <0.001 
Hosmer and Lemershow 0.434 0.4 0.002 
Percentage correctly predicted 60.90% 70.40% 73.10% 
Glu298Asp 0.944 (0.272-3.276) 0.986 (0.256-3.797) 0.967 (0.239-3.903) 
T-786C 1.268 (0.461-3.487) 1.106 (0.374-3.277) 0.976 (0.313-3.039) 
Intron 4 2.383 (0.401-14.168) 5.490 (0.738-40.860) 7.933 (0.923-68.210) 
ACE 1.363 (0.881-2.110) 1.226 (0.746-2.016) 1.247 (0.747-2.081) 
In this eNOS T2DM analysis for each locus 12 chi squares were carried out in the categorical data 
set, 5 in gene association analysis and 8 in sub group analysis, altogether 25 chi-square related p 
values were calculated. The nominal p value (0.05) is divided by the number of comparisons. The 
bonferroni correction was applied and the nominal p value (0.05) was divided by the number of 
comparisons, in this case this was 0.05/25 = 0.002. Therefore the corrected p value should be 
considered when making inferences about the associations. 
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5.4 Discussion 
This study analysed the frequency of the Glu298Asp, T-786C and Intron 4 27bp repeat 
polymorphisms in 321 T2DM patients and 309 matched controls within a Northern Indian 
population. T2DM is a multifactorial disease affected by both genes and the environment, 
identification of its genetic elements will enhance the understanding of the disease and its 
progression, it will also enable the identification of high risk individuals. The eNOS gene has been 
examined through a number of different studies due to a possible association with T2DM (Monti et 
al. 2003, Ezzidi et al. 2008, Franks et al. 2005). T2DM association of the eNOS variants has been 
based on the putative mechanism that the variants influence the levels of NO (Hayden & Tyagi 
2003).   
5.4.1 Glu298Asp T2DM Association 
The results of this study have rejected the null hypothesis and confirmed this variant to be 
significantly associated with T2DM. This suggests that within this population this variant may 
affect an individual’s risk of T2DM.  
The control group of the current study was found to be representative of the populational region 
and were in HWE evaluated by three independent methods. The GT and GG genotypes showed 
consistency with other frequencies found, finding very similar values to those found within studies 
of a Caucasian ethnicity. The homozygotes for the TT mutant genotype was at a frequency of 
4.45% in the control group this was towards the lower end of the range found in previous studies 
(0.95-14.05%) (appendix 8, section 8.8). There are no published studies on T2DM controls among 
South Asians, so direct comparisons were not possible. However, a small number of studies on Ht 
controls were available for comparison and the reported frequency of the TT mutant genotype was 
found to be at a range of 0.72-2.5% (Srivastava et al. 2008, Periaswamy et al. 2008, Khawaja et al. 
2007, Srivastava et al. 2005). These are all very low frequencies, particularly when comparing to 
the Caucasian population groups where frequencies were found to be around 10% for this variant 
(appendix 7, section 8.8).  The 4.45% found in the current study is slightly higher than the previous 
found frequencies in South Asians, yet this value remains more consistent with South Asian 
controls than the Caucasian controls. 
 The T2DM patients were also found to be in accordance to HWE (Table 80). The TT genotype 
showed a lower frequency than the control group at 3.8%, this was also comparable to previously 
published findings falling within the range of frequencies found 1-27.7% (appendix 8, section 8.8).  
As control frequencies are comparable and representative of the South Asian populations one can 
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be confident that conclusions drawn would be reasonably applicable to a larger South Asian 
population group, although this should be confirmed with further studies within this region.   
The Glu298Asp variant was tested under multiple models (including recessive and dominant) to 
investigate a possible influence on T2DM disease status (Table 81 and Table 82) A protective 
association of the Glu298Asp variant with T2DM was identified and was most prominent when 
considering heterozygotes; the heterozygote model (GT vs. GG) found a significantly protective 
OR value of 0.488 (p<0.05). A dominant model (TT+GT vs. GG) also revealed a significant 
protective OR value of 0.51 (CI: 0.35-0.73), p<0.001. This result is in contrast to a number of 
studies who had identified the mutant asp allele to be associated with an increased risk. Monti et al. 
(2003) under the hypothesised T ‘risk’ allele found OR values for the mutant asp allele of up to 
2.66 in a recessive model. Ezzidi et al. (2008) also found similar findings supporting the same 
increased disease risk associated with the mutant T allele (Monti et al. 2003, Ezzidi et al. 2008).   
Although this study contradicts these studies, it is not isolated in these findings of a protective 
effect; Odeberg et al. (2008) found similar effects in both men and women, finding a 
‘protectiveness’ associated with the T mutant allele (or conversely this could be considered a risk 
associated with the G allele).  The study undertaken by Odeberg et al. (2008) was in a Caucasian 
population group, more specifically Swedish and although it showed a similar pattern seen in the 
current study, unlike the current it failed to reach statistical significance. It was highlighted in the 
literature review as being a good study due to its large sample sizes (403 patients and 799 controls) 
(Odeberg et al. 2008). The significant effects seen in opposing directions for T2DM have been 
mirrored in other disease groups, for example Khawaja et al. (2007) found the TT genotype to be 
protective against hypertension (Khawaja et al. 2007). Logistic regression analysis confirmed the 
protective role of this locus OR=0.574 (CI: 0.355-0.927) to remain after adjustments for diet, sex, 
alcohol intake, physical activity, obesity, age, hypertension, family history and lipid parameters. 
The large sample size in Odeberg et al. (2008), and the protective findings in other disease and 
population groups collectively provide evidence against the asp variant as a significant T2DM risk 
factor, within this population, and support a possible protective role. The protective findings also 
remained present following subgroup analysis; the OR in both genders under a dominant model 
(TT+GT vs. GG) were shown to have half the risk of T2DM, with the OR value remaining very 
close to 0.5, and was significant in both groups (p<0.05). This provides further evidence for the 
protective effect identified in the basic and adjusted whole sample calculations. 
Genotypic influences were significant between genotypes GG (n= 324) and GT (n =165) for 
glucose and VLDL levels. In both cases individuals of the GG genotype had higher levels of these 
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parameters. The differences in glucose are a causal and determinant variable in T2DM clinical 
status. This supports the association found of the homozygote wild type GG genotype with an 
increased disease risk. As expected no other significant differences were found between any of the 
genotypes and any of the remaining lipid parameters and other continuous variables.  
Diabetic associated conditions and complications such as retinopathy, nephropathy and CHD have 
been shown to be associated with this variant in some studies (Ezzidi et al. 2008, Ahluwalia et al. 
2008).  The current findings showed in all cases a ‘protective’ effect for the asp variant, which was 
statistically significant under a recessive model for retinopathy (OR = 0.12 (CI: 0.01-0.93), 
p=0.036). The effect of the asp mutant allele (as with T2DM disease status) is for the most part not 
in keeping with the previous studies found. For example, Ezzidi et al. (2008) reported a 
significantly higher frequency of TT mutant genotype in 515 patients with nephropathy than the 
402 nephropathy free patients. Li et al. (2002) also found a significantly higher frequency of the T 
mutant allele and TG genotype in those with nephropathy than without in a Chinese population; 
this was shown to be an independent risk factor following adjustment by logistic regression. Whilst 
Ahluwalia et al. (2008) found an OR of 1.8 (CI: 1.03-3.16), p=0.03 in Asian Indians (Ahluwalia et 
al. 2008). Diabetic retinopathy is a major cause of blindness among adults, so confirming this 
protective effect is a possible area for future research.  
These findings provide evidence against the Glu298Asp variant as a risk factor for T2DM among 
this population, further to this the current findings suggest a protective association for the asp 
mutant variant under a dominant effect, which remained present following adjustment for 
conventional risk factors and in sub group analysis. The number of previous studies investigating 
the eNOS Glu298Asp polymorphism is limited to a few and as stated this is not the first study in 
this disease group or others to find association in this direction and in both cases the sample size 
was large. In contrast to CAD and Ht the literature review revealed there was not a majority of 
studies in either direction, and this variant remains understudied, despite the previous associations.   
The mechanism of this variant and this novel finding remains unclear, with the majority of 
functional evidence supporting reduced NO synthesis associated with this variant. Studies have 
shown T2DM to be characterised by endothelial dysfunction (Rask-Madsen & King 2007, 
McVeigh et al. 1992, De Vriese et al. 2000). Endothelium dependent relaxations have been shown 
to be significantly impaired demonstrated in both human and animal studies (Calver et al. 1992, 
Durante et al. 1988, Pieper & Gross 1988, Meraji et al. 1987, Abiru et al. 1990, Mayhan 1989, 
Oyama et al. 1986, Pieper et al. 1997).  Whilst eNOS knockout mice have been shown to become 
insulin resistant (Shankar et al. 2000). 
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The endothelium dysfunction that is characteristic of diabetes has been attributed to an increased 
generation of reactive oxygen species (ROS). ROS renders NO unavailable and enhances eNOS 
uncoupling. When eNOS becomes uncoupled it alters its role from NO generating to ROS 
generating (Bitar et al. 2005, Sobrevia & Mann 1997, Bevers et al. 2006, Muller & Morawietz 
2009). Variations in mRNA and protein levels have been associated with this variant (Wang et al. 
2000, Senthil et al. 2005, Dosenko et al. 2006). One possibility is that the variant may influence 
this process, further research is required to clarify this possibility.    
Deciphering the true effect of this variant is difficult, with the evident contrasting functional 
implications and the lack of comparable studies. Identifying the true meaningful significance as 
appose to the statistical significance remains difficult. It is plausible that the effect is a result of 
linkage disequilibrium or interaction with another functional variant which plays a role in the 
aetiology of T2DM. Consequently these findings do not provide evidence for a lack of functional 
relevance of the Glu298Asp variant, but do support it not to be a risk factor with respect to T2DM.  
Particularly with the sample showing a larger frequency of the TT and TG genotypes further 
sampling among this population is required to confirm the significant effect of this variant and to 
eliminate the possibility the small frequency found in the patients was not a result of random 
chance. Retrospective power analysis of the diabetes sample indicated that it was adequately 
powered (82%) to detect an OR of 1.51 or above with allele frequencies observed in this 
population. The results identified in the Glu298Asp variant also remained significant when 
considering the bonferroni correction. 
5.4.2 T-786C T2DM Association 
The second variant of the eNOS gene analysed in this study was the T-786C variant. This study has 
accepted the null hypothesis and confirmed this variant not to be significantly associated with 
T2DM. This suggests that within this population group this variant does not affect an individual’s 
risk of T2DM.  
The T2DM control group of the current study were found to be in accordance with HWE. 
Comparison of the T-786C genotype distribution beyond this was difficult due to a limited number 
of comparable studies. The frequency for the homozygotes for the C mutant allele in the current 
study was found to be 8.19%. This was slightly higher than the 1.72% and 4.9% found by Ohtoshi 
et al. (2002) and Ezzidi et al. (2008) respectively. The 8.19% found in the current study was 
almost identical to the 8.84% found in the T2DM patients. This consistency not only suggests there 
to be no influence on disease status but also suggests it is likely to be representative of populations 
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of North India. The T2DM patients CC genotype frequency was higher than that found by Ohstoshi 
et al. (2002) who found 1%, in their Japanese patient population, but was more comparable to 
Ezzidi et al. (2008) who found a frequency of 7.29% (Ezzidi et al. 2008, Ohtoshi et al. 2002).  
The evidence in the literature has suggested the C allele of the T-786C variant to be associated 
with reduced NO production and an increased susceptibility to diseases including CAD and more 
recently hypertension (Colombo et al. 2003a, Han et al. 2010). In this study no effect was observed 
for this variant, ORs were remarkably similar under both the hypothesised C and T ‘risk’ alleles, 
with the C vs. T allele showing close proximity to 1 (OR=1.013 (CI: 0.783-1.309)) clearly 
indicating no effect on disease status. There was only one study found looking directly at this 
variant and T2DM association this was undertaken by Ohtoshi et al. (2002), the results found in the 
current study are comparable to this study which  also found OR values close to 1 (Ohtoshi et al. 
2002). Collectively this supports there to be no effect of this variant on T2DM disease status.  
To ensure the effect of the variant was not being masked by other significant differences between 
the patient and control groups, the continuous variables were assessed for differences by using an 
independent samples t test (Table 89) and a contingency chi-square test was used to test for 
possible differences between non-continuous variables (Table 90). This analysis revealed 
significant differences between age, gender and family history. Due to the presence of the 
differences between patients and controls it was important to recalculate ORs adjusted for these 
risk factors. Logistic regression analysis confirmed that T-786C variant has minimal effect on 
disease susceptibility in this population under both dominant and recessive models.   
The three different T-786C genotypes were also further analysed for any influence on any of the 
continuous variables. The CC genotype group were found to have a significantly older mean age 
than the TT individuals. A difference in age groups could potentially mask results, with age being 
an established risk factor for T2DM. The current study has adjusted for age within the logistic 
regression, however differences in age can cause major problems for younger individuals going on 
to develop the disease, something that is often not investigated. This is less likely to be an issue in 
this direction with the CC group being older. 
All other statistical analysis including patient only disease association and interaction with the 
ACE variant revealed no significant effects of the T-786C variant within this North Indian 
population.  
The lack of association found in this study for basic ORs, when adjusted and following subgroup 
analysis suggests this variant does not have a role as a risk factor for diabetes in this population. 
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This conclusion is supported by a number of studies that have failed to find any influence of this T-
786C variant when looking at functional consequences. This includes a study by Sim et al. (1998) 
who investigated plasma nitrate and nitrite levels as an indirect measure of NO levels, this study 
looked at healthy subjects only; The TT, TC and CC were 35.9+/-3.1umol/L, 40+/-2.9umol/L and 
37.7+/-6.3umol/L respectively showing no significant differences between genotypes (Sim et al. 
1998). Jeeroburkhan et al. (2001) and Rossi et al. (2006) undertook similar studies also 
investigating the relationship between this variant and nitrate/nitrite levels, these studies also failed 
to find a functional effect (Jeerooburkhan et al. 2001, Rossi et al. 2006).  Dell’Omo et al. (2007) 
used the technique of the forearm blood flow vasodilation as a reflection on NO activity and found 
responses to acetylcholine to exhibit no differences between T-786C genotypes (Dell'Omo et al. 
2007). Overall this information suggests the T-786C variant does not affect an individual’s risk of 
T2DM in this north Indian population group. 
5.4.3 Intron 4 T2DM Association 
The third and final eNOS variant analysed in the current study was the Intron 4 variant, a 27bp 
VNTR variant in Intron 4 of the eNOS gene. This study has accepted the null hypothesis and 
confirmed this variant is not significantly associated with T2DM. This suggests that within this 
population group this variant does not act as a major risk factor for T2DM. 
There were only two studies found that investigated the Intron 4 variant among T2DM controls, 
details of these can be found in appendix 8, section 8.8 and there were no studies identified within 
a South Asian population group. The percentage of homozygotes for the 4a allele (genotype 4aa) 
within the T2DM controls in the current study is 4.07% this is in keeping with previously reported 
findings falling within the range of frequencies found (0.25-14.25%). The 4ab genotype showed 
less consistency with the other two studies finding a higher frequency of individuals 29% 
compared to 14% (appendix 8, section 8.8). However, with no studies in a South Asian population 
group it cannot be concluded whether this is a population specific effect. The control group were 
found to be in accordance with HWE evaluated by three independent methods and had a low 
inbreeding coefficient of 0.038 supporting this sample to be representative of a North Indian 
population. 
Equally, the T2DM patients were in accordance with HWE (Table 102) and in keeping with 
previously reported findings. Homozygotes for the mutant 4a allele were found to be at a frequency 
of 3.60%, falling within the range of frequencies found (1.2-10.8%) (appendix 7, section 8.8). 
There was one comparable study in Asian Indians undertaken by Ahluwalia et al. (2008). Their 
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group found a higher frequency of this variant than the current study and was the highest reported 
frequency of the 4aa genotype at 10.8% (Ahluwalia et al. 2008).   
The Intron 4 variant was tested under both recessive and dominant models to investigate a possible 
influence on T2DM disease status. The evidence in the literature has suggested the 4a allele of the 
Intron 4 variant may be associated with changes in NO production and an increased susceptibility 
to disease including CAD and more recently hypertension (Colomba et al. 2008, Matyar et al. 
2005). It was apparent when considering all models there is no effect of this variant on disease 
status. ORs were remarkably similar under both the 4a hypothesised ‘risk’ allele and the 4b ‘risk’ 
allele. With the 4a vs. 4b allele showing close proximity to 1 (OR=1.048 (CI: 0.775-1.417)) 
indicating no effect. This was in keeping with Lee et al. (2003) who also failed to find a significant 
effect of the variant with disease status,  this was a strong study (800 patients and 398 controls) 
(Lee et al. 2003). Although no significant results were found this study under a recessive model did 
find an OR of 7.07 which was just outside statistical significance. Statistical significance for an OR 
at this level is challenging and consequently this study does not provide strong evidence supporting 
the lack of disease risk.  These current findings are contradictory of those reported by Ksiazek et 
al. (2003) who found the 4a allele to be associated with T2DM with an OR of 2.24 (CI: 1.12-3.40), 
and a very recent study (2011) where twice the risk of T2DM was found under a dominant model 
(Ksiazek et al. 2003, Mehrab-Mohseni et al. 2011). Consequently the lack of association in this 
study although partially supported by Lee et al. (2003) may not be conclusive.  
The patient group were found to be significantly different in a number of variables including age 
and gender. The strongest difference was seen in terms of family history, with 84.3% of patients 
having a positive family history compared to 50.5% of controls (p<0.001), this supports the 
heritability of the disease. Due to the presence of these differences between patients and controls it 
was important to recalculate ORs adjusting for these risk factors. Logistic regression analysis 
confirmed the Intron 4 variant to have a minimal effect on disease status under a dominant model. 
However, the recessive model showed a large increase in the OR values increasing to 4.729 (CI: 
0.918-24.366) in Model 3, but was outside statistical significance. These findings are more 
comparable to those studies discussed previously finding an association, but may be attributable to 
the small frequency of the variant (Ksiazek et al. 2003, Mehrab-Mohseni et al. 2011). 
The lack of association found in this study for basic ORs, when adjusted and following subgroup 
analysis suggests this variant does not act as a major risk factor for T2DM among this population. 
This is supported by a number of studies that failed to find significant associations with 
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endothelium dependent relaxations or with plasma NOx levels (Dell'Omo et al. 2007, Yoon et al. 
2000, Jeerooburkhan et al. 2001, Salimi et al. 2008).  
Although the functional consequence of the variant has not been supported in these said studies, 
other studies disagree with these and have found the eNOS Intron 4 polymorphism to be associated 
with a reduction in NO synthesis among individuals prone to T2DM (Rittig et al. 2008). 
Collectively the evidence suggests the Intron 4 variant does not act as a major risk factor for 
T2DM,  however it cannot be ruled out that the Intron 4 variant may influence NO synthesis with 
logistic regression revealing an effect just outside statistical significance. It is however, unlikely to 
strongly influence T2DM status in a North Indian population. The lack of comparable studies 
investigating the role of the Intron 4 variant means this would need to be verified by further studies 
within this population and others. 
5.4.4 eNOS gene T2DM Association 
5.4.4.1 Synergistic effect of eNOS Gene Variants 
A number of previous studies have shown no association of the individual eNOS variants, however 
following combined analysis synergistic or haplotypic effects have been identified. Consequently 
the three eNOS variants were also analysed collectively, the genotype combinations at the three 
eNOS loci were assessed for a possible synergistic effect to identify a possible high ‘risk’ or 
equally a possible ‘protective’ composite genotype. Table 111 demonstrated that the frequency of 
each combination was not uniform, which was expected considering the different frequencies of 
the 3 different genotypes at each loci. The analysis revealed the combination of TT, TT and 4bb of 
Glu298Asp, T-786C and Intron 4 respectively was shown to be significantly protective against 
T2DM with an OR value of 0.20 (CI: 0.04-0.92), p=0.046. Similar effects were seen for the 
combination GT, TC and 4ab and GT, TT and 4bb (OR<1 p<0.05). Conversely the GG, TT and 
4bb combination was found to be at a significantly increased risk of the disease, OR 1.62 (CI: 1.09-
2.39) p=0.02.  These effects are likely to be due to the effect found individually for the Glu298Asp 
variant as the TT genotype was incorporated in all the protective combinations whilst the GG 
genotype was present in the combination resulting in a significantly increased risk. This was 
confirmed by the finding that carrying the T allele of the Glu298Asp variant or carrying the C 
allele of the T-786C variant had an OR of 0.46 (0.32-0.68), p<0.001. These results suggest that 
there may be an additive effect. A synergistic effect has been investigated previously but in only a 
small number of studies, these are limited often to only two variants, and were absent among 
T2DM.   
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5.4.4.2 Linkage Disequilibrium  
Linkage disequilibrium analysis was run to determine any possible linkage disequilibrium between 
the three eNOS variants. The largest linkage disequilibrium was found to be between the Intron 4 
variant and the T-786C variants.  This is consistent with Tanus-santos et al. (2001) who identified 
the same linkage disequilibrium between these two eNOS variants among Asians (Tanus-Santos et 
al. 2001). In contrast, Ahluwalia et al. (2008) failed to find any linkage disequilibrium between 
any of the three eNOS variants included in the current research (Ahluwalia et al. 2008). There is 
apparent ethnic differences, identifying these may aid the understanding of disease contribution 
(Tanus-Santos et al. 2001). 
5.4.4.3 Haplotype Analysis 
Haplotype frequencies were estimated using the online programme SNPStats. With the G-T-4b 
haplotype as the reference group haplotype 3 (T-T-4b) was found to be significantly protective for 
T2DM (OR=0.41 (CI: 0.26-0.65), p<0.001). None of the other haplotypes were found to be 
significantly associated with T2DM.  
There are very few studies that have investigated the effect of all three eNOS variants and 
consequently a haplotypic effect has been vastly understudied. Franks et al. (2005) also 
investigated multiple eNOS variants, however their study used different eNOS variants to the 
current. With 2 representing the mutant alleles their findings showed an overall association relative 
to the most common haplotype 1-1-1 for two haplotypes 1-2-1 and 2-1-2 which were both reported 
to increase the risk of diabetes whilst 1-2-2 reduced diabetes risk (Franks et al. 2005). Although 
this study used different eNOS gene variants to the current study, it does supply evidence 
supporting haplotype disease association as an area for further research. The same three eNOS 
variants were investigated by Ahluwalia et al. (2008) investigating nephropathy risk, their group 
found the wild type allele (G-4b-T) to be associated with a reduced nephropathy risk (OR=0.68, 
p=0.005), whilst the haplotype for the mutant alleles (T-C-4a) was found to increase nephropathy 
risk (OR=2.6, p=0.14) (Ahluwalia et al. 2008). Gonzale et al. (2007) also undertook eNOS 
haplotype analysis investigating metabolic syndrome, they found when including the Glu298Asp 
variant with two other eNOS variants (neither T-786C or Intron 4 variant) there was an increased 
risk of metabolic syndrome with an OR of 1.89 (CI: 1.24-2.88), p=0.002 (Gonzalez-Sanchez et al. 
2007).   
It is difficult to compare the current outcome with no previous studies found investigating the same 
three eNOS variants for T2DM status. Although, the few studies mentioned above suggest a 
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possible eNOS haplotype risk not all have reported significant effects of eNOS haplotypes. For 
example Conen et al. (2008) investigated eNOS haplotypes and T2DM risk using a prospective 
cohort, this study incorporated the Glu298Asp variant of the eNOS gene and two other eNOS 
variants finding no significant relationship between haplotype and T2DM risk (Conen et al. 2008). 
The significantly protective T-T-4b haplotype therefore requires confirmation. 
5.4.5 ACE Variant 
The ACE gene has been implicated in the development of diabetes; ACE inhibitors have been 
shown to reduce the risk of diabetes and insulin resistance (Tikellis et al. 2004, Carlsson et al. 
1998, Malik 2000). The ACE deletion variant has been shown to increase ACE levels; increases in 
angiotensisn II have been shown to cause insulin resistance. In addition both lipoprotein and lipid 
metabolism are thought to be influenced by the ACE gene (Singh et al. 2006).  
This variant was found to be a significant risk factor for T2DM finding under dominant, 
hetrozygote and recessive models OR values >2.5. This finding is not novel and is supportive of 
previous findings in multiple populations including a North Indian sample (Singh et al. 2006, 
Ramachandran et al. 2008). It is comparable to Singh et al. (2006) who found an association with 
T2DM, with the DD mutant genotype and the D mutant allele to have ORs of 1.90 and 1.58 
respectively and has also been shown in meta-analyses (Singh et al. 2006, Niu et al. 2010, Zhou et 
al. 2010). There was also a synergistic effect of this polymorphism found with the APOE gene, this 
was among a North Indian population group and therefore provides evidence for a role of this 
variant within this same population group (Singh et al. 2006).  
The ACE variant was tested for significant differences using a chi-square test for each of the three 
eNOS variants, no differences were evident. However, for the case of the T-786C variant including 
the ACE variant in logistic regression modified the results gained through individual analyses. This 
was unclear if the changes found were due to the presence of the ACE variant, the two alternate 
eNOS variants, or the smaller sample size; further research is required to clarify this effect.  
Although these findings support the ACE deletion variant to be a strong significant risk factor for 
T2DM it did not appear to be interactive with the three eNOS variants incorporated in the current 
study. This is comparable to a study undertaken by Conen et al. (2008) who also investigated the 
link between the eNOS polymorphisms and the ACE gene in a prospective large cohort in 
Caucasian women. Conen et al. (2008) investigated six variants of the eNOS and rennin-
angiotensin genes and failed to find any association with T2DM (Conen et al. 2008). The current 
findings suggest that this variant, although found to be a strong independent risk factor for T2DM, 
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did not interact or influence the effect of the Glu298Asp or Intron 4 eNOS variants. It may have 
influenced the effect of the T-786C variant but this would need to be confirmed by further 
research. 
5.4.5.1 Interaction of Genetic Variants 
Logistic regression analysis was carried out to incorporate all the eNOS variants and the ACE 
variant alongside the conventional risk factors.  The dominant and recessive models both correctly 
predicted 73.10% of T2DM disease status’. The dominant model found the Glu298Asp variant’s 
protective effect remained significant following adjustment, this further confirms the effect of this 
variant.  The T-786C variant had previously found no effect under a dominant model however, this 
variant was found to increase when more covariates were included, this was something that had 
been evident in the individual T-786C logistic regression but the effect seen when including other 
genetic variants was larger and was just outside statistical significance OR=2.027 (CI: 0.984-
4.175), p=0.055. This effect was not seen under a recessive model. The Intron 4 variant was once 
more confirmed to have no significant effects under a dominant or recessive model. Finally the 
ACE variant lost the statistical significance previously found. This analysis including all the eNOS 
variants and the ACE seems to be showing there may be an interactive or missed effect of the T-
786C variant.  
5.4.6 Confirmed Risk Factors 
This study incorporated a number of conventional risk factors. An increased age, male gender and 
family history were all confirmed as non-modifiable risk factors for T2DM. Family history 
strongly supports the heritability of the disease and was found to be the strongest independent risk 
factor incorporated in the study. This remained a significant risk factor after adjustment for other 
classical risk factors following logistic regression.  Lifestyle choices were also shown to influence 
disease progression such as sedentary behaviours, which were shown to increase disease risk by 
more than 2.5 times. Physical activity is therefore a strong candidate modifiable risk factor in this 
population group. Finally complications associated with T2DM including coronary heart disease 
and hypertension were also shown to be significantly associated with the disease; the presence of 
CHD shown to be greater than 3.5 times in T2DM patients.  These findings confirm the risk 
factors, providing a valuable insight into their magnitude within this North Indian population. 
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5.5 Overall Discussion and Conclusions 
This study successfully analysed the frequency of three different genetic variants of the eNOS gene 
in a North Indian population among T2DM patients and ethically matched controls. This was 
undertaken with the aim to greater the understanding of the genetic basis of T2DM. Deciphering 
the genetic basis to T2DM is a challenging task, with the disease shown to have a complex 
aetiology (Jin & Patti 2009). The association of the eNOS gene with T2DM has been less 
researched than other diseases such as CAD and Ht. It has received more attention recently with 
studies such as Mehrab-Mohseni et al. (2011) finding association between the eNOS gene with 
T2DM and it’s complications (Mehrab-Mohseni et al. 2011). Subsequently, further research is 
required in this disease group to clarify the role of this gene in multiple populations. 
With any study design there will be a number of associated limitations, there are also number of 
challenges that exist with respect to T2DM, which include the difficult definition of cases. Glucose 
is a continuous variable and borderline cases could undoubtedly pose a problem. The term ‘pre 
diabetes’ has been coined to describe such cases that fail to reach clinical diabetes reflecting the 
insulin resistance and beta-cell dysfunction known to preceed clinical diabetes (Leahy 2005). ‘Pre-
diabetes’ is defined as impaired fasting glucose and impaired glucose tolerance. The definition of 
clinical diabetes is essentially a cut off point on a continuum and has been described as arbitrary. 
Glucose has a normal distribution and consequently there are no distinguishing differences 
between normal glucose function, pre-diabetes or clinical diabetes (Vistisen et al. 2009). This was 
limited in the current study by delivering a 2-hour oral glucose tolerance test to all controls 
included in the study to rule out impaired glucose tolerance. The complex aetiology of T2DM 
means multiple environmental and genetic factors will interact and collectively contribute to 
disease development. The controls were matched by gender, age, ethnicity and living environments 
to manage this.  
More recently, the role of epigenetic modifications including DNA methylation, histone 
modification and microRNA has become increasingly of interest with respect to T2DM. Among 
diabetes a number of environmental factors have been identified to influence epigenetic changes. 
An increased age has been shown to affect DNA methylation, whilst exercise has been shown to 
induce histone modifications (Ling & Groop 2009). There are a limited number of studies that have 
investigated epigenetic modifications in T2DM patients and consequently the alterations present 
among this condition are not well understood. It has been anticipated that epigenetic drugs may 
play a strong role in the future treatment of diabetes and its related complications (Ling & Groop 
2009). 
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Overall Conclusions 
Retrospective power analysis of the diabetes sample indicated that it was adequately powered 
(82%) to detect an OR of 1.51 or above with allele frequencies observed in this population. A 
number of conclusions can be drawn from these findings. All samples were shown to be consistent 
with previous studies and representative; finding all controls to be in agreement with HWE. 
Overall the eNOS gene was found to influence T2DM risk. The Glu298Asp variant was found to 
be a significant risk factor for T2DM with the findings supporting a protective effect, which 
remained following adjustment for conventional risk factors and other genetic variants. The T-
786C variant showed no overall influence on T2DM risk, with a possible effect when adjusted for 
other genetic variants. The Intron 4 variant also found no statistically significant association with 
T2DM following adjustment or when incorporating other genetic variants. The study revealed a 
significantly protective haplotype T-T-4b. Finally this study confirmed a number of risk factors for 
T2DM with family history shown to be the most pronounced.  
These findings require confirmation among this population group with an apparent lack of 
comparable studies, particularly to confirm the protective effect of the Glu298Asp variant and the 
protective haplotype. 
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6 Chapter 6-Overall Discussion and Conclusions 
The benefits of identifying true genetic susceptibility genes/variants are reflected in the rate at 
which studies are being published. With the eNOS gene’s clear physiological role in disease and 
previously identified disease association, this gene has proven to be a strong candidate gene for a 
multitude of diseases (Hingorani et al. 1999, Tesauro et al. 2000, Casas et al. 2004, Odeberg et al. 
2008, Galanakis et al. 2008, Patkar et al. 2009, Kitsios & Zintzaras 2010). The aim of this study 
was to contribute to the field of medical genomics by evaluating three variants of the eNOS gene 
and one from the ACE gene in three complex diseases in North Indian populations. 
This study has supported previous literature and confirmed a number of different variables to be 
associated with the specific diseases analysed, including male gender and smoking for CAD, age 
for Ht and family history for T2DM. As expected, among the confirmed risk factors family history 
was repeatedly found to be most prominent. A positive family history was highly associated with 
disease risk in these complex diseases, with values of nearly five times the risk of T2DM in the 
presence of affected family members. Family history is a well established risk factor for all three 
complex diseases and the strength of these findings confirms this and supports the genetic 
predisposition among South Asians. 
A case control approach was considered most cost effective and was adopted in the current study, 
with the goal to detect genetic variations/differences among cases and controls. The current study 
can only offer hypotheses for the role of the variants analysed, which requires confirmation in 
additional studies. Deciphering the action of a variant is challenging and there are a number of 
recurring possibilities. When association is present, this may be a reflection of the variant causing a 
functional change altering eNOS activity and NO synthesis. Equally the identified association may 
be indirect, a result of linkage disequilibrium with another functional variant. Finally, the 
association may be a result of confounding variables, bias or chance (Campbell & Rudan 2002). In 
contrast, possible reasons for an absence of an association may be a small effect size requiring a 
greater sample size to reach statistical significance. The true effects of the variant may be masked 
by, or present only in combination with other gene variants/risk factors. Finally, the absence of a 
significant effect could be due to the variant exhibiting no functional consequence. 
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The effect of a variant is likely to be populational specific. In addition, there will be differences 
within a single populational group, for example religious and social practices, that are known to 
influence lifestyle choices risk factors such as smoking and diet. Identifying the true nature of the 
eNOS gene variants is further complicated by the multitude of factors affecting gene expression 
and NO synthesis.  
The current study has evaluated the role of each variant in three complex diseases, these findings 
will contribute to the understanding of the disease physiology and provide evidence, which in 
addition with further research will greatly aid the identifications of high risk individuals and target 
them for lifestyle and pharmaceutical modifications. The main findings for each variant will be 
discussed in the following section. 
6.1.1 The Glu298Asp Variant 
The Glu298Asp was the most extensively studied of the three eNOS gene variants incorporated in 
the current study. The literature review revealed this variant to show inconclusive findings; the T 
mutant allele has been found to be a risk factor for, and protective against a number of different 
diseases. 
The current findings identified the Glu298Asp variant to be a significant risk factor for CAD in a 
smoking dependent manner. These findings implicated a functional effect. In brief, the increased 
risk of the Glu298Asp variant amongst smokers is likely to be due to a functional effect of this 
variant in reducing NO bioavailability combined with the dual role of smoking in further reducing 
NO availability and enhancing the atherosclerosis process independently.  
However, the effect of this variant in Ht patients revealed there to be no effect. The lack of 
association in the Ht group may be a result of the increased CAD susceptibility not being a solely a 
result of NO’s role as a endothelial dependent vasodilator, but a combined effect of the multiple 
attributable effects NO plays on atherosclerosis pathophysiology (Bath et al. 1991, Kubes et al. 
1991, Radomski et al. 1991, Sarkar et al. 1996, Scott-Burden & Vanhoutte 1993, Hogg et al. 1993, 
Rubbo et al. 2002). This is plausible considering the role of the variant in CAD failed to reach 
statistical significance independently and only when combined with smoking did this effect 
become significant. As the Ht study is based on a Sikh population who normally do not profess to 
smoking due to their religion, it was not possible to investigate an additive interactive effect of this 
variant with smoking in Ht. This provides an area of investigation for future research before ruling 
out a direct functional role of the variant.   
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The Glu298Asp variant was found to be associated with T2DM, this is a novel finding with the T 
mutant allele being found to be protective against disease development and particularly against 
diabetic retinopathy. The rationale for this is unclear and may be a result of the variant being in 
linkage disequilibrium with another functional variant which has a physiological role in T2DM, it 
may influence the ROS generation evident to occur under T2DM conditions, or alternatively it 
could be a result of chance alone.   
The strong role of the Glu298Asp variant in disease was evident from the current study, further 
research is required to clarify the true effects of the variant, particularly investigating the 
interaction with smoking and to clarify the novel protective finding in T2DM and its related 
conditions.  
6.1.2 The T-786C Variant 
Of the three eNOS variants analysed in the current study the literature review revealed this variant 
to have been the least well studied. The reduced number of studies may be a result of a smaller 
magnitude of the association found, in combination with a lack of association in many studies. 
Interestingly, unlike the Glu298Asp and Intron 4 variants when association is found it appears to 
be restricted to one direction only, with the rare C allele causing an increased risk to disease. These 
findings from the literature review have been mirrored in the current study finding no overall effect 
for CAD or T2DM with ORs very close to 1 indicating a neutral effect. The Ht analysis revealed 
there was an increased OR, albeit non significant. The Ht sample was the smallest of all three and 
this could have contributed to non-significant results. This effect was lost when adjustment for 
classical risk factors and other variants were made. This variant is situated in the promoter region 
of the gene, so may have a limited effect on the disease (Jeerooburkhan et al. 2001, Rossi et al. 
2003). Therefore the association seen in previous studies may not be directly a result of this 
variant, and a result of alternate risk factors. Alternatively the previous association could be a 
result of linkage disequilibrium with an alternate functional variant. The current study found this 
variant to be in linkage disequilibrium with the Intron 4 variant of the eNOS gene. To conclude, of 
the three variants of the eNOS gene the T-786C seemed to have the smallest effect, and is unlikely 
to significantly affect any of these diseases in these North Indian populations. Unless there are 
strong studies which suggest that this locus is of relevance, it can be ignored, but may be of value 
in haplotypic analysis and risk calculations. 
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6.1.3 The Intron 4 Variant 
The frequency of this variant was found to be very low in all three control and disease groups, 
however, this was consistent with previous studies. Unlike the Glu298Asp variant, the Intron 4 
variant (4a) showed the strongest relationship with Ht. Conversely, the Intron 4 variant was found 
to be protective against CAD in smokers. Whilst in T2DM group, there was no association for this 
locus. This study helps to understand the role of the variant in disease susceptibility, however the 
overall functional affect of this variant on NO production remains unclear. This variant has been 
shown to alter gene expression and protein levels, it has been hypothesised to alter microRNA 
production (discussed in the respective discussions) (Wang et al. 2000, Zhang et al. 2005). Further 
research is required to identify if the effect is direct or a result of linkage disequilibrium. Although 
the differing protective and increased risk associated with this variant may provide evidence that 
the previous association is a result of chance alone possibly caused by the low frequency, or it may 
be a result of the fine balance between eNOS producing NO and generating ROS under adverse 
conditions (Fatehi-Hassanabad et al. 2010, Deanfield et al. 2007, Cosentino et al. 1998, Vásquez-
Vivar et al. 1998). The small frequency of this variant means large samples are required to 
investigate what appears to be a strong influence on disease susceptibility. Therefore further 
research is recommended for this variant and in combination with other eNOS variants. 
Overall the eNOS gene showed association at a variety of levels, this included at a haplotypic and 
synergistic level. eNOS haplotypes were shown to have significant associations in all diseases with 
the G-C-4b haplotype proving to increase CAD risk, the T-C-4b haplotype was found to be 
protective against Ht and the T-T-4b was also protective against T2DM. Haplotype analysis can 
provide a clearer picture than investigating single genetic variants because it incorporates potential 
interaction among variants. The literature review revealed this kind of association is often 
uninvestigated/unreported and future work should give a higher priority to disease association at 
this level.  
6.1.4 The ACE Variant 
This study confirmed the ACE deletion variant as a significant risk factor for CAD, Ht and T2DM, 
which was in keeping with previous studies including a number of meta-analyses (Zintzaras et al. 
2008, Qiu et al. 1998, Qu et al. 2001, Niu et al. 2010, Zhou et al. 2010). No overall influence was 
shown between the ACE variant and any of the eNOS variants, therefore the effects of these genes 
can be considered independent which is similar to findings by Nakagami et al. (1999) (Nakagami 
et al. 1999).   
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6.1.5 Lifestyle Choices and Disease 
The influence of lifestyle choices on CVD is substantial and an individual’s relative risk of CVD 
had been shown to be reduced by as much as 80% (Stampfer et al. 2000). Similarly this is true for 
Ht and T2DM. Endothelial dysfunction is also directly influenced by lifestyle choices (Deanfield et 
al. 2007, Wang & Widlansky 2009). The eNOS variants are also influenced by lifestyle choices, 
previously they have been shown to interact with smoking and be influenced by age, of which 
smoking has been confirmed in the current study (Rios et al. 2007, Jia et al. 2007). 
The effects of environmental factors on endothelial function are well established and are 
summarised in detail in a review article by Wang and Widlanski (2009), they highlighted that  a 
high fat diet, smoking, obesity, physical inactivity, psychological stress, all have an appreciable 
effect on endothelial response resulting in reduced NO (Wang & Widlansky 2009). It is therefore 
unsurprising that previous research, along with the current have shown these factors to interact 
with eNOS variants and further increase disease susceptibility, for example the effect of smoking. 
This has vastly increased the difficulty of true identification and is likely to explain a proportion of 
the mixed findings. 
On a finer level epigenetics covers the chromatin based changes involved in gene regulation that 
do not directly alter the DNA sequence. These changes are difficult to detect and have been shown 
to impact the effect of a polymorphism. For example, the b1-AR gene polymorphism has shown 
different antihypertensive responses, which has been attributed to differences in an individual’s 
epigenetic profile (Shirodkar & Marsden 2011, Guang-Wei et al. 2010). 
The relationship and effect of these lifestyle factors is somewhat unique to a population, so 
identifying the strength and interactions is crucial in the role of genetic variants in disease. It also 
implicates areas of intervention for reducing the disease burden. 
6.1.6 Smoking 
Of all the lifestyle factors incorporated in this study, smoking was found to be the most interactive 
with the eNOS gene.  The rationale behind this has been alluded to in the relevant sections. These 
findings though not novel are reported for the first time in this CAD population. Mortality 
attributable to tobacco has been predicted to increase from 3.0 million in the year 1990 to 8.4 
million in 2020. With tobacco being responsible for almost 10% of the global mortality (Murray & 
Lopez 1997).  
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The interaction with genetic variants is not unique to the eNOS gene. For example, the 807T allele 
of the platelet glycoprotein la/lla receptor was found to have an individual risk of MI of 3.3, whilst 
smoking was shown to have an individual risk of 4.3, collectively the odds ratio for homozygotes 
for the 807T allele was shown to be 25 (Moshfegh et al. 1999). The Gln-Arg192 variant of the 
paraoxonase gene has shown similar interaction with smoking (Sen-Banerjee et al. 2000). Other 
polymorphisms of this gene (PON-Q192R variant) have also shown association among smoking 
also in a North Indian homogenous population (Agrawal et al. 2009). 
With this evident interaction with genetic variants, it may be that the effects of smoking have been 
vastly underestimated and highlight this factor as a target for intervention. It also unravels the 
strength of the physiological role of ROS in vascular homeostasis and may provide greater insight 
into the pharmacological management of the diseases. 
6.1.7  India 
This study analysed three complex diseases in North Indian populations. North India forms part of 
South Asia, which is made up by Pakistan, Bangladesh and India. South Asia, specifically India, 
has a complex architecture and evolutionary history that has shaped the current genetic diversity 
within the country. India in the past had interaction with other regions over a long period of time. 
There was a conquest from central Asia of Indo-European speakers that brought with it the 
hierarchical system (the caste system). The caste system has influenced the genetic variation of the 
country through stringent social rules which leads to endogamy and strict marriage practices. There 
are believed to be more than 4000 caste groups and 400 tribal groups. The arrival of the indo-
European speakers added to the already present genetic variation, whilst endogamy has resulted in 
significant genetic separation between the caste and tribal populations (Majumder 2008). This has 
resulted in wide variance even amongst South Asians, that will have shaped the genetic risk of 
diseases in different population groups. Overall Indian populations with their unique population 
history, endogamy, geographical location, dietary and religious practice provide a good platform to 
study interaction of gene and environment and their contribution to the disease processes. 
When disease risk has been determined in South Asians it has been shown to be substantially 
underestimated. For example CVD risk when determined using the Framingham risk score, Finland 
cardiovascular risk (FINRISK) and the systemic Coronary Risk evaluation (SCORE) were all 
shown to underestimate disease prevalence. It is therefore possible that alleles significantly 
involved in disease susceptibility may be unique to India. The allelic variation/ distribution of 
genetic markers analysed in other world populations may not be as useful as investigating genetic 
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variation within India itself. An example of this is provided by a variant present in the MYBPC3 
gene,  the 25bp deletion is present at a frequency of 4% within India yet is extremely rare 
throughout the world. This deletion has been established as a unique risk factor for heart failure in 
Indians. The complex evolutionary past of India has resulted in the present allele frequencies 
having been subjected to the founder effect. Consequently it has been shown that there is a greater 
difference between groups within India than that in Europe. Reich et al. (2009) subsequently 
predicted that recessive diseases will be at a greater frequency in India (Reich et al. 2009). This 
further supports the need for research in this population group and the necessary precautions 
required for the matching of cases and controls.  
As stated the influence of a variant will be vastly affected by numerous lifestyle factors. The effect 
of these lifestyle factors will be in combination with each other, and other genetic variants. 
Consequently, the effect of variants in complex diseases will be populational specific. Previous 
studies have found a disagreement in the prevalence of the conventional risk factors (Chapter 1) 
the importance of each risk factor may vary between populations and it has been suggested that the 
same risk is associated with a lower BMI among South Asians. South Asians typically are falling 
into the category of a normal weight whilst being metabolically obese, with both Diabetes and 
metabolic syndrome shown to develop in this community at a lower BMI (<25kg/m
2
) (Enas et al. 
2007). This also signifies that the novel findings may be a result of the unique genetic architecture 
and prevalence of both conventional and novel risk factors present in this population.  
The current study has provided evidence for the role of the eNOS gene but with the very limited 
data available from other South Asian groups (which in themselves exhibit variance) comparisons 
were limited. It is therefore important to verify/confirm these findings, with replication in the same 
populational groups. 
6.1.8 Limitations and possible cause of Mixed Results 
The choice of a case control study design was made based on a variety of factors. It is considered 
more powerful compared to family based design in collecting relatively large numbers of affected 
and apparently normal participants. Also, the previous studies investigating the role of the eNOS 
gene in disease had, for the most part adopted this study design, allowing easier comparisons. 
Available resources and time constraints enabled this study to be the most feasible whilst 
maintaining power. However, in any study design there are a number of possible limitations, 
although these have been minimised as best as possible it is important to consider these possible 
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causes of mixed results. These limitations are not unique and are likely to be present not only for 
the current practical work but also in the related literature. 
6.1.8.1 Practical limitations:  
When undertaking any case control study design researchers are faced with a number of 
challenges: 
1. Statistical inferences 
2. Defining cases and controls 
3. Imperfect matching of cases and controls (ethnicity, age, gender etc.) 
4. Controls becoming cases in later life 
5. Sample size 
6. Errors in genotyping 
7. Human errors in data upload and statistical analysis 
8. Confounding factors  
Interpreting the results of a case control study faces challenges, there are number of possibilities 
that could result in a false positive, including chance, bias and confounding variables (Campbell & 
Rudan 2002). In the presence of a significant result, typically 95% confidence is the acceptable 
standard, consequently chance cannot be entirely accounted for (Campbell & Rudan 2002).  
Bias is the second possible cause of false association and includes the imperfect matching of cases 
and controls. Firstly, the definition of cases and controls may be difficult this has been limited in 
the current study, by diagnosing disease via a clear criteria, which followed in most cases the 
WHO recommendations, allowing for easier comparisons with other studies. This difficulty of 
defining cases and controls is particularly apparent in late onset diseases like the ones analysed in 
this thesis. There were a number of individuals in the control group below the typical age of onset 
of disease, it is plausible a number of these individuals may later become cases. To reduce this 
error a longitudinal study would be required, however this is not always applicable and contains 
it’s own limitations and problems including longer time frame, cost, infrastructure and logistical 
issues.  
Defining cases and controls in complex diseases such as these is also difficult because diagnosis is 
based on a continuum, for example CAD is defined by 50% stenosis. The techniques used for 
determining disease status are not always available or desirable, as seen in the CAD group where 
angiography is required a relatively invasive procedure. The controls incorporated in the current 
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study was under a strict specification to minimise the chance of disease presence, this has been 
detailed in Chapter 3. 
With the genetic variation within India greater than that of Europe ensuring ethnicity was matched 
was particularly vital to identify true genetic association (Reich et al. 2009). Although this was 
done, there were still a number of differences present between the cases and controls with respect 
to other lifestyle factors and risk factors. This was a result of a number of lifestyle choices directly 
affecting disease status alongside the requirement of a large sample size to identify true disease 
susceptibility. The presence of these differences can mask the true effects of a genetic variant. This 
was minimised in the current study by ensuring logistic regression was run to adjust the odds ratios 
and ensure the values were a true reflection of an independent association of the variants with the 
respective disease.  
Differences in ethnicity in the subjects could also provide a source of error, particularly in light of 
the complex genetic architecture within India alone (Reich et al. 2009). Taking the Glu298Asp 
variant the homozygotes for the mutant T allele was revealed in the literature review to be at a 
range of around 40%, The current study identified a frequency of 2.75% similar to other studies of 
north India (3%) (Shankarishan et al. 2011) however, even small differences in ethnicity which is 
self reported may have substantial effects in both directions. This was minimised in the current 
populations by ensuring 5 consecutive generations prior to the participation had lived in the same 
geographical region and environment. 
Another limitation to any study is sample size, although all samples sizes were reasonable and 
comparatively large with respect to the literature, these remain a limiting factor particularly within 
the Ht groups. This is unlikely to be a large factor because all control groups were found to be in 
accordance to HWE and were comparable to frequencies previously found. Therefore the 
frequencies of the genotypes and alleles should be reasonably representative of this region of India 
and a South Asian population. The frequencies of all variants were consistently lower in South 
Asians, both in this study and others. Consequently in many instances the analysis suggested a 
possible relationship, yet the small frequencies resulted in a requirement of a larger sample size to 
reach statistical significance. During the study further samples were obtained to extend the initial 
analysis to help reduce the impact of this effect, as ever, time and financial restraints exist, making 
this only achievable to a point. There were also a number of samples that failed to be successfully 
genotyped, this was down to the quality of the DNA and repeats were done using increased 
quantities, yet in some cases they still failed, or gave ambiguous results so were excluded. 
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The genotyping of the variants itself contains a number of errors. When viewing bands by eye 
there is an associated human error, there can be some ambiguity with the presence or absence of 
the band sizes. The quality of the DNA may also result in the sample being incorrectly genotyped. 
There has been a hypothesised error level of 1-3% associated with a gel electrophoresis technique, 
this is particularly dangerous with respect to genetic association if the error is a systematic error 
(Hattersley & McCarthy 2005). This was minimised by independent readings of gels by another 
colleague/supervisor. Any ambiguous results were repeated. In addition a small number of the 
samples were repeated to check genotype callings.    
6.1.8.2 General Limitations and Considerations 
The successful identification of the eNOS gene in disease has meant the rate of publication is 
substantial and inevitably there will be a number of studies investigating the eNOS gene in disease 
that have been missed and may have benefited the understanding and aided the conclusions made 
in the current study.  
There are other considerations that may be confounding factors and can not be controlled for. As 
seen in the background eNOS function is affected at many different levels, and genetic variants are 
only one of many factors that may affect NO production within the endothelial cells. eNOS is also 
not the only source of NO in the body, as iNOS and nNOS are two similar isoforms controlled by 
two alternative genes (Alderton et al. 2001). Equally the role of NO as a vasodilator is not unique, 
this role was implicated in all three disease. The endothelium produces a variety of substances, 
these include alternate vasodilators such as bradykinin. Lamping et al. (2000) suggested that in the 
absence of eNOS, other pathways involved in vasodilations are able to compensate the effects 
(Lamping et al. 2000).   
More so, the evidence for the function of the eNOS variants faces its own set of problems, the 
rationale was based upon the evidence that the eNOS variants exhibited a functional effect 
influencing NO synthesis. This evidence was provided in part by studies investigating endothelial 
function as a reflection of NO levels, currently there is no clear gold standard for assessment 
(Flammer & Luscher 2010). This may be in part, responsible for the mixed findings and ultimately 
could have indicated a functional relevance of the variants that is absent.  
Identifying genetic variants influencing disease status is further complicated by many of the risk 
factors associated with the disease having their own genetic architecture. A number of examples 
were provided in the background for conditions such as hypercholesterolemia which has strong 
influences on the lipid profile and consequently CAD risk. The heritability of the conventional risk 
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factors for CAD has been shown to be extensive (Padmanabhan et al. 2010).  Collectively these 
issues make the task of identifying the effects of the eNOS variants challenging.  
6.1.9 Strengths of this Study 
These limitations have been controlled for as best as possible and are not unique to this study. In 
contrast this study contains a number of strengths that are somewhat unique. 
 Multiple gene variants in the eNOS gene 
 A second variant in a different gene 
 Three different complex diseases 
The first of these strengths is that the study examined three different variants of the same gene, this 
enabled a synergistic effect, linkage disequilibrium and haplotype analysis to be undertaken. 
Haplotype analysis can provide a clearer incorporating potential interaction among variants 
(Cardon & Abecasis 2003). Haplotype analysis has also been highlighted as a key area for future 
research on the eNOS gene and revealed significant findings for all three diseases (Pereira et al. 
2007).  
This study also analysed a variant on an alternative gene which confirmed that ACE is commonly 
associated with these diseases in North Indian populations and further systematic studies are 
required in ACE and RAS pathway to verify these associations in complex diseases.  
This study also compared genotypes and their influence on continuous variables such as lipid 
parameters. This type of analysis can discover new associations that may be direct (even though 
the physiology pathway may not yet be understood), therefore highlighting areas for further 
research. Alternatively this type of analysis could discover populational specific risks caused by 
linkage disequilibrium that may aid the discovery of other functional variants. 
6.2 Implications of Research 
The identification of genes and genetic variants associated with disease risk could provide earlier 
detection, intervention and possibly personalized medicine. This is ever important in diseases such 
as CAD and hypertension where they have been termed ‘silent’ killers. Often the first observable 
consequence may be an acute MI and potentially death. The role of eNOS gene variants 
highlighted in this study contributes towards this, further studies in these population groups are 
required to confirm these findings.   
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There is an evident relationship of the eNOS gene variants on disease status. This was particularly 
marked when other factors such as smoking behaviours were considered, this has confirmed a 
relationship previously identified in a small number of studies and has highlighted the need for 
further research in this area. The effect of these environmental factors as independent risk factors 
for metabolic diseases are established, yet this recent discovery of interaction with risk gene 
variants means their effect may have been critically underestimated, and may be specific to 
populational groups. The identification of the risk variants in this gene and others will enable a 
comprehensive risk profile to be formed for each individual, particularly through the identification 
of the interaction. Specific more effective advice can be targeted to high risk individuals. 
This genetic susceptibility to smoking in this population group may be addressed with practical 
interventions created to prevent and reduce smoking prevalence within this population. This is 
likely to be more beneficial than targeting some of the other conventional risk factors. 
There have been a number of studies that have shown successful interventions under   adverse 
conditions; in animal tests investigating eNOS gene deficiency, vascular homeostasis has been 
shown that it can be restored with the provision of nitrite through dietary means. Thus proving that 
identifying eNOS gene deficiency in humans could provide a clear pathway to protecting the 
individuals from CVD and diabetes by treatment through these means (Bryan et al. 2008). Equally 
the substrate for the eNOS gene; L-arginine has been shown to influence improvements through 
supplementation (Aji et al. 1997, Boger et al. 1997). Animal models using the diabetic rat have 
shown that in the presence of reduced BH4 levels and reduced NO production, supplementation of 
BH4 has been shown to improve EDRs in T2DM patients and smokers (Meininger et al. 2000, 
Heitzer et al. 2000).  
There is also evidence for increasing NO production of the genetic variants. For example, Zhang et 
al. (2006) identified an association of the Intron 4 variant with micro RNA production; 
hypothesised to cause the functional differences between the variants. The effect was shown to be 
reversible in the presence of vascular endothelial growth factor (VEGF). VEGF is a known 
enhancer of the eNOS gene expression, it was able to enhance expression without enhancing 
further production of micro RNA (Zhang et al. 2005).  
The key aspect is due to the multifactorial basis to these diseases, treatment needs to be more 
specific, in terms of drug treatment, modification of lifestyle risk factors and possible lifestyle 
interventions such as dietary nitrite. The promise of personalised medicine is based on the 
collective understanding of an individual’s information to successfully prevent, diagnose and treat 
illness. This information will be based upon the individual’s proteins, genes, metabolites and 
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environment (Müller 2010). Information on the genetic analysis of the eNOS variants contributes 
towards this aim.   
6.3 Where next... 
There are number of suggestions for future research that would greatly benefit the findings in the 
current study and aid the implications of this research in the field of medical genomics. 
1. Confirmation of the current findings through larger sample sizes 
2. Investigating the effect of smoking in T2DM and Ht in different population groups where 
smoking is a variable in disease and prevalent  
3. Further genetic variants in the eNOS and alternate genes, in these and other diseases 
4. Measuring NOx levels in by genotype/haplotype. Also to conduct sub-group analysis in 
smokers 
5. Investigate the interaction of eNOS variants with other nutrients such as omega-3 
polyunsaturated fatty acids 
6. Further research and collate current knowledge to greater the understanding of this gene 
and to enable complex risk profiling and effective personalised medicines  
To ensure the findings in the current study are not due to chance alone, or confounding variables, 
replication is required to confirm the nature of the eNOS variants in disease. Increased sample size 
would also help to reach statistical significance; this is particularly prominent considering the low 
frequency of the variants among this group. 
The interaction between the eNOS gene variants and smoking was evident. Consequently, through 
gaining information on smoking behaviours in Ht and T2DM patients, this interaction could be 
assessed which may have been missed. Smoking has been shown to stimulate insulin resistance, 
suggesting a similar additive effect is plausible. 
Sticchi et al. (2010) have provided evidence for the role of smoking and interaction between the 
ACE and eNOS gene. Their group found smokers carrying the D allele of the ACE variant with the 
eNOS-786C/4a haplotype to have an increased PAD predisposition (OR, 2.71 to 3.79). With three 
diseases and three different variants of the eNOS gene alongside the ACE deletion, the possibilities 
for analyses are infinite, but due to time and space constraints these are not included in the present 
report.  
Currently, the study has identified differences in the frequency of the eNOS variants as an indicator 
of disease association. This was based on the putative mechanism that the variants influenced 
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disease status through a reduction in NO synthesis. Measurements on nitrite/nitrate levels by 
genotype could benefit these findings. It would also be insightful where the opposite effects were 
found. This would also benefit the understanding of the association found of the haplotypes. Which 
have previously been shown to have a direct functional effect, but is very much understudied. For 
example Metzger et al. (2007) reported the G-C-4b haplotype to be at an estimated frequency of 
16% in individuals with low NOx levels whilst only 4% for those with high NOx levels (Metzger 
et al. 2007).  
This study benefited from investigating the ACE deletion variant, which in the literature was 
shown to be previously associated with the eNOS gene above that of any other variants. However 
there are also a number of alternative variants that have shown gene-gene interplay with the eNOS 
gene and successful genotyping of these variants could provide a greater insight into the role of 
eNOS. Very recently, Jafari et al. (2011) found an interaction between the C677T and A1298C 
variants of the MTHFR gene, and the Glu298Asp variant of the eNOS gene, this was when 
investigating diabetic complications (Jafari et al. 2011). Szolnoki et al. (2005) had also previously 
provided evidence for a relationship between the eNOS gene and the MTHFR gene. This gene 
would act as a good candidate gene to assess in these three diseases. 
The Apo E gene is another gene that could be a useful next step. Animal studies have supported a 
relationship between these two genes (Knowles & Maeda 2000, Kuhlencordt et al. 2006) 
Kuhlencordt et al. (2006) found that when the eNOS gene was deleted in mice they became 
hypertensive, when the Apo E gene was also deleted the mice showed an increased susceptibility to 
atherosclerosis (Kuhlencordt et al. 2006). 
The literature has also revealed further possible directions to investigate. The eNOS gene variants 
have been shown to interact with nutrients and this interaction may ultimately be crucial influential 
factors in the development of CVDs and other complex diseases. There has been evidence 
supporting an interaction with omega-3 polyunsaturated fatty acids (n-3 PUFA), with respect to the 
plasma triacylglycerol (TAG) concentrations (Ferguson et al. 2010). 
Recently Müller et al. (2010) provided a review on the promise of personalised prognosis and 
diagnosis for T2DM, they concluded that there are ample reasons for continuing the search for 
susceptibility genes when in combination with protein analysis, metabolite analysis and analysis of 
both traditional and novel risk factors. They believe this will add to the medical genomics field. 
However, they highlight a key point that the benefit of this research will only be fulfilled if the 
current expenditure on this research is ultimately matched by expenditure on developing the 
promised personalised medicines, prognosis and diagnosis (Müller 2010). Similar conclusions 
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were drawn by Cook et al. (2007) who produced a paper entitled ‘endothelial nitric oxide synthase 
gene: prospects for treatment of heart disease’, they concluded success in the future requires a 
systematic approach identifying genetic information and the subsequent phenotypes, alongside 
prospective phamacogenetic studies to provide the true significance and understanding of NO in 
the system (Cooke et al. 2007). The benefits of identifying genetic variants will be utilised, when 
research is extended to multiple levels, through the studies of transcriptomics, proteomics and 
metabolomics and epigenetics.  
To conclude this study has successfully identified the frequency of three eNOS variants and the 
ACE deletion variant in three complex diseases within North Indian populations. There is a clear 
role of this gene in all three diseases and consequently the genetic variants. The said association 
with disease was found to be present at an individual level, in association with risk factors and at a 
haplotypic level. The benefits of these findings (with the addition of replicative studies) will 
contribute to the field of medical genomics, these findings have also provided evidence for 
recommendations that would further enhance this field. 
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8 Appendices 
8.1 Appendix 1- Other eNOS gene variants disease association 
Table 120- Other eNOS gene variants key findings from previous studies  
Intron 23 G10T 
Disease Population Study type Study size Patients Controls Association reference 
CAD  Korean Case control 110 Patients 
128 controls 
GG=98.2% 
GT=1.8% 
TT=0.0% 
GG=87.5% 
GT=12.5% 
TT=0.0% 
Significant differences 
between patients and controls 
p=0.002 
(Yoon et al. 
2000) 
Ht Polish Case control 108 patients 
118 controls 
GG=37.0% (40) 
GT=48.2% (52) 
TT=14.8% (16) 
GG=42.4% (50) 
GT=46.6% (55) 
TT=11.0% (13) 
No significant differences 
between patients and controls 
p>0.05 
(Derebecka et al. 
2002) 
Ht unknown Case control 309 patients 
123 controls 
Unavailable Unavailable No significant differences 
between patients and controls 
(Lacolley et al. 
1998) 
Ht French Case control 198 patients 
106 controls 
GG=47.5% (94) 
GT=41.9% (83) 
TT=10.6% (21) 
GG=43.4% (46) 
GT=43.4% (46) 
TT=13.2% (14) 
No significant differences 
between patients and controls 
p>0.70, χ2=0.69 
OR=0.86 (0.60-1.24) 
χ2=0.70 
(Bonnardeaux et 
al. 1995) 
Ht Kyoto Japanese Case control 218 
hypertensive 
and 240 controls 
GG=35.8% (78) 
GT+TT=64.2% 
(140) 
GG=32.95 (79) 
GT+TT=67.1% (161) 
No significant differences 
between patients and controls 
p=0.555 OR=1.1 (0.8-1.7) 
T allele in strong linkage 
disequilibrium with Intron 4 
4a allele. 
(Miyamoto et al. 
1998) 
MI Polish Case control 273 patients GG=41% GG=46.0% No significant differences (Gluba et al. 
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Intron 23 G10T 
Disease Population Study type Study size Patients Controls Association reference 
134 controls GT=49.85 
TT=9.2% 
GT=39.4% 
TT=4.6% 
between cases and controls. 
TT vs. GG OR=0.59 (0.31-
1.11) 
TT+TG vs. GG OR=1.22 
(0.81-1.85) 
2009) 
 
 
Intron 18 A27C 
Disease Population Study type Study size Patients Controls Association reference 
Ht Japanese Case control 218 patients 
240 controls 
AA=95.0% (207) 
AC+CC=5.0% (11) 
AA=96.3% (231) 
AC+CC=3.8% (9) 
No significant differences 
between groups P=0.326 
OR=1.4 (0.6-3.3) 
(Miyamoto et al. 
1998) 
Ht French Case control 198 patients 
106 controls 
AA=48.5% (96) 
AC=40.9% (81) 
CC=10.6% (21) 
AA=46.2% (49) 
AC=39.6% 
(42) 
CC=14.2% (15) 
No significant differences 
between patients and controls 
p>0.60 x2=0.83 OR=0.88 
(0.60-1.27) 
χ2=0.53 
OR=0.86 (0.60-1.24) 
χ2=0.70 
(Bonnardeaux et 
al. 1995) 
 
A-922 G 
Disease Population Study type Study size Patients Controls Association reference 
Ht Chinese Han Case control 192 patients 
122 controls 
Unavailable Unavailable No significant differences 
between patients and controls 
(Ma et al. 2006) 
IS Chinese Case control 309 Patients 
309 controls 
AA==78.96% (244) 
AG=17.8% (55) 
GG=3.24% (10) 
AA=85.11% 
(263) 
AG=13.59% (42) 
GG=1.30% (4) 
AG+GG vs AA OR=1.523 
(1.005-2.309) 
(Cheng et al. 
2008b) 
MI Korean Case control 129 patients 
803 controls 
Unavailable unavailable OR=1.69 p<0.05 
Smoking further increased risk 
(Jo et al. 2006) 
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A-922 G 
Disease Population Study type Study size Patients Controls Association reference 
to OR=2.04 
Mutant allele completely 
linked to C allele of T-786c 
variant and the -1468TA 
IS American Case control Young 
Women only: 
Whites 52 
patients 
110 controls 
Blacks: 
49 patients 
75 controls 
Whites: 
AA=40% 
AG:42% 
GG=15% 
Blacks: 
AA=80% 
AG=20% 
GG=0% 
Whites: 
AA=36% 
AG=49% 
GG=15% 
Blacks: 
AA=57% 
AG=35% 
GG=8.0% 
Possible association with the 
T allele of the glu298asp 
polymorphism. Significant 
association with blacks for 
ischemic stroke OR=3.0 (1.3-
6.8) 
Whites: 
No significant differences 
between genotypes p=0.66 or 
alleles p=0.88 
Blacks significant differences 
between both genotypes 
p=0.0093 and allele p=0.005. 
 
(Howard et al. 
2005) 
 
-1468T/A 
Disease Population Study type Study size Patients Controls Association reference 
IS American Case 
control 
Young Women 
only: 
Whites 50 
patients 
116 controls 
Blacks: 
50 patients 
76 controls 
Whites: 
TT= 42% 
AT=42% 
AA=16% 
Blacks: 
TT=46% 
AT=36% 
AA=18% 
 
Whites: 
TT=33% 
AT=52% 
AA=16% 
Blacks: 
TT=30% 
AT=46% 
AA=18% 
Whites no significant 
association between genotypes 
p=0.95 or alleles p=0.54 
Blacks: 
No significant differences 
between genotypes p=0.36 or 
allele p=0.078 
(Howard et al. 
2005) 
Myocardial Korean Case 129 patients Unavailable Unavailable OR=1.69 p<0.05 (Jo et al. 2006) 
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-1468T/A 
Disease Population Study type Study size Patients Controls Association reference 
Infarction control 803 controls Smoking further increased risk 
to OR=2.04 
Completely linked to the T-
786c mutation and the A-922 
G 
 
CA repeat Intron 13 
Disease Population Study type Study size Patients Controls Association reference 
CAD unknown Case control 1000 patients 
1000 controls 
28 different 
alleles found 
Not possible 28 different alleles 17-44 CA 
repeats. This study found the 
presence of one allele containing 
> 38 repeats increased risk of 
CAD OR=1.94 (1.31-2.86) 
p=0.001 following logistic 
regression CA repeats is an 
independent risk factor; 
RR=2.17 (1.44-3.27) p=0.0002 
(Stangl et al. 
2000) 
Ht Japanese Case control 100 patients 
123 controls 
23 different 
alleles found 
unavailable 23 alleles identified. No 
significant differences in the 
frequency of the alleles between 
patients and controls. However 
sub group analysis of individuals 
without left ventricular 
hypertrophy (LVH)  the 33 
repeat allele was more frequent 
in HT group without LVH and 
control groups OR=3.71 
p=0.000047. 
(Nakayama et al. 
1997) 
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CA repeat Intron 13 
Disease Population Study type Study size Patients Controls Association reference 
ACS German All patients 1000 patients 
attending coronary 
angiography. 235 
CAD patients with 
ACS 
Women: 
The number of 
individuals with 
great than or 
equal to number 
of repeats 
34=14 
35=11 
36=10 
37=4 
Men: 
34=47 
35=37 
36=23 
37=15 
38=7 
 Cut off ≥34 up to ≥ 3.No 
significant association for CA 
repeats with ACS in all patients 
(n=974) women only (235) or 
men only (739) further sub 
group analysis showed 
significant association found in 
women with homocysteine 
greater than 9.4µmol/l RR=4.89 
AT 36 repeats and RR=11.20 for 
37 repeats and 18.32 for 38 
repeats. Not observed in men. 
(Laule et al. 2003) 
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8.2 Appendix 2-ACE method 
 Primers 
Primer ACE-F (10 µM) 5’ ctggagaccactcccatcctttct 3’  
Primer ACE-R (10 µM) 5’ gatgtggccatcacattcgtcagat 3’ 
 PCR mastermix preparation     
ReddyMix      =10 µl 
ACE-F       =0.4 µl 
ACE-R       =0.4 µl 
Water       =8.2 µl 
Aliquot out 19 µl per tube and add 1 µl DNA (100 ng/µl) 
 Thermal cycling conditions 
94 
o
C   5 mins  x1 
94 
o
C  1 min 
58 
o
C  1 min   x 32 
72 
o
C  1 min  
72 
o
C  10 mins x1 
4 
o
C  ∞ 
 
 Gel electrophoresis 
Run on 2 % agarose gel. Results indicated the II genotype in the presence of 1 band at 190bp, the 
ID genotype in the presence of two bands at 190bp, and 490bp respectively and the DD genotype 
in the presence of1 band at 490bp. 
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8.3 Appendix 3- T-786C method 
 Primer details 
The details of the primers are provided in Table 121. 
Table 121-T-786C primer details 
Variant Sequence Purchased 
concentration 
DNA/RNA 
free water 
added 
Final 
concentration 
T-786C 
Forward 
primer 
5’-
TGGAGAGTGCTGGTGTACCCCA
-3’ 
46.0nmol 460.0 µl 100 µMol 
Reverse 
Primer 
5’-GCCTCCACCCCCACCCTGTC-
3’ 
44.9nmol 449.0 µl 100 µMol 
The stock forward and reverse oligonucleotide primers were further diluted down s by adding 20µl 
of stock (100µMol) primer and 180µl nuclease free water.  
1. PCR Mastermix preparation 
The final concentrations for the mastermix for this variant were determined following a process of 
standardisation and were as follows: 
 2X ReddymixTM PCR mastermix =                          10µl 
 Nuclease free water=           7.4µl 
 T-786C Forward primer=      0.8µl 
 T-786C Reverse primer=     0.8µl 
The total mastermix excluding the DNA totalled 19µl per sample.  
 PCR Conditions 
PCR was performed in a thermocycler and underwent a total of 35 cycles. Prior to the 35 cycles an 
initial hold at 94 °C was undertaken for 5 minutes.  
The PCR product was 180bp in size. To determine the success of PCR the products were required 
to be run on a 2% agarose gel. This was made up as before following the 2% agarose gel protocol. 
 PCR loading 
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The PCR product was loaded as stated in ‘PCR loading’ for the glu298asp variant. In the case of T-
786C variant the gel was run for approximately 45 minutes. In the presence of a180bp fragment, 
restriction digestion was undertaken.  
 T-786C Restriction Enzyme Digestion Protocol  
The restriction digestions mastermix contained; 7.6µl nuclease free water, 2.0µl of buffer 4 and 
0.4µl of an enzyme Msp1. 10µl of mastermix was required per 10µl of PCR product.   
All samples were then centrifuged on pulse for 10 seconds and placed into an oven at 37°for 3 
hours. 
 Restriction Product loading 
This gel was prepared and loaded exactly as previously stated for the Glu298Asp A sample gel is 
given in Figure 22. The genotypes were then scored, in the presence of no mutation one restriction 
site existed for the Msp1 enzyme, subsequently fragmenting the PCR 180bp product into two 
fragments of 140bp and 40bp in size respectively. In the presence of the thymine to cytosine SNP a 
second restriction site was also present within the 140bp fragment, creating two new fragments of 
50 and 90bp. Thus the following genotypes were identified by bands of the following sizes; TT: 2 
bands at 40bp and 140bp, TC: 4 bands at 40bp, 50bp,90bp and 140bp, CC : 3 bands at 40bp,50bp 
and 90bp (Figure 22). 
 
 
Figure 22-T-786C RFLP gel electrophoresis 
TC 
genotype 
TT 
genotype 
DNA ladder 
Appendices  
280 | P a g e  
 
8.4 Appendix 4 Coronary artery disease results tables 
Table 122-:CAD Glu298Asp Independent samples T test between genotype TT vs. GG for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
Total Cholesterol 
(mg/dl) 
TT 21 167.190 52.281 11.409 0.257 3.019 -0.797 
GG 415 164.171 52.535 2.579       
Triglyceride 
(mg/dl) 
TT 21 146.524 87.531 19.101 0.215 4.882 0.830 
GG 416 141.642 102.219 5.012       
High density 
Lipoprotein 
(mg/dl) 
TT 21 95.333 148.384 32.380 *1.055 34.302 0.304 
GG 416 61.031 60.125 2.948       
Low density 
lipoprotein (mg/dl) 
TT 21 98.257 39.769 8.678 0.015 0.156 0.988 
GG 411 98.101 45.696 2.254       
very low density 
lipoprotein (mg/dl) 
TT 20 42.550 24.375 5.450 *1.628 8.964 0.119 
GG 383 33.586 15.414 0.788       
APOB (mg/dl) 
TT 11 123.055 63.169 19.046 -0.318 -5.155 0.751 
GG 231 128.210 52.062 3.425       
 
Table 123: CAD Glu298Asp Independent samples T test between genotype TT vs. GT for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
Total Cholesterol 
(mg/dl) 
TT 21 167.191 52.281 11.409 .349 3.687 0.727 
GT 195 163.503 45.258 3.241       
Triglyceride 
(mg/dl) 
TT 21 146.524 87.531 19.101 .534 11.498 0.594 
GT 195 135.026 94.342 6.756       
High density 
Lipoprotein (mg/dl) 
TT 21 95.333 148.384 32.380 *0.941 30.851 0.357 
GT 195 64.482 72.154 5.167       
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Table 123: CAD Glu298Asp Independent samples T test between genotype TT vs. GT for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
Low density 
lipoprotein (mg/dl) 
TT 21 98.257 39.769 8.678 .307 2.469 0.759 
GT 193 95.789 34.482 2.482       
very low density 
lipoprotein (mg/dl) 
TT 20 42.550 24.375 5.450 *1.454 8.101 0.161 
GT 185 34.449 15.747 1.1578       
APOB (mg/dl) 
TT 11 123.055 63.169 19.046 -.219 -3.215 0.827 
GT 106 126.270 44.446 4.317       
 
Table 124: CAD Glu298Asp Independent samples T test between genotype GG vs. GT for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl) 
GG 415 164.171 52.535 2.579 .153 .669 0.878 
GT 195 163.503 45.258 3.241       
TG (mg/dl) 
GG 416 141.642 102.219 5.012 .764 6.616 0.445 
GT 195 135.026 94.342 6.756       
HDL (mg/dl) 
GG 416 61.031 60.125 2.948 -.619 -3.451 0.536 
GT 195 64.482 72.153 5.167       
LDL (mg/dl) 
GG 411 98.101 45.696 2.254 .624 2.312 0.533 
GT 193 95.789 34.482 2.482       
VLDL (mg/dl) 
GG 383 33.586 15.414 .788 -.621 -.863 0.535 
GT 185 34.449 15.747 1.158       
APOB (mg/dl) 
GG 231 128.2095 52.062 3.425 *0.352 1.940 0.725 
GT 106 126.2700 44.446 4.317       
 
Table 125-CAD T-786C Independent T-test genotypes CC vs. TC for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
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Table 125-CAD T-786C Independent T-test genotypes CC vs. TC for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl) 
CC 28 167.179 53.037 10.023 -0.273 -4.924 0.785 
TC 214 166.701 49.810 3.405 0.047 0.478 0.962 
TG (mg/dl)  
CC 28 137.607 60.374 11.410 0.258 4.868 0.796 
TC 215 132.740 97.232 6.631       
HDL (mg/dl)  
CC 28 45.750 48.346 9.137 -1.732 -27.376 0.085 
TC 215 73.126 81.701 5.572       
LDL (mg/dl) 
CC 28 105.850 39.728 7.508 0.742 5.919 0.459 
TC 213 99.931 39.702 2.720       
VLDL (mg/dl)  
CC 26 35.692 15.333 3.007 0.235 0.820 0.814 
TC 196 34.872 16.876 1.205       
APOB (mg/dl)  
CC 16 132.988 36.256 9.064 0.024 0.314 0.981 
TC 106 132.673 49.892 4.846       
 
Table 126- CAD T-786C Independent sample T test comparing genotype CC vs. TT for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl) 
CC 28 167.179 53.037 10.023 0.425 4.324 0.671 
TT 379 162.855 51.908 2.666       
TG (mg/dl) 
CC 28 137.607 60.374 11.410 -0.354 -6.981 0.724 
TT 379 144.588 102.990 5.290       
HDL (mg/dl) 
CC 28 45.750 48.346 9.137 -1.103 -12.464 0.271 
TT 379 58.214 58.333 2.996       
LDL (mg/dl) 
CC 28 105.850 39.728 7.508 1.080 9.543 0.281 
TT 375 96.307 45.451 2.347       
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Table 126- CAD T-786C Independent sample T test comparing genotype CC vs. TT for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
VLDL (mg/dl) 
CC 26 35.692 15.333 3.007 0.433 1.454 0.665 
TT 355 34.238 16.610 0.882     
APOB (mg/dl)  
CC 16 132.988 36.256 9.064 *0.609 5.959 0.549 
TT 214 127.028 53.849 3.681       
 
Table 127-CAD T-786C Independent T- test comparing genotypes TC vs. TT for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl) 
TC 214 166.701 49.810 3.405 0.879 3.845 0.380 
TT 379 162.855 51.908 2.666       
TG (mg/dl) 
TC 215 132.740 97.232 6.631 -1.375 -11.849 0.170 
TT 379 144.588 102.990 5.290       
HDL (mg/dl)  
TC 215 73.126 81.701 5.572 *2.357 14.912 0.019 
TT 379 58.214 58.333 2.996       
LDL (mg/dl) 
  
TC 213 99.931 39.702 2.720 0.972 3.624 0.332 
TT 375 96.307 45.451 2.347       
very low density 
lipoprotein (mg/dl)  
TC 196 34.872 16.876 1.205 0.427 0.634 0.670 
TT 355 34.238 16.610 0.882       
APOB (mg/dl)   
TC 106 132.673 49.892 4.846 0.904 5.645 0.367 
TT 214 127.028 53.849 3.681       
 
 
Table 128- CAD Intron 4 independent samples t-test between genotypes 4aa and 4ab for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
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Table 128- CAD Intron 4 independent samples t-test between genotypes 4aa and 4ab for entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl) 
4aa 17 144.412 41.794 10.137 -1.076 -19.935 0.109 
4ab 173 164.347 49.356 3.752       
TG (mg/dl)  
4aa 17 149.471 69.098 16.759 0.825 18.057 0.410 
4ab 174 131.414 87.540 6.636       
HDL (mg/dl)  
4aa 17 34.471 21.901 5.312 *-4.284 -33.259 <0.001 
4ab 174 67.730 74.674 5.661       
LDL (mg/dl) 
4aa 17 88.400 26.107 6.332 -1.079 -11.338 0.282 
4ab 174 99.738 42.501 3.222       
VLDL (mg/dl)  
4aa 15 34.533 17.792 4.594 0.112 0.490 0.911 
4ab 162 34.043 16.007 1.258       
APOB (mg/dl)  
4aa 12 131.050 47.211 13.629 -0.229 -3.614 0.820 
4ab 95 134.664 52.058 5.341       
 
Table 129- CAD Intron 4 independent samples t-test comparing genotypes 4aa and 4bb for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl)  
4aa 17 144.412 41.794 10.137 -1.613 -20.411 0.107 
4bb 457 164.823 51.541 2.411       
TG (mg/dl)  
4aa 17 149.471 69.098 16.759 0.459 11.602 0.647 
4bb 457 137.869 103.383 4.836       
HDL (mg/dl)  
4aa 17 34.471 21.901 5.312 *-5.150 -32.610 <0.001 
4bb 457 67.081 73.684 3.447       
LDL (mg/dl)  
4aa 17 88.400 26.107 6.332 -0.867 -9.218 0.386 
4bb 451 97.618 43.506 2.049       
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Table 129- CAD Intron 4 independent samples t-test comparing genotypes 4aa and 4bb for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
VLDL (mg/dl)  
4aa 15 34.533 17.792 4.594 0.016 0.070 0.987 
4bb 424 34.463 16.822 0.817       
APOB (mg/dl)  
4aa 12 131.050 47.211 13.629 0.311 4.659 0.756 
4bb 232 126.391 50.775 3.334       
 
Table 130-CAD Intron 4 independent samples t-test comparing genotypes 4ab and 4bb for the entire sample 
Variable Genotype N Mean SD SE t value mean difference p value 
TC (mg/dl)  
4ab 173 164.347 49.356 3.752 -0.105 -0.476 0.917 
4bb 457 164.823 51.541 2.411       
TG (mg/dl)  
4ab 174 131.414 87.540 6.636 -0.730 -6.455 0.466 
4bb 457 137.869 103.383 4.836       
HDL (mg/dl)  
4ab 174 67.730 74.674 5.661 0.098 0.649 0.922 
4bb 457 67.081 73.684 3.447       
LDL (mg/dl)  
4ab 174 99.738 42.501 3.222 0.550 2.120 0.583 
4bb 451 97.618 43.506 2.049       
Very low density 
lipoprotein (mg/dl)  
4ab 162 34.043 16.007 1.258 -0.274 -0.420 0.784 
4bb 424 34.463 16.822 0.817       
APOB  (mg/dl)  
4ab 95 134.664 52.058 5.341 1.328 8.273 0.185 
4bb 232 126.391 50.775 3.334       
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Table 131- ACE and eNOS association in CAD sample 
Glu298Asp eNOS-GG eNOS-GT eNOS-TT χ2 P 
ACE-II 85 (19.7%) 37 (18.2%) 3 (13.0%) 4.086 0.395 
ACE-ID 224 (51.9%) 106 (52.2%) 9 (39.1%)    
ACE-DD 123 (28.5%) 60 (29.6%) 11(47.8%)    
Total 432 (100%) 203 (100%) 23 (100%)     
T-786C eNOS-TT eNOS-TC eNOS-CC χ2 P 
ACE-II 79 (20.2%) 38 (16.9%) 4 (13.8%) 1.943 0.746 
ACE-ID 198 (50.6%) 124 (55.1%) 16 (55.2%)    
ACE-DD 114 (29.3%) 63 (28.0%) 9 (31.0%)    
Total 391 (100%) 225 (100%) 29 (100%)     
Intron 4 eNOS-4bb eNOS-4ab eNOS-4aa χ2 P 
ACE-II 93 (19.5%) 27 (15.0%) 2 (11.8%) 3.434 0.488 
ACE-ID 249 (52.2%) 94 (52.2%) 11 (64.7%)    
ACE-DD 135 (28.3%) 59 (32.8%) 4 (23.5%)    
Total 477 (100%) 180 (100%) 17 (100%)     
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8.5 Appendix 5- Coronary artery disease discussion tables 
Table 132- Glu298Asp reported genotype frequencies in previous CVD control groups 
Heart Disease Population Subjects GG GT TT Study 
CVD Eastern Taiwan 78 controls 62.8% 29.5% 7.7% (Lin et al. 2008) 
CHD Japanese 249 Controls 80.3% 18.1% 1.6% (Ameno et al. 2006) 
CHD United States 
Diabetic men only  
631 controls 
34.0% 50.0% 16.0% (Zhang et al. 2006) 
IHD Japanese 283 controls 88.0% 11.3% 0.7% (Tamemoto et al. 2008) 
CAD Caucasian Men- 574 controls 37.6% 47.0% 15.3% (Agema et al. 2004) 
CAD Italian 147 controls 44.2% 49.0% 6.8% (Colombo et al. 2003a) 
CAD Italian  114 controls 42.1% 51.8% 6.1% (Colombo et al. 2003b) 
PCAD Turkish 83 controls 68.7% 28.9% 2.4% (Berdeli et al. 2005) 
PCAD Turkish 83 controls 68.7% 28.9% 2.4% (Cam et al. 2005) 
CAD and MI Germany 533 controls 48.03% 45.59% 9.38% (Gardemann et al. 2002) 
CAD and MI United Kingdom 183 controls 42.1% 51.8% 6.1% (Hingorani et al. 1999) 
CAD Turkish 150 controls 49.3% 41.3% 9.3% (Afrasyap & Ozturk 2004) 
CAD North Turkish Caucasian 103 controls 56.3% 34.0% 9.7% (Kara et al. 2007) 
CAD (>75% stenosis) 
Southern Brazilians 
(European descent) 
129 controls 45.7% 40.3% 4.0% (Rios et al. 2005)   
CAD and MI Austrian 248 controls 49% 41.0% 10.0% (Schmoelzer et al. 2003) 
CAD Greek 161 controls 47% 46.0% 7.0% (Vasilakou et al. 2008) 
CAD 
Brazilians- Caucasian and 
African 
267 controls 
Caucasian-
Brazilians 
Caucasian-
Brazilians 
Caucasian-
Brazilians 
(Rios et al. 2007)  
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Table 132- Glu298Asp reported genotype frequencies in previous CVD control groups 
Heart Disease Population Subjects GG GT TT Study 
Smoking 
55.7% 
Non-smoking 
57.6% 
African-
Brazilians 
Smoking 
70.0% 
Non-smoking 
47.5% 
 
Smoking: 
36.1% 
Non-smoking: 
32.9% 
African-
Brazilians 
Smoking: 
26.7% 
Non-smoking: 
49.2% 
Smoking: 
8.2% 
Non-smoking: 
9.4% 
African-
Brazilians 
Smoking: 
3.3% 
Non-smoking: 
3.3% 
CAD Chinese Han 108 controls 91% 8.8% 0.2% (Wei et al. 2002) 
CAD and MI Taiwan 218 controls 81.2% 17.4% 1.4% (Wang et al. 2001) 
CAD Korean-Bungdang 222 controls 81.5% 17.1% 0.0% (Kim et al. 2007) 
PCAD Taiwan 65 controls 81.5% 15.4% 3.1% (Wu et al. 2003) 
CAD Chilean 72 controls 71% 28.0% 1.0% (Jaramillo et al. 2006) 
CAD Chilean 12 controls 66% 32% 2.0% (Jaramillo et al. 2010) 
CAD Australian Caucasian 624 controls 43.4% 46.1% 10.6% (Granath et al. 2001) 
CAD  Australian-White 158controls 41.77% 44.30% 13.92% (Cai et al. 1999) 
CAD Tamilian south Indian 100 controls 79% 18.0% 3.0% (Nishevitha et al. 2009) 
CAD North Indian 218 controls 69.72% 27.52% 2.75% Current Study 
CAD Iranian 261 controls 61.35% 32.2% 6.5% (Salimi et al. 2010) 
IS Hungarian Caucasian 295 controls 48.8% 46.4% 4.8% (Szolnoki et al. 2005) 
IS France 
491 controls 
460 matched pairs 
35.4% 50.4% 14.1%  (Elbaz et al. 2000) 
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Table 132- Glu298Asp reported genotype frequencies in previous CVD control groups 
Heart Disease Population Subjects GG GT TT Study 
IS 
American Stroke prevention 
in Young women case 
control study 
120 White controls 
78 black controls 
Whites: 
(N=120) 
47.0% 
Blacks: (N=78) 
68.0% 
Whites: 
(N=120): 
42.0% 
Blacks: (N=78) 
32.0% 
Whites: 
(N=120) 
12.05% 
Blacks: (N=78) 
0.0% 
(Howard et al. 2005)  
 
IS Chinese 309 controls 78.64% 19.74% 1.62% (Cheng et al. 2008a) 
MI Greek Caucasians 205 controls 49.1% 41.8% 9.1% (Antoniades et al. 2005) 
MI French  421 controls 35.15% 52.02% 12.83% (Poirier et al. 1999) 
MI Swedish 
MEN: 
156 no MI 
WOMEN: 
162 no MI 
Men: 
57.05% 
Women: 
55.56% 
Men: 
36.53% 
Women: 
39.50% 
Men: 
6.4% 
Women: 
4.93% 
(Odeberg et al. 2008) 
MI Northern Ireland 155 controls 37.42% 46.45% 16.13% (Poirier et al. 1999) 
MI Polish 134 controls (>45yrs) 46.3% 45.55% 8.2% (Gluba et al. 2009) 
AMI and extent of CAD. Greek 727 controls 40.9% 40.9% 10.7% (Andrikopoulos et al. 2008) 
MI Japanese 607 controls 86.7% 13.2% 0.2% (Shimasaki et al. 1998) 
AMI Japanese 357 controls 82.6% 17.4% 0.0% (Hibi et al. 1998) 
MI Korean 803 controls 83.06% 16.31% 0.62% (Jo et al. 2006) 
MI Australian 457 controls 48.14% 39.82% 12.04% (Cai et al. 1999) 
Cardiovascular damage Italian 67 controls 28.0% 61.0% 11% (Colomba et al. 2008) 
ACS Italy 537 controls 43.9% 45.2% 10.8% (Fatini et al. 2004) 
ACS Korean 142 controls 83.1% 15.5% 1.4% (Park et al. 2004) 
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Table 132- Glu298Asp reported genotype frequencies in previous CVD control groups 
Heart Disease Population Subjects GG GT TT Study 
Internal carotid artery stenosis Italian? 133 controls 42.0% 53.0% 5.0% (Ghilardi et al. 2003) 
Cerebral  SVD White 600 controls 40.5% 49.2% 10.4% (Hassan et al. 2004) 
Ischemic cerebro-vascular 
disease and carotid atheroma 
American 236 controls 40.7% 44.1% 15.3% (Markus et al. 1998) 
 
Table 133- Glu298Asp reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects GG GT TT Reference 
CVD Eastern Taiwan 120 patients 20.8% 74.2% 5.0% (Lin et al. 2008) 
CHD Japanese 36 patients 44.4% 41.7% 13.9% (Ameno et al. 2006) 
CHD United States 215 patients 38.0% 48.0% 14.0% (Zhang et al. 2006) 
IHD Japanese 54 patients 70.4% 24.1% 5.6% (Tamemoto et al. 2008) 
CAD Caucasian Men- 755 patients 45.4% 44.1% 10.5% (Agema et al. 2004) 
CAD Italian 268 patients 40.7% 43.3% 16.0% (Colombo et al. 2003a) 
CAD Italian 201 patients 45.3% 38.8% 15.9% (Colombo et al. 2003b) 
CAD Turkish 250 patients 45.6% 41.2% 13.2% (Afrasyap & Ozturk 2004) 
CAD North Turkish Caucasian 102 patients 58.8% 34.3% 6.9% (Kara et al. 2007) 
CAD (>75% stenosis) 
Southern Brazilians 
(European descent) 
219 patients 
(>75% stenosis) 
37.9% 50.2% 11.9% (Rios et al. 2005) 
CAD  and MI Austrian 240 patients 43% 46% 11% (Schmoelzer et al. 2003) 
CAD Greek 209 patients 52% 41% 7% (Vasilakou et al. 2008) 
PCAD Turkish 115 patients 38.3% 32.2% 29.5% (Berdeli et al. 2005) 
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PCAD Turkish 115 patients 38.3% 32.2% 29.5% (Cam et al. 2005) 
CAD and MI United Kingdom 
CHAOS: 
298 Patients 
CHAOS II: 249 patients with 
recent MI  
CHAOS: 
40.3% 
CHAOS II: 
38.9% 
CHAOS: 
23.8% 
CHAOS II: 
43.0% 
CHAOS: 
35.9% 
CHAOS II: 
18.1% 
(Hingorani et al. 1999) 
 
AD and MI Taiwan 218 patients 81.7% 17.4% 0.9% (Wang et al. 2001) 
CAD Korean-Bungdang 147 patients 25.2% 80.9% 0.0% (Kim et al. 2007) 
PCAD Taiwan 114 patients 79.8% 20.2% 0.0% (Wu et al. 2003) 
CAD 
Brazilians- Caucasian 
and African 
448 patients 
 
Caucasian-
Brazilians 
Smoking 
53.3% 
Non-smoking 
49.2% 
African-
Brazilians 
SMOKING 
51.2% 
Non-smoking: 
57.4% 
 
Caucasian-
Brazilians 
Smoking: 
39.1% 
Non-smoking 
40.2% 
African-
Brazilians 
SMOKING: 
41.9% 
Non-smoking: 
31.1% 
Caucasian-
Brazilians 
Smoking: 
7.7% 
Non-smoking 
10.6% 
African-
Brazilians 
SMOKING: 
7.0% 
Non-smoking: 
11.5% 
(Rios et al. 2007) 
CAD Chilean 112 patients 65% 28% 7% (Jaramillo et al. 2006) 
CAD Chilean 112 patients 65% 28% 7% (Jaramillo et al. 2010) 
CAD Australian Caucasian 573 patients 45.5% 43.4% 11.0% (Granath et al. 2001) 
CAD Australian-White 605 patients 47.27% 41.16% 11.57% (Cai et al. 1999) 
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PCAD Canadian 
299 patients two groups early 
and late onset 
G1 (149 CAD 
before 50years) 
GG=34.9% 
G2 (150 Patients) 
GG=29.3% 
 
G1 (149 CAD 
before 50years): 
46.3% 
G2 (150 
Patients): 
56% 
G1 (149 CAD 
before 50years): 
18.8% 
G2 (150 
Patients): 
14.7% 
(Nassar et al. 2001) 
CAD Tamilian south Indian 100 patients 72% 26% 2% (Nishevitha et al. 2009) 
CAD Iranian 241 patients 46.55% 42.7% 10.8% (Salimi et al. 2010) 
CAD North Indian 443patients 63.43% 32.51% 4.06% Current Study 
IS Hungarian Caucasian 407 patients 50.4% 44.0% 5.7% (Szolnoki et al. 2005) 
IS France 474 patients 46.1% 40.7% 13.3% (Elbaz et al. 2000) 
IS 
American Stroke 
prevention in Young 
women case control 
study 
White: 59 patients 
Black : 50 patients 
Whites (N=59): 
49.0% 
Blacks: (N=50) 
80.0% 
Whites (N=59): 
39.05% 
Blacks: (N=50) 
20.0% 
Whites (N=59): 
12.0% 
Blacks: (N=50) 
0.0% 
(Howard et al. 2005) 
 
IS Chinese 309 patients 76.05% 22.65% 1.30% (Cheng et al. 2008a) 
MI Northern Ireland-Belfast 163 patients 33.74% 46.62% 19.63% (Poirier et al. 1999) 
MI Polish 273 patients (MI<45yrs) 50.4% 42.6% 7.0% (Gluba et al. 2009) 
AMI and severity of 
CAD. 
Greek 1602 patients 43.8% 43.8% 11.2% (Andrikopoulos et al. 2008) 
MI Greek Caucasians 
61 patients (first event 
premature MI) 
42.5% 43.5% 14.0% (Antoniades et al. 2005) 
MI French 368 patients 44.29% 42.39% 13.32% (Poirier et al. 1999) 
MI Swedish 
MEN: 
46 patients 
WOMEN: 
39 patients 
Men: 
50% 
Women: 
51.28% 
 
Men: 
39.13% 
Women: 
35.9% 
Men: 
10.87% 
Women: 
12.82% 
(Odeberg et al. 2008) 
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Table 134-T-786C reported genotype frequencies in previous CVD control groups 
CVD group Population Subjects TT TC CC Study 
CHD Japanese 215 Controls 87.9% 11.6% 1.6% (Ameno et al. 2006) 
CHD United States 641 controls 51.0% 38.05% 11.0% (Zhang et al. 2006) 
CAD Spanish- Caucasian 300 controls 40% 46.0% 14.0% (Alvarez et al. 2001) 
CAD Italian 138 controls 34.1% 51.4% 14.5% (Colombo et al. 2003a) 
CAD Turkish 52 controls 59.6% 28.8% 11.5% (Tangurek et al. 2006) 
MI Japanese 285 Patients 78.95% 20.7% 0.4% (Shimasaki et al. 1998) 
AMI Japanese 226 patients 83.6% 14.2% 2.2% (Hibi et al. 1998) 
MI Korean 129 patients 80.62% 17.83% 1.55% (Jo et al. 2006) 
MI Australian 306 patients 43.79% 44.77% 11.44% (Cai et al. 1999) 
CCD Turkey-Ankara 473 patients 46.5% 39.7% 13.7% (Gulec et al. 2007) 
Cardiovascular damage Italian 127 patients 35.4% 55.1% 9.5% (Colomba et al. 2008) 
Coronary stent outcomes Finland 
1850 CAD patients treated 
with a stent implantation 
46.8% 42.8% 10.4% (Gorchakova et al. 2003) 
ACS Florence Italy 477 patients 38.8% 44.6% 16.5% (Fatini et al. 2004) 
ACS Korean 164 patients 78.0% 21.3% 0.6% (Park et al. 2004) 
Internal carotid artery 
stenosis 
Italian? 88 patients 44.0% 48.0% 8.0% (Ghilardi et al. 2003) 
Cerebral small vessel 
disease (SVD) 
White 
300 patients 
 
39.4% 46.5% 14.1% (Hassan et al. 2004) 
Ischemic cerebro-
vascular disease and 
carotid atheroma 
American-Dallas 361 patients 35.2% 51.2% 13.0% (Markus et al. 1998) 
Appendices  
294 | P a g e  
 
Table 134-T-786C reported genotype frequencies in previous CVD control groups 
CVD group Population Subjects TT TC CC Study 
CAD Caucasian Men-Netherlands? 387 controls 42.4% 42.9% 14.7% (Agema et al. 2004) 
CAD Czech republic 57 controls  44% 49% 7% (Meluzin et al. 2009) 
CAD North Turkish  103 controls 45.6% 45.6% 8.8% (Kara et al. 2007) 
CAD Korean-Bungdang 222 controls 82.0% 17.1% 0.0% (Kim et al. 2007) 
CAD Australian Caucasian 624 controls 39.3% 45.7% 14.9% (Granath et al. 2001) 
CAD Chilean 112 controls 59% 38.0% 4.0% (Jaramillo et al. 2010) 
CAD 
Brazilians- Caucasian and 
African 
267 controls 
Caucasian-
Brazilians 
Smoking 
63.9% 
Non-smoking 
40% 
African-
Brazilians 
Smoking 
73.3% 
Non-smoking 
52.5% 
Caucasian-
Brazilians 
Smoking 
26.2% 
Non-smoking 
40.0% 
African-
Brazilians 
Smoking: 
23.3% 
Non-smoking: 
37.7% 
Caucasian-
Brazilians 
Smoking 
9.8% 
Non-smoking 
20.0% 
African-
Brazilians 
Smoking 
3.3% 
Non-smoking 
9.8% 
(Rios et al. 2007) 
CAD (>75% 
stenosis) 
Southern Brazilians 
(European descent) 
129 controls 49.9% 39.5% 11.6% (Rios et al. 2005)   
CAD North Indian 212 controls 62.74% 33.02% 4.25% Current study (including old method) 
CAD North Indian 187 controls 61.50% 33.69% 4.81% Current Study (Real time only) 
IS Chinese 309 controls 80.91% 18.12 0.97% (Cheng et al. 2008a) 
IS 
American Stroke prevention 
in Young women case 
control study 
117 white controls 
75 black controls 
Whites: (N=117) 
34.0% 
Blacks: (N=75) 
Whites: (N=117) 
50.0% 
Blacks: (N=75) 
Whites: (N=117) 
15.0% 
Blacks: (N=75) 
(Howard et al. 2005)  
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Table 134-T-786C reported genotype frequencies in previous CVD control groups 
CVD group Population Subjects TT TC CC Study 
56.0% 36.0% 8.0% 
MI Polish 134 controls (>45yrs) 62.3% 32.8% 4.9% (Gluba et al. 2009) 
MI Korean 803 controls 80.07% 18.68% 1.25% (Jo et al. 2006) 
ACS and CHD Turkish 31 controls 67.7% 25.8% 6.5% (Ciftci et al. 2008) 
ACS  Florence Italy 537 controls 37.0% 48.3% 14.5% (Fatini et al. 2004) 
Coronary spasm Japanese 161 controls 93% 7% 0% (Nakayama et al. 1999)) 
Internal carotid 
artery stenosis 
Italian? 133 controls 41.0% 46.0% 13.0% (Ghilardi et al. 2003)  
Cerebral SVD White 600 controls 40.5% 49.2% 10.4% (Hassan et al. 2004)  
 
Table 135- T-786C reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects TT TC CC Study 
CHD Japanese 37 Dead patients  89.2% 10.8% 0.0% (Ameno et al. 2006) 
CHD United States 220 patients 47% 44.0% 8.0% (Zhang et al. 2006) 
CAD Spanish- Caucasian 170 patients 31% 47% 22% (Alvarez et al. 2001) 
CAD Italian 236 patients 22.9% 52.5% 24.6% (Colombo et al. 2003a) 
CAD Turkish 159 patients 39.6% 45.9% 13.8% (Tangurek et al. 2006) 
CAD 
Caucasian Men-
Netherlands? 
709 
patients 
39.6% 44.7% 15.7% (Agema et al. 2004) 
CAD Czech republic 
321 patients significant 
atherosclerosis 
41 patients insignificant 
Patients with sig 
atherosclerosis 
37% 
Patients with sig 
atherosclerosis 
50% 
Patients with sig 
atherosclerosis 
13% 
(Meluzin et al. 2009) 
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Table 135- T-786C reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects TT TC CC Study 
atherosclerosis  Patients with insig 
atherosclerosis 
37% 
Patients with insig 
atherosclerosis 
59% 
Patients with insig 
atherosclerosis 
4% 
CAD North Turkish Caucasian 102 patients 56.9% 36.3% 6.8% (Kara et al. 2007) 
CAD Korean-Bungdang 147 patients 74.8% 23.8% 1.4% (Kim et al. 2007) 
PCAD  Chinese- Shandong 167 patients 71.86% 26.9% 1.2% (Jia et al. 2007)  
CAD Australian Caucasian 508 patients 43.1% 46.9% 10.0% (Sim et al. 1998) 
CAD Australian Caucasian 573 patients 38.45% 46.6% 15.0% (Granath et al. 2001) 
CAD 
Brazilians- Caucasian and 
African 
448 patients 
267 controls 
Caucasian-
Brazilians 
Smoking 
42% 
Non-smoking 
40.2% 
African-Brazilians 
Smoking 
46.5% 
Non-smoking 
47.5 
Caucasian-Brazilians 
Smoking 
43.8% 
Non-smoking 
50.0% 
African-Brazilians 
Smoking 
45.3% 
Non-smoking 
36.1% 
Caucasian-
Brazilians 
Smoking 
14.2% 
Non-smoking 
9.8% 
African-Brazilians 
Smoking 
8.1% 
Non-smoking 
16.4% 
(Rios et al. 2007)  
CAD >75 
stenosis 
Southern Brazilians 
(European descent) 
219 patients 
(>75% stenosis) 
27.9% 55.7% 16.4% (Rios et al. 2005)  
CAD Chilean 112 patients 58% 36% 6% (Jaramillo et al. 2010) 
CAD North Indian 437 patients 59.27% 36.16% 4.58% 
Current study (including old 
method) 
CAD North Indian 384 patients 57.03% 37.76% 5.21% Current Study (real time only) 
IS Chinese 309 patients 77.67% 18.7% 3.56% (Cheng et al. 2008a) 
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Table 135- T-786C reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects TT TC CC Study 
IS 
American Stroke 
prevention in Young 
women case control study 
50 white patients 
50 black patients 
Whites: 
40.0% 
Blacks:  
78.0% 
Whites; 
40.0% 
Blacks 
22.0% 
Whites: 
20.0% 
Blacks: 
0.0% 
(Howard et al. 2005)  
MI Polish 273 patients (MI<45yrs) 65% 31% 5.4% (Gluba et al. 2009) 
MI Korean 129 patients 70.54% 27.9% 1.55% (Jo et al. 2006) 
ACS and CHD Turkish 
30 patients (10ACS) 
(20CHD) 
ACS: 
10% 
CHD: 
75% 
ACS: 
40.0% 
CHD: 
20.0% 
ACS: 
50.0% 
CHD: 
5.0% 
(Ciftci et al. 2008) 
ACS  Florence Italy 477 patients 25.7% 51.8% 22.4% (Fatini et al. 2004) 
Coronary 
spasm 
Japanese 174 patients 70% 28.% 2.% (Nakayama et al. 1999)) 
Internal carotid 
artery stenosis 
Italian? 88 patients 25.0% 49.0% 26.0% (Ghilardi et al. 2003) 
cerebral (SVD) White 300 patients 39.4% 46.5% 14.1% (Hassan et al. 2004)  
 
Table 136-Intron 4 reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects 4bb 4ab 4aa Study 
CHD Scottish 189  patients 70.3% 27.0% 2.7% (Fowkes et al. 2000) 
CAD 
Caucasian Men-
Netherlands? 
752 patients 72.5% 25.9% 1.6% (Agema et al. 2004) 
CAD Turkish-southern 133 patients 60.9% 35.3% 3.8% (Matyar et al. 2005) 
CAD Czech republic 939 patients 67.31% 28.97% 3.73% (Kincl et al. 2009) 
CAD European 630 patients 73.0% 25.0% 2.0% (Sigusch et al. 2000) 
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Table 136-Intron 4 reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects 4bb 4ab 4aa Study 
PCAD 
Slovenian Caucasian 
women 
151 patients (<65 yrs) 68.8% 27.2% 4.0% (Letonja 2004) 
CAD Slovene men 215 patients 67.1% 27.9% 5.0% (Milutinovic & Hruskovicova 2005) 
CAD Spanish- Caucasian 
All male smokers: 
170 patients 
77% 22% 1% (Alvarez et al. 2001) 
CAD- number of 
carotid plaques 
Italian 
206 carotid plaque 
presence patients 
69.9% 26.7% 3.4% (Lembo et al. 2001) 
CAD Greek 209 patients 67% 29% 4% (Vasilakou et al. 2008) 
CAD Iran 141 patients 68.8% 29.1% 2.1% (Salimi et al. 2006) 
PCAD Taiwan 114 patients 70.2% 28.9% 0.9% (Wu et al. 2003) 
CAD Korean males 305 male patients 83.0% 14.8% 2.3% (Lee et al. 2001) 
CAD Korean-Bungdang 147 patients 74.8% 23.8% 1.4% (Kim et al. 2007) 
CAD and MI Australian (Caucasian) 573 patients 73.8% 24.3% 1.9% (Granath et al. 2001) 
CAD 
Brazilians- Caucasian 
and African 
448 patients 
 
Caucasian-
Brazilians 
Smoking 
66.9% 
Non-smoking 
67.4% 
African-Brazilians 
smoking 
61.6% 
Non-smoking 
62.3% 
Caucasian-Brazilians 
Smoking 
30.2% 
Non-smoking 
27.3% 
African-Brazilians 
Smoking 
32.6% 
Non-smoking 
36.1% 
Caucasian-
Brazilians 
Smoking 
3% 
Non-smoking 
5.3% 
African-Brazilians 
Smoking 
5.8% 
Non-smoking 
1.6% 
(Rios et al. 2007) 
CAD Chilean 112 patients 86% 12% 2% (Jaramillo et al. 2010) 
CAD North Indian 457 patients 71.12% 27.13% 1.75% Current Study 
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Table 136-Intron 4 reported genotype frequencies in previous CVD patient groups 
CVD group Population Subjects 4bb 4ab 4aa Study 
MI Turkish 207 patients 69.1% 26.6% 4.3% (Cine et al. 2002) 
MI Tunisian 310 patients 61.3% 33.9% 4.8% (Jemaa et al. 2007) 
MI Japanese 455 patients 75.0% 23% 2.0% (Ichihara et al. 1998) 
AMI and CAD 
severity 
Japanese 226 patients 77.0% 21.2% 1.8% (Hibi et al. 1998) 
ACS and MI Italian 477 patients 66.0% 28.9% 5.0% (Fatini et al. 2004) 
ACS Korean 164 patients 84.8% 12.8% 2.4% (Park et al. 2004) 
 
Table 137- Intron 4 reported genotype frequencies in previous CVD control groups 
CVD group Population Subjects 4bb 4ab 4aa Study 
CHD Scottish 300 controls 77.0% 21.3% 1.7% (Fowkes et al. 2000)  
CAD 
Caucasian Men-
Netherlands? 
466 controls 81.8% 16.5% 1.7% (Agema et al. 2004) 
CAD Turkish-southern 133 controls 72.9% 26.3% 0.8% (Matyar et al. 2005) 
CAD Czech republic 222 controls 67.57% 28.38% 4.05% (Kincl et al. 2009) 
CAD Czech republic 57 controls  70% 30% 0% (Meluzin et al. 2009) 
CAD European 413 controls 69.0% 28.0% 3.0% (Sigusch et al. 2000) 
PCAD 
Slovenian Caucasian 
women 
109 controls 67.0% 26.6% 6.4% (Letonja 2004) 
CAD Slovene men 188 controls 63.8% 30.9% 5.3% (Milutinovic & Hruskovicova 2005) 
CAD Spanish- Caucasian 
All male smokers: 
300 controls 
73% 24% 2% (Alvarez et al. 2001) 
CAD- number of 
carotid plaques 
Italian 
169 controls-no carotid 
plaques 
69.9% 26.6% 4.1% (Lembo et al. 2001) 
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Table 137- Intron 4 reported genotype frequencies in previous CVD control groups 
CVD group Population Subjects 4bb 4ab 4aa Study 
CAD Greek 161 controls 73% 24% 3% (Vasilakou et al. 2008) 
PCAD  Taiwan 65 controls 76.9% 23.1% 0% (Wu et al. 2003) 
CAD Korean males 215 male controls 76.7% 22.8% 0.5% (Lee et al. 2001)  
CAD Korean-Bungdang 211 controls 77.0% 18.0% 0% (Kim et al. 2007) 
CAD and MI Australian (Caucasian) 624 controls 72.3% 25.5% 2.2% (Granath et al. 2001) 
CAD Chilean 112 controls 85% 14.05% 1% (Jaramillo et al. 2010) 
CAD Iran 159 controls 81.0% 18.4% 0.6% (Salimi et al. 2006) 
CAD North Indian 220 controls 69.55% 26.36% 4.09% Current Study 
IS 
American Stroke 
prevention in Young 
women case control 
study 
121 white control 
67 black controls 
Whites: 
73.0% 
Blacks:  
45.0% 
Whites:  
25.0% 
Blacks:  
45.0% 
Whites:  
2.0% 
Blacks:  
8.0% 
(Howard et al. 2005)  
 MI Turkish 306 controls 81.4% 18.0% 0.6% (Cine et al. 2002)  
MI Tunisian 250 controls 74.0% 24.4% 1.6% (Jemaa et al. 2007) 
MI  Japanese 550 controls 81.0% 18.0% 1.0% (Ichihara et al. 1998) 
ACS and AMI Florence Italy 537 controls 71.7% 25.7% 2.6% (Fatini et al. 2004) 
ACS Korean 142 controls 74.0% 21.1% 4.9% (Park et al. 2004) 
Cerebral SVD White 600 controls 72.8% 24.4% 2.9% (Hassan et al. 2004) 
AMI,  severity 
CAD 
Japanese 357 controls 79.6% 19.0% 1.4% (Hibi et al. 1998) 
CAL in Kawasaki 
disease 
Japanese  187 controls 79.7% 17.6% 2.7% (Khajoee et al. 2003) 
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8.6 Appendix 6 hypertension results tables 
Table 138-Independent samples t-test for genotypes  TT vs. GG for entire sample (Ht Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 
TT 19 48.826 12.774 2.931 -1.1516 -3.377 0.251 
GG 220 52.204 12.222 0.824       
SBP 
TT 19 125.895 12.732 2.921 *-1.850 -5.987 0.075 
GG 220 131.882 20.643 1.392       
DBP 
TT 19 80.474 7.799 1.789 *-1.984 -3.890 0.058 
GG 220 84.364 11.912 0.803       
FBS 
TT 12 146.583 87.294 25.200 0.033 0.777 0.974 
GG 160 145.806 79.303 6.269       
BMI 
TT 19 27.267 4.577 1.050 1.306 1.473 0.193 
GG 220 25.794 4.728 0.319       
WHR 
TT 19 0.935 0.094 0.022 -1.834 -0.031 0.068 
GG 220 0.966 0.068 0.005       
AGE OF ONSET  
TT 3 47.000 9.165 5.292 -0.776 -5.407 0.440 
GG 81 52.407 11.910 1.323 -0.991 -5.407 0.416 
 
Table 139-Independent samples t-test for genotype TT vs. GT for the entire sample (Ht Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 
TT 19 48.826 12.774 2.931 -1.28935 -3.752 0.199 
GT 129 52.578 11.705 1.031       
SBP 
TT 19 125.895 12.732 2.921 -1.20751 -6.772 0.229 
GT 129 132.667 23.902 2.104       
DBP 
TT 19 80.474 7.799 1.789 -1.10974 -3.790 0.269 
GT 129 84.264 14.552 1.281       
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Table 139-Independent samples t-test for genotype TT vs. GT for the entire sample (Ht Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
FBS 
TT 12 146.583 87.294 25.200 0.076 1.752 0.940 
GT 77 144.831 72.426 8.254       
BMI 
TT 19 27.267 4.577 1.050 1.285 1.745 0.201 
GT 129 25.522 5.649 0.497       
WHR 
TT 19 0.935 0.094 0.022 -0.961 -0.017 0.338 
GT 129 0.952 0.069 0.006       
AGE OF ONSET TT 3 47.000 9.165 5.292 -0.962 -6.140 0.341 
  GT 43 53.140 10.756 1.640       
 
Table 140-Independent samples t-test between genotypes GG vs. GT (Ht Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 
GG 220 52.204 12.222 0.824 -0.28075 -0.375 0.779 
GT 129 52.578 11.705 1.031       
SBP 
GG 220 131.882 20.643 1.392 -0.32314 -0.785 0.747 
GT 129 132.667 23.902 2.104       
DBP 
GG 220 84.364 11.912 0.803 *0.066 0.100 0.947 
GT 129 84.264 14.552 1.281       
FBS 
GG 160 145.806 79.303 6.269 0.091 0.975 0.927 
GT 77 144.831 72.426 8.254       
BMI 
GG 220 25.794 4.728 0.319 0.483 0.272 0.630 
GT 129 25.522 5.649 0.497       
WHR 
GG 220 0.966 0.068 0.005 1.800 0.014 0.073 
GT 129 0.952 0.069 0.006       
AGE OF ONSETT GG 81 52.407 11.910 1.323 -0.337 -0.732 0.737 
  GT 43 53.140 10.756 1.640       
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Table 141-Independent samples t-test for genotypes TC vs. CC for entire sample (Ht T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 
CC 36 52.883 10.775 1.796 0.5077 1.134 0.612 
TC 152 51.749 12.325 1.000       
SBP 
CC 36 131.722 19.645 3.274 -0.0123 -0.048 0.990 
TC 152 131.770 21.027 1.706       
DBP 
CC 36 85.611 13.904 2.317 0.5555 1.440 0.579 
TC 152 84.171 14.004 1.136       
FBS 
CC 29 156.483 75.249 13.973 0.134 2.463 0.894 
TC 100 154.020 90.278 9.028       
BMI 
CC 36 25.552 4.553 0.759 0.126 0.121 0.900 
TC 152 25.431 5.335 0.433       
WHR 
CC 36 0.969 0.065 0.011 1.376 0.018 0.170 
TC 152 0.951 0.070 0.006       
AGEONSET 
CC 18 46.056 9.142 2.155 -1.678 -4.703 0.097 
TC 62 50.758 10.805 1.372       
 
Table 142- Independent samples t-test for genotype CC vs. TT for the entire sample (Ht T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE CC 36 52.883 10.775 1.796 .373 .77710 0.709 
TT 289 52.106 11.900 0.700    
SBP CC 36 131.722 19.645 3.274 -.600 -2.45771 0.549 
TT 289 134.180 23.579 1.387    
DBP CC 36 85.611 13.904 2.317 .058 .13360 0.954 
TT 289 85.478 13.015 0.766    
FBS CC 29 156.483 75.249 13.973 .788 12.06881 0.432 
Appendices  
304 | P a g e  
 
Table 142- Independent samples t-test for genotype CC vs. TT for the entire sample (Ht T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
TT 215 144.414 77.742 5.302    
BMI CC 36 25.552 4.553 0.759 -.625 -.59165 0.533 
TT 289 26.144 5.450 0.321    
WHR CC 36 0.969 0.065 0.011 -.080 -.00094 0.936 
TT 289 0.970 0.067 0.004    
AGE  OF 
ONSET 
CC 18 46.0556 9.142481 2.155 -2.318 -6.24444 0.022 
TT 110 52.3 10.80651 1.030    
 
Table 143-Independent samples t-test between genotypes TC vs. TT for the entire population (Ht T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 
TC 152 51.749 12.325 1.000 -0.29564 -0.357 0.768 
TT 289 52.106 11.900 0.700       
SBP 
TC 152 131.770 21.027 1.706 -1.05812 -2.410 0.291 
TT 289 134.180 23.579 1.387       
DBP 
TC 152 84.171 14.004 1.136 -0.97571 -1.306 0.330 
TT 289 85.478 13.015 0.766       
FBS 
TC 100 154.020 90.278 9.028 0.969 9.606 0.333 
TT 215 144.414 77.742 5.302       
BMI 
TC 152 25.431 5.335 0.433 -1.315 -0.713 0.189 
TT 289 26.144 5.450 0.321       
WHR 
TC 152 0.951 0.070 0.006 -2.722 -0.018 0.007 
TT 289 0.970 0.067 0.004       
AGE OF ONSET 
TC 62 50.758 10.805 1.372 -0.89853 -1.542 0.370 
TT 110 52.3 10.807 1.030       
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Table 144-Independent samples t-test for genotypes 4aa vs. 4ab for entire sample (Ht Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 4aa 7 56.000 13.154 4.972 0.778 3.880 0.438 
4ab 120 52.120 12.816 1.170       
SBP 4aa 7 149.571 37.567 14.199 *1.267 18.138 0.251 
4ab 120 131.433 19.519 1.782       
DBP 4aa 7 89.714 18.661 7.053 0.783 4.523 0.435 
4ab 120 85.192 14.643 1.337       
FBS 4aa 5 193.800 82.863 37.057 1.227 45.347 0.223 
4ab 86 148.453 80.195 8.648       
BMI 4aa 7 26.046 3.182 1.203 0.292 0.633 0.771 
4ab 120 25.412 5.674 0.518       
WHR 4aa 7 0.956 0.075 0.028 -0.302 -0.008 0.763 
4ab 120 0.964 0.067 0.006       
AGE OF ONSET 4aa 5 48.800 9.680 4.329 -0.265 -1.380 0.792 
4ab 50 50.180 11.192 1.583       
 
Table 145-Independent samples t-test for genotypes 4aa vs. 4bb for the entire sample (Ht Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 4aa 7 56.000 13.154 4.972 0.976 4.373 
  
0.330 
  4bb 348 51.627 11.710 0.628 
SBP 4aa 7 149.571 37.567 14.199 1.821 16.221 0.069 
4bb 348 133.351 23.005 1.233       
DBP 4aa 7 89.714 18.661 7.053 1.009 4.936 0.313 
4bb 348 84.779 12.683 0.680       
FBS 4aa 5 193.800 82.863 37.057 1.167 44.812 0.244 
4bb 255 148.988 85.086 5.328       
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Table 145-Independent samples t-test for genotypes 4aa vs. 4bb for the entire sample (Ht Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
BMI 4aa 7 26.046 3.182 1.203 0.029 0.058 0.977 
4bb 348 25.988 5.272 0.283       
WHR 4aa 7 0.956 0.075 0.028 -0.285 -0.008 0.776 
4bb 348 0.963 0.070 0.004     
AGEONSET 4aa 5 48.800 9.680 4.329 -0.663 -3.230 0.508 
4bb 132 52.030 10.723 0.933       
 
Table 146-Independent samples t-tests between genotypes 4ab vs. 4bb (Ht Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
AGE 4ab 120 52.120 12.816 1.170 0.388 0.493 0.698 
4bb 348 51.627 11.710 0.628       
SBP 4ab 120 131.433 19.519 1.782 -0.817 -1.917 0.414 
4bb 348 133.351 23.005 1.233       
DBP 4ab 120 85.192 14.643 1.337 0.295 0.413 0.768 
4bb 348 84.779 12.683 0.680       
FBS 4ab 86 148.453 80.195 8.648 -0.051 -0.535 0.959 
4bb 255 148.988 85.086 5.328 
      
BMI 4ab 120 25.412 5.674 0.518 -1.011 -0.575 0.313 
4bb 348 25.988 5.272 0.283       
WHR 4ab 120 0.964 0.067 0.006 0.038 0.000 0.970 
4bb 348 0.963 0.070 0.004       
AGE OF 
ONSET 
4ab 50 50.18 11.192 1.583 -1.027 -1.8503 0.306 
4bb 132 52.0303 10.723 0.933       
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Table 147-ACE and eNOS association in Hypertension sample 
Glu298Asp eNOS-GG eNOS-GT eNOS-TT Χ2 P 
ACE-II 49 (22.4%) 33 (25.8%) 3 (16.7%) 6.369 0.173 
ACE-ID 106 (48.4%) 68 (53.1%) 13 (72.2%) df=4   
ACE-DD 64 (29.2%) 27 (21.1%) 2 (11.1%)    
Total 219 (100%) 128 (100%) 18 (100%)     
T-786C eNOS-TT eNOS-TC eNOS-CC χ2 P 
ACE-II 81 (28.2%) 29 (19.2%) 6 (16.7%) 8.831 0.065 
ACE-ID 134 (46.7%) 85 (56.3%) 16 (44.4%) df=4   
ACE-DD 72 (25.1%) 37 (24.5%) 14 (38.9%)   
Total 287 (100%) 151 (100%) 36 (7.6%)     
Intron 4 eNOS-4aa eNOS-4ab eNOS-4bb χ2 P 
ACE-II 0 (0%) 21 (17.6%) 92 (26.7%) 8.437 0.077 
ACE-ID 3 (42.9%) 66 (55.5%) 165 (47.8%) df=4   
ACE-DD 4 (57.1%) 32 (26.9%) 88 (25.5%)   
Total 7 (100%) 119 (100%) 345 (100%)   
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8.7 Appendix 7 T2DM Results tables  
Table 148-Independent samples t-test comparing genotypes TT and GG for entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 
TT 21 60.167 9.750 2.128 
-0.960 -2.559 0.923 
GG 324 60.423 11.904 0.661 
Height (cm) 
TT 21 161.000 10.004 2.183 
0.377 0.778 0.706 
GG 324 160.222 9.099 0.505 
Weight  (Kg) 
TT 21 67.414 14.253 3.110 
-0.905 -2.741 0.366 
GG 324 70.156 13.395 0.744 
Body Mass Index 
TT 21 25.942 4.914 1.072 
-1.298 -1.361 0.195 
GG 324 27.304 4.641 0.258 
Triceps Skin folds  (mm) 
TT 21 21.362 8.565 1.869 
-0.256 -0.506 0.798 
GG 324 21.868 8.787 0.488 
Sub Scapula Skin folds (mm) 
TT 21 28.657 10.224 2.231 
-0.654 -1.292 0.513 
GG 324 29.949 8.674 0.482 
Waist (inches) 
TT 21 34.886 4.670 1.019 
-1.597 -1.607 0.111 
GG 324 36.493 4.456 0.248 
Hip (inches) 
TT 21 37.019 3.221 0.703 
-1.428 -1.197 0.154 
GG 324 38.216 3.751 0.208 
Waist Hip Ratio 
TT 11 0.893 0.086 0.026 
-1.696 -0.042 0.092 
GG 137 0.935 0.078 0.007 
Systoloic BP (mmHg) 
TT 21 146.619 28.540 6.228 
0.153 0.878 0.879 
GG 324 145.741 25.323 1.407 
Diastolic BP (mmHg) 
TT 21 83.381 22.062 4.814 
-0.355 -1.051 0.723 
GG 324 84.432 12.386 0.688 
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Table 148-Independent samples t-test comparing genotypes TT and GG for entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
 Glucose (mg/dl) 
TT 21 148.714 62.924 13.731 
-0.080 -1.215 0.937 
GG 324 149.929 68.029 3.779 
OGTT 
TT 4 124.500 9.147 4.573 
0.710 8.500 0.483 
GG 26 116.000 23.370 4.583 
Cholesterol (mg/dl) 
TT 14 192.429 47.270 12.633 
0.325 4.652 0.746 
GG 268 187.776 52.465 3.205 
Glyceride (mg/dl) 
TT 14 193.036 73.287 19.587 
0.561 15.913 0.575 
GG 268 177.123 104.702 6.396 
HDL (mg/dl) 
TT 14 39.471 11.794 3.152 
-0.357 -1.204 0.722 
GG 268 40.675 12.332 0.753 
LDL (mg/dl) 
TT 14 112.386 37.042 9.900 
0.362 4.126 0.718 
GG 267 108.260 41.791 2.558 
VLDL (mg/dl) 
  
TT 14 38.607 14.682 3.924 
0.143 1.037 0.887 
GG 266 37.570 26.920 1.651 
Waist (inches) 
TT 21 34.886 4.670 1.019 
-1.597 -1.607 0.111 
GG 324 36.493 4.456 0.248 
 
 
 Table 149-Independent samples t-test between genotypes TT and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 
TT 21 60.167 9.750 2.128 
*-0.043 -0.102 0.966 
GT 165 60.269 13.310 1.036 
Height (cm) 
TT 21 161.000 10.004 2.183 
0.437 0.950 0.663 
GT 165 160.050 9.306 0.724 
Weight  (Kg) TT 21 67.414 14.253 3.110 -0.840 -2.588 0.402 
Appendices  
310 | P a g e  
 
 Table 149-Independent samples t-test between genotypes TT and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
GT 165 70.002 13.179 1.026 
Body Mass Index 
TT 21 25.942 4.914 1.072 
-1.238 -1.459 0.217 
GT 165 27.401 5.105 0.397 
Triceps Skin folds  (mm) 
TT 21 21.362 8.565 1.869 
-0.840 -1.751 0.402 
GT 165 23.113 9.046 0.704 
Sub Scapula Skin folds 
(mm) 
TT 21 28.657 10.224 2.231 
-1.392 -2.851 0.166 
GT 165 31.508 8.653 0.674 
Waist (inches) 
TT 21 34.886 4.670 1.019 
-1.282 -1.335 0.201 
GT 165 36.221 4.472 0.348 
Hip (inches) 
TT 21 37.019 3.221 0.703 
-1.531 -1.347 0.128 
GT 165 38.366 3.862 0.301 
Waist Hip Ratio 
TT 11 0.893 0.086 0.026 
-1.815 -0.048 0.072 
GT 99 0.940 0.082 0.008 
Systolic BP (mmHg) 
TT 21 146.619 28.540 6.228 
1.225 6.892 0.222 
GT 165 139.727 23.709 1.846 
Diastolic BP (mmHg) 
TT 21 83.381 22.062 4.814 
0.617 1.963 0.538 
GT 165 81.418 12.323 0.959 
 Glucose (mg/dl) 
TT 21 148.714 62.924 13.731 
1.231 17.811 0.220 
GT 165 130.903 62.369 4.855 
OGTT 
TT 4 124.500 9.147 4.573 
1.050 11.556 0.306 
GT 18 112.944 21.256 5.010 
Cholesterol (mg/dl) 
TT 14 192.429 47.270 12.633 
1.382 15.484 0.169 
GT 127 176.945 38.920 3.454 
Glyceride (mg/dl) TT 14 193.036 73.287 19.587 1.325 28.645 0.188 
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 Table 149-Independent samples t-test between genotypes TT and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
GT 127 164.391 77.152 6.846 
HDL (mg/dl) 
TT 14 39.471 11.794 3.152 
-0.213 -0.649 0.832 
GT 127 40.120 10.721 0.951 
LDL (mg/dl) 
TT 14 112.386 37.042 9.900 
0.761 7.898 0.448 
GT 127 104.487 36.837 3.269 
VLDL (mg/dl) TT 14 38.607 14.682 3.924 
1.316 5.662 0.190 
  GT 127 32.945 15.338 1.361 
Waist (inches) 
TT 21 34.886 4.670 1.019 
-1.282 -1.335 0.201 
GT 165 36.221 4.472 0.348 
 
Table 150-Independent samples t-test between GG and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 
GG 324 60.423 11.904 0.661 
0.129 0.153 0.897 
GT 165 60.269 13.310 1.036 
Height (cm) 
GG 324 160.222 9.099 0.505 
0.196 0.172 0.844 
GT 165 160.050 9.306 0.724 
Weight  (Kg) 
GG 324 70.156 13.395 0.744 
0.121 0.154 0.904 
GT 165 70.002 13.179 1.026 
Body Mass Index 
GG 324 27.304 4.641 0.258 
-0.211 -0.097 0.833 
GT 165 27.401 5.105 0.397 
Triceps Skin folds  (mm) 
GG 324 21.868 8.787 0.488 
-1.468 -1.246 0.143 
GT 165 23.113 9.046 0.704 
Sub Scapula Skin folds (mm) 
GG 324 29.949 8.674 0.482 
-1.880 -1.558 0.061 
GT 165 31.508 8.653 0.674 
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Table 150-Independent samples t-test between GG and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
Waist (inches) 
GG 324 36.493 4.456 0.248 
0.637 0.272 0.524 
GT 165 36.221 4.472 0.348 
Hip (inches) 
GG 324 38.216 3.751 0.208 
-0.414 -0.150 0.679 
TT 165 38.366 3.862 0.301 
Waist Hip Ratio 
GG 137 0.935 0.078 0.007 
-0.543 -0.006 0.588 
GT 99 0.940 0.082 0.008 
Systolic BP (mmHg) 
GG 324 145.741 25.323 1.407 
2.536 6.013 0.012 
GT 165 139.727 23.709 1.846 
Diastolic BP (mmHg) 
GG 324 84.432 12.386 0.688 
2.549 3.014 0.011 
GT 165 81.418 12.323 0.959 
 Glucose (mg/dl) 
GG 324 149.929 68.029 3.779 
3.006 19.026 0.003 
GT 165 130.903 62.369 4.855 
OGTT 
GG 26 116.000 23.370 4.583 
0.442 3.056 0.661 
GT 18 112.944 21.256 5.010 
Cholesterol (mg/dl) 
GG 268 187.776 52.465 3.205 
2.072 10.831 0.039 
GT 127 176.945 38.920 3.454 
Glyceride (mg/dl) 
GG 268 177.123 104.702 6.396 
*1.359 12.732 0.175 
GT 127 164.391 77.152 6.846 
HDL (mg/dl) 
GG 268 40.675 12.332 0.753 
0.435 0.555 0.664 
GT 127 40.120 10.721 0.951 
LDL (mg/dl) 
GG 267 108.260 41.791 2.558 
0.869 3.772 0.385 
GT 127 104.487 36.837 3.269 
VLDL (mg/dl) 
GG 266 37.570 26.920 1.651 
*2.161 4.625 0.031 
GT 127 32.945 15.338 1.361 
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Table 150-Independent samples t-test between GG and GT for the entire sample (T2DM Glu298Asp) 
Variable Genotype N Mean SD SE t value mean difference p value 
Waist (inches) 
GG 324 36.493 4.456 0.248 
0.637 0.272 0.524 
GT 165 36.221 4.472 0.348 
 
 
Table 151- Independent samples t-test comparing genotypes TC and CC for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) TC 50 64.484 11.528 1.630 1.929 3.817 .055 
CC 220 60.667 12.860 .867       
Age of onset TC 26 54.458 9.637 1.890 .333 .752 .740 
CC 109 53.706 10.505 1.006       
Height (cm) TC 50 159.950 9.355 1.323 .051 .072 .959 
CC 220 159.878 8.939 .603       
Weight  (Kg) TC 50 69.886 13.016 1.841 .143 .296 .886 
CC 220 69.590 13.268 .895       
Body Mass Index TC 50 27.416 5.260 .744 .313 .228 .755 
CC 220 27.187 4.518 .305       
Triceps Skin folds  (mm) TC 50 22.564 9.397 1.329 .184 .254 .854 
CC 220 22.310 8.687 .586       
Sub Scapula Skin folds (mm) TC 50 30.398 9.490 1.342 -.137 -.195 .891 
CC 220 30.593 8.954 .604       
Waist (inches) TC 50 36.780 4.274 .604 .980 .659 .328 
CC 220 36.121 4.291 .289       
Hip (inches) TC 50 37.872 3.617 .512 -.594 -.333 .553 
CC 220 38.205 3.566 .240       
Systolic BP (mmHg) TC 50 148.000 28.584 4.042 1.336 5.155 .183 
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Table 151- Independent samples t-test comparing genotypes TC and CC for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
CC 220 142.845 23.641 1.594       
Diastolic BP (mmHg) TC 50 83.420 17.383 2.458 .586 1.193 .559 
CC 220 82.227 11.794 .795       
 Glucose (mg/dl) TC 50 146.020 58.747 8.308 .283 2.947 .777 
CC 220 143.073 67.973 4.583       
OGTT TC 6 130.000 18.580 7.585 2.862 22.037 .007 
CC 27 107.963 16.755 3.224       
Cholesterol (mg/dl) TC 38 181.158 55.972 9.080 -.475 -4.339 .636 
CC 171 185.497 49.836 3.811       
Glyceride (mg/dl) TC 38 153.284 67.100 10.885 -1.366 -24.520 .174 
CC 171 177.805 105.944 8.102       
HDL (mg/dl) TC 38 37.663 13.345 2.165 -1.643 -3.514 .102 
CC 170 41.177 11.583 .888       
LDL (mg/dl) TC 38 110.366 46.493 7.542 .744 5.166 .457 
CC 169 105.200 36.700 2.823       
VLDL (mg/dl) TC 38 32.679 15.307 2.483 -.889 -3.667 .375 
CC 169 36.346 24.354 1.873       
 
 
Table 152-Independent samples t-test between genotypes TT and CC for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) CC 50 64.484 11.528 1.630 2.786 4.991 .006 
TT 317 59.493 11.811 0.663       
Age of onset CC 26 54.458 9.637 1.890 1.087 2.321 .279 
TT 159 52.137 10.164 0.806       
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Table 152-Independent samples t-test between genotypes TT and CC for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
Height (cm) CC 50 159.950 9.355 1.323 -.396 -.565 .692 
TT 317 160.515 9.384 0.527       
Weight  (Kg) CC 50 69.886 13.016 1.841 -.147 -.297 .883 
TT 317 70.183 13.353 0.750       
Body Mass Index CC 50 27.416 5.260 0.744 .232 .170 .817 
TT 317 27.246 4.727 0.265       
Triceps Skin folds  (mm) CC 50 22.564 9.397 1.329 .368 .494 .713 
TT 317 22.070 8.730 0.490       
Sub Scapula Skin folds (mm) CC 50 30.398 9.490 1.342 .156 .201 .876 
TT 317 30.197 8.300 0.466       
Waist (inches) CC 50 36.780 4.274 0.604 .676 .451 .499 
TT 317 36.329 4.396 0.247       
Hip (inches) CC 50 37.872 3.617 0.512 -.466 -.261 .642 
TT 317 38.133 3.691 0.207       
Systolic BP (mmHg) CC 50 148.000 28.584 4.042 .943 3.726 .346 
TT 317 144.274 25.537 1.434       
Diastolic BP (mmHg) CC 50 83.420 17.383 2.458 -.488 -.990 .626 
TT 317 84.410 12.593 0.707       
 Glucose (mg/dl) CC 50 146.020 58.747 8.308 .557 5.427 .578 
TT 317 140.593 64.856 3.643       
OGTT CC 6 130.000 18.580 7.585 1.206 12.833 .236 
TT 30 117.167 24.577 4.487       
Cholesterol (mg/dl) CC 38 181.158 55.972 9.080 *-0.605 -5.742 .548 
TT 261 186.900 44.854 2.776       
Glyceride (mg/dl) CC 38 153.284 67.100 10.885 -1.800 -29.331 .073 
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Table 152-Independent samples t-test between genotypes TT and CC for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
TT 261 182.615 97.073 6.009       
HDL (mg/dl) CC 38 37.663 13.345 2.165 -1.483 -3.137 .139 
CC 261 40.800 12.008 0.743       
LDL (mg/dl) TT 38 110.366 46.493 7.542 .108 .777 .914 
CC 261 109.589 40.696 2.519       
VLDL (mg/dl) TT 38 32.679 15.307 2.483 -1.339 -5.326 .182 
  CC 260 38.005 23.800 1.476       
 
 
Table 153-Independent samples t-test between genotypes TC and TT for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) TC 220 60.667 12.860 0.867 1.093 1.175 0.275 
TT 317 59.493 11.811 0.663       
Age of onset TC 109 53.706 10.505 1.006 1.224 1.568 0.222 
TT 159 52.137 10.164 0.806       
Height (cm) TC 220 159.878 8.939 0.603 -0.789 -0.637 0.431 
TT 317 160.515 9.384 0.527       
Weight  (Kg) TC 220 69.590 13.268 0.895 -0.507 -0.593 0.612 
TT 317 70.183 13.353 0.750       
Body Mass Index TC 220 27.187 4.518 0.305 -0.144 -0.059 0.885 
TT 317 27.246 4.727 0.265       
Triceps Skin folds  (mm) TC 220 22.310 8.687 0.586 0.313 0.239 0.754 
TT 317 22.070 8.730 0.490       
Sub Scapula Skin folds (mm) TC 220 30.593 8.954 0.604 0.525 0.395 0.600 
TT 317 30.197 8.300 0.466       
Appendices  
317 | P a g e  
 
Table 153-Independent samples t-test between genotypes TC and TT for the entire sample (T2DM T-786C) 
Variable Genotype N Mean SD SE t value mean difference p value 
Waist (inches) TC 220 36.121 4.291 0.289 -0.544 -0.208 0.586 
TT 317 36.329 4.396 0.247       
Hip (inches) TC 220 38.205 3.566 0.240 0.225 0.072 0.822 
TT 317 38.133 3.691 0.207       
Systolic BP (mmHg) TC 220 142.845 23.641 1.594 -0.657 -1.429 0.511 
TT 317 144.274 25.537 1.434       
Diastolic BP (mmHg) TC 220 82.227 11.794 0.795 -2.027 -2.183 0.043 
TT 317 84.410 12.593 0.707       
 Glucose (mg/dl) TC 220 143.073 67.973 4.583 0.427 2.480 0.669 
TT 317 140.593 64.856 3.643       
OGTT TC 27 107.963 16.755 3.224 -1.633 -9.204 0.108 
TT 30 117.167 24.577 4.487       
Cholesterol (mg/dl) TC 171 185.497 49.836 3.811 -0.304 -1.403 0.761 
TT 261 186.900 44.854 2.776       
Glyceride (mg/dl) TC 171 177.805 105.944 8.102 -0.486 -4.811 0.627 
TT 261 182.615 97.073 6.009       
HDL (mg/dl) TC 170 41.177 11.583 0.888 0.323 0.377 0.747 
TT 261 40.800 12.008 0.743       
LDL (mg/dl) TC 169 105.200 36.700 2.823 -1.135 -4.389 0.257 
TT 261 109.589 40.696 2.519       
VLDL (mg/dl) TC 169 36.346 24.354 1.873 -0.699 -1.659 0.485 
  TT 260 38.005 23.800 1.476       
  
Table 154-Independent samples t-test comparing genotypes 4aa and 4ab for the entire sample (T2DM Intron 4) 
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Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 4aa 21 65.748 11.767 2.568 1.571 4.605 0.118 
4ab 167 61.143 12.759 0.987       
Height (cm) 4aa 21 159.067 7.498 1.636 -0.438 -0.933 0.662 
4ab 167 160.000 9.386 0.726       
Weight  (Kg) 4aa 21 69.614 13.846 3.021 -0.086 -0.256 0.932 
4ab 167 69.871 12.757 0.987       
Body Mass Index 4aa 21 27.410 4.503 0.983 0.100 0.106 0.920 
4ab 167 27.304 4.571 0.354       
Triceps Skin folds  (mm) 4aa 21 20.876 6.873 1.500 -0.835 -1.647 0.405 
4ab 167 22.523 8.699 0.673       
Sub Scapula Skin folds (mm) 4aa 21 28.676 7.606 1.660 -1.042 -2.209 0.299 
4ab 167 30.885 9.320 0.721       
Waist (inches) 4aa 21 36.310 4.262 0.930 -0.183 -0.184 0.855 
4ab 167 36.494 4.355 0.337       
Hip (inches) 4aa 21 37.690 3.389 0.740 -0.743 -0.598 0.458 
4ab 167 38.288 3.482 0.269       
Systolic BP (mmHg) 4aa 21 144.000 26.989 5.889 -0.173 -0.958 0.862 
4ab 167 144.958 23.448 1.814       
Diastolic BP (mmHg) 4aa 21 83.524 11.978 2.614 -0.102 -0.279 0.919 
4ab 167 83.802 11.799 0.913       
 Glucose (mg/dl) 4aa 21 132.476 47.640 10.396 -0.602 -8.644 0.548 
4ab 167 141.120 63.504 4.914       
OGTT 4aa 3 126.000 16.823 9.713 1.115 13.000 0.276 
4ab 22 113.000 19.131 4.079       
Cholesterol (mg/dl) 4aa 13 170.615 57.932 16.067 -0.882 -13.018 0.379 
4ab 131 183.634 50.030 4.371       
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Table 154-Independent samples t-test comparing genotypes 4aa and 4ab for the entire sample (T2DM Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
Glyceride (mg/dl) 4aa 13 117.869 42.636 11.825 -1.968 -60.686 0.051 
4ab 131 178.556 110.054 9.615       
HDL (mg/dl) 4aa 13 38.077 16.261 4.510 -0.689 -2.326 0.492 
4ab 131 40.403 11.088 0.969       
LDL (mg/dl) 4aa 13 106.462 59.040 16.375 0.111 1.302 0.912 
4ab 130 105.160 38.164 3.347       
VLDL (mg/dl) 4aa 13 28.092 16.914 4.691 -1.168 -8.602 0.245 
  4ab 130 36.694 25.951 2.276       
 
Table 155-Independent samples t-test between genotypes 4aa and 4bb for the entire sample (Intron 4 T2DM) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 
4aa 21 65.748 11.767 2.568 2.162 5.985 0.031 
4bb 360 59.763 12.359 0.651    
Height (cm) 
4aa 21 159.067 7.498 1.636 -0.693 -1.414 0.489 
4bb 360 160.480 9.174 0.484    
Weight  (Kg) 
4aa 21 69.614 13.846 3.021 0.010 0.029 0.992 
4bb 360 69.585 13.573 0.715    
Body Mass Index 
4aa 21 27.410 4.503 0.983 0.365 0.393 0.716 
4bb 360 27.016 4.820 0.254    
Triceps Skin folds  (mm) 
4aa 21 20.876 6.873 1.500 -0.526 -1.045 0.599 
4bb 360 21.921 8.943 0.471    
Sub Scapula Skin folds (mm) 
4aa 21 28.676 7.606 1.660 -0.799 -1.528 0.425 
4bb 360 30.204 8.563 0.451    
Waist (inches) 
4aa 21 36.310 4.262 0.930 0.195 0.201 0.845 
4bb 360 36.109 4.598 0.242    
Hip (inches) 
4aa 21 37.690 3.389 0.740 -0.378 -0.325 0.705 
4bb 360 38.015 3.847 0.203    
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Table 155-Independent samples t-test between genotypes 4aa and 4bb for the entire sample (Intron 4 T2DM) 
Variable Genotype N Mean SD SE t value mean difference p value 
Systolic BP (mmHg) 
4aa 21 144.000 26.989 5.889 0.104 0.600 0.917 
4bb 360 143.400 25.658 1.352    
Diastolic BP (mmHg) 
4aa 21 83.524 11.978 2.614 0.120 0.352 0.905 
4bb 360 83.172 13.165 0.694    
 Glucose (mg/dl) 
4aa 21 132.476 47.640 10.396 -0.778 -11.535 0.437 
4bb 360 144.011 66.925 3.527    
OGTT 
4aa 3 126.000 16.823 9.713 0.710 9.970 0.482 
4bb 33 116.030 23.624 4.112    
Cholesterol (mg/dl) 
4aa 13 170.615 57.932 16.067 -1.350 -17.873 0.178 
4bb 293 188.488 46.174 2.698    
Glyceride (mg/dl) 
4aa 13 117.869 42.636 11.825 -2.321 -62.703 0.021 
4bb 293 180.573 96.877 5.660    
HDL (mg/dl) 
4aa 13 38.077 16.261 4.510 -0.925 -3.242 0.356 
4bb 292 41.319 12.174 0.712    
LDL (mg/dl) 
4aa 13 106.462 59.040 16.375 -0.295 -3.360 0.768 
4bb 291 109.822 39.209 2.298    
VLDL (mg/dl)  
4aa 13 28.092 16.914 4.691 -1.416 -9.246 0.158 
4bb 291 37.338 23.245 1.363    
 
Table 156-Independent samples t-test between genotypes 4ab and 4bb (T2DM Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
Age (years) 
4ab 167 61.143 12.759 0.987 1.181 1.380 0.238 
4bb 360 59.763 12.359 0.651       
Height (cm) 
4ab 167 160.000 9.386 0.726 -0.556 -0.481 0.579 
4bb 360 160.480 9.174 0.484       
Weight  (Kg) 
4ab 167 69.871 12.757 0.987 0.229 0.285 0.819 
4bb 360 69.585 13.573 0.715       
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Table 156-Independent samples t-test between genotypes 4ab and 4bb (T2DM Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
Body Mass Index 
4ab 167 27.304 4.571 0.354 0.647 0.287 0.518 
4bb 360 27.016 4.820 0.254       
Triceps Skin folds  
(mm) 
4ab 167 22.523 8.699 0.673 0.725 0.602 0.468 
4bb 360 21.921 8.943 0.471       
Sub Scapula Skin folds 
(mm) 
4ab 167 30.885 9.320 0.721 0.826 0.681 0.409 
4bb 360 30.204 8.563 0.451       
Waist (inches) 
4ab 167 36.494 4.355 0.337 0.910 0.385 0.363 
4bb 360 36.109 4.598 0.242       
Hip (inches) 
4ab 167 38.288 3.482 0.269 0.780 0.273 0.436 
4bb 360 38.015 3.847 0.203       
Systolic BP(mmHg) 
4ab 167 144.958 23.448 1.814 0.666 1.558 0.506 
4bb 360 143.400 25.658 1.352       
Diastolic BP (mmHg) 
4ab 167 83.802 11.799 0.913 0.528 0.630 0.598 
4bb 360 83.172 13.165 0.694       
 Glucose (mg/dl) 
4ab 167 141.120 63.504 4.914 -0.469 -2.891 0.639 
4bb 360 144.011 66.925 3.527       
OGTT 
4ab 22 113.000 19.131 4.079 -0.501 -3.030 0.618 
4bb 33 116.030 23.624 4.112       
Cholesterol (mg/dl) 
4ab 131 183.634 50.030 4.371 -0.975 -4.854 0.330 
4bb 293 188.488 46.174 2.698       
Glyceride (mg/dl) 
4ab 131 178.556 110.054 9.615 -0.190 -2.017 0.850 
4bb 293 180.573 96.877 5.660       
HDL (mg/dl) 
4ab 131 40.403 11.088 0.969 -0.735 -0.916 0.463 
4bb 292 41.319 12.174 0.712       
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Table 156-Independent samples t-test between genotypes 4ab and 4bb (T2DM Intron 4) 
Variable Genotype N Mean SD SE t value mean difference p value 
LDL (mg/dl) 
4ab 130 105.160 38.164 3.347 -1.136 -4.662 0.256 
4bb 291 109.822 39.209 2.298       
VLDL (mg/dl)  
4ab 130 36.694 25.951 2.276 -0.253 -0.644 0.800 
4bb 291 37.338 23.245 1.363       
 
Table 157-ACE and eNOS associationin T2DM sample 
Glu298Asp eNOS-GG eNOS-GT eNOS-TT χ2 P 
ACE-II 30 (9.3%) 22 (13.3%) 2 (9.5%) 5.272 0.261 
ACE-ID 159 (49.1%) 90 (54.5%) 12 (57.1%)    
ACE-DD 135 (41.7%) 53 (32.1%) 7 (33.3%)    
Total 324 (100%) 165 (100%) 21 (100%)     
T-786C eNOS-TT eNOS-TC eNOS-CC χ2 P 
ACE-II 42 (13.2%) 19 (8.6%) 6 (12.0%) 3.318 0.506 
ACE-ID 159 (50.2%) 116 (52.7%) 28 (56.0%)    
ACE-DD 116 (36.6%) 85 (14.5%) 16 (32.0%)    
Total 317 (100%) 220 (100%) 50 (100%)     
Intron 4 eNOS-4bb eNOS-4ab eNOS-4aa χ2 P 
ACE-II 43 (11.9%) 15 (9.0%) 1 (4.8%) 1.986 0.738 
ACE-ID 182 (50.6%) 85 (50.9%) 11 (52.4%)    
ACE-DD 135 (37.5%) 67 (40.1%) 9 (42.9%)    
Total 360 (100%) 167 (100%) 21 (100%)     
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8.8 Appendix 8- T2DM Discussion tables 
Table 158- Glu298Asp reported genotype frequencies in previous T2DM control groups 
T2DM Controls Population Subjects GG GT TT Study 
T2DM Italian 197 controls  46.4%  39.6% 14.0% 
(Monti et al. 2003) 
 
T2DM Finland 222 controls 50.45% 41.44% 8.11% (Ukkola et al. 2001) 
T2DM Swedish 799 controls 
Men: 
49.9% 
Women: 
52.0% 
Men: 
40.1% 
Women: 
40.4% 
Men: 
10.0% 
Women: 
7.6% 
(Odeberg et al. 2008) 
 
T2DM North Indian 247 controls 55.47% 40.08% 4.45% Current study 
Insulin levels Japanese 247 controls 86.6% 12.2% 1.2% (Maruyama et al. 2003) 
T2DM Japanese 233 controls 84.1% 15.0% 0.95% 
(Ohtoshi et al. 2002) 
 
 
Table 159- Glu298Asp reported genotype frequencies in previous T2DM patient groups 
Glu298asp T2DM 
patients 
Population Subjects GG GT TT Study 
T2DM Italian 159 patients 32.7% 39.6% 27.7% (Monti et al. 2003) 
T2DM Swedish 403 patients  
Men: 
55.5% 
Women: 
54.7% 
Men: 
37.1% 
Women: 
38.8% 
Men: 
7.4% 
Women: 
6.5% 
(Odeberg et al. 2008) 
 
T2DM Finland 216 patients 49.07% 43.06% 7.87% (Ukkola et al. 2001) 
T2DM 
United states 
Caucasian 
999 patients 45% 44% 11% (Conen et al. 2008) 
T2DM North Indians 263 patients 71.10% 25.10% 3.80% Current Study 
T2DM Japanese 301 patients 85.0% 14.05% 1.0% (Ohtoshi et al. 2002) 
T2DM Japanese 337 patients 85.16% 13.35% 1.48% (Tamemoto et al. 2008)  
 
Table 160-T-786C reported genotype frequencies in previous T2DM control groups 
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T2DM controls Population Subjects TT TC CC Reference 
T2DM Japanese 233  83.26% 15.02% 1.72% (Ohtoshi et al. 2002) 
T2DM Tunisia 736 59.2% 35.9% 4.9% (Ezzidi et al. 2008) 
 
Table 161-T-786C reported genotype frequencies in previous T2DM patient groups 
T2DM Patients Population Subjects TT TC CC Reference 
T2DM Japanese 301  83.06% 15.95% 1% (Ohtoshi et al. 2002) 
T2DM Tunisia 905 53.59% 39.1% 7.29% (Ezzidi et al. 2008) 
 
Table 162- Intron 4 reported genotype frequencies in previous T2DM control groups 
T2DM controls Population Subjects 4bb 4ab 4aa Reference 
T2DM DN Japanese 155  85.8% 14.2% 14.2% (Neugebauer et al. 2000) 
T2DM Chinese 398  85.43% 14.3% 0.25% (Lee et al. 2003) 
 
Table 163- Intron 4 reported genotype frequencies in previous T2DM patient groups 
Disease Population Subjects 4bb 4ab 4aa Study 
T1DM 
 
Unknown 147 T1DM patients 61.9% 30.5% 7.55% (Frost et al. 2003) 
T2DM and Diabetic 
nephropathy status 
Japanese 
82 T2DM without 
nephropathy (WON) 
39 with nephropathy 
(WN) 
WON: 
86.6% 
 
WN: 
69.2% 
WON: 
12.2% 
 
WN: 
23.0% 
WON: 
1.2% 
 
WN: 
8.0% 
(Neugebauer et al. 2000) 
T2DM and Diabetic 
Nephropathy status 
Asian Indians 
195 T2DM with 
nephropathy 
WN: 
74.8% 
WN: 
14.4% 
WN: 
10.8% 
(Ahluwalia et al. 2008) 
T2DM Chinese 800 patients 84.25% 28.14% 1.75% (Lee et al. 2003) 
T2DM and Diabetic 
Nephropathy status 
United kingdom 
Caucasian 
464 patients with overt 
protein urea and diabetic 
retinopathy 
74.1% 23.3% 2.6% (Rippin et al. 2003)  
T2DM and diabetic 
Nephropathy (DN) 
Japanese 
All type 2 diabetes 
mellitus: 
123 advanced diabetic 
Diabetic 
nephropathy 
75.7% 
Diabetic 
nephropathy: 
21.9% 
Diabetic nephropathy: 
2.4% 
Overt proteinuria 
(Shimizu et al. 2002)  
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nephropathy 
107 overt proteinuria and 
normal serum creatinine 
levels 
203 normal renal function 
but diabetes >10 years 
Overt 
proteinuria: 
81.4% 
Overt proteinuria 
15.8% 
2.8% 
 
